UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-KSB

(X) ANNUAL REPORT UNDER SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2004

OR

( ) TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ______________

Commission file number
000-22923

INTERNATIONAL ISOTOPES INC.
(Exact name of issuer as specified in its charter)

          Texas                       74-2763837
------------------------   ------------------------------------
(State of incorporation)   (IRS Employer Identification Number)

               4137 Commerce Circle
                Idaho Falls, Idaho                   83401
    ----------------------------------------       ----------
    (Address of principal executive offices)       (zip code)

                         (208) 524-5300
      ----------------------------------------------------
      (Registrant's telephone number, including area code)

Securities registered under Section 12(b) of the Exchange Act:
COMMON STOCK, $.01 PAR VALUE
(Title of Class)

Securities registered under Section 12(g) of the Exchange Act:
COMMON STOCK, $.01 PAR VALUE
(Title of Class)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES (X) NO ( )

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. (X)

The Issuer's revenue for the fiscal year ended December 31, 2004 was $2,848,844.

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to be the average bid and asked price of such common equity at March 1, 2005 was $3,464,766.

As of March 1, 2005 the number of shares outstanding of common stock, $.01 par value was 183,315,081 shares.

Documents Incorporated by Reference

Certain information called for in Parts II and III of this Annual Report on Form 10-KSB is incorporated by reference to the definitive proxy statement for the annual meeting of shareholders of the Company, which will be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2004.


INTERNATIONAL ISOTOPES INC.

FORM 10-KSB

TABLE OF CONTENTS

                                                                        Page No.
Part I.

Item 1.   Business ....................................................     3
Item 2.   Properties ..................................................     6
Item 3.   Legal Proceedings ...........................................     7
Item 4.   Submission of Matters to a Vote of Securities-Holders .......     7

Part II.

Item 5.   Market for the Registrant's Common Equity and
             Related Stockholder Matters ..............................     8
Item 6.   Management's Discussion and Analysis of Financial
             Condition and Results of Operations ......................     8
Item 7.   Financial Statements.........................................    13
Item 8.   Changes in and Disagreements with Accountants on
             Accounting and Financial Disclosure ......................    14
Item 8A   Controls and Procedures......................................    14

Part III.

Item 9.   Directors and Executive Officers of Registrant ..............    14
Item 10.  Executive Compensation ......................................    14
Item 11.  Security Ownership of Certain Beneficial Owners
             and Management ...........................................    15
Item 12.  Certain Relationships and Related Transactions ..............    15
Item 13.  Exhibits, Financial Statement Schedule
             and Reports on Form 8-K ..................................    15
Item 14.  Principal Accountant Fees and Services ......................    16
Power of Attorney .....................................................    16
Signatures ............................................................    17

2

PART I

This Annual Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This Act provides a "safe harbor" for forward-looking statements to encourage companies to provide prospective information about themselves so long as they identify these statements as forward-looking and provide meaningful cautionary statements identifying important factors that could cause actual results to differ from the projected results. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Annual Report are forward looking. Words such as "anticipates," "believes," "expects," "future" and "intends" and similar expressions identify forward-looking statements. In particular, statements regarding: the sufficiency of our available cash and revenues from operations to meet our operating needs; our ability to generate revenue; improvements in our gross profit; our 2005 goals and objectives; the improvement in our financial performance due to an anticipated decrease in operating expenses; anticipated growth in any of our business segments; the impact of expansion efforts on our revenues; the effect of our ability to use our patents; the anticipated approval dates for government permits; the improvement of our competitive position based on decreased production costs; anticipated completion dates for our plant construction and resulting production capabilities; the extension of the maturity date of our bank debt; the outcome of litigation pending against us and the establishment of additional manufacturing capacity are forward-looking. Forward-looking statements reflect management's current expectations, plans or projections and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Certain risks and uncertainties that could cause actual results to differ significantly from management's expectations are described in the section entitled "Factors Affecting Future Results." That section, along with other sections of this Annual Report, describes some, but not all, of the factors that could cause actual results to differ significantly from management's expectations. The company undertakes no obligation to publicly release any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the factors set forth in reports that the company files from time to time with the Securities and Exchange Commission.

Item 1. BUSINESS

General Business and Products Description International Isotopes Inc., a Texas corporation, (together with its wholly owned subsidiary, International Isotopes Idaho Inc.) was formed as a Texas corporation in 1995. Our headquarters and all operations are currently located in Idaho Falls, Idaho. Our business consists of five reportable segments which include; Nuclear Medicine Reference and Calibration Standards, Cobalt Products, Radiochemical Products, Fluorine Extraction Process Products, and Radiological Processing Services.

Nuclear Medicine Reference and Calibration Standards This segment consists of the manufacture of sources and standards associated with SPECT (Single Photon Emission Computed Tomography), patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy business. These items include flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot markers, pen point markers, and a host of specialty design items. One customer accounts for most of our sales in this segment. We are the exclusive contract manufacturer for this customer for these products. There are over 5,000 nuclear medicine centers around the country that require these types of products on a regular repeat basis. We have been manufacturing these products since 2001 and have continued to grow this business at an annual rate of approximately 12% per year. The nuclear pharmacy business has been growing, and is anticipated to continue to grow, at an annual rate of about 5%.

3

Cobalt Products
This segment includes the production of high and medium specific activity bulk cobalt, recycling expended cobalt sources, and fabrication of a wide array of cobalt teletherapy and experimental irradiator source capsules. In prior years our only cobalt product revenues were from the sale of bulk cobalt metal. However, in 2004, we made several major accomplishments, which will allow for significant growth of this segment.

o We made a significant financial investment to install hot cells and related processing equipment to permit on site processing of cobalt-60 isotope.

o We have been able to contract for the receipt and recycling of certain cobalt sources utilizing these facilities.

o We have designed a series of Sealed Source and Special Form capsules, which will allow us to recycle, re-encapsulate, and sell a variety of new cobalt products utilizing recycled material or material we produce in reactors.

This expanded cobalt production capability is expected to have a significant positive impact upon our revenues in 2005 and beyond.

Radiochemical Products
This segment includes production of various isotopically pure radiochemicals for medical, industrial, or research applications. These products are either directly produced by us or are purchased in bulk from other producers and distributed by us in customized packages and chemical forms tailored to meet customer requirements. Our sales in this segment consist of Cobalt-60 (Co-60), Cobalt-57 (Co-57), Cesium-137 (Cs-137), Iodine-131 (I-131), Sodium-22 (Na-22), and Barium-133 (Ba-133) isotopes. We initiated fairly wide scale distribution of Iodine-131 in 2004. Radiopharmaceuticals produced with Iodine-131 are used in the treatment and diagnosis of various diseases of the thyroid such as Graves disease, thyroid cancer, and hyperthyroidism and are also used in a host of investigational and clinical trials such as for the treatment of breast, lung, prostate, and ovarian cancers.

Fluorine Products
We acquired seven patents for the Fluorine Extraction Process (FEP) in January 2004 and plan to use this technology to produce several high purity fluorine products, such as germanium tetrafluoride. High purity fluorine gases are in ever-increasing demand for ion-implantation or chemical vapor deposition processes for microelectronics components and high-speed silicon chip manufacture. The FEP fluorine product is expected to be very high purity which makes it ideally suited to these specialty applications, where ultra high purity gas is required. In addition, we anticipate that the production costs of FEP products will be low in comparison with ultra pure fluorine products manufactured by other common commercial methods enabling us to effectively compete with existing high purity fluorine product suppliers.

In addition to acquiring these patents, we have undertaken several additional steps in 2004 towards manufacturing these high purity fluoride gases.

o We have established a marketing and technology consulting agreement with individuals knowledgeable and experienced with the processing technology and market applications for fluorine products.

o We have leased an additional industrial facility for production of FEP gases.

o We have hired management and laboratory process operations staff.

o We have completed a process system design and started plant construction.

We expect to complete plant construction and begin fluorine gas production during the second quarter of 2005. We believe that the market size and growth outlook for high purity fluorine products is excellent and this business segment should provide us with an excellent opportunity to grow our revenue substantially in coming years.

4

Radiological Processing Services
This segment concerns a wide array of miscellaneous services the largest of which is processing of gemstones which has undergone irradiation for color enhancement. One customer accounts for most of our sales in this segment. We have an exclusive contract with a this customer for the gemstone processing service. Other services in this segment consist of radiological engineering consultant services, Type A package certification testing, and waste packaging/recycle services.

We believe that all of these business segments will perform well and should continue to demonstrate continued growth. We expect that revenues generated from these operations should be expected to produce sufficient cash to meet our operational needs.

Industry Overview, Target Markets, and Competition

The industries and markets that require or involve the use of radioactive material are diverse. Our current operations involve products that are used in a wide variety of applications and in various markets.

Nuclear Medicine Reference and Calibration Standards Calibration and Reference Standards are required for the daily operational checks and calibration of the measurement of SPECT imaging devices frequently used in nuclear medicine. This calibration and quality assurance testing is required as a routine part of the normal operations of this equipment to ensure its reliability and accuracy. We exclusively manufacture many of these products for Radqual LLC, which in turn sells the products to several distributors around the U.S. We directly ship these products to all 50 states and several overseas locations. There are two other major producers of these products within the U.S. and that directly compete with us for these products.

Cobalt Products
We sell high activity bulk cobalt to a customer that uses it to fabricate sealed sources for the Elekta Gamma knife unit. The gamma knife is a device used for the precise radiation treatment of certain tumors and vascular deformities of the brain. There are over seventy-five treatment centers around the U.S that are using the gamma knife and through 2003 it is estimated that over 80,000 patients have been successfully treated with this device. We also accept old gamma knife sources for recycling when they have decayed past their useful activity in the gamma knife. This recycled cobalt, along with lower activity cobalt we produce in a reactor, is incorporated into new sealed sources for teletherapy or experimental irradiators.

Radiochemical Products
We typically supply radioisotope products in bulk form. The markets for most radiochemicals are highly competitive. The target markets for these products are customers who 1) incorporate them into finished industrial or medical devices;
2) use radioisotope products in clinical trials for various medical applications; or 3) further process and include the radioisotope products into a pharmaceutical product for FDA approved therapy or imaging.

Fluorine Products
We are developing our fluorine products to address an opportunity we see in the increased market demand for certain high purity fluorine compounds in the microelectronics industry. Emerging technologies, such as the increased use of silicon germanium processing chips for the wireless industry will require the use of high purity fluorine compounds, such as germanium tetra fluoride. We plan to establish manufacturing capacity for at least one of these compounds in 2005. Several of these fluorine compounds are already under production by other businesses. Since the cost of the FEP process is low, we anticipate being able to be very price competitive with our fluorine products. However, this price advantage may initially be our only competitive advantage in this market.

5

Radiological Processing Services

Most of our general measurement and radiological services are performed in support of gemstone processing. This material has undergone color enhancement by irradiation at the Missouri University Research Reactor (MURR). The gemstones are used in commercial jewelry manufactured by other companies in overseas locations. The color enhancement process is a highly competitive industry and there are several alternatives to irradiation treatment. There are also other reactors located in other regions of the world that offer this irradiation service capability. The jewelry manufacturing industry is a highly competitive industry.

Government Regulation

We have obtained a license from the Nuclear Regulatory Commission, Region IV that permits use and possession of by-product material. The scope of this license includes calibration and reference standard manufacturing and distribution, radioisotope processing and distribution, large scale cobalt processing and recycle operations, radioactive gemstone processing, environmental sample analysis, and various research and development activities. The existing license and permits are adequate to allow all of our current business operations. Expansion into FEP production will require additional permitting both through the NRC, State of Idaho, and the Environmental Protection Agency. We started this permitting process in 2004 and expect to complete it in 2005. We will make every effort to prepare well-planned and detailed applications for these additional permits; however, there can be no assurance of the time frame required for the various governmental agencies to review and approve these permits.

Regulation of Radioisotope Production Radioactive Waste

All of our manufacturing processes generate some radioactive waste. We must handle this waste pursuant to the Low Level Radioactive Waste Policy Act of 1980, which requires the safe disposal of mildly radioactive materials. The estimated costs for storage and disposal of these materials have been included in the manufacturing and sales price of our products. However, actual disposal costs are subject to change at the discretion of the disposal site and are ultimately applied at the time of disposal.

The operating permit from the NRC also requires that we maintain an adequate cash reserve, in the form of a certificate of deposit and irrevocable letter of credit to the NRC to support our estimated decommissioning and disposal costs for the facility. We do not handle "special nuclear materials" (i.e. nuclear fuels and weapons grade uranium, thorium and plutonium) and, therefore, our facility is not designated as a "nuclear" facility.

Other Regulations

Registration of any of our radiochemicals into a Drug Master File (DMF) could subject us to the additional regulations of the Food and Drug Administration (FDA). We are registered as a medical device manufacturer through the FDA for several of our nuclear medicine reference and calibration standards. We are registered with the U.S. Department of Transportation for the shipment of radioactive materials and may be subjected to additional licensing requirements from the NRC for the import or export of radioactive materials commencing in 2005.

Employees

As of December 31, 2004 we had sixteen employees, all of whom are full-time.

Item 2. PROPERTIES

We lease two properties. The following paragraphs provide a brief summary of these properties.

4137 Commerce Circle - The facility located on this property houses our main corporate headquarters and all of our manufacturing operations except our FEP operations. We hold this property pursuant to a lease that extends through August 2008. The facility was new when leased in March 2001 and remains in excellent condition. Our lease includes unlimited automatic five year extensions of the lease at our sole discretion. Lease payments are adjusted annually based upon changes in the CPI. We also have a purchase option and a right of first refusal on this property which allows us to purchase this property at any time for a stated amount.

6

3159 Commerce Way - The facility located on this property houses our FEP production operations. The facility was first leased in February 2004 and is in excellent overall condition. We hold this property pursuant to a lease that extends through March 2009. The facility is in excellent condition. Our lease includes unlimited automatic five year extensions of the lease at our sole discretion. Lease payments are adjusted annually based upon changes in the CPI. We also have a purchase option and a right of first refusal on this property which allows us to purchase this property at any time for a stated amount.

Item 3. LEGAL PROCEEDINGS

During February 2004, a lawsuit was filed by Iso-Science Laboratories, Inc. in the Superior Court of the State of California for the County of Los Angeles against the company, our President and CEO, one of our customers and certain officers of this customer. The lawsuit contains numerous allegations against the defendants relating to the manufacture and sale of calibration and reference standards for nuclear medicine. The lawsuit alleges the defendants are using information and equipment that the plaintiff acquired from a previous employer of one of the defendants. The lawsuit also alleges unfair trade practices, interference with prospective business relationships, and conspiracy. The plaintiff seeks (i) an injunction to restrain us from manufacturing, marketing, or selling any of the products in question; (ii) a 55% royalty on the price of all related products we sell; (iii) the return of all equipment and information in question; (iv) disgorgement of profits received from the manufacture and sale of the products in question; and (v) general and punitive damages in an amount to be shown at the time of trial. In March 2004, we filed a response to the lawsuit in which we denied all of the allegations. In addition, we have filed a counterclaim against the plaintiff on the basis that the plaintiff filed the suit against the Company and our President and CEO with the knowledge that the plaintiff had no basis in law or fact and that the lawsuit was calculated to interfere with the our contractual arrangements and prospective business with our customers.

On July 29, 2004 the court granted our motion to dismiss all charges against our President and CEO. On October 25, 2004 the court established an anticipated trial start date of December 5, 2005. We will continue to vigorously defend against this lawsuit; however, a favorable outcome is not determinable at this time. Should this lawsuit be settled in a manner unfavorable to us, we could lose our major line of revenues and could be required to make substantial payments to the plaintiff. We have a manufacturing agreement in place with our customer and co-defendant pursuant to which the customer will indemnify us and our officers from any loss arising from this lawsuit. Therefore, we do not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations, or cash flow. However, there is no guarantee that our customer can bear the financial burden arising from defending and possible settlement of this lawsuit.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS

An annual meeting of shareholders was held on June 25, 2004.

1) Election of Directors All three incumbent directors were reelected without opposition to serve one-year terms in office. The results of this election were as follows:

Name of Director                    For              Withheld
----------------                 -----------         --------

Dr. Ralph Richart                106,908,919          320,801
Steve T. Laflin                  107,183,731           45,989
Christopher Grosso               106,908,919          320,801

7

2) Ratification of Independent Auditors The appointment of Hansen Barnett & Maxwell as the independent certified public accountants for fiscal year 2004 was ratified. The results of the shareholder vote were as follows:

                                                                                    Broker
                                                     For       Against   Abstain   Non-Votes
                                                 -----------   -------   -------   ---------
Appointment of Hansen Barnett & Maxwell          107,197,661    29,304     2,755          -
 as independent certified public accountants

PART II

Item 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

In the second quarter of 2001 our common stock was delisted from the Nasdaq Small Cap Market and was traded solely over the counter on the Pink Sheets. On August 13, 2004, Nasdaq approved the reporting of our common stock on the Over the Counter Bulletin Board (OTCB) under the trading symbol "INIS." High asked prices and low bid prices reported by the respective trading sectors during the periods indicated are shown below:

Fiscal Year                Quarter      High Asked       Low Bid

   2004*                     1st          $0.19           $0.09
   2004*                     2nd          $0.19           $0.17
   2004@                     3rd          $0.19           $0.16
   2004#                     4th          $0.15           $0.08

   2003*                     1st          $0.05           $0.04
   2003*                     2nd          $0.08           $0.03
   2003*                     3rd          $0.14           $0.03
   2003*                     4th          $0.10           $0.03

* As reported on the pink sheets. @ As reported on the Pink Sheets from the beginning of the quarter through August 12, 2004 and as reported on the OTCBB from August 13, 2004 through the end of the quarter. # As reported on the OTCBB.

On December 31, 2004, there were 342 holders of record our common stock. We have never paid any cash dividends on our common stock. In the future, and based upon our profit performance, our Board of Directors will evaluate and determine whether to issue dividends or retain funds for research and development and expansion of our business. It is unlikely that we will pay any dividends to shareholders for the foreseeable future.

Additional information called for by this item will be included in our Proxy Statement for our 2005 annual meeting of shareholders, which will be filed within 120 days after December 31, 2004.

Additional information called for by this item will be included in our Proxy Statement for our 2005 annual meeting of shareholders, which will be filed within 120 days after December 31, 2004.

Item 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion of the results of the company's operations and financial condition should be read in conjunction with the accompanying financial statements and the notes thereto included within this report.

8

Overview

Our business consists of five reportable segments which include; Nuclear Medicine Reference and Calibration Standards, Cobalt Products, Radiochemical Products, Fluorine Extraction Process Products, and Radiological Processing Services.

Nuclear Medicine Reference and Calibration Standards This segment consists of the manufacture of sources and standards associated with SPECT (Single Photon Emission Computed Tomography), patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy business. These items include flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot markers, pen point markers, and a host of specialty design items.

Cobalt Products
This segment includes the production of high and medium specific activity bulk cobalt, recycling expended cobalt sources, and fabrication of a wide array of cobalt teletherapy and experimental irradiator source capsules. In prior years our only cobalt product revenues were from the sale of bulk cobalt metal. However, in 2004, we made several major accomplishments, including a significant investment to install hot cells and related processing equipment to permit on site processing of cobalt-60 isotope.

Radiochemical Products
This segment includes production of various isotopically pure radiochemicals for medical, industrial, or research applications. These products are either directly produced by us or are purchased in bulk from other producers and distributed by us in customized packages and chemical forms tailored to meet customer requirements. Our sales in this segment consist of Cobalt-60 (Co-60), Cobalt-57 (Co-57), Cesium-137 (Cs-137), Iodine-131 (I-131), Sodium-22 (Na-22), and Barium-133 (Ba-133) isotopes. We initiated fairly wide scale distribution of Iodine-131 in 2004. Radiopharmaceuticals produced with Iodine-131 are used in the treatment and diagnosis of various diseases of the thyroid such as Graves disease, thyroid cancer, and hyperthyroidism and are also used in a host of investigational and clinical trials such as for the treatment of breast, lung, prostate, and ovarian cancers.

Fluorine Products
We acquired seven patents for the Fluorine Extraction Process (FEP) in January 2004 and plan to use this technology to produce several high purity fluorine products, such as germanium tetrafluoride. High purity fluorine gases are in ever-increasing demand for ion-implantation or chemical vapor deposition processes for microelectronics components and high-speed silicon chip manufacture. The FEP fluorine product is equal to or greater than 99.999% pure with no detectable uranium in the product gas. This makes our FEP products ideally suited to these specialty applications, where ultra high purity gas is required. In addition, we anticipate that the production costs of FEP products will be low in comparison with ultra pure fluorine products manufactured by other common commercial methods enabling us to effectively compete with existing high purity fluorine product suppliers.

Radiological Processing Services
This segment concerns a wide array of miscellaneous services such as processing of gemstones which has undergone irradiation for color enhancement. Other general services in this segment consist of radiological engineering consultant services, Type A package certification testing, and waste packaging/recycle services.

We believe that all of these business segments will perform well and should continue to demonstrate continued growth. We expect that revenues generated from these operations should produce sufficient cash to meet our operational needs.

We believe that revenues generated from these business activities can be expected to have a positive effect upon our projections for continued growth in 2005 and should produce sufficient cash to meet our operational needs.

9

Liquidity and Capital Resources

On December 31, 2004 we had cash and cash equivalents of $150,051 compared to $160,216 at December 31, 2003. For the year ended December 31, 2004, our cash flows included net cash used in operating activities of $621,005, net cash provided by financing activities of $1,383,090 and cash used in investing activities of $772,250.

We incurred a loss applicable to common shareholders of $844,736 for the year ended December 31, 2004 and has an accumulated deficit of $88,813,386 since inception. Prior to 2004, our operations and plant and equipment expenditures were funded principally from proceeds from public and private sales of equity as well as through asset sales.

As of December 31, 2004, we had net borrowings of $733,595 with Texas State Bank. The current maturity date of this loan is February 2006. We made interest-only payments on this loan during 2004, but have been making principal and interest payments effective in January 2005. We anticipate working with Texas State Bank to extend the maturity date of this loan. We also have a $250,000 revolving line of credit with Texas State Bank. As of December 31, 2004, we had not drawn against this line of credit.

We completed an unsecured note purchase agreement on January 21, 2004 with certain of our principal investors and Directors totaling $650,000. Pursuant to the terms of the note purchase agreement, we issued unsecured notes, which accrue interest at 6% per year with a maturity date of December 31, 2005. Interest is paid on the notes on a semi-annual basis and the company has the option to prepay the principal balance at any time prior to maturity. The principal of the notes and any accrued interest is convertible into shares of our common stock at any time at the option of the holder prior to maturity. The conversion price for this conversion option was based on the market value of the common stock at the time the notes were issued and was determined to be $0.18 per share.

During 2004, there were a significant number of Series A warrants, and a few Series B warrants, issued from the 2003 rights offering that were exercised by shareholders for common stock. The total Series A and B warrant exercise in 2004 generated $802,034 and resulted in the issuance of an additional 19,714,894 shares of common stock. In January 2005, the company announced a mandatory redemption on all remaining Series A warrants by February 25, 2005. Consequently, shareholders exercised Series A warrants for $969,690 and the company issued an additional 24,842,259 shares of common stock. As of March 1, 2005 there are still 42,421,483 Series B warrants outstanding, which, if exercised would generate an additional $2,121,074 in capital and result in the issuance of an additional 42,421,483 shares of common stock.

Results of Operations

Year ended December 31, 2004 compared to year ended December 31, 2003

Revenues

Total revenues were $2,848,844 in 2004 as compared to $2,070,592 in 2003, an increase of $778,251 or 37.5%. The significant increase in revenues was attributable to increases in nearly every business segment. Cobalt Product sales and Radiochemical Products sales both approximately doubled. In our largest business segment, Nuclear Medicine Reference and Calibration Standards, sales increased by 11%. Only the Radiological Processing Services segment declined in 2004 (down 53.6%) primarily due to the continued decline in gemstone processing that continues to be subject to intense competition in the color enhancement and costume jewelry industries.

Cost of Revenues and Gross Profit

Cost of revenue for 2004 was $1,719,251 compared to $1,151,161 in 2003, an increase of $568,090 or 49%. Gross profit for 2004 was $1,129,592 or 40% as compared to $919,431 or 44% in 2003. The increase in cost of revenues and decrease in gross profit is attributable to the cost of launching Radiochemical Products in 2004 and the relatively high production costs associated with these new products. Improvements in production efficiencies, implementation of cost saving measures, and elimination of low margin products during the course of 2004 has lead to considerable improvements in gross profit performance which we expect will become evident in 2005.

10

Operating Costs and Expenses

Total operating costs and expenses for 2004 were $1,828,293, as compared to $1,582,512 in 2003, an increase of $245,781 or 15%. The increase was largely attributable to increased salaries and contract labor resulting from increased staffing and marketing contract consultant costs. Measured as a percentage of total revenue, operating expense has decreased 12% from 76% in 2003 to 64% in 2004. Limiting increases in staffing and eliminating most of our marketing consultant costs are expected to further decrease operating expenses in 2005.

Other Income (expense)

Other (expense) in 2004 was ($146,035) compared to other income of $108,332 in 2003. The difference was principally attributable to the sale of fully impaired assets in 2003. We no longer expect to realize any significant revenues from the sale of impaired assets.

Net Loss

The Net Loss from continuing operations was $844,736 in 2004 compared to a loss of $578,485 in 2003. The $266,251 increase in net loss was primarily attributable to the lack of income from sales of fully impaired assets in 2004 since all of the assets from discontinued operations have now been sold. Enhancements in production process efficiencies, production cost saving measures, elimination of marketing consultant expense, and elimination of low margin radiochemical products are all expected to contribute to improved financial performance in 2005.

Forward Looking Information

This Annual Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This Act provides a "safe harbor" for forward-looking statements to encourage companies to provide prospective information about themselves so long as they identify these statements as forward-looking and provide meaningful cautionary statements identifying important factors that could cause actual results to differ from the projected results. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Annual Report are forward looking. Words such as "anticipates," "believes," "expects," "future" and "intends" and similar expressions identify forward-looking statements. In particular, statements regarding: the sufficiency of our available cash and revenues from operations to meet our operating needs; our ability to generate revenue; improvements in our gross profit; our 2005 goals and objectives; the improvement in our financial performance due to an anticipated decrease in operating expenses; anticipated growth in any of our business segments; the impact of expansion efforts on our revenues; the effect of our ability to use our patents; the anticipated approval dates for government permits; the improvement of our competitive position based on decreased production costs; anticipated completion dates for our plant construction and resulting production capabilities; the extension of the maturity date of our bank debt; the outcome of litigation pending against us and the establishment of additional manufacturing capacity are forward-looking. Forward-looking statements reflect management's current expectations, plans or projections and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Certain risks and uncertainties that could cause actual results to differ significantly from management's expectations are described in the section entitled "Factors Affecting Future Results." That section, along with other sections of this Annual Report, describes some, but not all, of the factors that could cause actual results to differ significantly from management's expectations. The company undertakes no obligation to publicly release any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the factors set forth in reports that the company files from time to time with the Securities and Exchange Commission.

11

In 2004, we continued to build on various business segments, make investments into facilities and infrastructure, launch new products, and improve operating cost controls. The following is a list of some of the more significant accomplishments in 2004.

o Significant financial investment to install cobalt hot cells and related processing equipment to permit on site processing of cobalt-60 isotope, recycling expended cobalt sources, and fabrication of teletherapy capsules.

o Obtained contracts for receipt and recycle of certain cobalt sources.

o Obtained transportation container to allow shipment and processing of cobalt and other radioisotopes produced in other reactor locations.

o Designed a series of Sealed Source and Special Form capsules, which will allow us to recycle, re-encapsulate, and sell a variety of new cobalt products utilizing recycled material or material we produce in reactors.

o Installed new radiochemical processing hot cells and initiated sales of new radiochemical products.

o Acquired seven patents for the Fluorine Extraction Process (FEP) and have established marketing and technology consulting agreements, leased an additional industrial facility for FEP production, hired management and laboratory process FEP operations staff, and completed FEP process system design and initiated plant construction.

Based upon the investments we have made in our facilities and products developed in 2004 we have the following goals and objectives for 2005:

o To continue to expand our customer base and increase cobalt revenues through sales of cobalt sealed sources once NRC sealed source approval is obtained.

o To explore participation in contracts for various government sponsored source recovery and recycle programs expected to be funded through the federal government and to which we are uniquely suited to provide services.

o To launch at least one new radiochemical product and explore establishing partnerships with radiopharmaceutical manufacturers.

o To complete initial Fluorine gas plant construction, begin FEP gas production, and obtain gas supply contracts by the second quarter of 2005. We believe that the market size and growth outlook for high purity fluorine products is excellent and this business segment should provide the Company with an excellent opportunity to grow our revenue substantially in coming years.

o To continue to grow market share of all products in the Nuclear Medicine Reference and Calibration Standards business segment

o To continue to increase efficiencies and reduce production costs necessary to achieve profitability

12

We believe that revenues generated from these business activities will have a positive effect upon our business in 2005 and should produce sufficient cash to meet our operational needs.

Company Risk Factors

Readers should carefully consider the following factors that may affect our business, future operating results and financial condition, as well as other information included in this Annual Report. The risks and uncertainties described below are not the only ones the company faces. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.

We have incurred and may continue to incur losses. With the exception of 2002, we have incurred net losses for most fiscal periods since our inception. From inception through December 31, 2004, we have generated $22,165,661 in revenues and accumulated deficit (including preferred stock dividends and returns) in the amount of $88,813,306.

We may need additional financing to continue operations. As of December 31, 2004, we have an outstanding debt of $650,000 pursuant to short term notes with certain major shareholders and Directors of the Company that mature on December 31, 2005. We also have a loan from Texas State Bank in the amount of $733,595 as of December 31, 2004, which matures in February 2006 and is secured by our accounts receivable and fixed assets. We must negotiate an extension of this note on or before the maturity date. We also owe $840,753 to our former Chairman of the Board pursuant to a note that matures in April, 2012. Principal and interest payments on this note are paid annually based upon net profits (annual principal payment to equal 30% of net pre-tax profits).

Remaining company obligations on the Texas State Bank loan for the Waxahachie property. In 2002, Texas State Bank agreed to the assumption of our loan by an individual upon our sale of the Waxahachie property. As of December 31, 2004, the remaining outstanding balance on this loan was $312,391.44. Should this individual default on the assumed loan, the liability for the loan will revert to the Company.

There is no long-term contract in place with the Department of Energy contractor for continued HSA Cobalt production. We have put short term specific "work for non-government sponsor agreements" in place with the Department of Energy contractor to continue sales of HSA cobalt irradiated at the Idaho reactor facility. We expect that these agreements will continue; however, there is no assurance these contracts will be equitable or continuing.

Operational hazards could result in the spread of contamination within our facility and require additional funding to correct. An irrevocable, automatic renewable letter of credit against a certificate of deposit at Texas State Bank has been used to provide the financial assurance required by the Nuclear Regulatory Commission for our Idaho facility license. If a contamination event resulted in greater liability to us, we would have to borrow money or fund the liability from our future revenue.

Government regulation could adversely affect our business. Operations within our Idaho facility are subject to U.S. Nuclear Regulatory Commission and Food and Drug Administration regulations. To the extent these regulations are or become burdensome, our business development could be adversely affected.

We are dependent upon key personnel. Our ongoing operations are dependent on Steve T. Laflin, President and Chief Executive Officer. The loss of Mr. Laflin could have a material adverse effect on our business. We have a $2 million dollar key man life insurance policy on Mr. Laflin and two years remaining on Mr. Laflin's employment agreement. There is no assurance that we will be able to retain Mr. Laflin or our existing personnel or attract additional qualified employees. The loss of any of our key personnel or an inability to attract additional qualified employees could result in a significant decline in revenue.

We are dependent on various third parties in connection with our business operations. The production of HSA Cobalt is dependent upon the Department of Energy, and its prime-operating contractor, which controls the Idaho reactor and laboratory operations. Our gemstone production is tied to an exclusive agreement with Quali Tech Inc. Nuclear medicine calibration and reference standard manufacturing is conducted under an exclusive contract with RadQual, LLC, which in turn has agreements in place with several companies for marketing and sales.

13

We are subject to competition from other companies. Each of our business areas has direct competition from other businesses. HSA cobalt is supplied by other reactor facilities around the world. Nuclear medicine calibration and reference standards are being produced by several other manufacturers in the U.S. and overseas, and there is at least one other gemstone processor in Europe. Most of our radiochemicals are also manufactured by several other companies in the world, and there are other suppliers of high purity fluorine products. Each of our competitors has significantly greater financial resources that could give them competitive advantage over us.

We are named as defendant in a lawsuit filed by Iso-Science Laboratories Inc. A lawsuit has been filed by Iso-Science Laboratories, Inc. We believe the allegations of the petition are without merit. However, there is no guarantee of a favorable outcome of this suit and an unfavorable outcome could result in the loss of major revenues and require substantial payments to the plaintiff.

Item 7. FINANCIAL STATEMENTS

The following financial statements are included herewith:

Report of Independent Registered Public Accounting Firm

Consolidated Balance Sheets as of December 31, 2004 and 2003

Consolidated Statements of Operations for the years ended December 31, 2004 and 2003

Consolidated Statement of Shareholders' Equity (Deficit) for the years ended December 31, 2004 and 2003

Consolidated Statements of Cash Flows for the years ended December 31, 2004 and 2003

Notes to Consolidated Financial Statements

Item 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None

Item 8A. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, the company conducted an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")). Based on this evaluation, the principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures are effective to ensure that material information relating to the company was made known to them by others within the company, particularly during the period in which this Annual Report on Form 10-KSB was being prepared.

There was no change in the Company's internal control over financial reporting during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

14

PART III.

Item 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

We have adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. Our Code of Ethics is posted on our website and can be accessed, free of charge, at www.intisoid.com.

The information set forth under the captions "Election of Directors" and "Executive Officers of the Company" of the Company's definitive Proxy Statement for the Company's 2005 Annual Meeting of Shareholders (the "Proxy Statement") is incorporated herein by reference. The Company's Proxy Statement will be filed by the Company with the SEC not later than 120 days after December 31, 2004, the close of our fiscal year.

Item 10. EXECUTIVE COMPENSATION

The information set forth under the captions "Executive Compensation and Other Matters" of the Company's Proxy Statement is incorporated herein by reference. The Company's Proxy Statement will be filed by the Company with the SEC not later than 120 days after December 31, 2004, the close of our fiscal year.

15

Item 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENTAND RELATED STOCKHOLDER MATTERS

The information set forth under the captions "Outstanding Capital Stock and Stock Ownership of Directors, Certain Executive Officers and Principal Shareholders" of the Company's Proxy Statement is incorporated herein by reference. The Company's Proxy Statement will be filed by the Company with the SEC not later than 120 days after December 31, 2004, the close of our fiscal year.

Item 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

The information set forth under the captions "Certain Transactions" of the Company's Proxy Statement is incorporated herein by reference. The Company's Proxy Statement will be filed by the Company with the SEC not later than 120 days after December 31, 2004, the close of our fiscal year.

Item 13. EXHIBITS AND REPORTS ON FORM 8-K

The following documents are filed or incorporated by reference as exhibits to this Report:

3.1      Restated  Articles of  Incorporation  of the Company  (incorporated  by
         Reference  to Exhibit 3.1 to the  Company's  Registration  Statement on
         Form SB-2 filed on May 1, 1997 (Registration No. 333-26269)).

3.2      Articles of Amendment to the Restated  Articles of incorporation of the
         Company  (incorporated  by  reference  to Exhibit 3.2 to the  Company's
         Registration  Statement  on Form  S-8  filed  on  September  12,  2003)
         (Registration No. 333-108776).

3.3      Bylaws of the Company  (incorporated by reference to Exhibit 3.2 to the
         Company's  Registration  Statement  on Form  SB-2  filed on May 1, 1997
         (Registration No. 333-26269)).

4.1      International   Isotopes   Subscription   Rights  Agreement  and  Proxy
         Statement

10.1     * 2002 Long Term Incentive Plan  (incorporated  by reference to Exhibit
         10.1 to the  Company's  Annual  Report on Form 10KSB for the year ended
         December 31, 2002

10.2     Form of Incentive Stock Option Agreement

10.3     Series A and B  Warrant  Agreement  and Form of  Series A and B Warrant
         (incorporated by reference to the Company's  Registration  Statement on
         Form S-3 filed on June 18,2003 (Registration No. 333-106215)

10.4     *International Isotopes Employee Stock Purchase Plan

10.5     *International Isotopes Employment Agreement with Steve T. Laflin

10.6     Lease Agreement 4137 Commerce Circle

10.7     Option to Purchase and Right of First  Refusal for Property  located at
         4137 Commerce Circle

10.8     Lease Agreement 3159 Commerce Way

10.9     Option to Purchase and Right of First  Refusal for Property  located at
         3159 Commerce Way

10.10    Promissory Note with Texas State Bank for $250,000 Line of Credit

10.11    Promissory Note with Texas State Bank for Commercial Loan

10.12    Unsecured Note to former Chairman of the Board, Dated April 1, 2002

10.13    Form of Note  Purchase  Agreement  and  Form of  Unsecured  Convertible
         Promissory Notes

16

21.      International  Isotopes  Idaho  Inc.  is  the  sole  subsidiary  of the
         Company.

23.      Power of Attorney (included as part of signature page).

31.1     Certification  under section 302 of the  Sarbanes-Oxley Act of 2002 for
         Chief Executive Officer.

31.2     Certification  under section 302 of the  Sarbanes-Oxley Act of 2002 for
         Chief Financial Officer.

32.1     Certification under section 906 of the Sarbanes-Oxley Act of 2002.

*This exhibit constitutes a management contract or compensatory plan or arrangement.

Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Hansen, Barnett & Maxwell served as our independent accountants for the years ended December 31, 2004, and 2003, and is expected to serve in that capacity for the current year. Principal accounting fees for professional services rendered for us by Hansen, Barnett & Maxwell for the years ended December 31, 2004 and 2003 are summarized as follows:

                            2004           2003
                           -------        -------
Audit Fees                 $56,939        $65,496
Audit Related Fees              $0             $0
Tax Fees                        $0             $0
All Other Fees                  $0             $0
                           -------        -------
Total                      $56,939        $65,496

Audit Committee Pre-Approval Policies and Procedures. At its regularly scheduled and special meetings, the Audit Committee of the Board of Directors, which is comprised of independent directors knowledgeable about financial reporting, considers and pre-approves all audit and non-audit services to be performed by the company's independent accountants. The Audit Committee has the authority to grant pre-approvals of non-audit services. All Audit, Audit-Related, Tax and Other Fees in 2003 and 2004 were approved by the Audit Committee.

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS that each of International Isotopes Inc., a Texas corporation, and the undersigned directors and officer of International Isotopes Inc. hereby constitutes and appoints Steve Laflin its, or his, true and lawful attorney-in-fact and agent, for it or him and in its or his name, place and stead, in any and all capacities, with full power to act alone, to sign any and all amendments to this report, and to file each such amendment to the Report, with all exhibits thereto, and any and all other documents in connection therewith, with the Securities and Exchange Commission, hereby granting unto said attorney in-fact and agent full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as it or he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

17

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

International Isotopes Inc.

By: /S/ Steve T. Laflin
    ------------------------------
    Steve T. Laflin
    President, Chief Executive Officer
    and Chief Financial Officer

SIGNATURES

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

March 30, 2005                           By:  /s/ Dr. Ralph Richart
                                              ----------------------------
                                              Dr. Ralph Richart
                                              Chairman of the Board of Directors


March  30, 2005                          By:  /s/ Steve T. Laflin
                                              ----------------------------
                                              Steve T. Laflin
                                              President, Chief Executive Officer
                                              (Principal Executive Officer),
                                              Chief Financial Officer (Principal
                                              Accounting Officer) and Director


March 30, 2005                           By:  /s/ Christopher Grosso
                                              ----------------------------
                                              Christopher Grosso
                                              Director, Audit Committee Chairman

18

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

FINANCIAL STATEMENTS

TABLE OF CONTENTS

                                                                       Page No.

Report of Independent Registered Public Accounting Firm...............    20

FINANCIAL STATEMENTS

Consolidated Balance Sheets
    as of December 31, 2004 and 2003..................................    21

Consolidated Statements of Operations for the years ended
   December 31, 2004 and 2003.........................................    22

Consolidated Statements of Shareholders' Equity (Deficit) for
   the years ended December 31, 2003 and 2004.........................    23

Consolidated Statements of Cash Flows for the years ended
   December 31, 2004 and 2003.........................................    24

Notes to Consolidated Financial Statements ...........................    26

19

HANSEN, BARNETT & MAXWELL
A Professional Corporation

CERTIFIED PUBLIC ACCOUNTANTS
5 Triad Center, Suite 750
Salt Lake City, UT 84180-1128
Phone: (801) 532-2200
Fax: (801) 532-7944
www.hbmcpas.com

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTING FIRM

To the Board of Directors and the Shareholders International Isotopes Inc

We have audited the accompanying consolidated balance sheets of International Isotopes Inc and subsidiaries as of December 31, 2004 and 2003, and the related consolidated statements of operations, shareholders' equity (deficit), and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of International Isotopes Inc and subsidiaries as of December 31, 2004 and 2003, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

HANSEN, BARNETT & MAXWELL

Salt Lake City, Utah
February 11, 2005

20

                  INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
                           Consolidated Balance Sheets


                                                                           December 31,
                                                                  -----------------------------
                      Assets                                          2004             2003
 ------------------------------------------------------           ------------     ------------
Current assets:
    Cash and cash equivalents                                     $    150,051     $    160,216
    Accounts receivable                                                432,750          203,152
    Inventories (Note 3)                                             2,237,421        2,283,752
    Prepaids and other current assets                                   91,520          190,979
                                                                  ------------     ------------
      Total current assets                                           2,911,742        2,838,099

Long-term assets
    Restricted certificate of deposit                                  152,728          150,573
    Property, plant and equipment, net (Note 4)                      1,123,226          617,287
    Capitalized lease disposal costs, net of accumulated
      amortization of $47,472 & $35,604 respectivly (Note11)           101,860          113,728
    Patents, net of accumulated amortization                            98,433             --
                                                                  ------------     ------------
      Total long-term assets                                         1,476,247          881,588
                                                                  ------------     ------------
      Total assets                                                $  4,387,989     $  3,719,687
                                                                  ============     ============


          Liabilities and Stockholders' Equity
 ------------------------------------------------------
Current liabilities
    Accounts payable                                              $    328,589     $    320,554
    Accrued liabilities                                                226,338          150,475
    Current installments of mortgage and notes
      payable (Note 6)                                               1,520,570          756,725
                                                                  ------------     ------------
      Total current liabilities                                      2,075,497        1,227,754

Long-term liabilities
    Obligation for lease disposal costs (Note 11)                      149,332          149,332
    Mortgage and notes payable, excluding current
      installments (Note 6)                                            761,775          898,664
    Mandatorily redeemable preferred stock, $0.01 par value;
      850 shares (Note 7)                                             (850,000          850,000
                                                                  ------------     ------------
      Total long-term liabilities                                    1,761,107        1,897,996
                                                                  ------------     ------------
      Total liabilities                                              3,836,604        3,125,750

Stockholders' equity (Note 7)
    Common stock, $0.01 par value; 250,000,000 shares
      authorized; 159,077,940 issued                                 1,590,779        1,393,630
    Additional paid-in capital                                      87,773,992       87,168,957
    Accumulated deficit                                            (88,813,386)     (87,968,650)
                                                                  ------------     ------------
      Total stockholders' equity                                       551,381          593,937
                                                                  ------------     ------------
      Total liabilities and stockholders' equity                  $  4,387,989     $  3,719,687
                                                                  ============     ============

See accompanying notes to consolidated financial statements.

21

                  INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
                      Consolidated Statements of Operations

                                                          Years ended December 31,
                                                       -------------------------------
                                                           2004              2003
                                                       -------------     -------------
 Sales of product                                      $   2,848,844     $   2,070,592

 Cost of products                                          1,719,251         1,151,161
                                                       -------------     -------------
     Gross profit                                          1,129,592           919,431
                                                       -------------     -------------

 Operating costs and expenses:
   Salaries and contract labor                               720,383           495,724
   General, administrative and consulting                  1,058,812         1,029,602
   Research and development                                   49,098            57,186
                                                       -------------     -------------
     Total operating expenses                              1,828,293         1,582,512
                                                       -------------     -------------

     Operating loss                                         (698,701)         (663,081)
                                                       -------------     -------------

Other income (expense):
   Other income                                               10,476            35,996
   Gain from sale of fully impaired assets                      --             212,200
   Interest income                                             2,323             3,626
   Interest expense                                         (158,834)         (143,490)
                                                       -------------     -------------
     Total other income (expense)                           (146,035)          108,332
                                                       -------------     -------------

   Loss before cumulative effect of change
     in accounting principle                           $    (844,736)    $    (554,749)

Cumulative effect of change in accounting principle             --             (23,736)
                                                       -------------     -------------

Net loss                                               $    (844,736)    $    (578,485)
                                                       =============     =============

Net loss per common share - basic and diluted:
   Loss before culumative effect of change
     in accounting principle                           $       (0.01)    $       (0.01)
   Net loss                                            $       (0.01)    $       (0.01)
                                                       =============     =============

Weighted average common shares outstanding -
   basic and diluted                                     150,721,137       108,346,738
                                                       =============     =============

See accompanying notes to consolidated financial statements.

22

                   INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES
            Consolidated Statement of Stockholders' Equity (Deficit)
                     Years ended December 31, 2004 and 2003

                                                                                                                  Total
                                                         Common Stock             Additional                    Stockholders'
                                                  ---------------------------      Paid-in      Accumulated       Equity/
                                                    Shares          Amount         Capital        Deficit        (Deficit)
                                                  -----------    ------------    ------------   ------------    ------------
Balance January 1, 2003                            95,581,135    $    955,812    $ 86,416,002   $(87,390,165)   $    (18,351)

Cancelation of 8,242 shares of common
  stock as part of a licensing agreement               (8,242)            (82)             82           --              --
Common stock issued as part of rights
  offering net of offering costs of $122,906       43,790,153         437,900         752,873           --         1,190,773

Net loss                                                 --              --              --         (578,485)       (578,485)
                                                  -----------    ------------    ------------   ------------    ------------
Balance December 31, 2003                         139,363,046       1,393,630      87,168,957    (87,968,650)        593,937

Exercise of 19,714,894 Series A and B warrants     19,714,894         197,149         604,885           --           802,034

Net loss                                                 --              --              --         (844,736)       (844,736)
                                                  -----------    ------------    ------------   ------------    ------------
Balance December 31, 2004                         159,077,940    $  1,590,779    $ 87,773,992   $(88,813,386)   $    551,385
                                                  ===========    ============    ============   ============    ============

See accompanying notes to consolidated financial statements.

23

                  INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
                      Consolidated Statements of Cash Flows

                                                                  Years ended December 31,
                                                                 --------------------------
                                                                    2004           2003
                                                                 -----------    -----------
Cash flows from operating activities:
   Net loss                                                      $  (844,736)   $  (578,485)
   Adjustments to reconcile net loss to net cash used in
   operating activities
    Depreciation and amortization                                    179,364        112,753
    Gain from sale of assets fully impaired                             --         (212,200)
    Loss on disposal of property, plant and equipment                    381           --
    Cumulative effect of change in accounting principle                 --           23,736
    Changes in operating assets and liabilities:
       Accrued interest on restricted certificate of deposit          (2,155)        (3,415)
       Accounts receivable                                          (229,597)        15,771
       Prepaids and other current assets                              99,459        (62,149)
       Inventories                                                    46,331         (3,924)
       Accounts payable and accrued liabilities                      129,948        (81,011)
                                                                 -----------    -----------
         Net cash used in operating activities                      (621,005)      (788,924)
                                                                 -----------    -----------

Cash flows from investing activities:
   Purchase of patents                                              (109,000)          --
   Purchase of property, plant and equipment                        (663,250)      (392,460)
   Proceeds from assets held for sale                                   --          474,436
                                                                 -----------    -----------
         Net cash (used in) provided by investing activites         (772,250)        81,976
                                                                 -----------    -----------

Cash flows from financing activities:
   Proceeds from exercise of warrants                                802,184           --
   Proceeds from issuance of common stock                               --          406,868
   Payments for offering costs                                          --         (122,906)
   Proceeds from issuance of debt                                    603,950        760,000
   Principal payments on notes payable                               (23,044)      (471,544)
                                                                 -----------    -----------
         Net cash provided by financing activities                 1,383,090        572,418
                                                                 -----------    -----------

Net change in cash and cash equivalents                              (10,165)      (134,530)
Cash and cash equivalents at beginning of year                       160,216        294,746
                                                                 -----------    -----------
Cash and cash equivalents at end of year                         $   150,051    $   160,216
                                                                 ===========    ===========

(Continued)

24

                  INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
                      Consolidated Statements of Cash Flows

                                    Continued

                                                                  Years ended December 31,
                                                                 --------------------------
                                                                    2004           2003
                                                                 -----------    -----------
Supplemental disclosure of cash flow activities:
   Cash paid for interest                                        $    75,092    $   113,462
                                                                 ===========    ===========

Supplemental disclosure of noncash financing and
  investing transactions:

   Note payable converted from interest payable                  $    46,050    $      --

   Renewal/renogiation of note payable                               733,595           --

   Acquisition of equipment for note payable                            --           89,660

   Sale of assets held for sale through assumption of debt              --          345,295

   Conversion of debt and accrued interest to rights offering           --          906,811

See accompanying notes to consolidated financial statements.

25

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

NOTE 1 - DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

Description of Business

International Isotopes Inc (the Company) was incorporated in Texas in November 1995. The Company owns 100% of the outstanding common shares of International Isotopes Idaho, Inc.

Nature of Operations -The Company's business consists of five major business segments which include: Nuclear Medicine Reference and Calibration Standards, Cobalt Products, Radiochemical Products, Fluorine Extraction Process Products, and Radiological Processing Services.

With the exception of certain unique products, the Company's normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company's operating cycle for those products is considered to be three years. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets. As of December 31, 2004, the Company had sixteen full time employees.

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary International Isotopes Idaho, Inc. All significant intercompany accounts and transactions have been eliminated in consolidation.

Significant Accounting Policies

(a) Financial Instruments and Cash Equivalents

The carrying value of notes payable approximates fair value because they bear interest at rates which approximate market rates.

Cash, cash equivalents, and a restricted certificate of deposit totaling $302,779 and $310,789 at December 31, 2004 and 2003, respectively, consist of operating accounts, money market accounts and a certificate of deposit. For purposes of the consolidated statements of cash flows, the Company considers all highly-liquid financial instruments with original maturities of three months or less at date of purchase to be cash equivalents.

At December 31, 2004 the Company has pledged a certificate of deposit as security on a letter of credit. The letter of credit is required as part of the licensing agreement with the Nuclear Regulatory Commission ("NRC"). Among other things, the licensing agreement calls for a letter of credit to provide a level of financial assurance to maintain licensing with the NRC. Accordingly, withdrawal of the certificate is restricted over the remaining life of the license.

At December 31, 2004, the Company had $152,606 of cash deposits in excess of federally insured limits.

26

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

(b) Property, Plant and Equipment

Depreciation on property, plant and equipment is computed using the straight-line method over the estimated useful life of the asset. The ranges of estimated useful lives are as follows:

                           Years
Furniture & fixtures        3-5
Plant and improvements       5
Production equipment        5-10

Depreciation and amortization expense was $179,364 and $112,753 for the years ended December 31, 2004 and 2003, respectively.

(c) Inventories

Inventories are carried at the lower of cost or market. Cost is determined using the first in, first out method. Work in progress inventory contains product that is undergoing irradiation. This irradiation process can take up to three years to reach high specific activity (HSA) levels.

(d) Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date.

(e) Use of Estimates

Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period to prepare these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. Actual results could differ from those estimates.

(f) Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed Of

Long-lived assets are reviewed for impairment yearly. Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Based on the evaluation, no impairment was considered necessary during the years ended December 31, 2004 or 2003.

27

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

(g) Cumulative Effect of Change in Accounting Principle

The Company adopted SFAS No. 143, Accounting for Asset Retirement Obligations, on January 1, 2003. In accordance with the transition provisions of SFAS No. 143, on that date the Company recorded asset retirement costs and liabilities and recorded an adjustment for the cumulative effect on prior years of adopting SFAS No. 143 in the amount of $23,736 as a reduction in earnings, which had no effect on basic or diluted income per common share.

(h) Revenue Recognition

Revenue is recognized when products are shipped. No warranty coverage or right of return provisions are provided to customers.

Sales to one major customer accounted for 49% and 60% of the sales during 2004 and 2003 respectively.

(i) Research and Development Costs

The Company had research and development expenses totaling $49,098 in 2004 and $57,186 in 2003. These expenses were associated with initial development of the processing opportunities for new radiochemical products and for development work associated with the addition of several new products in the nuclear medicine reference and calibration business including several measurement devices, calibrated vials, and various markers.

(j) Shipping and Handling Costs

The Company expenses all shipping and handling costs incurred. For the years ended December 31, 2004 and 2003, the Company expensed $4,672 and $108,751, respectively of shipping and handling costs. These costs are reported as general, administrative and consulting costs in the statements of operations.

(k) Stock Option Plan

The Company accounts for stock options issued to directors, officers and employees under Accounting Principles Board Opinion No. 25 and related interpretations ("APB 25"). The Company accounts for options and warrants issued to non-employees at their fair value in accordance with SFAS No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123").

28

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

No compensation cost has been recognized for stock options in the accompanying consolidated financial statements. Had the Company determined compensation cost based on the fair value at the grant date for its stock options under SFAS No. 123, the Company's net loss would have been increased to the pro forma amounts indicated below for the years ended December 31, 2004 and 2003:

                                                        2004           2003
                                                    ------------    -----------

Net loss, as reported                               $   (844,736)   $  (578,485)

Deduct:  Total stock-based employee compensation
   expense determined under fair value based
   method for all awards, net of related tax
   effects                                              (174,561)       (95,319)
                                                    ------------    -----------
Pro forma net loss                                  $ (1,019,297)   $  (673,804)
                                                    ============    ===========

Loss per share, basic and diluted:
   As reported                                      $      (0.01)   $     (0.01)
                                                    ============    ===========
   Pro forma                                        $      (0.01)   $     (0.01)
                                                    ============    ===========

(l) Net Loss Per Common Share-Basic and Diluted

Basic loss per share is computed on the basis of the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed on the basis of the weighted-average number of common shares and all dilutive potentially issuable common shares outstanding during the year. Net loss per common share is calculated for both continuing and discontinued operations.

As of December 31, 2003 and 2004, there were 103,580,306 and 85,865,412 options/warrants and 850 and 850 shares of Series B redeemable convertible preferred stock outstanding, respectively, that were not included in the computation of diluted net loss per common share as their effect would have been anti-dilutive, thereby decreasing the net loss per common share.

(m) Recent Accounting Pronouncements

In May 2003 the FASB issued SFAS No. 150, "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity", which requires that certain financial instruments be presented as liabilities that were previously presented as equity or as temporary equity. Such instruments include mandatory redeemable preferred and common stock, and certain options and warrants. The Company adopted the requirements of SFAS 150 on July 1, 2003. This adoption had no effect on reported net loss.

29

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

In December 2004, the FASB issued Statement No. 123 (Revised 2004), Share-Based Payment ("Statement 123(R)"). Statement 123(R) revises Statement No. 123, Accounting for Stock-Based Compensation, and supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees. Statement 123(R) requires the recognition of the cost of employee services received in exchange for stock options and awards of equity instruments based on the grant-date fair value of such options and awards, over the period they vest. Under the options for adoption available under Statement 123(R), the Company has determined to adopt Statement 123(R) on the modified-prospective basis beginning on July 1, 2005, which will result in the recognition of the remaining unamortized grant-date fair value compensation over the remaining vesting period. The effect of adopting Statement 123(R) on options outstanding at December 31, 2004 will result in recognition of $48,688 of additional compensation during the year ending December 31, 2005.

(n) Reclassifications

Certain 2003 amounts have been reclassified to conform to the 2004 presentation. These reclassifications had no effect on the previously reported net loss.

NOTE 2 - BUSINESS CONDITION AND LIQUIDITY

Business Condition - The Company has a history of recurring losses with an accumulated deficit of $88,813,386 at December 31, 2004 and a net loss of $844,736 for the year then ended. The Company's working capital has decreased by $774,100 from the prior year, working capital includes inventory which will not be sold for up to three years, and the Company has used cash flows from operations of $621,005. During 2004, the Company sought to improve future cash flows from operating activities through significant investments into facilities and infrastructure, launching new products and implementing and improving operating cost control measures. The Company has been able to grow the Nuclear Medicine Reference and Calibration Standards segment at an annual rate of approximately 12% per year and anticipates similar growth trends over the coming year.

During March 2005, the Company obtained approval from the Nuclear Regulatory Commission ("NRC") to manufacture a wide range of cobalt irradiator and teletherapy capsules and plans to expand their customer base and increase cobalt revenues through recycling various expended sealed sources and sales of cobalt sealed sources utilizing recycled material or material produced in reactors. During 2005, the Company has also signed contracts for the sale of HSA Cobalt through December 2007 and for the sale of Cobalt sealed source sets. Management believes that this expanded cobalt production capability should increase future revenues.

During 2004, the Company acquired seven patents for the Fluorine Extraction Process (FEP) and began construction of a plant to use this technology to produce several high purity fluorine products, such as germanium tetrafluoride. The Company expects to complete plant construction and begin fluorine gas production during the second quarter of 2005. Based on the market size and growth outlook for high purity fluorine products, management believes this plan and its operations should increase future revenues.

Subsequent to December 31, 2004, certain series A and B warrants were exercised resulting in the issuance of 24,252,059 shares of common stock for proceeds of $970,180.

Management believes these changes to operations and the additional capital received from the exercise of warrants will be sufficient to enable the Company to continue its operations as a going concern; however, there is no assurance that management's plans will be fulfilled or that profitable operations will be obtained.

30

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

NOTE 3 - INVENTORIES

Included in inventory are the various pellet holders and housings involved in target fabrication, raw cobalt, nickel and other raw elements, and completed flood sources and irradiated cobalt. Inventories consisted of the following at December 31, 2004 and 2003:

                            2004           2003
                         ----------     ----------

Raw materials            $  267,850     $  268,265
Work in progress          1,968,177      2,007,066
Finished goods                1,394          8,421
                         ----------     ----------
                         $2,237,421     $2,283,752

Work in progress includes cobalt-60 isotopes that are located in the U.S. federal government's Advanced Test Reactor (ATR) located outside Idaho Falls, Idaho. These isotopes are at various stages of irradiation. Some isotopes are near completion and others may require up to three years to complete. At December 31, 2004 and 2003, these isotopes had a carrying value of $1,764,659 and $1,889,003, respectively.

NOTE 4 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are summarized as follows at December 31, 2004 and 2003:

                                        2004            2003
                                     -----------     -----------
Furniture and fixtures               $    63,062     $    49,931
Plant and improvements                    53,647          48,507
Production equipment                   1,432,235         791,444
                                     -----------     -----------
                                       1,548,944         889,882
Less accumulated depreciation           (425,718)       (272,595)
                                     -----------     -----------
Property, plant & equipment, net     $ 1,123,226     $   617,287
                                     ===========     ===========

31

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

NOTE 5 - PATENTS

During the year ended December 31, 2004, the Company obtained certain patents and patents pending related to a Fluorine Extraction Process and a container to transport radioactive materials. Patents, as of December 31, 2004, are as follows:

                                                  2004
                                                --------
Patents                                         $109,000
Less accumulated amortization                    (10,567)
                                                --------
Patents - net                                   $ 98,433
                                                ========

During the year ended December 31, 2004, the Company recognized $10,567 of amortization expense. Estimated amortization expense of patents for the next five years is as follows:

Years Ending December 31:
2005                                            $ 10,896
2006                                              10,896
2007                                              10,896
2008                                              10,896
2009                                              10,896
Thereafter                                        43,953
                                                --------
Total                                           $ 98,433
                                                ========

NOTE 6 - MORTGAGE AND NOTES PAYABLE

At December 31, 2002, the Company had a note payable to the former chairman of the board in the amount of $909,737. In connection with the rights offering completed in September 2003, $68,985 of principal and $33,500 of accrued interest on this note was converted to common stock. The conversion rate was not beneficial to the holder, based on the market value of the common stock on the conversion date.

During 2004, the Company negotiated a line of credit with a bank. The maximum amount available to borrow is $250,000. The line accrues interest at the bank prime rate plus 1% not to be less than 7.5%. The line comes due in July 2005 and is secured by equipment, accounts receivable and inventory. As of December 31, 2004, the Company had not drawn any funds against this line of credit.

32

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

Mortgage and notes payable as of December 31, 2004 and 2003, consist of the following:

                                                          2004          2003
                                                      -----------   -----------
Unsecured note payable to certain directors
and shareholders, accrues interest at 6%,
convertible to common stock at the option
of the creditor, due December 31, 2005.
Convertible at $0.18 per share, which was
the market value on the date of the grant.            $   650,000   $         -

Note payable to a finance company accrues
interest at 8.7% due in monthly installments
of $1,488; secured by equipment; due in 2008.              57,997        69,161

Note payable to a company, accrues interest at
0%; payable in quarterly installments of
$2,970; secured by equipment; due in 2005.                      -        11,880

Promissory note to a bank, bearing interest at
7.5% through July 2005 then at prime plus 1%
due monthly; secured by equipment, accounts
receivable and inventory; due February 2006.              733,595       733,595

Note payable to the former chairman of the
board, interest accrues at 7%; payable annually
on April 1; principal payments are due annually
on April 1 consisting of 30% of prior year net
income, with remaining balance due April 2012;
secured.                                                  840,753       840,753
                                                      -----------   -----------
Total mortage and notes payable                         2,282,345     1,655,389
Less: current maturities                               (1,520,570)     (756,725)
                                                      -----------   -----------
Mortgage and notes payable, excluding current
installments                                          $   761,775   $   898,664
                                                      ===========   ===========

The aggregate annual maturities of mortgage and notes payable as of December 31, 2004 for the next five years are as follows:

Years Ending December 31:
_________________________
2005                                                  $ 1,520,570
2006                                                      731,623
2007                                                       15,849
2008                                                       14,303
                                                                -
                                                      -----------
                                                      $ 2,282,345
                                                      ===========

NOTE 7 - SHAREHOLDERS' EQUITY, REDEEMABLE CONVERTIBLE PREFERRED STOCK, OPTIONS AND WARRANTS

Stock Rights Offering

On August 12, 2003, the Company completed a rights offering to its common shareholders. Under the terms of the offering, the Company issued one right for each 2.5 common shares outstanding and, in addition, common shareholders who fully subscribed were collectively issued 14,500,000 additional rights. Each right issued was exercisable at $0.03 in exchange for the issuance of one common share, a Series A warrant to purchase one common share at $0.04 and a Series B warrant to purchase one common share at $0.05. Common shareholders exercised 43,790,153 Rights in exchange for cash proceeds totaling $406,868 and through the conversion of $906,810 of notes payable and accrued interest, before $122,906 of offering costs. The warrants are exercisable through July 2007.

33

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

During 2004 there were 18,356,024 Series A warrants, and 1,358,870 Series B warrants, issued from the 2003 rights offering that were exercised by shareholders for common stock generating $802,184 and resulted in the Company issuing an additional 19,714,894 shares of common stock. The Series A warrant agreement contained a provision allowing the Company to redeem the Series A warrants at any time, provided the average closing price of the Company's common stock equaled, or exceeded, $0.12 for 30 consecutive trading days. The Company stock met this requirement and in January 2005, the Company announced that the Series A warrants would be redeemed on February 25, 2005 at a redemption price of $0.001 per warrant. Prior to the redemption date of February 25, 2005, 24,242,259 of Series A warrants were exercised for cash proceeds of $969,690. On February 25, 2005 the Company redeemed the remaining 1,191,870 Series A warrants for $1,192.

Subsequent to December 31, 2004, 9,800 Series B warrants were exercised for cash proceeds of $490.

Redeemable Convertible Preferred Stock

The Company is authorized to issue up to 5,000,000 shares of Preferred Stock, par value $0.01 per share. The Board of Directors is authorized to set the distinguishing characteristics of each series prior to issuance, including the granting of limited or full voting rights, rights to the payment of dividends and amounts payable in event of liquidation, dissolution or winding up of the Company.

At December 31, 2004, there were 850 shares of the Series B Preferred Stock outstanding with a mandatory redemption date of May 2022. The Company adopted SFAS 150 at July 1, 2003, that required the Company to reclassify its 850 shares of mandatorily redeemable preferred stock with a redemption value and carrying amount of $850,000 from temporary equity to long-term liabilities. The adoption of this standard had no effect on net loss.

Employee Stock Purchase Plan

On September 30, 2004, the Company's Board of Directors approved an employee stock purchase plan for an aggregate of up to 2,000,000 shares of the Company's common stock. The plan allows employees to deduct up to 15% of their payroll each pay period to be used for the purchase of common stock at a discounted rate. The common shares will be purchased at the end of each three month offering period or other period as determined by the Board. The Plan is intended to qualify as an "employee stock purchase plan" under Section 423 of the Internal Revenue Code. Employees began making payroll deductions in January 2005. The plan is subject to shareholder approval at the next annual shareholder meeting.

Stock Option Plan

In January 1997, the Company adopted a Stock Incentive Plan (the Plan) pursuant to which the Company's Board of Directors may grant stock options to officers, key employees, and consultants. The Plan was amended in 2000 to authorize grants of options to purchase up to 1,000,000 shares of authorized but unissued common stock. Stock options are granted with an exercise price of not less than 85% of the reported market value of the common stock at the date of grant. Effective March 2002, the Company amended and restated the 2000 Stock Incentive Plan. The 2002 Long-Term Incentive Plan (the Plan) authorizes grants of options to purchase up to 20,000,000 shares of common stock. The maximum number of options that can be granted to each employee in one year is 10,000,000.

34

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

In February 2002, the Company granted an additional 13,000,000 options to key employees to purchase shares of common stock with an exercise price of $0.02 per share, which was equal to the closing market price of the common stock on the date of grant. These options were fully vested as of February 2005. In June 2003, the Company granted 2,000,000 options to certain directors to purchase shares of common stock with an exercise price of $0.03 per share, which was equal to the closing market price of the common stock on the date of grant. During 2004 the Company granted 1,500,000 options to purchase common stock with an exercise price of $0.17 and 500,000 options to purchase shares of common stock at an exercise price of $0.12 which was equal to the closing market price of the common stock on the grant dates.

A summary of the stock options issued under the Company's Plan is as follows:

                                                     Weighted-Average
Fixed Options                           Shares        Exercise Price
---------------------------------------------------------------------
Outstanding at January 1, 2003         14,000,000       $      0.02
Granted                                 2,000,000       $      0.03
                                     ------------       -----------
Outstanding at December 31, 2003       16,000,000       $      0.03
Granted                                 2,000,000       $      0.16
                                     ------------       -----------
Outstanding at December 31, 2004       18,000,000       $      0.04
                                     ============       ===========

Exercisable at December 31, 2003        8,000,000       $      0.03
                                     ============       ===========

Exercisable at December 31, 2004       12,250,000       $      0.03
                                     ============       ===========

The following table summarizes information about fixed stock options under the Plan outstanding at December 31, 2004:

                 Options           Weighted-         Weighted          Number          Weighted-
 Range of     Outstanding at        Average          Average       Exerciseable at      Average
 Exercise      December 31,        Remaining         Exercise        December 31,      Exercise
  Prices           2004         Contractual Life      Price              2004           Price
-------------------------------------------------------------------------------------------------

 .02-.03        15,000,000            7.33            $ 0.02          10,750,000         $ 0.02
   0.08          1,000,000            6.31            $ 0.08           1,000,000         $ 0.08
   0.12            500,000            9.85            $ 0.12             125,000         $ 0.12
   0.17          1,500,000            9.59            $ 0.17             375,000         $ 0.17

35

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

                                      2004          2003
                                    --------      --------
Expected dividend yield                   -             -
Risk-free interest rate                 4.4%          3.4%
Expected volatility                     150%          159%
Expected life                       10 years      10 years
Weighted average fair value
  per share                            $0.16         $0.03

Warrants

The following summarizes warrant activity for the years ended December 31, 2004 and 2003:

                                                     Weighted-Average
                                                         Exercise
     Fixed Warrants                      Shares           Price
----------------------------------------------------------------------
Outstanding at January 1, 2003          3,027,326      $      4.26
Granted                                87,580,306             0.05
Expired                                (3,027,326)            4.26
                                      -----------      -----------
Outstanding at December 31, 2003       87,580,306             0.05
Exercised                             (19,714,894)            0.04
                                      -----------      -----------
Outstanding at December 31, 2004       67,865,412      $      0.05
                                      ===========      ===========

The following table summarizes information about warrant outstanding at December 31, 2004:

Outstanding and Exerciseable at December 31, 2004

                                      Weighted Average
                                         Remaining
Exercise Prices        Warrants       Contractual Life
----------------------------------------------------------
$0.04                   25,434,129          2.58
$0.05                   42,431,283          2.58
                      ------------
                        67,865,412
                      ============

36

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

NOTE 8 - INCOME TAXES

The Company paid no federal or state income taxes during 2004 or 2003. Income tax expense on loss before cumulative effect of change in accounting principle differed from the amounts computed by applying the U.S. federal income tax rate of 34% to pretax losses as a result of the following:

                                         2004            2003
                                      ----------      ----------
Income tax benefit                    $ (287,210)     $ (188,615)
Nondeductible expenses                       409              38
State taxes net of federal benefit       (44,100)        (28,961)
Change in valuation allowance            330,901         217,538
                                      ----------      ----------
Total income tax expense              $        -      $        -
                                      ==========      ==========

The tax effects of temporary differences that give rise to significant portions of the Company's deferred tax assets (liabilities) as of December 31, 2004 and 2003 are presented below:

                                            2004            2003
                                         -----------     -----------
Deferred income tax asset
  Net operating loss carryforward        $ 1,397,335     $ 1,050,377
                                                   -               -
                                         -----------     -----------
Total deferred income tax asset            1,397,335       1,050,377
Deferred income tax liability -
  depreciation                               (35,084)         (9,718)
Valuation allowance                       (1,362,251)     (1,040,659)
                                         -----------     -----------
Deferred tax asset (liability)           $         -     $         -
                                         ===========     ===========

At December 31, 2004 the Company had net operating losses of $3,562,759 that will begin to expire in 2023. The valuation allowances for 2004 and 2003 have been applied to offset the deferred tax assets in recognition of the uncertainty that such benefits will be realized.

The Internal Revenue Code contains provisions which reduce or limit the availability and utilization of net operating loss carryforwards in the event of a more than 50% change in ownership. If such an ownership change occurs with the Company, the use of these net operating losses could be limited.

NOTE 9 - COMMITMENTS AND CONTINGENCIES

Litigation

During February 2004, a lawsuit was filed by Iso-Science Laboratories, Inc. in the Superior Court of the State of California for the County of Los Angeles against the Company, its President and CEO, one of its customers and certain officers of this customer. The lawsuit contains numerous allegations against the defendants relating to the manufacture and sale of calibration and reference standards for nuclear medicine. The lawsuit alleges the defendants are using information and equipment that the plaintiff acquired from a previous employer of one of the defendants. The lawsuit also alleges unfair trade practices, interference with prospective business relationships, and conspiracy. The plaintiff seeks (i) an injunction to restrain the Company from manufacturing, marketing, or selling any of the products in question;
(ii) a 55% royalty on the price of all related products the Company sells; (iii) the return of all equipment and information in question;
(iv) disgorgement of profits received from the manufacture and sale of the products in question; and (v) general and punitive damages in an amount to be shown at the time of trial. In March 2004, the Company filed a response to the lawsuit in which the Company denied all of the allegations. In addition, the Company has filed a counterclaim against the plaintiff on the basis that the plaintiff filed the suit against the Company and our President and CEO with the knowledge that the plaintiff had no basis in law or fact and that the lawsuit was calculated to interfere with our contractual arrangements and prospective business with our customers.

37

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

On July 29, 2004 the court granted our motion to dismiss all charges against our President and CEO. On October 25, 2004 the court established an anticipated trial start date of December 5, 2005. The Company will continue to vigorously defend against this lawsuit; however, the likelihood of an unfavorable outcome is not determinable at this time. Should this lawsuit be settled in a manner unfavorable to the Company, the Company could lose our major line of revenues and could be required to make substantial payments to the plaintiff. The Company has a manufacturing agreement in place with our customer and co-defendant pursuant to which the customer will indemnify us and our officers from any loss arising from this lawsuit. Therefore, the Company does not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations, or cash flow in the future. However, there is no guarantee that our customer can bear the financial burden arising from defending and possible settlement of this lawsuit.

Lease Commitments

The Company leases office space, certain office equipment and production equipment under operating leases expiring at various dates through 2009. Rental expense under such leases for the years ended December 31, 2004 and 2003 was $143,922 and $82,242 respectively.

Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) as of December 31, 2004 are:

                                               Operating
Years ending December 31                        Leases
                                               ---------
2005                                             143,719
2006                                             138,744
2007                                             138,744
2008                                             102,484
2009                                               4,310
                                               ---------
Total minimum lease payments                   $ 528,001
                                               =========

Employment Contract

The Company has a five-year employment contract with the Company's president. The employment agreement extends through February 2007.

Dependence on Third Parties

The production of HSA Cobalt is dependent upon the U.S. Department of Energy, and its prime operating contractor, who controls the reactor and laboratory operations. The revenue associated with the sale of HSA Cobalt is largely dependent on the Company's sole customer for this product. Nuclear Medicine Reference and Calibration Standard manufacturing is conducted under an exclusive contract with RadQual,
LLC. who in turn has an agreement in place with several companies for distributing the product. A loss of either of these customers could adversely affect operating results by causing a delay in production or a possible loss of sales.

38

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

Contingencies

Because all of the Company's business segments involve radioactive materials the Company is required to have an operating license from the Nuclear Regulatory Commission ("NRC") and specially trained staff to handle these materials. The Company has an NRC operating license and has amended this license several times a year to increase the amount of material permitted within the facility. Additional processing capabilities and license amendments could be implemented that would permit processing of other reactor produced radioisotopes by the Company but this license does not currently restrict the volume of business operation performed or projected to be performed in the coming year. An irrevocable, automatic renewable letter of credit against a Certificate of Deposit at Texas State Bank has been used to provide the financial assurance required by the NRC for the Idaho facility license.

NOTE 10 - SALE OF ASSETS

Sale of Waxahachie Real Estate

In January 2003, the Company entered into an agreement to sell real estate in Waxahachie ,Texas for the assumption of $345,295 of debt associated with the property. The Company remains contingently liable to Texas State Bank for the debt on the real estate for the remainder of the term of the debt and could become liable should the purchaser default on the note.

In accordance with FASB No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, the Company has recognized a $10,000 obligation under the guarantee that consists of the obligation to stand ready to reassume the note held at Texas State Bank in the event the purchaser defaults on the note. The obligation is based on the cost necessary for the purchaser to refinance the note, which would release Company from the guarantor position. Should the purchaser default on the note and the Company reassumes the liability, the Company would also regain the real estate.

NOTE 11 - ASSET RETIREMENT OBLIGATION

Effective January 1, 2003, the Company adopted SFAS No. 143, Accounting for Asset Retirement Obligations, which requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. The standard applies to legal obligations associated with the retirement of long-lived assets that result from the acquisition, construction, development or normal use of the asset. The Company's asset retirement obligations relate primarily to the decommissioning of the manufacturing facility at the conclusion of operations in that facility.

SFAS No. 143 requires that the fair value of a liability for an asset retirement obligation be recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. When the liability is initially recorded, the related cost is capitalized by increasing the carrying amount of the related asset, in the case of a leased facility the cost is capitalized as capitalized lease disposal costs. Over time, the liability is accreted upward for the change in its present value each period until the obligation is settled.

39

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

The following summarizes the asset retirement obligation activity for the years ended December 31, 2004 and 2003:

Balance January 1, 2003                       $ 149,332
 Accretion expense                               11,947
 Revision to cashflow estimates                 (11,947)
                                              ---------
Balance December 31, 2003                       149,332
 Accretion expense                               11,947
 Revision to cashflow estimates                 (11,947)
                                              ---------
Balance December 31, 2004                     $ 149,332
                                              =========

NOTE 12 - SEGMENTS INFORMATION

The Company has five reportable segments which include: Nuclear Medicine Reference and Calibration Standards, Cobalt Products, Radiochemical Products, Fluorine Extraction Process and Radiological Processing Services. Each of these segments is briefly described in the following paragraphs:

o Nuclear Medicine Reference and Calibration Standards segment consists of manufacture of sources and standards associated with SPECT imaging, patient positioning, and calibration or operational testing of dose measuring equipment for nuclear pharmacy.

o Cobalt Products segment includes the production of high and medium specific activity bulk cobalt, recycling expended cobalt sources, and fabrication of a wide array of cobalt teletherapy and experimental irradiator source capsules.

o Radiochemical Products segment includes production of various isotopically pure radiochemical for medical, industrial, or research applications. These products are either directly produced by the company or are purchased in bulk from other producers and distributed by the Company in customized packages and chemical forms tailored to customer and market demands.

o Fluorine Extraction Process (FEP) segment concerns the production of high purity fluorine gas compounds (such as germanium tetrafluioride) for the electronics and silicon chip manufacturing industry. The Company has acquired all patent rights to this process and is in the process of constructing/licensing a separate FEP production facility.

o Radiological Processing Services segment concerns a wide array of miscellaneous services such as processing of gemstone which has undergone irradiation for color enhancement, radiological engineering consultant services, Type A package certification testing, and waste packaging/recycle services.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before other income or expense.

40

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

The Company's reportable segments are strategic revenue sources that offer different products and services. They are managed separately because each segment requires different technology and marketing strategies.

                                                                Radio-        Fluorine
                                 Reference        Cobalt       chemical      Extraction     Radiological       Total
December 31, 2004                Standards      Production     Products       Process         Services        Segments
--------------------------       ----------     ----------     ---------     ----------     ------------     ----------

Revenues                         $1,377,281     $  923,262     $ 387,983     $        -     $    160,317     $2,848,843
Depreciation and amortization        35,984         16,726        48,427         12,199           29,096        142,432
Segment profit                      560,002        387,471      (284,752)      (226,549)         (13,379)       422,793
Segment assets                      687,267      2,509,904       543,576        263,967          167,391      4,172,105
Expenditures for segment assets       4,867        398,042        76,928        263,967                -        743,804


                                                                Radio-        Fluorine
                                 Reference        Cobalt       chemical      Extraction     Radiological       Total
December 31, 2003                Standards      Production     Products       Process         Services        Segments
--------------------------       ----------     ----------     ---------     ----------     ------------     ----------

Revenues                         $1,201,833     $  377,309     $ 145,763     $        -     $    345,687     $2,070,592
Depreciation and amortization        33,769          8,910         6,527              -           30,174         79,380
Segment profit (loss)               396,233        118,946      (217,807)             -          106,460        403,832
Segment assets                      467,963      2,183,791       426,510              -          168,497      3,246,761
Expenditures for segment assets      12,737         17,523       409,727              -                -        439,987

                                  Segment       Corporate         Total
December 31, 2004                  Totals        Amounts       Consolidated
--------------------------       ----------     ----------     ------------

Revenues                         $2,848,843     $        -     $  2,848,843
Depreciation and amortization       142,432         36,932          179,364
Net profit (loss)                   422,793     (1,267,529)        (844,736)
Total assets                      4,172,105        215,884        4,387,989
Expenditures for assets             743,804         28,446          772,250


                                  Segment       Corporate         Total
December 31, 2003                  Totals        Amounts       Consolidated
--------------------------       ----------     ----------     ------------

Revenues                         $2,070,592     $        -     $  2,070,592
Depreciation and amortization        79,380         33,373          112,753
Net loss                            403,832       (982,317)        (578,485)
Total assets                      3,246,761        472,926        3,719,687
Expenditures for assets             439,987         39,744          479,731

41

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Notes to Consolidated Financial Statements December 31, 2004 and 2003

NOTE 13 - SUBSEQUENT EVENTS

As discussed in Note 7, subsequent to year end 25,434,129 Series A warrants and 9,800 Series B warrants were exercised or redeemed for cash proceeds of $970,180.

In March 2005, the Company entered into two new multi-year agreements with customers for various cobalt products and services.

42

As filed with the Securities and Exchange Commission on July 24, 2003

Registration No. 333-106215

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.


AMENDMENT NO. 1
to
FORM S-3

Registration Statement
Under The
Securities Act of 1933


INTERNATIONAL ISOTOPES INC.
(Name of Small Business Issuer in its Charter)

Texas 2835 74-276837

(State or other Jurisdiction of (Primary Standard Industrial (I.R.S. Employer Incorporation or Organization) Classification Code Number) Identification Number)

4137 Commerce Circle Idaho Falls, Idaho 83401
(Address and Telephone Number of Principal Executive Offices and Principal Place of Business)

Steve T. Laflin 4137 Commerce Circle Idaho Falls, Idaho 83401 (208) 524-5300


(Name, Address and Telephone Number of Agent for Service)

Copy to:
Curtis R. Ashmos
Locke Liddell & Sapp LLP
100 Congress, Suite 300
Austin, Texas 78701
(512) 305-4716

Approximate Date of Proposed Sale to the Public:
From time to time after this Registration Statement becomes effective.

If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, check the following box. ||

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. |X|

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ||

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ||

If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. ||

                                                Proposed Maximum     Proposed Maximum
    Title of Each Class of       Amount to be    Offering Price     Aggregate Offering       Amount of
 Securities to be Registered      Registered        Per Unit              Price           Registration Fee
------------------------------   ------------   ----------------    ------------------    ----------------
Common Stock,  $.01 par value,    38,229,157         $ .03              $1,146,875            $ 92.78
included in the Units (1)
------------------------------   ------------   ----------------    ------------------    ----------------
Warrants (2)                      76,458,314          ----                 ----                    (2)
------------------------------   ------------   ----------------    ------------------    ----------------
Common Stock,  $.01 par value,    76,458,314         $.045              $3,440,625            $278.35
issuable  upon exercise of the
warrants (3)
------------------------------   ------------   ----------------    ------------------    ----------------
Common  Stock;  $.01 par value    14,500,000         $ .03              $  435,000            $ 35.19
(4)
------------------------------   ------------   ----------------    ------------------    ----------------
Warrants (2) (5)                  29,000,000                                                       (2)
------------------------------   ------------   ----------------    ------------------    ----------------
Common Stock;  $.01 par value,    29,000,000         $.045              $1,305,000            $105.58
issuable  upon exercise of the
oversubscription warrants
------------------------------   ------------   ----------------    ------------------    ----------------
Subscription Rights (7)           38,229,157          ----                 ----                 ----
------------------------------   ------------   ----------------    ------------------    ----------------


(1) The Company is offering Units; each Unit consists of one share of Common Stock and two warrants to purchase two additional shares of Common Stock at $.04 and $.05, respectively.
(2) The registration fee is being paid in connection with the registration of the underlying Common Stock.
(3) Includes 38,229,157 shares issuable upon exercise of warrants at $.04 per share, and an additional 38,229,157 shares issuable upon exercise of warrants at $.05 per share.

(4) Issuable to fill excess over-subscriptions.
(5) Includes the warrants  issuable in connection  with the  14,500,000
Unit over subscription option.

(6) Includes 14,500,000 shares issuable upon exercise of warrants at $.04 per share, and an additional 14,500,000 shares issuable upon exercise of warrants at $.05 per share.
(7) Evidencing the Rights to subscribe for Units.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

2

PROSPECTUS

INTERNATIONAL ISOTOPES INC.
38,229,157 Units

Issuable Upon the Exercise of Subscription Rights

International Isotopes Inc. ("I3" or the "Company") is issuing to its shareholders of record as of the close of business on July 15, 2003 new securities called "Rights". Holders of Rights will be entitled to subscribe for an aggregate of 38,229,157 Units of I3's securities at the rate of one Unit for each 2.5 Rights held. The terms of the Rights offering are as follows:

o You will receive one Right for each share of I3 common stock you owned on July 15, 2003.

o You may purchase one Unit for every 2.5 Rights you receive, at the Subscription Price of $.03 per Unit.

o Each Unit consists of (i) one share of common stock, (ii) one warrant to purchase an additional share of common stock for $.04 per share ("Series A Warrant"), and (iii) one warrant to purchase another share of common stock for $.05 per share ("Series B Warrant"). The warrants are exercisable through July 31, 2007.

o If you fully exercise your rights, you may subscribe for additional Units through an over-subscription privilege. If the over-subscriptions exceed the number of Units available, the Units will be allocated to those shareholders who over-subscribe, based upon their shareholdings on the record date as more fully described in this Prospectus.

o The Rights are not transferable and may be exercised only by record date shareholders.

o The offer expires on September 12, 2003. There is no minimum number of Units required to be sold as a condition to completing the Offering.

The Company's Common Stock is quoted in the over the counter market in the "pink sheets" under the symbol "INIS." On July 21, 2003, the last reported bid price for shares of the Company's Common Stock as reported in the pink sheets was $.03.

Shareholders of I3 who do not exercise all of their Rights will own a smaller relative equity ownership and voting interest in I3 after completion of this Offering than if they were to exercise all of their Rights.


The securities offered hereby involve a high degree of risk.


See "Risk Factors" commencing on page 9.


Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if this Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.


The Company has not authorized any person, agent or entity to give any information or make any representation other than those contained in this Prospectus (including material incorporated by reference herein). You should not rely on any such information or representation as having been authorized by the Company. This Prospectus is not an offer to sell the securities and it is not soliciting an offer to buy the securities in any state where offers or sales are not permitted.

Price to Public                        Proceeds to the Company
-------------------------------------- ----------------------------------------
Per Unit $.03                          $.03
-------------------------------------- ----------------------------------------
Total    $1,146,875                    $1,146,875
-------------------------------------- ----------------------------------------

Expenses of the Rights Offer are estimated to be $55,000. No underwriting discounts or discounts will be paid.

The date of this Prospectus is July 24, 2003

3

TABLE OF CONTENTS

                                                                          Page

Prospectus Summary..........................................................5
Risk Factors................................................................8
The Company................................................................11
The Rights Offer...........................................................13
Use of Proceeds............................................................19
Description of Securities..................................................20
Legal Matters..............................................................22
Experts....................................................................22
Incorporation of Certain Information by Reference..........................22
Additional Information.....................................................22

Exhibit A  Form of Subscription Certificate ..............................A-1
Exhibit B  Form of Notice of Guaranteed Delivery..........................B-1
Exhibit C  Form of Nominee Holder Over Subscription Exercise Form.........C-1
Exhibit D  Form of Warrant Agreement......................................D-1
Exhibit E  Form of Warrant Certificate....................................E-1

4

PROSPECTUS SUMMARY

The following summary explains only some of the information in this prospectus. More detailed information about International Isotopes Inc.("I3," the "Company," or "we") and the Rights offer, and financial statements appear elsewhere in this prospectus or in the documents incorporated by reference into this prospectus.

This prospectus is part of a registration statement on Form S-3 that we have filed with the Securities and Exchange Commission. The SEC allows us to "incorporate by reference" information that we file with them. This means that we can disclose important information to you by referring you to other documents that we have filed with the SEC. The information that is incorporated by reference is considered part of this prospectus, and information that we file later will automatically update and may supersede this information. For further information about I3 and the securities being offered, you should refer to the registration statement and the documents that are incorporated by reference. See "Incorporation of Certain Information by Reference" elsewhere in this prospectus.

Statements contained in this prospectus that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Words such as "expects," "may," `will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements. See "Risk Factors."

The Company

International Isotopes Inc. was established as a Texas corporation in 1995. The Company was initially formed to produce, market, and distribute a broad range of products used in diagnostic and therapeutic nuclear medicine, research and industry. In 1998 the Company acquired a subsidiary, subsequently named International Isotopes Idaho Inc., which specialized in sales of isotopes and providing hot cell services through a contract with the Department of Energy (DOE) Idaho Operations and using the Advanced Test Reactor (ATR). Because of difficulties encountered with start up of the Company's Radioisotope Production Facility and Linear Accelerator, and the high cost of conducting commercial operations in the midst of a DOE laboratory, the Company underwent a substantial change in mission and strategy during 2000 and 2001. This change resulted in the sales of the Radioisotope Production Facility and Linear Accelerator in Texas and termination of the commercial isotope production contract with the DOE's prime-operating contractor in Idaho. In June of 2001, the Company relocated its corporate headquarters to Idaho to continue the subsidiary's operations as the new, primary focus and mission of the Company.

In support of our new mission and strategy, in 2001 new contract manufacturing and processing agreements were put in place, a new operating facility was obtained and licensed through the Nuclear Regulatory Commission, and new contracts put in place with the DOE's prime-operating contractor for continued reactor production of high specific activity cobalt. These new agreements now fully support the Company's business products and services, which include manufacturing nuclear medicine reference and calibration standards, processing gemstones that have undergone treatment for color enhancement, and large volume production of high specific activity (HSA) cobalt. We have been able to continue steady growth in the amount of revenues generated from these business activities. We expect continued growth and the addition of new products in 2003, which management feels will produce sufficient cash to meet our operational needs. However, prospective investors are cautioned regarding the speculative nature of any forward-looking projections. For a discussion of these and other risk factors relating to the Company when considering an investment in our securities, see "Risk Factors."

Purpose of the Offer

The Board of Directors of I3 has determined that it is desirable to raise capital in order to finance an expansion of our business operations. This expansion will include construction of a building addition and acquisition of hot cells and related equipment for processing a wide range of new products. Although intended to provide a variety of processing capability, most of the planned operations expansion will be directed towards implementation and advancement of the Company's new Therapy Products business area.

This offering will allow us to raise additional capital without diluting the ownership interests of existing shareholders who exercise their Rights and without paying the higher underwriting commissions that would be required to raise capital from third parties who are not already shareholders.

5

Terms of the Offer

Description of the Rights               We are  issuing  Rights  to  each of our
Offering                                shareholders  who  owned  shares  of our
                                        common stock at the close of business on
                                        July  15,  2003.  You will  receive  one
                                        Right  for every  share of common  stock
                                        you  own.   You  will  be   entitled  to
                                        purchase one Unit of our securities (one
                                        share of common  stock and two  warrants
                                        to purchase two  additional  shares) for
                                        every 2.5  Rights  you own.  Holders  of
                                        Rights will be entitled to subscribe for
                                        and  purchase  up  to  an  aggregate  of
                                        38,229,157 Units.

Subscription Price                      If you wish to  exercise  your Rights to
                                        purchase Units, the  Subscription  Price
                                        will be $.03 per Unit. The  Subscription
                                        Price  is  payable  in  cash  (including
                                        check,  money order and wire  transfer),
                                        except    with    respect   to   certain
                                        shareholders of I3 who have loaned funds
                                        to the  Company and may choose to cancel
                                        I3 debt in exchange for Units.

Description of Units                    Each Unit will  consist of (i) one share
                                        of our common  stock,  (ii) one Series A
                                        Warrant to purchase an additional  share
                                        of our  common  stock at a price of $.04
                                        per  share,   and  (iii)  one  Series  B
                                        Warrant to purchase another share of our
                                        common  stock  at a price  of  $.05  per
                                        share.  The warrants are  exercisable at
                                        any time on or  prior to July 31,  2007.
                                        The warrants are  redeemable  and may be
                                        repurchased by the Company for $.001 per
                                        warrant if the average  closing price of
                                        I3's common stock equals or exceeds $.12
                                        per  share  with  respect  to  Series  A
                                        Warrants and $.15 per share with respect
                                        to   Series  B   Warrants   during   any
                                        consecutive 20 business day period.  The
                                        Warrants  will be  evidenced  by Warrant
                                        Certificates  and will be subject to the
                                        terms of a Warrant Agreement between the
                                        Company  and  American   Stock  Transfer
                                        Company,   as  Warrant  Agent.  See  the
                                        Warrant  Agreement  attached  hereto  as
                                        Exhibit  D  and  the  form  of   Warrant
                                        Certificate  attached  hereto as Exhibit
                                        E.

Over-Subscription Privilege             Shareholders  who fully  exercise  their
                                        Rights   will   be   entitled   to   the
                                        additional  privilege of subscribing for
                                        and   purchasing,   subject  to  certain
                                        limitations  and subject to  allocation,
                                        any Units not acquired by other  holders
                                        of Rights in the  primary  subscription.
                                        If  subscriptions  for Units through the
                                        over-subscription  privilege  exceed the
                                        number of Units available for sale after
                                        the primary  subscription,  we may issue
                                        up to  14,500,000  additional  Units  to
                                        fill  all or a  portion  of  the  excess
                                        over-subscriptions.

6

How to Exercise Rights                  The   Rights   will  be   evidenced   by
                                        Subscription Certificates, which will be
                                        distributed to record date shareholders.
                                        See Exhibit A hereto.  You may  exercise
                                        your    Rights   by    completing    the
                                        Subscription  Certificate and delivering
                                        it,   together   with   payment  of  the
                                        Subscription  Price, to the Subscription
                                        Agent,  American  Stock Transfer & Trust
                                        Company, 59 Maiden Lane, Plaza Entrance,
                                        New York, New York 10038. Payment may be
                                        made  either by check  drawn on a United
                                        States bank,  wire transfer or by notice
                                        of  guaranteed  delivery  (as  explained
                                        under  "The  Rights  Offer--Payment  for
                                        Shares").  Certain shareholders who have
                                        loaned  funds  to the  Company  have the
                                        additional  option of electing to cancel
                                        all or a portion  of the I3 debt owed to
                                        them in  exchange  for  Units.  You must
                                        exercise   your  Rights  no  later  than
                                        September 12, 2003.  You may not rescind
                                        your  purchase  after   exercising  your
                                        Rights.

Non-Transferability of Rights           The Rights are  non-transferable and may
                                        be  exercised  only  by  a  record  date
                                        shareholder.

When You Can Exercise Your Rights       You can exercise your Rights only during
                                        the period  beginning on August 12, 2003
                                        and ending on September 12, 2003 at 5:00
                                        p.m., New York City time.

Common Stock Outstanding Prior          95,572,893 shares of common stock.
to this Offering

Common Stock to be                      After this  Offering,  assuming the sale
Outstanding After the                   of  the   38,229,157   Units   initially
Offering                                offered   plus   the   14,500,000   unit
                                        over-subscription  option,   148,302,050
                                        shares   of   common   stock   will   be
                                        outstanding.    There   will   also   be
                                        outstanding   warrants  to  purchase  an
                                        additional 105,458,314 shares.

Important Dates to Remember             Record Date:  July 15, 2003
                                        Expiration Date:  September 12, 2003
                                        Last date of Guaranteed
                                        Delivery:  September 17, 2003

Amendment, Extension or                 The Company may in its sole  discretion:
Termination of the Offer                (a)   terminate   the  Offer   prior  to
                                        delivery  of the Units for which  Rights
                                        holders have subscribed  pursuant to the
                                        exercise   of  Rights  in  the   primary
                                        subscription  or  the  over-subscription
                                        privilege;  (b)  extend  the  expiration
                                        date to a later  date;  (c)  change  the
                                        record date prior to the distribution of
                                        the Rights to shareholders; or (d) amend
                                        or modify the terms of the Rights offer.

Closing bid price of the Company's      $.03 per share
common stock as reported in the
over the counter market pink sheets
on June 13, 2003 (the trading day
prior to announcement of the Rights
offering)

Closing bid price of the Company's      $.03 per share
common stock as reported in the
over the counter market pink sheets
on July 21, 2003

7

Risk Factors                            An  investment  in the Units  involves a
                                        high degree of risk. The Units should be
                                        purchased  only  by  investors  who  can
                                        afford   the   loss  of   their   entire
                                        investment. See "Risk Factors."

Use of Proceeds                         New  facilities   and  equipment,   debt
                                        reduction and working capital.  See "Use
                                        of Proceeds."

Trading Symbol                          Our common shares are traded in the over
                                        the  counter  market and reported in the
                                        pink  sheets  under  the  symbol "INIS."

Participation of Certain Certain of I3's shareholders have Shareholders recently loaned the Company the aggregate principal amount of $823,500.

Although there can be no assurance, we
expect each of these shareholders to
participate in the Rights offer by
canceling all or a portion of the amount
of I3 debt owed to them in exchange for
Units offered hereby.

RISK FACTORS

International Isotopes has incurred and may continue to incur losses. With the exception of 2002, we have incurred net losses for most fiscal periods since our inception. From inception (November 1995) through December 31, 2002 the Company generated $17,246,225 in revenues and had an accumulated deficit (including preferred stock dividends and returns) in the amount of $87,390,165. However, although we cannot provide any assurance we believe the Company's continued growth in our new business areas will produce sufficient revenue to meet our 2003 cash flow and operational needs.

We may need additional financing to continue operations. As of December 31, 2002 we have an outstanding debt of $1,046,520 on a $1.1 million revolving line of credit account with Texas State Bank. That note matures on December 31, 2003 and is secured with 80% of our accounts receivable and 50% of our fixed assets. Seventy-five percent (75%) of the cash resulting from the sale of any remaining Linac equipment must be applied to the principal of this note. Sales of about $460,000 of this equipment are expected in 2003. We will have to negotiate an extension of terms on this note at the end of 2003. The Company also has a ten-year note for $909,738 at 7% interest to our former Chairman of the Board. Principal and interest payments on this note are to be paid annually based upon net profits of the Company (annual principal payment to equal 30% of net pre-tax profits). At December 31, 2002, the note holder agreed to defer the April 2003 principal payment. The Company also has notes totaling $823,500 in principal amount with several of our principal shareholders, which mature in May 2004. We expect the holders of these notes to convert all or a portion of the outstanding amount of these notes to equity through the exercise of Rights in this offering.

Remaining Company Obligations on the Texas State Bank Loan for the Waxahachie Property. The Company and Texas State Bank have agreed to have the loan of $345,295 assumed by an individual in consideration of our sale of our Waxahachie property. Liability for this loan would, however, revert to the Company should this individual default on the assumed note.

8

We will continue to be dependent upon our remaining facilities and equipment to function properly in order to provide consistent, timely shipments of products that meet our customers' specifications. If we experience equipment failures or breakdowns we may be unable to satisfy our customers, which could result in the cancellation of contracts and the loss of revenues.

There is no long-term contract in place with the DOE Contractor for continued HSA Cobalt production. The Company has put short term specific "work for non-government sponsor agreements" in place with the DOE contractor to continue sales of HSA cobalt irradiated at the Idaho reactor facility. We expect that these agreements will continue, however, there is no assurance these contracts will be equitable or continuing.

Operational hazards (i.e., spills, faults, ventilation failure, etc.) could result in the spread of contamination within our facility and require additional funding to correct. An irrevocable, automatic renewable letter of credit against a $147,000 Certificate of Deposit at Texas State Bank has been used to provide the financial assurance required by the Nuclear Regulatory Commission for our Idaho facility license. If a contamination event resulted in greater liability to us we would have to borrow money or fund the liability from our future revenue.

Government regulation could adversely affect our business. Operations within our Idaho facility are subject to the U.S. Nuclear Regulatory Commission and Food and Drug Administration regulations. Nuclear medicine calibration and reference standards are licensed and regulated. To the extent these regulations are or become burdensome, our business development could be adversely affected.

We are dependent upon key personnel. Our ongoing operations are dependent on Steve T. Laflin, President and Chief Executive Officer. The Company is highly dependent upon this person and the loss of this individual could have a material adverse effect on us. We have a $2 million dollar key man life insurance policy on Mr. Laflin and a 5-year employment agreement with him extending through February 2007. The Company has revised our employee stock options to assist with offering incentives and retaining key personnel. In addition, there is no assurance the Company will be able to retain our existing personnel or attract additional qualified employees. Loss of any of these relationships would result in a significant decline in revenue.

We are dependent on various third parties in connection with our business operations. The production of HSA Cobalt is dependent upon the Department of Energy, and its prime-operating contractor, who controls the Idaho reactor and laboratory operations. Our gemstone production is tied to an exclusive agreement with Quali Tech Inc. Nuclear medicine calibration and reference standard manufacturing is conducted under an exclusive contract with RadQual, LLC who in turn has agreements in place with several companies for marketing and sales.

We are subject to competition from other companies. Each of the business areas of the Company has direct competition from other businesses. HSA cobalt is supplied by other reactor facilities around the world. Nuclear medicine calibration and reference standards are being produced by several other manufacturers in the U.S. and overseas, and there is at least one other gemstone processor in Europe. Each of our competitors has significantly greater financial resources than us and that could create a competitive advantage for them over us.

Regulation of Radioisotope Production and Radioactive Waste. The manufacture of radioisotopes, nuclear medicine calibration and reference standards, and processing gemstones are subject to extensive federal regulation. Prior to commencing operations in our newly leased Idaho facility, the Company obtained approval from the Nuclear Regulatory Commission. The nuclear medicine calibration and reference standards are licensed as Sealed Sources through the State of Texas Department of Health. The Company's production facility does not handle "special nuclear materials" (i.e. nuclear fuels and weapons grade uranium, thorium and plutonium) and, therefore, is not designated as a "nuclear" facility.

9

Pursuant to the Low Level Radioactive Waste Policy Act of 1980, states are required to assure the safe disposal of mildly radioactive materials. The Nuclear Regulatory Commission, Region IV, regulates the disposal of radioactive waste for facilities operating in Idaho. The radioactive waste we produce falls into the category of low-level radioactive waste.

Other Regulations. In the event we enter into agreements with suppliers to acquire neutron-produced research and therapeutic radioisotopes we could be subject to additional regulations of the Nuclear Regulatory Commission or the Food and Drug Administration.

Our shares are not currently listed on a securities exchange or traded on Nasdaq. As a result, our shares are thinly traded and there can be no assurance that an active trading market will develop for our stock. Accordingly, owners of our shares may have a difficult time selling large blocks of shares at market prices.

No Trading market is expected to develop for the Warrants. Although the Series A Warrants and Series B Warrants are being registered and will be freely tradeable (including through the Depository Trust Company), the Company does not expect an active trading market to develop for the Warrants.

Shareholders of I3 who do not exercise all of their Rights will own a smaller relative percentage of I3 after the Offering and could experience dilution in the value of their stock. The Rights Offer is being made to all I3 shareholders and if all shareholders exercise all of their rights, each shareholder's pro rata ownership interest will remain the same. However, if a shareholder does not exercise his Rights or exercises less than all his Rights, his percentage ownership interest could be reduced significantly. A non-participating shareholder's interest will be reduced even more to the extent other shareholders exercise their oversubscription privilege. To the extent the offered Unit price is less than the then market price of I3's stock, non-participating shareholders could also experience dilution in the value of their shares. The same is true for non-participating shareholders if participating shareholders later exercise their Warrants when the Warrant Exercise Price is less than the then market price of I3's stock.

10

THE COMPANY

General

I3 was established as a Texas corporation in 1995. The Company was initially formed to produce, market, and distribute a broad range of products used in diagnostic and therapeutic nuclear medicine, research and industry. In 1998 the Company acquired a subsidiary, subsequently named International Isotopes Idaho Inc., which specialized in sales of isotopes and providing hot cell services through a contract with the Department Of Energy (DOE) Idaho Operations and using the Advanced Test Reactor (ATR). Because of difficulties encountered with start up of the Company's Radioisotope Production Facility and Linear Accelerator, and the high cost of conducting commercial operations in the midst of a DOE laboratory, the Company underwent a substantial change in mission and strategy during 2000 and 2001. This change resulted in the sales of the Radioisotope Production Facility and Linear Accelerator in Texas and termination of the commercial isotope production contract with the DOE's prime-operating contractor in Idaho. In June of 2001, the Company relocated its corporate headquarters to Idaho to continue the subsidiary's operations as the new, primary focus and mission of the Company.

In support of our new mission and strategy, in 2001 new contract manufacturing and processing agreements were put in place, a new operating facility was obtained and licensed through the Nuclear Regulatory Commission, and new contracts put in place with the DOE's prime-operating contractor for continued reactor production of high specific activity cobalt. These new agreements now fully support the Company's business products and services, which include manufacturing nuclear medicine reference and calibration standards, processing gemstones that have undergone treatment for color enhancement, and large volume production of high specific activity (HSA) cobalt. We have been able to continue steady growth in the amount of revenues generated from these business activities. We expect continued growth and the addition of new products in 2003, which management feels will produce sufficient cash to meet our operational needs. However, prospective investors are cautioned regarding the speculative nature of any forward-looking projections. For a discussion of these and other risk factors relating to the Company when considering an investment in our securities, see "Risk Factors."

Company Licensing, Capabilities, and Qualifications

We have a fully implemented Quality Assurance program which meets the requirements of ANSI/ASME NQA-1 and 10 CFR 830.120. In order to support the production of Nuclear Medicine calibration and reference standards the Company is also a participating member of the National Institute of Standards and Technology/ Nuclear Energy Institute's (NIST/NEI) Measurement Assurance Program (MAP) for the radiopharmaceutical industry. This program participation ensures that we can provide analytical methods and standards necessary for accurate radioactivity measurement. The Company is also a registered Food and Drug Administration (FDA) medical device manufacturer for Class I medical devices, including Nuclear Sealed Calibration Sources (892.1400) and Nuclear Flood Source Phantoms (892.1380).

Industry Overview and Target Markets

The industries and markets that require or involve the use of radioactive material are diverse. Our current operations involve products that are used in a wide variety of applications and in various markets. First, our HSA cobalt is supplied as bulk material, which is subsequently assembled into medical devices by our customer. Second, we are a contract manufacturer of several nuclear medicine reference and calibrations standards used for operational checks of various imaging and measurement systems for nuclear medicine. And third, we support the special packaging and measurement of gemstones that have undergone irradiation for color enhancement.

We conduct our operations in Idaho Falls, Idaho. Although the cobalt, nuclear medicine calibration and reference standards, and gemstone products appear diverse, they share the common links of being radioactive materials requiring extensive process quality control. Therefore, the Company is required to have an operating license from the Nuclear Regulatory Commission and specially trained staff with rigorously employed quality standards to produce and process these materials.

11

Products

HSA Cobalt - The Company is one of a very few sources of this material worldwide. High Specific Activity (HSA) cobalt is used primarily in external beam radiation medical devices such as Elekta's Leksell Gamma Knife. This device is used for non-surgical radiation treatment of vascular deformities and non-malignant tumors in the brain. The HSA cobalt requires three to five years of irradiation to reach the necessary level of activity for this medical application. We manage an inventory of approximately 800,000 curies of this material in various stages of production, thus ensuring a long and continuous supply of material. After irradiation the material is shipped by us directly from the DOE reactor laboratory to the customer's facilities, thus eliminating the need for any on site processing of the material following irradiation.

Other Reactor Produced Radioisotopes - The Company's facility and NRC license permits processing of a wide variety of radioisotopes. We are evaluating establishing additional radioisotope transport and processing capabilities that would permit production and sale of various new radioisotopes using the DOE laboratory test reactor for production and our Idaho Falls facility for processing.

Nuclear medicine calibration and reference standards manufacturing - The Company is an exclusive contract manufacturer to RadQual LLC for several of these types of standards. There are approximately 6,000 nuclear medicine centers around the U.S. and the number of these centers is expected to grow at an annual rate of about 5%. Each of these centers has a variety of measurement and imaging systems that require frequent use of calibration and reference standards to ensure their proper operation. Because of the relatively short lived nature of the radioactivity used in these standards, the customers are required to replace them approximately once every 12 to 18 months.

Gemstone Processing - The Company has an exclusive contract with Quali-Tech Inc. for processing gemstones. The processing involves special packaging of the gemstones in containers, which allow them to undergo irradiation for color enhancement. The processing we perform entails initial receipt of the gemstones, packaging the gemstones for irradiation, managing the transport of the stones to and from the reactor facility, and then completing post irradiation processing of the stones before return shipment to the customer. In 2001 the production volume of the gemstones was limited by the availability of irradiation containers due to the difficulty involved with repairing and constructing these containers. However, in January 2002 we had solved container construction problems and implemented a new technology to repair containers. As a result we have been able to double the number of containers available for irradiation of the gemstones. During 2002, however, the general slowdown of the economy impacted the market demand for gemstones and thus the Company's revenue resulting from processing did not meet expectations.

Competition

HSA cobalt is produced in some other reactors, but we do not believe any in the U.S. are capable of producing the high activity level and volume required for meaningful commercial production. The two domestic reactor sources are the University of Missouri Research Reactor and the High Flux Isotope Reactor located in Oak Ridge Tennessee. There are, however, numerous foreign reactors actively producing high and low specific activity cobalt. While the logistics of international transport of cobalt presents some competitive barriers, the Company must always consider the potential threat these other suppliers pose to our HSA cobalt business.

Nuclear medicine calibration and reference standards - The Company is the smallest of three major producers of these sources within the U.S. The Company's customer (RadQual, LLC) has increased the number of authorized distributors and plans to make further expansion into the market in 2003. However, there can be no assurance of increased sales.

Gemstone processing - there is no other commercial company or reactor in the U.S. processing irradiated gemstones. We believe there are one or two other reactors in the world that support this business with other companies overseas.

Government Regulation

The Company has obtained a license from the Nuclear Regulatory Commission, Region IV that permits use and possession of by-product material. The scope of this license includes calibration and reference standard manufacturing and distribution, radioactive gemstone processing, environmental sample analysis, and various research and development activities. The scope and activities permitted by this license are broad enough that it is not expected to restrict any anticipated business activities in the coming year. The Company is also registered as a medical device manufacturer through the U.S. Food and Drug Administration (FDA).

12

THE RIGHTS OFFER

Issuance of Rights

We are issuing Rights to subscribe for Units of the Company's securities. Each Unit consists of (i) one share of common stock, (ii) one Series A Warrant to purchase an additional share of common stock at an exercise price of $.04, and (iii) one Series B Warrant to purchase another share of common stock at $.05 per share. The warrants are exercisable anytime prior to and including July 31, 2007. Each shareholder as of the record date will be issued one nontransferable Right for each share of common stock owned. No fractional Rights will be issued. The Rights entitle the holder to acquire at the Subscription Price one Unit for each 2.5 Rights held. The Rights will be evidenced by Subscription Certificates (see Appendix A) which will be mailed to shareholders.

The Rights are not transferable and will not be quoted for trading in the over the counter market nor on any stock exchange. Shareholders who, after exercising their Rights, are left with fewer than 2.5 Rights, will be unable to exercise those remaining Rights and will not be entitled to receive any cash from the Company in lieu of those remaining Rights.

Purpose of Offer

The Board of Directors of I3 has determined that it is desirable to raise capital in order to finance an expansion of our business operations. This expansion will include construction of a building addition and acquisition of hot cells and related equipment for processing a wide range of new products. Although intended to provide a variety of processing capability, most of the planned operations expansion will be directed towards implementation and advancement of the Company's new Therapy Products business area.

This Offering will allow us to raise additional capital without diluting the ownership interests of existing shareholders who exercise their Rights and without paying the higher underwriting commissions that would be required to raise capital from third parties who are not already shareholders.

The Subscription Price

The Subscription Price for the Units to be issued pursuant to the Rights is $.03 per Unit. We announced the offer on June 13, 2003. The last reported bid prices of the common stock in the over the counter market pink sheets on June 13, 2003, and July 21, 2003, were $.03 and $.03, respectively. The Subscription Price is payable in cash (by check, money order or wire transfer), except with respect to certain shareholders of I3 who have loaned funds to the Company and may elect to cancel I3 debt in exchange for Units.

Expiration of the Offer

The Offer will expire at 5:00 p.m. New York City time on September 12, 2003 (the "Expiration Date"). Rights will expire on the Expiration Date and may not be exercised after that date.

Exercise of Rights

In order to exercise your Rights you must do all of the following:

o Fill in and sign the reverse side of the Subscription Certificate which accompanies this prospectus;
o Deliver the completed and signed Subscription Certificate to the Subscription Agent with your payment in full for the Units you wish to purchase. You may use the enclosed envelope to mail the Subscription Certificate and payment to the Subscription Agent, or you may arrange for one of the alternative methods of delivery described below. Shareholders choosing to cancel I3 debt owed to them in exchange for Units should so indicate on their Subscription Certificate.

13

o The method of making payment for your Units is described below under "Payment for Shares."
o Properly completed and executed Subscription Certificates must be received by the Subscription Agent at the offices of the Subscription Agent at the address set forth below prior to 5:00 pm, New York City time, on the Expiration Date, unless payment is effected by means of a notice of guaranteed delivery as described below under "Payment for Shares."
o Rights may also be exercised through a broker, who may charge you a servicing fee.

Signed Subscription Certificates, accompanied by payment of the Subscription Price, should be sent to American Stock Transfer & Trust Company, the Subscription Agent, by one of the methods described below:

1. By mail or by hand:


American Stock Transfer & Trust Company
59 Maiden Lane, Plaza Entrance
New York, NY 10038

2. By express mail or overnight courier:


American Stock Transfer & Trust Company
59 Maiden Lane, Plaza Entrance
New York, NY 10038

3. By facsimile (telecopier):


718/234-5001

with a copy of the original Subscription Certificate to be sent by one of the methods described above. Confirm facsimile by telephone to 800/937-5449.

Do Not Send Subscription Certificates to the Company.

A subscription will be deemed accepted by the Subscription Agent when payment (which may take the form of an election to cancel I3 debt owed to the shareholder), together with a properly completed and executed Subscription Certificate, and is received by the Subscription Agent.

If you are issued fewer than 2.5 Rights, you may subscribe for one full Unit. Fractional Units will not be issued, and if after exercising your Rights you are left with fewer than 2.5 Rights, you will not be able to exercise your remaining Rights.

If you do not indicate the number of Rights you are exercising, or if you do not deliver full payment of the Subscription Price for the number of Units that you indicate you are subscribing for (which payment may take the form of an election to cancel I3 debt owed to you), then you will be deemed to have exercised Rights to purchase the maximum number of Units determined by dividing the total Subscription Price you paid by the Subscription Price per Unit.

If you submit payment for more Units than may be purchased through the regular exercise of your Rights, your excess payment will be deemed to be a Subscription Payment for additional Units through the Over-Subscription Privilege. The number of additional Units that you will be deemed to have subscribed for in the Over-Subscription Privilege will be determined by dividing the amount of the excess payment by the Subscription Price per Unit.

14

All questions concerning the time limits, validity, form and eligibility of any exercise of Rights for subscriptions pursuant to the Over-Subscription Privilege will be determined by I3, whose determination will be final and binding. I3 in its sole discretion may waive any defect or irregularity, or may permit any defect or irregularity to be corrected, within such time as the Company may determine, or I3 may reject, in whole or in part, the purported exercise of any Right in the primary subscription or any subscription pursuant to the Over-Subscription Privilege. Neither I3 nor the Subscription Agent will be under any duty or obligation to give any notification or permit the cure of any defect or irregularity in connection with the submission of any Subscription Certificate, the exercise or attempt to exercise any Right or the Over-Subscription Privilege, or the payment of the Subscription Price. Subscriptions through the exercise of Rights or the Over-Subscription Privilege will not be deemed to have been received or accepted by I3 until all irregularities or defects have been waived by I3 or cured to the satisfaction of, and within the time allocated by, I3 in its sole discretion.

Over-Subscription Privilege

The Over-Subscription Privilege may allow you to acquire more Units than the number issuable upon the exercise of the Rights initially issued to you. By exercising the Over-Subscription Privilege, you may purchase any Units that are left over by shareholders who fail to exercise their Rights.

The Over-Subscription Privilege may only be exercised by Rights holders who were shareholders on the record date and who exercise all of the rights they received from I3. Shareholders such as broker-dealers, banks, and other professional intermediaries who hold I3 securities on behalf of clients, may participate in the Over-Subscription Privilege for the client if the client fully exercises all Rights attributable to him.

If you are eligible to exercise the Over-Subscription Privilege and you wish to do so, you should indicate on your Subscription Certificate how many Units you are willing to acquire through the Over-Subscription Privilege. If sufficient common shares remain unsold, all over-subscriptions will be honored in full.

If you were a shareholder on the record date and you wish to exercise the Over-Subscription Privilege through The Depository Trust Corporation, you must properly execute and deliver to the Subscription Agent a DTC Participant Over-Subscription Form, together with payment of the Subscription Price for the number of Units that you wish to purchase through the Over-Subscription Privilege. Copies of the DTC Participant Over-Subscription Form and payment must be received by the Subscription Agent at or prior to 5:00 p.m. New York City time on the Expiration Date.

If you are eligible to exercise the Over-Subscription Privilege but do not deliver full payment of the Subscription Price for the number of Units that you indicate you are subscribing for through the Over-Subscription Privilege, then you will be deemed to have exercised the Over-Subscription Privilege to purchase the maximum number of Units determined by dividing the total Subscription Price paid (in excess of the Subscription Price for the number of Units you purchased through the full exercise of your Rights) by the Subscription Price per Unit.

If subscriptions for Units through the Over-Subscription Privilege exceed the initial 38,229,157 Units being offered by I3 through the exercise of the Rights, I3 may issue up to 14,500,000 additional Units to fill all or a portion of the over-subscriptions. The issuance of additional Units to fill over-subscriptions may dilute the percentage ownership interests of other shareholders.

I3 will not be obligated to issue any Units to fill over-subscriptions, but we may do so in our sole and absolute discretion. We reserve the right to limit the number of Units issued to fill an over-subscription from any single shareholder or from shareholders that are known or believed by us to be under common control or acting as a group for the purpose of acquiring Units.

15

Subject to the right of I3 to limit the number of Units issuable to any shareholder, if the Rights offer is over-subscribed so that over-subscriptions cannot be filled in full, the available Units will be allocated among those who over-subscribe based on the number of Rights originally issued to them, so that the number of Units issued to shareholders who subscribe pursuant to the Over-Subscription Privilege will generally be in proportion to the number of shares of common stock owned by them on the record date. The percentage of available Units each over-subscribing shareholder may acquire may be rounded up or down to result in delivery of whole Units. The allocation process may involve a series of allocations in order to assure that the total number of Units available for over-subscriptions is distributed on a prorata basis. If you are not allocated the full amount of Units that you subscribe for pursuant to the Over-Subscription Privilege, you will receive a refund of the Subscription Price you paid for Units that are not allocated to and purchased by you. The refund will be made by a check mailed by the Subscription Agent.

Payment for Units

If you wish to exercise your Rights or to acquire Units pursuant to the Over-Subscription Privilege, you may choose between the following methods of payment:

1. You may send the Subscription Certificate together with payment (which may take the form of a written election on the Subscription Certificate indicating your desire to cancel I3 debt owed to you in exchange for the issuance of Units) for the Units acquired on primary subscription and any additional Units that the you desire to acquire through the Over Subscription Privilege to the Subscription Agent. A subscription will be deemed accepted when payment, together with a properly completed and executed Subscription Certificate, is received by the Subscription Agent. Such payment and properly executed Subscription Certificate must be received by the Subscription Agent no later than 5:00 p.m., New York City time on the Expiration Date. The Subscription Agent will deposit all checks received by it for the purchase of Units into a segregated interest bearing account of I3 (the interest of which will belong to I3) pending pro ration and distribution of the Units. To be accepted, a payment pursuant to this method must be in U.S. dollars by money order or check drawn on a bank located in the United States, must be payable to International Isotopes Inc., and must accompany a properly completed and executed Subscription Certificate.

2. Alternatively, a subscription will be accepted by the Subscription Agent if, prior to 5:00 p.m., New York City time, on the Expiration Date, the Subscription Agent has received a Notice of Guaranteed Delivery by facsimile (telecopy) or otherwise from a bank, trust company, or a New York Stock Exchange member guaranteeing delivery of (i) payment of the full Subscription Price for the Units subscribed for in the primary subscription and any additional Units subscribed for pursuant to the Over Subscription Privilege (which may take the form of a written election on the Subscription Certificate indicating your desire to cancel I3 debt owed to you in exchange for the issuance of Units), and (ii) a properly completed and executed Subscription Certificate. The Subscription Agent will not honor a Notice of Guaranteed Delivery unless a properly completed and executed Subscription Certificate and full payment for the Units is received by the Subscription Agent by the close of business on the third business day after the Expiration Date.

You will not be allowed to rescind a purchase after the Subscription Agent has received your payment either by means of a notice of guaranteed delivery or a check.

Nominees who hold common stock for the account of others, such as brokers, trustees or depositories for securities, should notify the respective beneficial owners of such common stock as soon as possible to ascertain such beneficial owners and to obtain instructions with respect to the Rights. If the beneficial owner so instructs, the nominee should complete the Subscription Certificate and submit it to the Subscription Agent with the proper payment. In addition, beneficial owners of common stock held through such a nominee should contact the nominee and request the nominee to effect the transactions in accordance with the beneficial owner's instructions.

No Transferability of Rights

The Rights evidenced by a Subscription Certificate may not be transferred and will not be listed for trading in the over the counter market or on any securities exchange.

16

Amendment, Extension or Termination of the Offer

The Company reserves the right, in its sole discretion to:

(a) terminate the Rights offer prior to delivery of the Units for which Rights holders have subscribed pursuant to the exercise of Rights in the primary subscription or the Over Subscription Privilege;

(b) extend the Expiration Date to a later date;

(c) change the record date prior to distribution of the Rights to shareholders; or

(d) amend or modify the terms of the Rights offer. If the Company amends the terms of the Rights offer, an amended Prospectus will be distributed to holders of record of Rights and to holders of Rights who have previously exercised Rights. All holders of Rights who exercise their Rights prior to such amendment or within four business days after the mailing of the amended Prospectus will be given the opportunity to confirm the exercise of their Rights by executing and delivering a consent form.

Any Rights holder who exercised Rights before or within four days after mailing of an amended Prospectus relating to an amendment of the Rights offer and fails to deliver, in a proper and timely manner, a properly executed consent form will be deemed to have rejected the amended terms of the Rights offer and have elected to revoke in full his exercise of the Rights and the Over Subscription Privilege. If a Rights holder's exercise of Rights is so revoked the full amount of the Subscription Price paid by such Right's holder will be returned to the Right's holder.

A Rights holder whose executed Subscription Certificate is received by the Subscription Agent more than four days after the mailing of an amended Prospectus will be deemed to have accepted any amended terms of the Rights offering in connection with the exercise of his Rights and the Over Subscription Privilege.

If the Company elects to terminate the Rights offer before delivering the Units for which Rights holders have subscribed, the Subscription Price paid will be returned by mail. Except for the obligation to return the Subscription Price paid by Right's holders who attempted to exercise their Rights, neither the Company or the Subscription Agent will have any obligation or liability to a Rights holder or purchaser of Rights in the event of an amendment or termination of the Rights offer.

Delivery of Share Certificates and Warrants

Certificates representing common stock and the warrants purchased pursuant to the primary subscription will be delivered to the purchasers as soon as practicable after the corresponding Rights have been validly exercised and full payment for such common stock and warrants represented by the Units has been received and cleared. Certificates representing common stock and the warrants purchased pursuant to the Over Subscription Privilege will be delivered to the purchaser as soon as practicable after the Expiration Date and after all allocations have been affected. It is expected that such stock certificates and warrant certificates will be available for delivery three business days following the Expiration Date.

Subscription Agent

The Subscription Agent is American Stock Transfer & Trust Company, which will receive for its administrative, processing, invoice and other services as subscription agent, a fee estimated at $15,000, and reimbursement for all out-of-pocket expenses related to the Rights offer. The Subscription Agent is also the Company's transfer agent and registrar and will serve as the Warrant Agent for the warrants. Questions regarding the Subscription Certificates should be directed to the American Stock Transfer & Trust Company, 59 Maiden Lane, Plaza Entrance, New York, New York 10038 (telephone:
(800) 937-5449). Shareholders may consult their brokers or nominees.

What Happens to Unsubscribed Units

To the extent that any unsubscribed Units remain as of the Expiration Date, they will expire.

17

Certain Federal Income Tax Considerations Regarding the Rights Offering

The following is a summary of certain income tax consequences to I3 and shareholders of I3 residing in the United States resulting from the Rights Offering. The discussion set forth below is based upon the Internal Revenue Code of 1986, as amended, the Treasury Regulations promulgated thereunder, judicial authority and current administrative rulings and pronouncements, as currently in effect. I3 has not requested a ruling from the Internal Revenue Service (the "IRS") with respect to the federal income tax consequences of the Rights Offering. Accordingly, no assurance can be given that the tax consequences will be as described below. Further, the federal income tax consequences to any particular shareholder may be affected by matters not discussed below. For example, certain types of investors (including individuals who are not United States citizens or residents, foreign corporations, life insurance companies and tax exempt organizations) may be subject to special rules not addressed herein. There also may be state, local or foreign tax considerations applicable to each shareholder. THE DISCUSSION SET FORTH BELOW IS INCLUDED FOR GENERAL INFORMATION ONLY. EACH SHAREHOLDER IS URGED TO CONSULT HIS OWN TAX ADVISOR AS TO THE CONSEQUENCES OF THE RIGHTS OFFERING TO HIM UNDER FEDERAL AND APPLICABLE STATE, LOCAL AND FOREIGN TAX LAWS.

Consequences of Rights Offering. The discussion of federal income tax consequences of the Rights Offering set forth below assumes that the shares of common stock owned by a shareholder and the shares issued pursuant to the Rights Offering constitute capital assets in the hands of such shareholder.

Subject to the assumptions and qualifications above, for federal income tax purposes:

1. A shareholder should not recognize any gain or loss upon his receipt of a Right.

2. If a shareholder exercises a Right, the tax basis of such Right in the hands of the shareholder will be determined by allocating the shareholder's existing tax basis for his shares with respect to which the Right was distributed ("Old Shares") between his Old Shares and the Right, in proportion to their relative fair market values on the date of distribution. If, however, the fair market value of the Rights distributed to the shareholder (on the date of distribution) is less than 15% of the fair market value of his Old Shares, the tax basis of each Right will be deemed to be zero unless the shareholder affirmatively elects, by attaching an election statement to his federal income tax return for the year in which he receives his Rights, to compute the tax basis of his Rights in accordance with the preceding sentence. Once made, such an election is irrevocable. A Right will not be treated as having any tax basis if it lapses and, therefore, the holder of an expired Right will not recognize a loss for tax purposes.

3. If a shareholder sells a Right, the shareholder will generally recognize capital gain or loss in an amount equal to the difference between the proceeds of the sale and the shareholder's tax basis for such Right. Such gain or loss will be long-term capital gain or loss if the shareholder's holding period for such Right (which will include the shareholder's holding period for his or her Old Shares) is more than one year on the date of sale. However, since the Rights are non-transferable, this provision of the tax law is inapplicable to the Rights.

4. No gain or loss will generally be recognized by a shareholder upon the purchase of a share pursuant to the exercise of a Right (or the Over-Subscription Privilege). The tax basis of the shares purchased pursuant to the exercise of Rights (or the Over-Subscription Privilege) will be equal to the sum of (a) the holder's tax basis for the Rights exercised, and (b) the Subscription Price paid for such shares. The holding period of the shares purchased pursuant to the exercise of Rights (or the Over-Subscription Privilege) will commence on the date of exercise. Upon the subsequent sale of such shares, the shareholder will generally recognize capital gain or loss in an amount equal to the difference between the proceeds of the sale and the shareholder's tax basis for such shares. Such gain or loss will be long-term capital gain or loss if the shareholder's holding period for such shares is more than one year on the date of sale.

5. I3 will generally not recognize any gain or loss upon (a) the issuance of Rights, (b) the receipt of payment for shares pursuant to the exercise of Rights (or the Over-Subscription Privilege) or (c) the lapse of Rights.

Participation of Certain Shareholders

Certain shareholders of I3, whom together own more than 50% of the Company's outstanding capital stock, have recently loaned I3 an aggregate of $823,500. Although there can be no assurance, the Company expects each of these shareholders to exercise his or her Rights to purchase shares of I3 common stock by canceling all or a portion of the principal amount of I3 debt owed to him or her in payment for Units.

18

USE OF PROCEEDS

The net proceeds to the Company from the sale of 38,229,157 Units offered hereby through the primary Rights offering are estimated to be approximately $1,146,875, assuming an offering price of $.03 per Unit, before deducting estimated offering expenses. With the balance of the funds, we will invest in new equipment and facilities and reduce short-term debt and current payables related to production equipment and supplies. Additional capital equipment for new product production lines is required for 2003 revenues. The balance of funds will be used for operations and general corporate purposes.

Facilities and Equipment................................          $  800,000

Debt Reduction..........................................          $  115,000

Legal and Fees..........................................          $   55,000

Working Capital.........................................          $  176,875

Total...................................................          $1,146,875

The amounts and timing of the Company's actual expenditures will depend on several factors, including the completion of equipment modifications and the amount of cash generated by the Company's operations. Pending such uses, the Company will invest the funds in short-term interest bearing accounts with a financial institution.

PRICE RANGE OF COMMON STOCK
AND DIVIDEND POLICY

The Company's Common Stock was quoted on the Nasdaq SmallCap Market under the symbol "INIS" from August 19, 1997, to April 2, 2001, at which time I3's stock was delisted from Nasdaq for failure to maintain a per share price of at least $1.00. Since that time, I3's common stock has been traded in the over the counter market in the "pink sheets." The table below sets forth, for the fiscal quarters indicated, the high and low sale prices for the Common Stock as reported by the Nasdaq SmallCap Market or the high and low closing bid prices as reported in the pink sheets, as the case may be.

                                                     High          Low
                                                     -----        -----
Fiscal Year Ended December 31, 2001
First Quarter                                        $0.35        $0.09
Second Quarter                                       $0.13        $0.04
Third Quarter                                        $0.09        $0.03
Fourth Quarter                                       $0.05        $0.02

Fiscal Year Ended December 31, 2002
First Quarter                                        $0.15        $0.02
Second Quarter                                       $0.13        $0.05
Third Quarter                                        $0.09        $0.05
Fourth Quarter                                       $0.06        $0.03

Fiscal Year Ending December 31, 2003
First Quarter                                        $0.06        $0.04
Second Quarter (through 7/21/03)                     $0.06        $0.03

19

On July 21, 2003, the last reported bid price for the Company's Common Stock as reported in the pink sheets was $.03. As of such date, there were approximately 320 holders of record of the Company's Common Stock (although the Company believes that the number of beneficial owners of its Common Stock is substantially higher).

We intend to retain any future earnings for use in the business and do not intend to pay cash dividends in the foreseeable future. The payment of future dividends, if any, will be at the discretion of the Company's Board of Directors and will depend, among other things, upon future earnings, operations, capital requirements, restrictions in future financing agreements, the general financial condition of the Company and general business conditions.

DESCRIPTION OF CAPITAL STOCK

The authorized capital stock of the Company consists of 250,000,000 shares of Common Stock, $.01 par value per share, and 5,000,000 shares of preferred Stock, $.01 par value per share ("Preferred Stock"). As of the date of this Prospectus, there are 95,572,893 shares of Common Stock issued and outstanding and held of record by approximately 320 stockholders and 850 issued and outstanding shares of Series B Preferred Stock.

Common Stock

The shares of Common Stock currently outstanding are, and the shares of Common Stock that will be outstanding upon the consummation of this Rights offering will be, validly issued, fully paid and non-assessable. Each holder of Common Stock is entitled to one vote for each share owned of record on all matters voted upon by the stockholders. In the event of a liquidation, dissolution or winding up of the Company, the holders of Common Stock are entitled to share equally and ratably in the assets of the Company, if any, remaining after the payment of all debts and liabilities of the Company and the liquidation preference of any outstanding Preferred Stock. The holders of the Common Stock have no preemptive rights or cumulative voting rights and there are no redemption, sinking fund or conversion provisions applicable to the Common Stock.

Holders of Common Stock are entitled to receive dividends if, as and when declared by the Board of Directors, out of funds legally available for such purpose, subject to the dividend and liquidation rights of any Preferred Stock that may be issued.

Preferred Stock

Pursuant to the Company's Restated Articles of Incorporation, the Board of Directors is authorized, without further action by the stockholders, to issue up to 5,000,000 shares of Preferred Stock in one or more series and to establish the designations, preferences, qualifications, privileges, limitations, restrictions, options, conversion rights and other special or relative rights of any series of Preferred Stock so issued. The issuance of shares of Preferred Stock could materially adversely affect the voting power and other rights of holders of Common Stock. Because the terms of the Preferred Stock may be fixed by the Board of Directors without stockholder action, the Preferred Stock could be issued quickly with terms designated to defeat a proposed takeover of the Company, or to make the removal of management or the directors of the Company more difficult. The authority to issue Preferred Stock or rights to purchase such stock could be used to discourage a change in control of the Company. Management of the Company is not aware of any threatened transactions to obtain control of the Company, and the Board has no current plans to issue any additional shares of Preferred Stock.

Series B Preferred Stock

The Series B Preferred Stock is redeemable at $1,000 per share in March 2022. The Series B Preferred Stock does not accrue a dividend and has no voting rights except in the case of certain major corporate actions.

20

Indemnification

As permitted by the Texas Business Corporation Act ("TBCA"), the Company's Restated Articles of Incorporation provide that the Company will indemnify its officers, directors, employees and agents to the fullest extent permitted by the TBCA against actions that may arise against them in such capacities and to advance expenses in connection with any such actions. The TBCA provides that a corporation may indemnify a person who was, is, or is threatened to be made a named defendant in a proceeding because such person is or was a director if it is determined in accordance with the provisions of the TBCA that the person (i) conducted himself in good faith, (ii) reasonably believed, in the case of conduct in his official capacity as director, that his conduct was in the corporation's best interests or, in other cases, that his conduct at least was not opposed to the corporation's interests and (iii) in the case of any criminal proceeding, had no reasonable cause to believe his conduct was unlawful. A director may not be indemnified with respect to a proceeding in which the person is found liable on the basis that personal benefit was improperly received by him, whether or not the benefit resulted from an action taken in the person's official capacity, or in which the person is found liable to the corporation. Officers, employees and agents of a corporation are entitled to be indemnified by the corporation as, and to the same extent provided for, directors of the corporation. The Company carries directors' and officers' liability insurance with an aggregate policy limit of $2,000,000.

Warrants

The warrants to be issued as part of the Units will entitle the holder thereof to purchase two additional shares of Common Stock for each Unit held. Each Unit includes one Series A Warrant with an exercise price of $.04 per share and one Series B Warrant exercisable at $.05 per share. The warrants are only exercisable on or prior to July 31, 2007. The warrants confer no voting rights until exercised for Common Stock. The Company has the right to redeem the warrants and repurchase them for $.001 per Warrant Share (the "Redemption Price") if the average closing price of I3's common stock equals or exceeds $.12 per share with respect to Series A Warrants and $.15 per share with respect to Series B Warrants for any 20 consecutive business day period. Warrant holders will be given a minimum of 30 days written notice of the date on which the Warrants will be redeemed. Holders of Warrants may exercise their Warrants up to the day before the Redemption Date, but thereafter their Warrant Certificates will only be exchangeable for the Redemption Price. The warrants are evidenced by Warrant Certificates that contain certain of the terms applicable to the warrants, but are also subject to the terms and conditions of a Warrant Agreement between the Company and the Warrant Agent. A copy of the Series A Warrant Agreement appears as Exhibit D to this Prospectus and a copy of the form of Series A Warrant Certificate is included as Exhibit E. The Series B Warrant Agreement and Series B Warrant Certificate are identical except for the amount of the Warrant Exercise Price and the Company Call Price.

Trading Market, Transfer Agent and Registrar

The Common Stock is traded in the over the counter market in the pink sheets under the symbol "INIS." American Stock Transfer & Trust Company, New York, New York is the transfer agent and registrar for the Common Stock.

Anti-Takeover Measures

As a Texas corporation, the Company is subject to the provisions of the TBCA that became effective on September 1, 1997. In general, the TBCA prohibits a Texas "issuing public corporation" (such as the Company) from engaging in a "business combination" with any shareholder who is a beneficial owner of 20% or more of the corporation's outstanding stock for a period of three years after such shareholder's acquisition of a 20% ownership interest, unless: (i) the board of directors of the corporation approves the transaction or the shareholder's acquisition of shares prior to the acquisition or (ii) two-thirds of the unaffiliated shareholders of the corporation approve the transaction at a shareholders' meeting. The TBCA may have the effect of inhibiting a non-negotiated merger or other business combination involving the Company. The Company is subject to the terms of the TBCA, unless its shareholders or directors take action electing not to be governed by its terms (which action is not currently contemplated).

21

LEGAL MATTERS

The validity of the shares of Common Stock and Warrants comprising the Units offered by the Company hereby will be passed upon for the Company by Locke Liddell & Sapp LLP.

EXPERTS

The consolidated balance sheets of International Isotopes Inc. and subsidiaries as of December 31, 2002, and 2001, and the consolidated statements of operations, stockholder deficit, and cash flows for the years then ended incorporated by reference in this prospectus, have been included in reliance upon the report of Hansen, Barnett & Maxwell, independent certified public accountants, given on the authority of that firm as experts in accounting and auditing.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

I3's Form 10-KSB for the fiscal year ended December 31, 2002, Form 10-QSB for the three months ended March 31, 2003, and all other reports filed by I3 pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, since the end of the fiscal year covered by such Form 10-KSB are incorporated into this prospectus by reference. I3 will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any and all of the information that has been incorporated by reference but not delivered with this prospectus. Such requests may be addressed to the Secretary of I3 at 4137 Commerce Circle, Idaho Falls, Idaho 83401; Telephone: (208) 524-5300.

I3 is subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith files quarterly, annual, and current reports and proxy statements and other information with the Securities and Exchange Commission. The public may read and copy any materials I3 files with the Securities and Exchange Commission at the Commission's Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330. The Commission maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Commission. The address of such site is http://www.sec.gov.

ADDITIONAL INFORMATION

The Company has filed with the Securities and Exchange Commission, Washington, D.C. 20549, a Registration Statement on Form S-3 under the Securities Act with respect to the Common Stock and Warrants offered hereby. This Prospectus does not contain all of the information set forth in the Registration Statement and exhibits and schedules thereto, certain parts of which having been omitted in accordance with the rules and regulations of the Commission. For further information with respect to the Company and the Common Stock, reference is made to the Registration Statement and the exhibits and schedules thereto which may be inspected and copied at the public reference facilities of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549. Copies of such material can be obtained from the Commission's Public Reference
Section at prescribed rates. The Commission maintains a Web site that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval ("EDGAR") system. The address of the Commission's Web site is http/www.sec.gov. The Registration Statement including all exhibits thereto and amendments thereof, has been filed with the Commission through EDGAR. Descriptions contained in this prospectus as to the contents of any contract or other documents filed as an exhibit to the Registration Statement are not necessarily complete and each such description is qualified by reference to such contract or document.

22

EXHIBIT A

Form of Subscription Certificate

A-1

 CERTIFICATE NUMBER                           INTERNATIONAL ISOTOPES INC.                            NUMBER OF RIGHTS
 ------------------                                                                                --------------------
                                          SUBSCRIPTION CERTIFICATE FOR RIGHTS

                                     SUBSCRIPTION CERTIFICATE FOR UNITS VOID IF NOT        SUBSCRIPTION PRICE U.S. $.03 PER UNIT
                                       EXERCISED AT OR BEFORE 5:00 P.M. (NEW YORK
                                      TIME) ON SEPTEMBER 12, 2003, THE EXPIRATION
                                       DATE. THIS SUBSCRIPTION CERTIFICATE IS NOT
                                                     TRANSFERABLE.

EXPIRATION DATE: September 12, 2003

THIS  SUBSCRIPTION   CERTIFICATE
MAY BE  USED  TO  SUBSCRIBE  FOR
UNITS. FULL INSTRUCTIONS  APPEAR
ON THE BACK OF THIS SUBSCRIPTION
CERTIFICATE.

REGISTERED OWNER:

The  registered  owner  of  this
Subscription Certificate,  named
above is  entitled to the number
of Rights to subscribe for Units
(each Unit consisting of (i) one
share of common stock, par value
$.01 per share,  (ii) one Series
A   Warrant   to   purchase   an
additional  share  at  $.04  per
share,  and (iii)  one  Series B
Warrant  to   purchase   another
share  at  $.05  per  share)  of
International    Isotopes   Inc.
shown above, in the ratio of one
Unit for each 2.5  Rights  held,
and   upon   the    terms    and
conditions  and at the price for
each  Unit   specified   in  the
Prospectus dated July 24, 2003.

Date:  _______________, 2003                                                     IMPORTANT:  Complete appropriate form on reverse.

   INTERNATIONAL ISOTOPES INC.
                                                                                       -------------------------------------
                                                                                                     PRESIDENT
   ---------------------------
            SECRETARY

A-2

                                                                      Expiration Date:  September 12, 2003



                             PLEASE COMPLETE ALL APPLICABLE INFORMATION


          By Mail:                            By Hand:                      By Overnight Courier:
 To:  American Stock Transfer        To:  American Stock Transfer        To:  American Stock Transfer
 & Trust Company                     & Trust Company                     & Trust Company
 59 Maiden Lane, Plaza Entrance      59 Maiden Lane, Plaza Entrance      59 Maiden Lane, Plaza Entrance
 New York, New York  10038           New York, New York  10038           New York, New York  10038


TO SUBSCRIBE:  I hereby irrevocably  subscribe for the dollar amount of Units indicated as the total
of A and B below upon the terms and conditions  specified in the Prospectus related hereto,  receipt
of which is acknowledged.

      Please check |_| below:

| |   A.  Subscription:

                        / 2.5 =             .000  x         $.03          =  $
      ------------------       -----------------     --------------------    -----------------
      (Rights Exercised)       (Units Requested)     (Subscription Price)    (Amount Required)

| |   B.  Over-Subscription Privilege:*

                                            .000  x         $.03          =  $
                               -----------------     --------------------    -----------------
                               (Units Requested)     (Subscription Price)    (Amount Required)

      C.  Total Subscription Price:  (A + B)                              =  $
                                                                             -----------------
      D.  Method of Payment (Check and Complete Appropriate Box(es)):

| |   Check in the amount of $_________ payable to Subscription Agent.
| |   Certified Check, bank draft or money order in the amount of $_________ payable to Subscription
      Agent.
| |   Wire transfer in the amount of $_________ directed to American Stock Transfer & Trust Company,
      Subscription  Agent,  JP Morgan  Chase Bank  WIRE  CLEARING  ACCOUNT  ABA #021000021,  Account
      #323890121, Attention: Reorg. Dept.
| |   Cancellation of Debt in the principal amount of $__________ owed by I3 to the undersigned.

      E.  Notice of Guaranteed Delivery:

| |   CHECK HERE IF RIGHTS ARE  BEING EXERCISED  PURSUANT TO A NOTICE OF GUARANTEED  DELIVERY TO THE
      SUBSCRIPTION AGENT PRIOR TO THE EXPIRATION DATE AND COMPLETE THE FOLLOWING:

      Name(s) of Registered Owner(s)_________________________________________________________
      Window Ticket Number (if any)__________________________________________________________
      Date of Execution of Notice of Guaranteed Delivery_____________________________________
      Name of Eligible Institution which Guaranteed Delivery_________________________________
      Registered Owner(s) Telephone Number___________________________________________________


                                    SPECIAL DELIVERY INSTRUCTIONS

Unless otherwise  indicated below, the Subscription  Agent is hereby authorized to issue and deliver
stock  certificates  and warrants to the  undersigned  at the address  appearing on the face of this
Subscription Certificate.

| |   Check this box if stock  certificates and warrants  are to be issued in a name other than that
      of the Rights Holder.

A-3

EXHIBIT B

Form of Notice of Guaranteed Delivery

B-1

NOTICE OF GUARANTEED DELIVERY OF
SUBSCRIPTION RIGHTS AND THE
SUBSCRIPTION PRICE FOR UNITS OF
INTERNATIONAL ISOTOPES INC.
SUBSCRIBED FOR IN THE RIGHTS OFFER

As set forth in the Prospectus under "The Rights Offer - Payment for Units," this form or one substantially equivalent may be used as a means of effecting subscription and payment for all Units of International Isotopes Inc. ("I(3)") subscribed for in the Rights offer. Such form may be delivered by hand or sent by facsimile transmission, overnight courier or mail to the Subscription Agent.

The Subscription Agent is:


American Stock Transfer & Trust Company

General Information
(800) 937-5449

                By Mail:                                   By Facsimile:
American Stock Transfer & Trust Company                   (718) 234-5001
    59 Maiden Lane, Plaza Entrance                     Confirm by Telephone
      New York, New York  10038                           (800) 937-5449

               By Hand:                                By Overnight Courier:
American Stock Transfer & Trust Company       American Stock Transfer & Trust Company
    59 Maiden Lane, Plaza Entrance                59 Maiden Lane, Plaza Entrance
       New York, New York  10038                     New York, New York  10038

DELIVERY OF THIS INSTRUMENT TO AN ADDRESS,
OR TRANSMISSION OF INSTRUCTIONS VIA
A TELECOPY OR FACSIMILE NUMBER, OTHER THAN AS
SET FORTH ABOVE, DOES NOT CONSTITUTE A VALID DELIVERY

The New York Stock Exchange member firm or bank or trust company which completes this form must communicate the guarantee and the number of Units subscribed for to the Subscription Agent and must deliver this Notice of Guaranteed Delivery guaranteeing delivery of (i) payment in full for all subscribed Units (including any Units subscribed for through the over-subscription privilege) and (ii) a properly completed and executed Subscription Certificate (which certificate and full payment must then be delivered by the close of business on the third business day after the expiration date) to the Subscription Agent prior to 5:00 p.m., New York time, on the expiration date (September 12, 2003, unless extended). Failure to do so will result in a forfeiture of the Rights.

B-2

GUARANTEE

The undersigned, a member firm of the New York Stock Exchange or a bank or trust company, guarantees delivery to the Subscription Agent by the close of business (5:00 p.m., New York time) on the third business day after the expiration date (September 17, 2003, unless extended) of (A) a properly completed and executed Subscription Certificate and (B) payment of the full subscription price of Units subscribed for in the Rights offer (including the over-subscription privilege, if applicable) as subscription for such Units as indicated herein or in the Subscription Certificate.

-------------------------------------------    ---------------------------------
Number of Units subscribed for                 Number of Units subscribed for
(excluding the over-subscription privilege)    pursuant to the over-subscription
for which you are guaranteeing delivery        privilege for which you are
of Rights and payment                          guaranteeing delivery of Rights
                                               and payment

Number of Rights to be delivered:              _____________________________

Total subscription price payment
to be delivered:                               $_____________________________

Method of delivery [circle one]                A.  Through DTC
                                               B.  Direct to Corporation

Please note that if you are guaranteeing for over-subscription Units, and are a DTC participant, you must also execute and forward to American Stock Transfer & Trust Company a Nominee Holder Over-Subscription Exercise Form.

------------------------------                -----------------------------
Name of Firm                                  Authorized Signature

------------------------------                -----------------------------
Address                                       Title

------------------------------                -----------------------------
Zip Code                                      (Type or Print)

------------------------------                -----------------------------
Name of Registered Holder (If Applicable)

------------------------------                -----------------------------
Telephone Number                              Date

IF THE RIGHTS ARE TO BE DELIVERED THROUGH DTC, A REPRESENTATIVE OF THE SUBSCRIPTION AGENT WILL PHONE YOU WITH A PROTECT IDENTIFICATION NUMBER, WHICH NEEDS TO BE COMMUNICATED BY YOU TO DTC.

PLEASE NOTE THAT IF YOU ARE GUARANTEEING FOR OVER-SUBSCRIPTION UNITS AND ARE A DTC PARTICIPANT YOU MUST ALSO EXECUTE AND FORWARD TO THE SUBSCRIPTION AGENT A NOMINEE HOLDER OVER-SUBSCRIPTION EXERCISE FORM.

B-3

EXHIBIT C

Form of Nominee Holder Over Subscription Exercise Form

C-1

INTERNATIONAL ISOTOPES INC.
RIGHTS OFFER
NOMINEE HOLDER OVER-SUBSCRIPTION EXERCISE FORM
PLEASE COMPLETE ALL APPLICABLE INFORMATION

         By Mail:                         By Hand:                   By Overnight Courier:
To: American Stock Transfer      To: American Stock Transfer      To: American Stock Transfer
& Trust Company                  & Trust Company                  & Trust Company
59 Maiden Lane, Plaza Entrance   59 Maiden Lane, Plaza Entrance   59 Maiden Lane, Plaza Entrance
New York, New York  10038        New York, New York  10038        New York, New York  10038

THIS FORM IS TO BE USED BY NOMINEE HOLDERS TO EXERCISE THE OVER-SUBSCRIPTION PRIVILEGE IN RESPECT OF RIGHTS THAT WERE EXERCISED AND DELIVERED THROUGH THE FACILITIES OF A COMMON DEPOSITORY. ALL OTHER EXERCISES OF OVER-SUBSCRIPTION PRIVILEGES MUST BE EFFECTED BY THE DELIVERY OF THE SUBSCRIPTION CERTIFICATES.


THE TERMS AND CONDITIONS OF THE RIGHTS OFFER ARE SET FORTH IN INTERNATIONAL ISOTOPES' PROSPECTUS DATED: JULY 24, 2003 (THE "PROSPECTUS") AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM INTERNATIONAL ISOTOPES.


VOID UNLESS RECEIVED BY THE SUBSCRIPTION AGENT WITH PAYMENT IN FULL BY 5:00 P.M., NEW YORK TIME, ON SEPTEMBER 12, 2003, UNLESS EXTENDED BY INTERNATIONAL ISOTOPES (THE "EXPIRATION DATE").

1. The undersigned hereby certifies to the Subscription Agent that it is a participant in ___________________ [Name of Depository] (the "Depository") and that it has either (i) exercised all of the Rights and delivered such exercised Rights to the Subscription Agent by means of transfer to the Depository Account of International Isotopes Inc., or (ii) delivered to the Subscription Agent a Notice of Guaranteed Delivery in respect of the exercise of the Rights and will deliver the Rights called for in such Notice of Guaranteed Delivery to the Subscription Agent by means of transfer to such Depository Account of International Isotopes Inc.

2. The undersigned hereby exercises the over-subscription privilege to purchase, to the extent available, Units and certifies to the Subscription Agent that such over-subscription privilege is being exercised for the account or accounts of persons (which may include the undersigned) on whose behalf all Rights have been exercised. (*)

3. The undersigned understands that payment of the subscription price of $.03 per Unit for each Unit (each Unit consists of one share of common stock and two warrants to purchase an additional two shares) subscribed for pursuant to the over-subscription privilege must be received by the Subscription Agent at or before 5:00 p.m., New York time, on the Expiration Date, and represents that such payment, in the aggregate amount of $___________ either (check appropriate box):

| | has been or is being delivered to the Subscription Agent pursuant to the Notice of Guaranteed Delivery referred to above or;

| | is being delivered to the Subscription Agent herewith; or

| | has been delivered separately to the Subscription Agent;

C-2

and, in the case of funds not delivered pursuant to a Notice of Guaranteed Delivery, is or was delivered in the manner set forth below (check appropriate box and complete information relating thereto):

| | uncertified check

| | certified check

| | bank draft

| | money order

| | cancellation of debt

________________________________________       ________________________________
Depository Subscription Confirmation           Name of Nominee Holder
Number

________________________________________       ________________________________
Depository Participant Number                  Address

Contact Name ___________________________       ________________________________
                                               City        State       Zip Code

Phone Number____________________________       By:_____________________________


Dated:___________________, 2003                Name:___________________________


                                               Title:__________________________

* PLEASE COMPLETE THE BENEFICIAL OWNER CERTIFICATION ON THE BACK HEREOF CONTAINING THE RECORD DATE POSITION OF RIGHTS OWNED, THE NUMBER OF UNITS SUBSCRIBED FOR (OTHER THAN OVER-SUBSCRIPTIONS) AND THE NUMBER OF OVER-SUBSCRIPTION UNITS, IF APPLICABLE, REQUESTED BY EACH SUCH OWNER.

C-3

INTERNATIONAL ISOTOPES INC.
BENEFICIAL OWNER CERTIFICATION

The undersigned, a bank, broker or other nominee holder of Rights ("Rights") to purchase Units (one share of common stock plus one warrant to purchase an additional share) ("Units") of International Isotopes Inc. ("I(3)") pursuant to the Rights offer described and provided for in I(3)'s Prospectus dated July 24, 2003 (the "Prospectus") hereby certifies to I(3) and to American Stock Transfer & Trust Company, as Subscription Agent for such Rights offer, that for each numbered line filled in below the undersigned has exercised, on behalf of the beneficial owner thereof (which may be the undersigned), the number of Rights specified on such line, and such beneficial owner wishes to subscribe for the purchase of additional Units pursuant to the over-subscription privilege (as defined in the Prospectus), in the amount set forth in the third column of such line:

Number of Units Requested Pursuant to the Record Date Shares Number of Rights Exercised Over-Subscription Privilege

     ------------------  --------------------------  ---------------------------
1.
     ------------------  --------------------------  ---------------------------
2.
     ------------------  --------------------------  ---------------------------
3.
     ------------------  --------------------------  ---------------------------
4.
     ------------------  --------------------------  ---------------------------
5.
     ------------------  --------------------------  ---------------------------
6.
     ------------------  --------------------------  ---------------------------
7.
     ------------------  --------------------------  ---------------------------
8.
     ------------------  --------------------------  ---------------------------
9.
     ------------------  --------------------------  ---------------------------
10.
     ------------------  --------------------------  ---------------------------


 ------------------------------                  -------------------------------
 Name of Nominee Holder                          Depository Participant Number


 ------------------------------                  -------------------------------
 Name:                                           Depository Primary Subscription
 Title:                                          Confirmation Number(s)

Dated: ___________, 2003

C-4

EXHIBIT D

Form of Warrant Agreement

D-1

SERIES A WARRANT AGREEMENT

AGREEMENT, dated as of this 15th day of July, 2003, by and between INTERNATIONAL ISOTOPES INC., a Texas corporation (the "Company") and AMERICAN STOCK TRANSFER & TRUST COMPANY, as warrant agent (the "Warrant Agent").

WHEREAS, in connection with a Rights Offering by the Company to its existing shareholders the Company is offering Rights to purchase Units of its securities consisting of (i) one share of Common Stock at $.03 per share, (ii) one warrant to purchase an additional share of Common Stock at $.04 per share (the "Series A Warrants"), and (iii) one warrant to purchase another share of Common Stock for $.05 per share (the "Series B Warrants");

WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, and exchange of the Series A Warrants, the issuance of certificates representing the Series A Warrants, the exercise of the Series A Warrants, and the rights of the Registered Holders thereof;

NOW THEREFORE, in consideration of the premises and the mutual agreements hereinafter set forth and for the purpose of defining the terms and provisions of the Series A Warrants and the certificates representing the Series A Warrants and the respective rights and obligations thereunder of the Company, the Registered Holders of certificates representing the Series A Warrants and the Warrant Agent, the parties hereto agree as follows:

1. Definitions. As used herein, the following terms shall have the following meanings, unless the context shall otherwise require:

(a) "Common Stock" shall mean the Common Stock of the Company, par value of $.01 per share.

(b) "Corporate Office" shall mean the office of the Warrant Agent (or its successor) at which at any particular time its principal business shall be administered, which office is located as of the date hereof at 59 Maiden Lane, Plaza Entrance, New York, New York 10038.

(c) "Depository" shall mean the Depository Trust Company or other securities depository serving the purpose of a book-entry registration and transfer system.

(d) "Exercise Price" shall mean the purchase price to be paid upon exercise of each Warrant in accordance with the terms hereof, which price shall be $.04 per share, subject to adjustment from time to time pursuant to the provisions of Section 6 hereof.

(e) "Registered Holder" shall mean the person in whose name any certificate representing Warrants shall be registered on the books maintained by the Warrant Agent pursuant to Section 7.

(f) "Redemption Price" shall mean $.001 per Warrant Share.

(g) "Transfer Agent" shall mean American Stock Transfer & Trust Company, as the Company's transfer agent, or its authorized successor, as such.

(h) "Warrant Shares" shall mean shares of Common Stock issuable upon exercise of Warrants.

(i) "Warrants" or "Series A Warrants" shall mean the Series A Warrants issued to Registered Holders pursuant to the terms of this Series A Warrant Agreement.

D-2

2. Warrants and Issuance of Warrant Certificates.

(a) A Warrant shall initially entitle the Registered Holder of the Warrant Certificate representing such Warrant to purchase one share of Common Stock upon the exercise thereof, in accordance with the terms hereof, subject to modification and adjustment as provided in Section 6.

(b) From time to time, up to the Warrant Expiration Date, the Transfer Agent shall execute and deliver stock certificates in required whole number denominations representing up to an aggregate of 38,229,157 shares of Common Stock, subject to adjustment as described herein, upon the exercise of Warrants in accordance with this Agreement.

(c) From time to time, up to the Warrant Expiration Date, the Warrant Agent shall execute and deliver Warrant Certificates in required whole number denominations to the persons entitled thereto in connection with any transfer or exchange permitted under this Agreement; provided that no Warrant Certificates shall be issued except
(i) those initially issued hereunder, (ii) those issued upon the exercise of fewer than all Warrants represented by any Warrant Certificate, to evidence any unexercised Warrants held by the exercising Registered Holder, (iii) those issued upon any transfer or exchange pursuant to Section 7; (iv) those issued in replacement of lost, stolen, destroyed or mutilated Warrant Certificates pursuant to
Section 8; and (v) at the option of the Company, in such form as may be approved by its Board of Directors, to reflect (a) any adjustment or change in the Exercise Price or the number of shares of Common Stock purchasable upon exercise of the Warrants, made pursuant to Section 6 hereof and (b) other modifications approved by Warrantholders in accordance with Section 13.4 hereof.

3. Form and Execution of Warrant Certificates.

(a) The Warrant Certificates shall be substantially in the form annexed hereto as Exhibit A (the provisions of which are hereby incorporated herein) and may have such letters, numbers or other marks of identification or designation and such legends, summaries or endorsements printed, lithographed, engraved or typed thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Agreement, or as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any stock exchange on which the Warrants may be listed, or to conform to usage. The Warrant Certificates shall be dated the date of issuance thereof (whether upon initial issuance, transfer, exchange or in lieu of mutilated, lost, stolen, or destroyed Warrant Certificates) and issued in registered form. Warrants shall be numbered serially with the letters AW.

(b) Warrant Certificates shall be executed on behalf of the Company by its Chairman of the Board, President or any Vice President and by its Secretary or an Assistant Secretary, by manual signatures or by facsimile signatures printed thereon. In case any officer of the Company who shall have signed any of the Warrant Certificates shall cease to be such officer of the Company before the date of issuance of the Warrant Certificates and issue and delivery thereof, such Warrant Certificates may nevertheless be issued and delivered with the same force and effect as though the person who signed such Warrant Certificates had not ceased to be such officer of the Company. After execution by the Company, Warrant Certificates shall be delivered by the Warrant Agent to the Registered Holder.

D-3

4. Cash Exercise and Redemption

4.1 Optional Exercise

Warrants may be exercised by a Registered Holder, at any time until July 31, 2007 (the "Warrant Expiration Date"), in whole or in part, by delivering to the Warrant Agent at 59 Maiden Lane, Plaza Entrance, New York, New York 10038 (or such other office or agency of the Warrant Agent as it may designate by notice in writing to the Registered Holder at the address of the Registered Holder appearing on the books of the Warrant Agent) (a) either (i) such Warrants by book-entry transfer through the facilities of the Depository or
(ii) the Warrant Certificates evidencing the Warrants if Warrant Certificates have been issued to the Registered Holder, (b) a certified or cashier's check payable to the Company or a wire transfer in the amount of the Exercise Price multiplied by the number of shares for which the Warrant is being exercised (the "Purchase Price"), and (c) written notice of such election to exercise, designated "International Isotopes Inc. Warrant Exercise," by hand or by facsimile, which notice shall be in the form of an election to purchase shares of Common Stock of the Company substantially in the form set forth on the reverse side of the Warrant Certificate, properly completed and executed by the Registered Holder. The Warrant Agent shall forward to the Company the Purchase Price received as a result of any exercise of Warrants by wire transfer within 2 business days.

4.2 Redemption

(a) Provided that adequate provision has been made therefor, upon the resolution of its Board of Directors , the Company may, but shall not be required to, call for redemption at a redemption price of $.001 per Warrant Share (the "Redemption Price") all of the Warrants at any time, provided: (i) it provides to each Registered Holder of Warrants to be redeemed a minimum of thirty (30) days' prior written notice, and (ii) if the average closing price or bid price of the Common Stock, as reported by the principal exchange on which the Common Stock is traded, the NASDAQ Stock Market, Inc., the OTC Bulletin Board or the Pink Sheet LLC, as the case may be, equals or exceeds $.12 for twenty (20) consecutive trading days ending within 180 days prior to the date of issuance of the notice of redemption. In such an event, the Company shall cause to be filed with the Warrant Agent a certified copy of such resolution and a form of notice of redemption and the Warrant Agent shall mail to each of the Registered Holders of the Warrant Certificates to be redeemed, by first class mail, postage prepaid, to his last address appearing on the records of the Warrant Agent, such written notice of such redemption. Such notice shall identify the Warrants to be redeemed, state the date set for redemption (the "Redemption Date"), the Redemption Price, and the date upon which the Registered Holder's right to exercise the Warrants will terminate, and describe the manner in which Warrant Certificates are to be surrendered. Any notice mailed in the manner provided herein shall be conclusively presumed to have been duly given whether or not the Registered Holder receives such notice. Failure to mail notice to any Registered Holder, shall not affect the validity of any other redemptions for which notice had been duly provided, only redemptions of persons lacking notice.

(b) On or before the Redemption Date, each Registered Holder of Warrants to be redeemed, unless he has previously exercised or will exercise such Warrants on or before the Redemption Date, shall surrender the Warrant Certificate or Certificates representing such Warrants to the Warrant Agent. The Warrants to be redeemed shall be exercisable up to and including the date immediately preceding the Redemption Date. Upon receipt of such Warrant Certificates, the Warrant Agent, as paying agent, shall pay the Redemption Price for such Warrants to the order of the Registered Holders thereof. Any Warrants to redeemed will be canceled by the Warrant Agent upon receipt. After the Redemption Date, all rights with respect to such Warrants shall cease, except for the right to receive the Redemption Price of the Warrants.

(c) Upon or prior to the Redemption Date, the Company shall deposit in trust with the Warrant Agent a sum equal to the Redemption Price of all Warrants called for redemption, with irrevocable instructions and authority to the Warrant Agent to pay, on and after the Redemption Date, the Redemption Price to the Registered Holders upon the surrender of the Warrant Certificates. The deposit shall constitute full payment of the Warrants to the Registered Holders, and from and after the date of the deposit, the Warrants shall be deemed to be no longer outstanding. The balance of the deposit remaining unclaimed at the end of one year from the Redemption Date shall be released to the Company, after which the holders of Warrants called for redemption shall be entitled to receive payment of the Redemption Price only from the Company.

D-4

5. Delivery of Stock Certificates; No Fractional Shares

5.1 Within ten (10) business days after the payment of the Purchase Price following the exercise by a Registered Holder of a Warrant (in whole or in part), the Warrant Agent, at Company expense, shall issue or cause the Company's stock transfer agent to issue in the name of and deliver to the Registered Holder (a) a certificate or certificates for the number of fully paid and nonassessable Warrant Shares to which the Registered Holder shall be entitled upon such exercise, and (b) a new Warrant of like tenor to purchase up to that number of Warrant Shares, if any, as to which such Warrant has not been exercised if such Warrant has not expired. The Registered Holder shall for all purposes be deemed to have become the holder of record of such Warrant Shares on the date such Warrant was exercised (the date the Registered Holder has fully complied with the requirements of Section 4.1), irrespective of the date of delivery of the certificate or certificates representing the Warrant Shares; provided that, if the date such exercise is made is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of record of such Warrant Shares at the close of business on the next succeeding date on which the stock transfer books are open.

5.2 No fractional shares shall be issued upon the exercise of any Warrant. In lieu of fractional shares, the Company shall pay the Registered Holder a sum in cash equal to the Daily Price (as defined below) of the fractional share on the date of exercise.

"Daily Price" of a Warrant Share shall mean:

(a) If the Company's Common Stock is listed and traded on an exchange or is quoted on the Nasdaq National Market, the closing or last sale price on such day;

(b) If the Company's Common Stock is not traded on and exchange or quoted on the Nasdaq National Market, but is traded in the over-the-counter market, the average of the closing bid and asked prices reported on such day; and

(c) If none of the above is applicable, the Daily Price shall be the fair market value of the Common Stock as determined in good faith by the Company's Board of Directors.

6. Adjustments Upon Certain Events

6.1 Effect of Reorganization

(a) Reorganization - No Change of Control

Upon a merger, consolidation, acquisition of all or substantially all of the property or stock, liquidation or other reorganization of the Company (collectively, a "Reorganization") during the Exercise Period, as a result of which the shareholders of the Company receive cash, stock or other property in exchange for their shares of Common Stock and the holders of the Company's voting equity securities immediately prior to the Reorganization together own a majority interest of the voting equity securities of the successor corporation following such Reorganization, lawful provision shall be made so that the holder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of shares of securities of the successor corporation resulting from such Reorganization (and cash and other property), to which a holder of the Warrant Shares issuable upon exercise of a Warrant would have been entitled in such Reorganization if such Warrant had been exercised immediately prior to such Reorganization. In any such case, appropriate adjustment (as determine in good faith by the Company's Board of Directors) shall be made in the application of the provisions of the Warrants with respect to the rights and interest of the Registered Holders after the Reorganization to the end that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and the number and type of securities purchasable pursuant to the terms of this Warrant Agreement) shall be applicable after that event, as near as reasonably may be, in relation to any shares deliverable after that event upon the exercise of any Warrant.

D-5

(b) Reorganization - Change of Control; Termination of Warrant

Upon a Reorganization prior to or during the Exercise Period, as a result of which the shareholders of the Company receive cash, stock or other property in exchange for their shares of Common Stock and the holders of the Company's voting equity securities immediately prior to such Reorganization together own less than a majority interest of the voting equity securities of any successor corporation following such Reorganization, Registered Holders of Warrants shall be given notice at least ten (10) days prior to the effectiveness thereof. Notwithstanding any other provision hereof, the Warrants shall become immediately exercisable in full upon such notice to the Registered Holders, subject to the effectiveness of the Reorganization, provided, however, that such acceleration of exercisability will not occur if, in the opinion of the Company's outside accountants, such acceleration would render unavailable "pooling of interests" accounting treatment for any Reorganization for which pooling of interests accounting treatment is sought by the Company (in which event, lawful provision shall be made so that the Registered Holders shall thereafter be entitled to receive, upon exercise of their Warrants up to the Warrant Expiration Date, the number of shares of securities of the successor corporation resulting from such Reorganization (and cash and other property) to which a Registered Holder of the Warrant Stock issuable upon exercise of such Warrants would have been entitled in such Reorganization if such Warrant had been exercised immediately prior to such Reorganization). Each Registered Holder shall have five (5) days from the receipt of such notice to give notice to the Warrant Agent, on behalf of the Company, whether it intends to conditionally exercise his Warrant, in whole or in part. Notwithstanding any other provision hereof, Warrants shall become forever null and void to the extent not conditionally exercised on or before 5:00 p.m., Eastern time, on the fifth day following the receipt by the Registered Holders thereof of notice of the proposed Reorganization (unless the acceleration of exercisability is denied by the Company in order to preserve "pooling of interests" accounting treatment as set forth above).

6.2 Adjustments for Stock Splits, Dividends

If the Company shall issue any shares of the same class as the Warrant Stock as a stock dividend or subdivide the number of outstanding shares of the same class as the Warrant Shares into a greater number of shares, then, in either such case, the Exercise Price in effect before such dividend or subdivision shall be proportionately reduced and the number of Warrant Shares at that time issuable pursuant to the exercise of the Warrants shall be proportionately increased; and, conversely, if the Company shall contract the number of outstanding shares of the same class as the Warrant Shares by combining such shares into a smaller number of shares, then the Exercise Price in effect before such combination shall be proportionately increased and the number of Warrant Shares at that time issuable pursuant to the exercise or conversion of the Warrants shall be proportionately decreased. Each adjustment in the number of Warrant Shares issuable shall be to the nearest whole share.

6.3 Certificate as to Adjustments

In the case of any adjustment in the Exercise Price or number and type of securities issuable upon exercise of the Warrants, the Company will promptly give written notice to the Registered Holders through the Warrant Agent in the form of a certificate, certified and confirmed by an officer of the Company, setting forth the adjustment in reasonable detail.

7. Exchange and Registration of Transfer.

(a) Warrant Certificates may be exchanged for other Warrant Certificates representing an equal aggregate number of Warrants of the same class or may be transferred in whole or in part. Warrant Certificates to be exchanged shall be surrendered to the Warrant Agent at its Corporate Office, and upon satisfaction for the terms and provisions hereof, the Company shall execute, and the Warrant Agent shall countersign, issue and deliver in exchange therefor the Warrant Certificate or Certificates which the Registered Holder making the exchange shall be entitled to receive.

D-6

(b) The Warrant Agent shall keep at its office books in which, subject to such reasonable regulations as it may prescribe, it shall register Warrant Certificates and the transfer thereof in accordance with its regular practice. Upon due presentment for registration of transfer of any Warrant Certificate at its office, the Company shall execute and the Warrant Agent shall issue and deliver to the transferee or transferees a new Warrant Certificate or Certificates representing an equal aggregate number of Warrants.

(c) With respect to all Warrant Certificates presented for registration of transfer, or for exchange or exercise, the subscription form on the reverse thereof shall be duly endorsed, or be accompanied by a written instrument or instruments of transfer and subscription, in form satisfactory to the Company, duly executed by the Registered Holder or his attorney-in-fact duly authorized in writing.

(d) The Company may require payment by such holder of a sum sufficient to cover any tax or other governmental charge that may be imposed in connection therewith.

(e) All Warrant Certificates surrendered for exercise or for exchange in case of mutilated Warrant Certificates shall be promptly cancelled by the Warrant Agent and thereafter retained by the Warrant Agent until termination of this Agreement or resignation of the Warrant Agent.

(f) Prior to due presentment for registration of transfer thereof, the Company and the Warrant Agent may deem and treat the Registered Holder of any Warrant Certificate as the absolute owner thereof and of each Warrant represented thereby (notwithstanding any notations of ownership or writing thereon made by anyone other than a duly authorized officer of the Company or the Warrant Agent) for all purposes and shall not be affected by any notice to the contrary.

8. Lost or Damaged Warrant Certificate

Upon receipt by the Warrant Agent of satisfactory evidence of the loss, theft, destruction or damage of any Warrant and either (in the case of loss, theft or destruction) reasonable indemnification or (in the case of damage) the surrender of such Warrant for cancellation, the Warrant Agent will execute and deliver to the Registered Holder, without charge, a new Warrant of like denomination.

9. Covenants as to Warrant Shares

9.1 Reservation of Shares

The Company covenants that at all times during the Exercise Period there shall be reserved for issuance and delivery upon exercise of the Warrants such number of Warrant Shares as is necessary for exercise in full of all outstanding Warrants and, from time to time, it will take all steps necessary to provide sufficient reserves of Warrant Shares. All shares of Warrant Stock issued pursuant to the exercise of the Warrants will, upon their issuance, be validly issued, fully paid and nonassessable, free and clear of all liens and other encumbrances or restrictions on sale and free and clear of all preemptive rights, except restrictions arising (a) under federal and state securities law,
(b) not by or through the Company, or (c) by agreement between the Company and the Registered Holders or their successors.

D-7

9.2 Registration of Warrant Shares

The Company has registered the Warrants and the Warrant Shares under the Securities Act of 1933 and Rule 415 thereunder pursuant to a Registration Statement on Form S-3. In connection with such Registration Statement, the Company agrees to use its best efforts to:

(a) prepare and file with the Commission such amendments and supplements to the Registration Statement and the Prospectus filed as part thereof and take such other action, if any, as may be necessary to keep the Registration Statement effective until the earlier of (i) the expiration, cancellation or repurchase of the Warrants, or (ii) when all of the Warrants have been exercised by the Registered Holders;

(b) during the period when the Registration Statement is required to remain effective, will file all documents required to be filed with the Commission pursuant to Section 13, 14 or 15 of the Exchange Act within the time periods requiring by the Exchange Act and the rules and regulations promulgated thereunder; and

(c) bear all expenses in connection with the procedures in paragraphs (a) and (b) of this Section 9.2 and the continued registration of the Warrant Shares pursuant to the Registration Statement, other than any fees and expenses of counsel or other advisers to the Registered Holders.

10. Agreement of Warrant Holders

Every holder of a Warrant, by his acceptance thereof, consents and agrees with the Company, the Warrant Agent and every other holder of a Warrant that:

(a) The Warrants are transferable only on the registry books of the Warrant Agent by the Registered Holder thereof in person or by his attorney duly authorized in writing and only if the Warrant Certificates representing such Warrants are surrendered at the office of the Warrant Agent, duly endorsed or accompanied by a proper instrument of transfer satisfactory to the Warrant Agent and the Company in their sole discretion, together with payment of any applicable transfer taxes; and

D-8

(b) The Company may deem and treat the person in whose name the Warrant Certificate is registered as the holder and as the absolute, true and lawful owner of the Warrants represented thereby for all purposes, and the Company shall not be affected by any notice or knowledge to the contrary.

11. Cancellation of Warrant Certificates

If the Company shall purchase or acquire any Warrant or Warrants, the Warrant Certificate or Warrant Certificates evidencing the same shall thereupon be cancelled by it and retired. The Warrant Agent shall also cancel Warrant Certificates following exercise of any or all of the Warrants represented thereby or delivered to it for transfer, split-up, combination or exchange.

12. Concerning the Warrant Agent

The Warrant Agent acts hereunder as agent and in a ministerial capacity for the Company, and its duties shall be determined solely by the provisions hereof. The Warrant Agent shall not, by issuing and delivering Warrant Certificates or by any other act hereunder be deemed to make any representations as to the validity, value or authorization of the Warrant Certificates or the Warrants represented thereby or of any securities or other property delivered upon exercise of any Warrant or whether any stock issued upon exercise of any Warrant is fully paid and nonassessable.

The Warrant Agent shall account promptly to the Company with respect to Warrants exercised and concurrently pay the Company, as provided in Section 4, all moneys received by the Warrant Agent upon the exercise of such Warrants. The Warrant Agent shall, upon request of the Company from time to time, deliver to the Company such complete reports of registered ownership of the Warrants and such complete records of transactions with respect to the Warrants and the shares of Common Stock as the Company may request. The Warrant Agent shall also make available to the Company for inspection by its agents or employees, from time to time as either of them may request, such original books of accounts and records (including original Warrant Certificates surrendered to the Warrant Agent upon exercise of Warrants) as may be maintained by the Warrant Agent in connection with the issuance and exercise of Warrants hereunder, such inspections to occur at the Warrant Agent's office during normal business hours.

The Warrant Agent shall not at any time be under any duty or responsibility to any holder of Warrant Certificates to make or cause to be made any adjustment of the Exercise Price provided in this Agreement, or to determine whether any fact exists which may require any such adjustments, or with respect to the nature or extent of any such adjustment, when made, or with respect to the method employed in making the same. It shall not (i) be liable for any recital or statement of facts contained herein or for any action taken, suffered or omitted by it in reliance on any Warrant Certificate or other document or instrument believed by it in good faith to be genuine and to have been signed or presented by the proper party or parties, (ii) be responsible for any failure on the part of the Company to comply with any of its covenants and obligations contained in this Agreement or in any Warrant Certificate, or (iii) be liable for any act or omission in connection with this Agreement except for its own negligence or willful misconduct.

The Warrant Agent may at any time consult with counsel satisfactory to it (who may be counsel for the Company) and shall incur no liability or responsibility for any action taken, suffered or omitted by it in good faith in accordance with the opinion or advice of such counsel.

D-9

Any notice, statement, instruction, request, direction, order or demand of the Company shall be sufficiently evidenced by an instrument signed by the Chairman of the Board, President, any Vice President, its Secretary, or Assistant Secretary, (unless other evidence in respect thereof is herein specifically prescribed). The Warrant Agent shall not be liable for any action taken, suffered or omitted by it in accordance with such notice, statement, instruction, request, direction, order or demand believed by it to be genuine.

The Company agrees to pay the Warrant Agent reasonable compensation for its services hereunder and to reimburse it for its reasonable expenses hereunder; it further agrees to indemnify the Warrant Agent and save it harmless against any and all losses, expenses and liabilities, including judgments, costs and counsel fees, for anything done or omitted by the Warrant Agent in the execution of its duties and powers hereunder except losses, expenses and liabilities arising as a result of the Warrant Agent's negligence or willful misconduct.

The Warrant Agent may resign its duties and be discharged from all further duties and liabilities hereunder (except liabilities arising as a result of the Warrant Agent's own negligence or willful misconduct), after giving 30 days' prior written notice to the Company. At least 15 days prior to the date such resignation is to become effective, the Warrant Agent shall cause a copy of such notice of resignation to be mailed to the Registered Holder of each Warrant Certificate at the Company's expense. Upon such resignation, or any inability of the Warrant Agent to act as such hereunder, the Company shall appoint a new Warrant Agent in writing. If the Company shall fail to make such appointment within a period of 15 days after it has been notified in writing of such resignation by the resigning Warrant Agent, then the Registered Holder of any Warrant Certificate may apply to any court of competent jurisdiction for the appointment of a new Warrant Agent. Any new Warrant Agent, whether appointed by the Company or by such a court shall be a bank or trust company having a capital and surplus, as shown by its last published report to its stockholders, of not less than $10,000,000 or a stock transfer company. After acceptance in writing of such appointment by the new Warrant Agent is received by the Company, such new Warrant Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named herein as the Warrant Agent, without any further assurance, conveyance, act or deed; but if for any reason it shall be necessary or expedient to execute and deliver any further assurance, conveyance, act or deed, the same shall be done at the expense of the Company and shall be legally and validly executed and delivered by the resigning Warrant Agent. Not later than the effective date of any such appointment the Company shall file notice thereof with the resigning Warrant Agent and shall forthwith cause a copy of such notice to be mailed to the Registered Holder of each Warrant Certificate.

Any corporation into which the Warrant Agent or any new Warrant Agent may be converted or merged or any corporation resulting from any consolidation to which the Warrant Agent or any new Warrant Agent shall be a party or any corporation succeeding to the trust business of the Warrant Agent shall be a successor Warrant Agent under this Agreement without any further act, provided that such corporation is eligible for appointment as successor to the Warrant Agent under the provisions of the preceding paragraph. Any such successor Warrant Agent shall promptly cause notice of its succession as Warrant Agent to be mailed to the Company and to the Registered Holder of each Warrant Certificate.

The Warrant Agent, its subsidiaries and affiliates, and any of its or their officers or directors, may buy and hold or sell Warrants or other securities of the Company and otherwise deal with the Company in the same manner and to the same extent and with like effects as though it were not the Warrant Agent. Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other legal entity.

13. Miscellaneous

13.1 Registered Holder as Owner

The Warrant Agent shall deem and treat the Registered Holder of record of any Warrant as the absolute owner for all purposes regardless of any notice to the contrary.

D-10

13.2 No Shareholder Rights

The Warrants shall not entitle the Registered Holders to any voting rights or any other rights as a shareholder of the Company or to any other rights except the rights stated herein; and no dividend or interest shall be payable or shall accrue in respect of the Warrant or the Warrant Shares, until the Warrants are exercised.

13.3 Notices

Unless otherwise provided, any notice under this Warrant Agreement shall be given in writing and shall be deemed effectively given (a) upon personal delivery to the party to be notified, (b) upon confirmation of receipt by fax by the party to be notified, (c) two business days after deposit with a reputable overnight courier, prepaid for overnight delivery and addressed as set forth in (d), or (d) five days after deposit with the United States Post Office or any foreign postal service, postage prepaid, registered or certified with return receipt requested and addressed to the party to be notified at the address indicated below, or at such other address as such party may designate by ten (10) days' advance written notice to the other party given in the foregoing manner.

If to the Warrant Agent: American Stock Transfer Company

                           59 Maiden Lane, Plaza Entrance
                           New York, New York  10038
                           Attn: Wilbert Myles
                           Telephone: (718) 921-8247
                           Facsimile: (718) 921-8323

If to the Company:         International Isotopes Inc.
                           4132 Commerce Circle
                           Idaho Falls, Idaho  83401
                           Attn:  Chief Executive Officer
                           Telephone:  (208) 524-5300
                           Facsimile:  (208) 524-1411

13.4 Amendments and Waivers

The Warrant Agent may by supplemental agreement make any changes or corrections in this Agreement (i) that it shall deem appropriate to cure any ambiguity or to correct any defective or inconsistent provision or manifest mistake or error herein contained; or (ii) that it may deem necessary or desirable and which shall not adversely affect the interests of the Registered Holders of Warrant Certificates; provided, however, that this Agreement shall not otherwise be modified, supplemented or altered in any respect except with the consent in writing of the Registered Holders of Warrant Certificates representing not less than 50% of the Warrants then outstanding; and provided, further, that no change in the number or nature of the securities purchasable upon the exercise of any Warrant, or the Purchase Price therefor, or the acceleration of the Warrant Expiration Date, shall be made without the consent in writing of the Registered Holder of the Warrant Certificate representing such Warrant, other than such changes as are specifically prescribed by this Agreement as originally executed.

13.5 Governing Law

This Warrant Agreement shall be governed by and construed under the laws of the State of Texas without regard to principles of conflict of laws. The parties irrevocably consent to the jurisdiction and venue of the state and federal courts located in Travis County, Texas in connection with any action relating to this Warrant Agreement.

D-11

13.6 Successors and Assigns; Transfer

The terms and conditions of this Warrant Agreement shall inure to the benefit of and be binding on the respective successors and assigns of the parties. This Warrant Agreement may not be transferred or assigned by the Warrant Agent without the consent of the Company.

13.7 Headings

The headings of the various sections of this Warrant Agreement have been inserted for convenience of reference only and shall not be deemed to be party of this Warrant Agreement.

13.8 Entire Agreement; Counterparts

This Warrant Agreement constitutes the entire agreement between the parties about its subject and supersedes all prior agreements. This Warrant Agreement may be executed in counterparts, which together shall constitute one agreement.

IN WITNESS WHEREOF, the parties have executed this Warrant Agreement as of the date first written above.

INTERNATIONAL ISOTOPES INC.

By: _______________________________
Steve T. Laflin, Chief Executive Officer

Warrant Agent:

AMERICAN STOCK TRANSFER COMPANY

By: ________________________________
Name:_______________________________
Title:______________________________

D-12

EXHIBIT E

Form of Warrant Certificate

E-1

___________________________________________________________________________________________________________________________________

NUMBER                                        VOID AFTER JULY 31, 2007                                       WARRANT TO PURCHASE

WA________                                                                                                  ______________________

                                                                                                            SHARES OF COMMON STOCK

                                                                                                            CUSIP ________________


                                             INTERNATIONAL ISOTOPES INC.

                                      SERIES A WARRANT TO PURCHASE COMMON STOCK




This Series A Warrant Certificate ("Warrant Certificate") certifies that




or its registered assigns, is the registered holder of a Warrant (the "Warrant") of International Isotopes Inc. (the "Company"), to
purchase the number of shares (the "Shares") of Common Stock,  par value $0.01 per share (the "Common  Stock"),  of the Company set
forth above. This Warrant expires on July 31, 2007 (such date, the "Expiration  Date") and entitles the holder to purchase from the
Company the number of fully paid and nonassessable  Shares set forth above at the exercise price (the "Exercise Price")  multiplied
by the number of shares set forth above (the "Purchase  Price"),  payable to the Company by wire transfer in immediately  available
funds of the Purchase  Price to an account of the Warrant  Agent  specified in writing by the Warrant  Agent for such purpose or by
delivery of a certified check in immediately  available funds of the Exercise Amount to the Warrant Agent at its corporate  office.
The initial Exercise Price shall be $.04 .
    Subject to the terms and conditions set forth herein and in the Warrant Agreement,  this Warrant may be exercised by the Holder
    thereof, by:
    (i) providing written notice of such election  ("Warrant  Exercise Notice") to exercise the Warrant to the Warrant Agent at the
address set forth in the Warrant Agreement,  "Re: International Isotopes Inc. Warrant Exercise," by hand or by facsimile,  no later
than 5:00 p.m., New York City time, on the Expiration  Date,  which Warrant  Exercise Notice shall be in the form of an election to
purchase  Shares of Common  Stock of the  Company  substantially  in the form set forth on the  reverse  side of this  certificate,
properly completed and executed by the Holder.
    (ii) delivering,  either (x) such Warrants to the Warrant Agent by book-entry transfer through the facilities of the Depository
or, (y) the  Warrant  Certificates  evidencing  such  Warrants to the Warrant  Agent if Warrant  Certificates  have been issued and
delivered pursuant to the Warrant Agreement; and
    (iii) paying the applicable Purchase Price, together with any applicable taxes and governmental charges.
    The  Exercise  Price and the number of Shares  purchasable  upon  exercise of this Warrant are subject to  adjustment  upon the
    occurrence of certain events as set forth in the Warrant Agreement.
    No Warrant may be exercised after the Expiration  Date.  After the Expiration Date, the Warrants will become wholly void and of
    no value.
    This Warrant may be redeemed by the Company at a  redemption price  of $.001 per warrant share  if the average closing price of
    the Company's Common Stock exceeds $.12 for twenty consecutive business days.
    REFERENCE IS HERBY MADE TO THE FURTHER  PROVISIONS OF THIS WARRANT  CERTIFICATE SET FORTH ON THE REVERSE  HEREOF.  SUCH FURTHER
PROVISIONS SHALL FOR ALL PURPOSES HAVE THE SAME EFFECT AS THOUGH FULLY SET FORTH AT THIS PLACE.
    This Warrant Certificate shall not be valid unless countersigned by the Warrant Agent.
    IN WITNESS WHEREOF, the Company has caused this Warrant Certificate to be executed by its duly authorized officer.

    Dated:                                                                                    INTERNATIONAL ISOTOPES INC.


    By:_________________________________                                                      By:_________________________________

       Secretary                                                                                 President

___________________________________________________________________________________________________________________________________

E-2

INTERNATIONAL ISOTOPES INC.

This Warrant evidenced by this Warrant Certificate is a part of a duly authorized issue of Warrants to purchase a maximum of 38,229,157 shares of Common Stock issued pursuant to that certain Series A Warrant Agreement, dated as of July 15, 2003 (the "Warrant Agreement"), duly executed and delivered by the Company and American Stock Transfer & Trust Company, as Warrant Agent (the "Warrant Agent"). The Warrant Agreement hereby is incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and the holders (the words "holders" or "holder" meaning the registered holders or registered holder) of the Warrants. A copy of the Warrant Agreement may be inspected at the Warrant Agent's corporate office and is available upon written request addressed to the Company. All capitalized terms used herein but not defined that are defined in the Warrant Agreement shall have the meanings assigned to them therein.

Warrants may be exercised to purchase Shares from the Company through 5:00 p.m. New York City time on the Expiration Date, at the Expiration Price set forth on the face hereof, subject to adjustment as described in the Warrant Agreement. Subject to the terms and conditions set forth herein and in the Warrant Agreement, the Holder of the Warrant evidenced by this Warrant Certificate may exercise such Warrant by:

(i) providing a Warrant Exercise Notice to the Warrant Agent at the address set forth in the Warrant Agreement, "Re: International Isotopes Inc. Warrant Exercise," by hand or by facsimile, no later than 5:00 p.m., New York City time, on the Expiration Date, which Warrant Exercise Notice shall be in the form of an election to purchase Shares of Common Stock of the Company substantially in the form set forth on the reverse side of this certificate, properly completed and executed by the Holder.

(ii) delivering, either (x) such Warrants to the Warrant Agent by book-entry transfer through the facilities of the Depository or (y) the Warrant Certificates evidencing such Warrants to the Warrant Agent if Warrant Certificates have been issued and delivered pursuant to the Warrant Agreement; and

(iii) paying the applicable Purchase Price, together with any applicable taxes and governmental charges.

The Exercise Amount shall be payable by wire transfer in immediately available funds of the Purchase Price to an account of the Warrant Agent specified in writing by the Warrant Agent for such purpose or by delivery of a certified check in immediately available funds of the Exercise Amount to the Warrant Agent at its corporate office. The initial Exercise Price shall be $.04.

In the event that upon any exercise of the Warrant evidenced hereby the number of Shares actually purchased shall be less than the total number of Shares purchasable upon exercise of the Warrant evidenced hereby, there shall be issued to the holder hereof, or such holder's assignee, a new Warrant Certificate evidencing a Warrant to purchase the Shares not so purchased. No adjustment shall be made for any cash dividends on any Shares issuable upon exercise of this Warrant. After the Expiration Date, unexercised Warrants shall become wholly void and of no value.

The Company shall not be required to issue fractions of Shares or any certificates that evidence fractional Shares. If any fraction of a share of Common Stock would, except for the provisions of the preceding sentence, be issuable upon exercise of any Warrant or Warrants, the Company shall, at its election, either (i) purchase such fraction for an amount in cash equal to such fraction of the Daily Price (as defined in the Warrant Agreement) of a share of Common Stock or (ii) round up the number of Shares issued upon exercise of such Warrant or Warrants to the next whole integer.

Warrant Certificates, when surrendered at the Warrant Agent Office by the registered holder thereof in person or by a legal representative or attorney duly authorized in writing, by mail or by book-entry delivery through the facilities of the Depositary may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor evidencing Warrants to purchase in the aggregate a like number of Shares.

The Company and Warrant Agent may deem and treat the registered holder hereof as the absolute owner of this Warrant Certificate (notwithstanding any notation of ownership or other writing hereon made by anyone) for the purpose of any exercise hereof and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

This Warrant may be redeemed by the Company at a repurchase price of $.001 per Warrant (the "Redemption Price") if the average closing price of the Company's Common Stock exceeds $.12 for twenty consecutive business days. The Company will give a minimum of 30 days notice of the Redemption Date. The holder may exercise this Warrant up to the day before the Redemption Date, but thereafter will only be entitled to receive the Redemption Price in exchange for this Warrant Certificate.

E-3

ELECTION TO EXERCISE
(TO BE EXECUTED UPON EXERCISE OF THE WARRANT)

The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to purchase ____________ newly issued shares of Common Stock of International Isotopes Inc. (the "Company") at the Exercise Price of $___________ per share. The undersigned represents, warrants and promises that it has the full power and authority to exercise and deliver the Warrants exercised hereby.

The undersigned represents, warrants and promises that it has delivered or will deliver in payment for such Shares $__________ by wire transfer in immediately available funds of the Purchase Price to an account of the Warrant Agent specified in writing by the Warrant Agent for such purpose or by delivery of a certified check in immediately available funds of the Purchase Price to the Warrant Agent at its corporate office.

The undersigned requests that a certificate representing the Shares be registered and delivered as follows:


Name


Address


Delivery Address (if different)

If such number of Shares is less than the aggregate number of Shares purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the balance of such Shares shall be registered and delivered as follows:


Name


Address


Delivery Address (if different)

_________________________________       ________________________________________
Social Security or Other Taxpayer                     Signature
 Identification Number of Holder

                                        Note:    The   above    signature   must
                                        correspond with the name as written upon
                                        the face of this Warrant  Certificate in
                                        every particular,  without alteration or
                                        enlargement or any change whatsoever. If
                                        the certificate  representing the Shares
                                        or any Warrant Certificate  representing
                                        Warrants   not   exercised   is   to  be
                                        registered  in a name other than that in
                                        which  this   Warrant   Certificate   is
                                        registered,  the signature of the holder
                                        hereof  must  be  guaranteed.

SIGNATURE GUARANTEED:

E-4

I3

INTERNATIONAL ISOTOPES INC.

38,229,157 Units, consisting of
38,229,157 Shares of Common Stock and
76,558,314 Warrants

E-5

PART II

Information Not Required in Prospectus

Item 13. Other Expenses of Issuance and Distribution.

The estimated expenses of this offering, all of which will be paid by Registrant, are as follows:

        SEC Registration Fee                                      $   512.00
        Accounting Fees and Expenses                              $ 5,000.00
        Registrant's Legal Fees and Expenses                      $45,000.00
        Printing Fees                                             $ 1,000.00
        Transfer Agent and Registrar's Fees and Expenses          $15,000.00
        Miscellaneous Expenses                                    $ 4,000.00
                                                                  ----------
        Total                                                     $70,512.00
------------------
o  To be completed by amendment

(a) Item 14. Indemnification of Directors and Officers

As permitted by the Texas Business Corporation Act ("TBCA"), the Company's Restated Articles of Incorporation provide that the Company will indemnify its officers, directors, employees and agents to the fullest extent permitted by the TBCA against actions that may arise against them in such capacities, and to advance expenses in connection with any such actions. Registrant's Restated Articles of Incorporation provides that directors of the Company will not be personally liable to Registrant or its stockholders for monetary damages for any act or omission in his capacity as a director except as authorized under the TBCA. The TBCA provides that a corporation may indemnify a person who was, is, or is threatened to be made a named defendant in a proceeding because such person is or was a director if it is determined in accordance with the provisions of the TBCA that the person (i) conducted himself in good faith, (ii) reasonably believed, in the case of conduct in his official capacity as director, that his conduct was in the corporation's best interests or, in other cases, that his conduct at least was not opposed to the corporation's interests and (iii) in the case of any criminal proceeding, had no reasonable cause to believe his conduct was unlawful. A director may not be indemnified with respect to a proceeding in which the person is found liable on the basis that personal benefit was improperly received by him, whether or not the benefit resulted from an action taken in the person's official capacity, or in which the person is found liable to the corporation. Officers, employees and agents of a corporation are entitled to be indemnified by the corporation as, and to the same extent provided for, directors of the corporation.

Registrant carries directors' and officers' liability insurance with an aggregate policy limit of $2,000,000.

Recent Sales of Unregistered Securities

In May 2003 eleven of the Company's current shareholders loaned the Company an aggregate of $823,500. The loans bear interest at 5% per annum and are due in May 2004. Each of the eleven shareholders is an accredited investor and the private placement of the debt securities was exempt pursuant to Section 4(2) of the Securities Act of 1933.

II-1


Item 16. Exhibits.

(a)      Exhibits

         3.1          Restated   Articles  of   Incorporation   of  the  Company
                      (incorporated  by reference to Exhibit 3.1 to the Company'
                      Registration  Statement  on form  SB-2  (Registration  No.
                      333-26269)).

         3.2          Bylaws  of  the  Company  (incorporated  by  reference  to
                      Exhibit 3.2 to the  Company's  Registration  Statement  on
                      Form SB-2 (Registration No. 333-26269)).

         4.1          Specimen  Common  Stock   Certificate   (incorporated   by
                      reference  to Exhibit  4.1 to the  Company's  Registration
                      Statement on Form SB-2 (Registration No. 333-26269)).

         5.1          Authorizing legal opinion of Locke Liddell & Sapp LLP with
                      respect to the issuance of the securities.

         10.1         Copy of Company's 2002 Long Term Incentive Plan, including
                      forms of nonqualified  Stock Option  Agreement,  Incentive
                      Stock  Option  Agreement  and  Restrictive   Stock  Option
                      Agreement  (incorporated  by  reference to Exhibit 10.1 to
                      the  Company's  Annual  Report on form 10-KSB for the year
                      ended December 31 2002).

         23.1         Consent of Hansen, Barnett & Maxwell.

         23.2         Consent of Locke  Liddell & Sapp LLP  (included in Exhibit
                      5.1).

         24           Power of Attorney (included as part of Signature page).

 --------------------

*To be filed by amendment.

Item 17. Undertakings.

Insofar as indemnification for liabilities arising under Securities Act of 1933, as amended (the `Act") may be permitted to directors, officers and controlling persons of Registrant pursuant to the provisions of its Restated Articles of Incorporation, its By-Laws, the Texas Business Corporation Act or otherwise, Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against liabilities (other than the payment by Registrant for expenses incurred or paid by an officer, director or controlling person of Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

The undersigned Registrant hereby undertakes:

(1) For purposes of determining any liability under the Securities Act, to treat the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by Registrant under Rule 424(b)(1), or (4), or 497(h) under the Securities Act as part of this Registration Statement as of the time the Commission declared it effective.

(2) For determining any liability under the Securities Act, to treat each post-effective amendment that contains a form of prospectus as a new registration statement for the securities offered in the registration statement, and that offering of the securities at that time as the initial bona fide offering of those securities.

II-2


POWER OF ATTORNEY TO SIGN AMENDMENTS

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Steve T. Laflin and Dr. Ralph M. Richart, and each of them, with full power to act without the other, his true and lawful attorney-in-fact and agent for him and in his name, place and stead, in any and all capacities, to sign any or all amendments to this Registration Statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises in order to effectuate the same, as fully, for all intents and purposes, as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

II-3


SIGNATURES

In accordance with the requirements of the Securities Act of 1933, Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and authorized this Amendment No. 1 to Registration Statement to be signed on its behalf by the undersigned, in Idaho Falls, State of Idaho, on the 23rd day of July, 2003.

INTERNATIONAL ISOTOPES INC.

By: /s/ Steve T. Laflin
    -------------------
    Steve T. Laflin
    President and CEO

In accordance with the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates stated.

Signature                       Title                         Date

/s/ Steve T. Laflin             President, CEO and CFO        July 23, 2003
------------------------
Steve T. Laflin

/s/ Dr. Ralph M. Richart        Chairman                      July 23, 2003
------------------------
Dr. Ralph M. Richart

/s/ Christopher Grosso          Director                      July 23, 2003
------------------------
Christopher Grosso

II-4


EXHIBIT 10.2

FORM OF

INCENTIVE STOCK OPTION AGREEMENT

INTERNATIONAL ISOTOPES INC.

Date of Grant:
Name of Optionee:
Number of Shares:         _______________ shares of Common Stock
Price Per Share:          $ ______ per share

International Isotopes Inc., a Texas corporation (the "Company"), hereby grants to the above-named optionee (the "Optionee") an option (the "Option") to purchase from the Company, for the price per share set forth above, the number of shares of Common Stock (the "Stock"), of the Company set forth above. This Option is granted pursuant to, and is subject to, the provisions of the International Isotopes Inc. 2002 Long-Term Incentive Plan, as amended from time to time. This Option is intended by the parties hereto to be an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code").

The terms and conditions of the Option granted hereby are as follows:

1. The price at which each share of Stock subject to this Option may be purchased shall be the price set forth above, subject to any adjustments that may be made pursuant to Section 10 hereof.

2. This Option may be exercised only to the extent that such Option is vested, subject to the provisions of Sections 8 and 9 hereof. This Option shall vest upon the Optionee's completion of a continuous period of satisfactory service as an Employee of the Company or one of its subsidiary corporations, in accordance with the following vesting table:


VESTING SCHEDULE

VESTING DATES                           NO. OF SHARES VESTED
-------------------                     --------------------

[at time of grant]                      25%
[after one year]                        50%
[after two years]                       75%
[after three years]                     100%

3. Except as provided in Section 8 hereof, this Option may not be exercised unless the Optionee is in the employ of the Company or one of its subsidiary corporations (within the meaning of Section 424(f) of the Code, and each individually referred to herein as a "Subsidiary") at the time of such exercise. Unless earlier terminated in accordance with its terms, this Option shall terminate in all events on date that is 10 years after date of grant (the "Expiration Date").

4. The Optionee (or his representative, guardian, devisee, or heir, as applicable) may exercise any portion of this Option that has become exercisable in accordance with the terms hereof as to all or any of the shares of Stock then available for purchase by delivering to the Company written notice specifying:

(i) the number of whole shares of Stock to be purchased together with payment in full of the aggregate option price of such shares, provided that this Option may not be exercised for less than fifty (50) shares of Stock or the number of shares of Stock remaining subject to this Option, whichever is smaller;

(ii) the address to which dividends, notices, reports, etc. are to be sent; and

(iii) the Optionee's social security number.

Payment shall be in cash, or by certified or cashier's check payable to the order of the Company, free from all collection charges, by delivery of shares of Common Stock already owned by the Optionee and having a fair market value equal to the aggregate Option Price, or by a combination of cash and shares of Common Stock. The Optionee shall not be entitled to any rights and privileges as a shareholder of the Company in respect of any shares of Stock covered by this Option until such shares of Stock shall have been paid for in full and issued to the Optionee.

2

5. As soon as practicable after the Company receives payment for shares of Stock covered by this Option, it shall deliver a certificate or certificates representing the shares of Stock so purchased to the Optionee. Such certificate shall be registered in the name of the Optionee. Optionee understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by state or federal securities laws at the time of the issuance of the Shares:

THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR THE ISSUER OF THE SHARES (THE "ISSUER") HAS RECEIVED AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE WITH THE ACT.

Optionee agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate "stop transfer" instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.

6. This Option is personal to the Optionee and during the Optionee's lifetime may be exercised only by the Optionee or his guardian or representative. This Option shall not be transferable other than by will or the laws of descent and distribution, or pursuant to a qualified domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder.

7. If the Optionee's employment with the Company or any Subsidiary shall terminate by reason of his death or disability, then the Optionee or his personal representative shall have the right to exercise any vested portion of this Option for a period of one (1) year following the date of termination, or if earlier, until the Expiration Date of the Option. If the Optionee's employment with the Company or any Subsidiary shall terminate for any other reason, then the Optionee shall have the right to exercise any vested portion of this Option for a period of ninety (90) days following the date of termination, or if earlier, until the Expiration Date of the Option.

3

8. This Option does not confer on the Optionee any right to continue in the employ of the Company or any Subsidiary or interfere in any way with the right of the Company or any Subsidiary to determine the terms of the Optionee's employment.

9. All interpretations or determinations of the Board of Directors with respect to this Option shall be binding and conclusive upon the Optionee and his legal representatives with respect to any question arising hereunder. Any powers, rights, or responsibilities of the Company's Board of Directors set forth herein may be delegated to and exercised by the Compensation Committee thereof.

10. In the event of any change in the outstanding shares of stock of the Company by reason of any stock dividend, stock split, spinoff, recapitalization, merger, consolidation, combination, exchange of shares or other similar change, the aggregate number of shares of stock covered by the Option and/the purchase price under the Option, shall be equitably adjusted by the Board in its sole discretion.

11. If, while the Option is outstanding, there shall occur (a) a merger or consolidation of the Company with or into another corporation in which the Company shall not be the surviving corporation, (b) a dissolution of the Company, or (c) a transfer of all or substantially all of the assets of the Company in one transaction or a series of related transactions to one or more other persons or entities, then, if provision is not otherwise made in writing in connection with such transaction for the substitution of securities of another corporation, and without the necessity of any action by the Board of Directors, the Option shall terminate, but the Optionee shall be entitled, immediately prior to the effective date of such transaction, to purchase the number of shares that are then vested and exercisable. The unexercised portion of the Option shall be terminated as of the effective date of such transaction.

12. All notices hereunder to the parties to this Incentive Stock Option Agreement shall be delivered or mailed to the following addresses:

If to the Company:       International Isotopes Inc.
                         4137 Commerce Circle
                         Idaho Falls, ID 83401

If to the Optionee:      ___________________________
                         ___________________________
                         ___________________________

4

Such addresses for the service of notices may be changed at any time provided notice of such change is furnished in advance to the other party.

13. This Incentive Stock Option Agreement shall be governed by and construed in accordance with the laws of the State of Texas without application of the conflict of laws principles thereof, except to the extent preempted by federal law, which shall govern to such extent.

IN WITNESS WHEREOF, the undersigned have caused this Incentive Stock Option Agreement to be duly executed as of the date first above written.

INTERNATIONAL ISOTOPES INC.

By: ________________________

Name: ______________________

Title: _____________________

OPTIONEE:


5

EXHIBIT 10.4

SUMMARY OF

INTERNATIONAL ISOTOPES INC.
EMPLOYEE STOCK PURCHASE PLAN

This Summary relates to an aggregate of up to 2,000,000 shares of common stock of International Isotopes Inc. offered pursuant to the International Isotopes Inc. Employee Stock Purchase Plan ("Plan"). This Summary sets forth certain information relating to the Plan. If there are any inconsistencies between this Summary and the Plan, the Plan will control.

No person is authorized to give any information or to make any representation not contained in this Summary, and, if given or made, such information or representation should not be relied upon as having been authorized by the Company. This Summary does not constitute an offer to sell, or a solicitation of an offer to purchase the securities offered by this Summary in any jurisdiction in which, or to or from any person to or from whom, it is unlawful to make such an offer, or solicitation of an offer. Neither the delivery of this Summary nor any distribution of the securities offered pursuant to this Summary shall, under any circumstances, create any implication that there has been no change in the information set forth herein or in the affairs of the Company since the date of this Summary or that the information herein is correct as of any time subsequent to its date.

THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS SUMMARY. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.


THIS DOCUMENT CONSTITUTES PART OF A
PROSPECTUS COVERING SECURITIES THAT HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.


The date of this Summary is December 15, 2004


TABLE OF CONTENTS

Page

THE COMPANY..........................................................1

DESCRIPTION OF THE PLAN..............................................1

   Eligibility and Enrollment........................................2

   Payroll Contributions.............................................2

   Stock Purchases and Sales.........................................4

   Taxes.............................................................6

   Stockholder Rights...............................................10

   Plan Administration and General Plan Provisions..................11

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE.....................12


THE COMPANY

International Isotopes Inc., a Texas corporation, is the issuer of the securities under the International Isotopes Inc. Employee Stock Purchase Plan described below. The term "Company" used in this Summary includes International Isotopes Inc. as well as any subsidiary of the Company designated by the Committee described below to participate in the Plan. The Company's executive offices are located at 4137 Commerce Circle, Idaho Falls, Idaho 83401, and the telephone number is (208) 524-5300.

DESCRIPTION OF THE PLAN

The Company established the Plan to provide eligible employees of the Company with an opportunity to purchase shares of common stock of International Isotopes Inc. ("Shares") through payroll contributions. These contributions are used at the end of an offering period to purchase Shares at a discount from the current market price.

The Plan was authorized by the Company's Board of Directors on September 30, 2004, subject to stockholder approval. The stockholders will be asked to approve the Plan at the stockholder annual meeting in 2005. If stockholder approval is not obtained, any payroll contributions deducted for the Plan will be returned.

The Plan is intended to qualify as an "employee stock purchase plan" under Section 423 of the Internal Revenue Code of 1986, as amended ("Code"), and the provisions of the Plan will be construed accordingly. The Plan is not intended to be a qualified plan under Section 401(a) of the Code and is not subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended.

The Plan is administered by the Compensation Committee or any other committee appointed by the Board to administer the Plan ("Committee"). You may contact the Committee at: Compensation Committee, 4137 Commerce Circle, Idaho Falls, Idaho 83401.

Additional information concerning the Plan and its administrators will be furnished upon request directed to the Chief Executive Officer of the Company at 4137 Commerce Circle, Idaho Falls, Idaho 83401, and the telephone number is
(208) 524-5300.

A summary of the major features of the Plan is set forth below in question and answer format:

1

Eligibility and Enrollment

Am I eligible to participate in the Plan?

You are eligible to participate in the Plan if you are an employee whose customary employment is more than 20 hours per week and more than 5 months per calendar year.

When may I enroll?

If you are an eligible employee before the first day of an offering period, you may begin participating on the first day of such offering period if you enroll in the Plan during the enrollment period for that offering period. The Committee determines the enrollment period. An enrollment period generally will end approximately two weeks before the first day of the offering period. You may not begin participating in an offering period if the enrollment period for that offering period has passed and you had not enrolled.

Does my enrollment carry over for future offering periods?

Yes. Once you have enrolled for one offering period, you will be re-enrolled automatically for future Plan offering periods at the same percentage unless:

o you actually elect not to contribute or elect a different contribution percentage during the enrollment period for such future offering period, or

o you suspended your contributions or withdrew during an offering period. (See discussion under "Can I change or stop my contributions during an offering period?" on page 3.)

Payroll Contributions

How much of my paycheck can I contribute?

You may authorize after-tax payroll contributions to the Plan of from 1 percent to 15 percent of your eligible pay (unless otherwise specified by the Committee). Your eligible pay

o includes your base salary, commissions, overtime pay and bonuses paid to you by the Company; and

o excludes reimbursements, allowances, disability pay not paid by the Company, severance payments, equity compensation and gain from stock option exercises.

Your percentage of eligible pay is determined before deductions such as 401(k) or other benefit contributions.

Under IRS rules, you generally may not purchase during any one calendar year more than $25,000 worth of Shares based on their fair market value on the first trading day of the offering period.

2

When do my payroll contributions begin?

Payroll contributions begin with the first paycheck following the first day of the offering period for which you are enrolling and continue at the same rate for future offering periods until you stop participating in the Plan. Contributions will not be prorated when the beginning or end of an offering period falls within a pay cycle. Payroll contributions from a paycheck will be for the offering period during which the paycheck was issued.

Can I change or stop my contributions during an offering period?

You may choose to change the percentage of your contributions or suspend contributions (elect 0 percent contribution) only once during any offering period. You may also withdraw from the Plan and have your contributions refunded to you.

o Change or Suspend - You may change or suspend your contributions in accordance with procedures determined by the Committee. If you suspend contributions, your contributions will be used to purchase Shares at the end of the offering period. Once you suspend contributions to the Plan, you will not be eligible to make further contributions until the next offering period. Once you change the percentage of your contributions, you will not be eligible to make further changes to your contributions percentage until the next offering period.

o Withdraw - Your accumulated contributions may also be withdrawn and refunded to you any time prior to 30 days before the end of an offering period (or such other period determined by the Committee). If you choose to withdraw from the Plan, you will not be eligible to make contributions to the Plan until the next offering period. No interest is paid on your contributions in the Plan. Refunds will be made through payroll as soon as practicable following your election to withdraw.

Of course, you will still own the Shares you have previously purchased under the Plan. Even if you stop contributing, you may re-enroll for any future offering period in which you are eligible to participate by enrolling during the applicable enrollment period for such future offering period.

How do I start making contributions again to the Plan?

Enroll during the enrollment period for a future offering period.

Do my payroll contributions earn interest?

No. Your contributions do not earn interest.

What happens to my payroll contributions?

Although a record is made of all your Plan payroll contributions, no separate account will actually be established to hold them. Instead, all payroll contributions received by the Company will be held without interest and may be integrated into the Company's general assets and used by the Company for any corporate purpose.

3

Can I make additional non-payroll contributions?

No. Contributions can only be made through payroll deductions.

Stock Purchases and Sales

What is an "offering period"?

o An offering period is a 3-month period or such other period determined by the Committee.

What is a "purchase date"?

A "purchase date" is the last trading day of the offering period, when Shares are purchased with your accumulated payroll contributions. On the purchase date, the total amount of payroll contributions credited to you during the offering period will be used to purchase whole Shares at the discount price.

When are my Shares purchased?

The Plan will purchase Shares for you on the last trading day of the offering period. The number of Shares purchased for you will be determined by how much money you have contributed by the purchase date and by the purchase price. Your contributions will be used to purchase as many whole Shares as possible. Any cash remaining will be added to your contributions for the next offering period. If you do not participate in the next offering period, excess cash will be refunded to you.

What is the purchase price of Shares?

At the end of each offering period, the fair market value of Shares on the purchase date is compared with the fair market value of Shares on the first day of the offering period. The price you pay for the Shares - called the "purchase price" - is 15% less than the lower of these two prices. You will always pay less than the current market price.

Example: When the share price goes up

Price on first trading day of offering period: $.20

Price on purchase date: $.25

What you pay: $.20 - 15% ($.03) = $.17

Example: When the share price goes down

Price on first trading day of offering period: $.20

4

Price on purchase date: $.15

What you pay: $.15 - 15% ($.0225) = $.1275

How is the fair market value of Shares determined?

"Fair market value" is the closing sales price per Share on the date in question as quoted on the OTC Bulletin Board.

Are there any limitations on the number of Shares I may purchase?

Yes. The following limitations apply:

o The total number of Shares available for purchase by all Plan participants is 2,000,000 Shares (subject to adjustment as discussed in "What happens if there is a change in the Company's capital structure?" on page 11).

o During any one calendar year, you generally may not purchase more than $25,000 worth of Shares based on the fair market value on the first trading day of an offering period. (Special rules apply to the calculation of this limit when the offering period spans two calendar years.)

o You may not purchase Shares in the Plan if you own 5% or more of the total voting power or value of all classes of stock of the Company or any parent or subsidiary corporation. (For purposes of determining 5% ownership, certain attribution rules apply and Shares which you may purchase under outstanding options are treated as owned by you.)

Any payroll contributions collected from you that cannot be applied to the purchase of Shares because of one or more of these limitations will be refunded.

Where do my Shares of stock go after they are purchased?

As soon as practicable after each three-month purchase date, your account at a designated broker will be credited with the Shares purchased on your behalf. No stock certificates will be issued.

Will I receive a statement indicating the amount and status of my account?

Yes. After each purchase date, you will receive a statement indicating the number of Shares purchased for you on the purchase date. After the end of each calendar year, you will also receive a statement regarding the contributions you made during the year and the number of Shares purchased for you during the year:

When can I sell my purchased Shares?

After the close of an offering period, Shares you purchased are deposited into a designated brokerage account as soon as administratively practicable. Subject to the Company's insider trading policies, you may sell your Shares as soon as this deposit is complete.

5

If Shares are disposed of in a disposition that does not satisfy the holding period requirements of Section 423 of the Code (generally, as discussed below, two years from the beginning of the applicable offering period), the Company must be notified. If you transfer your Shares from the designated brokerage account and then sell your Shares, you must notify the Company.

Federal income tax treatment of the sale proceeds will be more favorable if you hold your Shares for a certain period of time before selling them. Because of possible tax consequences, we suggest that you consult a tax advisor before you sell your Shares. (See "Taxes" on pages 6-10 for some general tax information.)

What happens if I leave the Company?

If you leave the Company, your contributions end automatically upon your termination of employment with the Company and your accumulated contributions for that offering period shall be returned. No interest is paid on your contributions to the Plan. The Shares you have already purchased through the Plan will remain yours after termination of your employment.

What happens if I take a leave of absence?

Depending on the length of the leave of absence, your participation may be terminated.

Taxes

The United States federal tax laws are technical and complex whereas the discussion herein is in general terms and relates solely to the regular United States income tax and not to the alternative minimum income tax, state, foreign or other income taxes or gift, estate or inheritance taxes unless specifically noted to the contrary. The following discussion is not a tax opinion and is not tax advice, but is merely a guide to assist employees and their advisers. Furthermore, the tax laws are subject to change (even retroactively) by legislation, administrative rulings and regulations, and judicial decisions. EMPLOYEES SHOULD CONSULT THEIR OWN TAX ADVISERS AS TO THE TAX CONSEQUENCES TO THEM OF THE PLAN.

The Plan is intended to qualify for favorable tax treatment under the Code. The favorable tax benefit is the deferral of taxable income related to the 15% discount. This amount will be deferred until the time you sell the Shares purchased through the Plan. Since the Plan provides you the opportunity to buy Shares at a discount, that discount is usually considered compensation income. If the Plan had not been designed to qualify for favorable tax treatment, that discount would be taxable to you at the time you purchase the Shares. Again, due to the favorable tax treatment, you generally will not have any income related to the discount until you sell the Shares.

The Plan allows you to purchase Shares with after-tax dollars at a 15% discount. The character of the income resulting from a sale of Shares is very important in determining your ultimate tax liability. The tax laws generally provide more favorable tax treatment when you hold the Shares for at least 21 months after the purchase date.

6

Will I have taxable income because I become a Plan participant or when Shares of Company common stock are purchased in my name?

Payroll contributions deducted from your pay for the Plan will be subject to federal income and employment taxes just as though such amounts were paid to you in cash.

The Plan is intended to be an "employee stock purchase plan" within the meaning of Code Section 423. Under such an employee stock purchase plan, no additional income will be recognized by you either at the time purchase rights are granted pursuant to the Plan or at the time you purchase Shares pursuant to the Plan.

When will I be subject to federal income tax on the purchased Shares?

You will have taxable income in the year in which there is a "disposition" of the purchased Shares. "Disposition" generally includes any transfer of legal title, including a transfer by sale, exchange or gift, but does not include a transfer to your spouse or a transfer into a joint ownership with right of survivorship if you remain one of the joint owners.

How is the federal income tax liability determined?

Your federal income tax liability will depend on whether you held the Shares for at least two years after the first day of the offering period for the Shares and at least one year after the Shares were acquired under the Plan ("Holding Period"). With 3-month offering periods under the Plan, you will meet the Holding Period if you do not dispose of the Shares for at least 21 months after the purchase date.

What if I sell or otherwise transfer my Shares before meeting the Holding Period requirement?

You will recognize ordinary income in the year of the disposition equal to the amount by which the market price of the Shares on the purchase date exceeded the purchase price. The amount of ordinary income will be added to your basis in the Shares, and any resulting gain or loss recognized upon the disposition will be a capital gain or loss. The capital gain or loss will be long term if the Shares are held for more than one year.

The Company will report the amount of ordinary income you recognize on your W-2 form for the year of the disposition.

Example: In September, 2005, you purchased Shares at $.17/Share when the market prices were $.25/share. In June, 2006, when the market price was $.17/Share, you sold the Shares within the two-year Holding Period.

Even though you had no gain on this sale, the income tax treatment would be:

Ordinary Income Per Share:

7

Market price on the purchase date in September, 2005 ($.25/Share) - Purchase price ($.17/Share) = $.08/Share

Short-Term Capital Loss Per Share:

Selling price ($.17/Share) - Your adjusted basis ($.17/Share purchase price + $.08/Share ordinary income = $.25/Share) = $.08/Share

In contrast, if you had held the Shares for the Holding Period, you would recognize no income.

What if I sell or otherwise transfer my Shares after meeting the Holding Period requirement?

You will realize ordinary income in the year of the sale or transfer equal to the lesser of (1) the amount by which the market price of the Shares on the first trading day of the offering period during which such Shares were purchased exceeds the purchase price, or (2) the amount by which the Shares' market price on the disposition date exceeds the purchase price. This amount of ordinary income will be added to your basis in the Shares, and any additional gain recognized upon the disposition will be a long-term capital gain. If the Shares' market price on the disposition date is less than the purchase price you paid for the Shares, there will be no ordinary income, and any loss recognized will be a long-term capital loss.

Example: On the first trading day of the offering period (July 1, 2005), the market price of a Share was $.20/Share. On the September 30, 2005 exercise date, you purchased Shares at $.17/Share when the market price was $.25/Share. In December of 2007, you sell the Shares for $.30/Share in a disposition meeting the Holding Period.

The income tax treatment of your $.13 gain/Share will be:

Ordinary Income Per Share is the Lower of:

o Shares' market price on the first day of the offering period ($.20) over the purchase price ($.17) = $.03/per Share.

o the excess of the Shares' market price on the date of the disposition ($.30/Share) over the purchase price ($.17/Share) = $.13/Share.

Therefore, Ordinary Income per Share is $.03.

Long-Term Capital Gain Per Share:

Selling price - (Your purchase price + ordinary income) [$.30 - ($.17 + $.03)] = $.10/Share.

8

In contrast, if you had disposed of the Shares before meeting the Holding Period, you would have ordinary income per Share of $.08 ($.25 - $.17) and long-term capital gain per Share of $.05 [$.30 - ($.17 + $.08)].

Are there special rules if I purchase Shares on a purchase date ending more than three months after my termination of employment?

Yes. To get the special tax treatment described above for employee stock purchase plans, you must be employed by the Company within three months of the purchase date. Generally, your participation in the Plan ends upon your termination of employment and contributions for the period are returned to you and no Shares are purchased for the period. However, if your employment terminates (other than because of death) more than three months before the end of an offering period and Shares are purchased at the next purchase date with payroll contributions prior to your termination of employment, the discount from the Shares' market value on the purchase date will be treated as ordinary income to you and subject to income tax withholding.

What if I die before disposing of my Shares?

Your estate must report as ordinary income in the year you die the lesser of (1) the amount by which the Shares' market price on the date of your death exceeds the purchase price paid for such Shares or (2) the amount by which the market price of the Shares on the first trading day of the offering period during which those Shares were purchased exceeds the purchase price paid for such Shares.

Is there income tax withholding if I dispose of my Shares before the Holding Period is met?

No. The IRS does not require the Company to withhold income taxes on the sale of any Shares acquired pursuant to the Plan (except as set forth in "Are there special rules if I purchase Shares on a purchase date ending more than three months after my termination of employment?" above). Because no income taxes will be withheld, you are responsible for paying any tax due and should evaluate whether you need to adjust your regular payroll withholding or make an estimated federal or state income tax payment. Failure to do this could result in the imposition of penalties and interest upon the filing of your tax returns.

Are there FICA and FUTA taxes applicable to the discount from market value on Share purchases pursuant to the Plan?

No. The IRS does not assess FICA and FUTA taxes on the discount from market value when Shares are purchased pursuant to the Plan.

What if the Company is required to withhold taxes?

If the Company is required to withhold taxes with respect to purchases or sales of Shares under the Plan, the Company may require you to pay such taxes to the Company or the Company may deduct such amounts from your wages.

9

What are the federal tax consequences to the Company?

The Company can take a federal income tax deduction only if the purchased Shares are sold before the Holding Period is met. The Company generally can take a deduction equal to the amount of ordinary income you recognize upon such disposition prior to the end of the Holding Period.

EACH EMPLOYEE SHOULD CONSULT HIS OR HER OWN TAX ADVISER AS TO FEDERAL AND OTHER TAX CONSEQUENCES WHICH MAY ARISE WITH RESPECT TO PARTICIPATION IN THE PLAN AND SHARES RECEIVED PURSUANT TO THE PLAN.

Stockholder Rights

When do I receive rights as a stockholder?

Once Shares are purchased for you, you will have the rights of a stockholder with respect to those Shares, including voting rights. This means that as long as you hold Shares you will receive the same information that all other shareholders receive. You will also be entitled to vote on matters submitted to the company's stockholders.

What happens to any dividends?

If dividends on Shares are ever paid, such dividends would be deposited into your brokerage account holding such Shares.

Can I assign or transfer my rights to purchase Shares under the Plan?

No. Your Plan purchase rights cannot be assigned or transferred to anyone else, except by will or the laws of inheritance following your death.

Are there any restrictions on my ability to sell Shares?

All employees are subject to the Company's insider trading policy. The Committee may impose additional restrictions or limitations on the sale of Shares purchased under the Plan.

What additional restrictions apply if I become an "affiliate" or "Section 16 insider"?

Only a few members of top management are "affiliates" or "Section 16 insiders." In general, Rule 144 of the Securities Act of 1933 and Section 16 of the Securities Exchange Act of 1934 restrict the transfer of stock by "affiliates" of the Company and "Section 16 insiders," as defined in those sections. If you become an affiliate or Section 16 insider, you may become subject to, among other rules, special notice requirements, limits on the number of Shares you can sell and the short-swing profit rules of Section 16.

10

Does participating in the Plan affect the terms of my employment?

Participating in the Plan does not provide you with any right to continued employment at the Company, and your employment may be terminated at any time for any reason.

Plan Administration and General Plan Provisions

Who administers the Plan?

The Plan is administered by the Committee. The Board determines the Committee.

The Committee has the full and exclusive discretionary authority to construe and interpret the Plan and the rights granted under it, to designate from time to time which subsidiaries of the Company shall participate in the Plan, to establish rules and regulations for the administration of the Plan and to amend the Plan to satisfy applicable laws, to obtain any exemption under such laws or to reduce or eliminate any unfavorable accounting consequences.

You should address any inquiries you may have to the Committee at the Company's executive offices in Idaho Falls.

Who pays for the brokerage commissions and record keeping costs associated with the Plan?

The Company pays for the administrative costs as well as any fees associated with the purchase of Shares under the Plan. You will pay brokerage fees and any costs associated with the sale of your Shares when you decide to sell the Shares.

What is the total number of Shares that may be issued under the Plan?

No more than 2,000,000 Shares may be issued as part of the Plan (subject to adjustment as discussed in "What happens if there's a change in the Company's capital structure?" below).

What happens if there is a change in the Company's capital structure?

If there is any increase or decrease in the number of Shares resulting from a stock split, reverse stock split, stock dividend, extraordinary cash dividend, combination or reclassification of Shares or recapitalization, reorganization, consolidation, split-up, spin-off or any other increase or decrease in the number of Shares affected without receipt of consideration by the Company, the Plan provides for adjustment of the number of Shares which may be granted under the Plan as well as the purchase price per Share and the number of Shares covered by each purchase right.

What happens if there is a sale of the Company or other significant corporate event?

In the event of a proposed sale of the Company, outstanding rights to purchase Shares will be assumed or an equivalent right to purchase shares substituted by the successor corporation or a parent or affiliate of the successor corporation. If the successor corporation refuses to assume or substitute the right to purchase shares, any offering period then in progress will be shortened by setting a new purchase date and any offering period then in progress will end on the new purchase date.

11

In the event of any corporate transaction, the Committee may make such adjustment it deems appropriate to prevent dilution or enlargement of rights in the Plan, in the number, class of or price of Shares available for purchase under the Plan and in the number of Shares which an employee is entitled to purchase and any other adjustments it deems appropriate. In the event of any transaction, the Committee may elect to have the purchase rights under the Plan assumed or such purchase rights substituted by a successor entity, to terminate all outstanding purchase rights either prior to their expiration or upon completion of the purchase of Shares on the next purchase date, or to take such other action deemed appropriate by the Committee.

What if there are not enough Shares available to cover all the exercised purchase rights on a particular exercise date?

If the total number of Shares to be issued on any particular exercise date is greater than the maximum number of Shares that may be issued under the Plan, the Committee will:

o allocate the available Shares pro rata to participants; and

o promptly refund to participants any remaining payroll contributions not applied to the purchase of Shares.

Can the Plan be amended?

The Board may amend the Plan at any time, provided such amendment does not cause rights issued under the Plan to fail to meet the requirements of
Section 423 of the Code. Any amendment for which shareholder approval is required under Section 423 of the Code or such securities exchange must be submitted to the shareholders for approval.

What is the maximum life of the Plan?

The Plan will terminate when all Shares available for issuance under it have been sold, unless the Board terminates the Plan earlier.

When can the Company terminate the Plan?

The Board may terminate the Plan at any time. If it does, no additional purchases of Shares will occur and no additional rights to purchase Shares will be granted and no further payroll contributions will be collected.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The Company has registered the Shares reserved for issuance under the Plan on a Form S-8 Registration Statement (the "Registration Statement"), filed with the Securities and Exchange Commission under the 1933 Act. The documents incorporated by reference in Item 3 of Part II of the Registration Statement are also incorporated herein by reference and made a part hereof.

12

All reports and other documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the 1934 Act subsequent to the date of this Summary and prior to the filing of a post-effective amendment to the Registration Statement which indicates that all of the Shares have been sold or which deregisters all Shares then remaining unsold, shall be deemed to be incorporated by reference into and made a part of the Registration Statement and this Summary from the date of filing of such documents.

The Company is subject to the informational requirements of the 1934 Act, and will file reports, proxy statements and other information with the Securities and Exchange Commission. Employees may read and copy the Registration Statement, the documents that the Company incorporates by reference into this prospectus and the other reports, proxy statements and other information that the Company files with the Securities and Exchange Commission at the Securities and Exchange Commission's Public Reference Room at 450 Fifth Street N.W., Washington, D.C. 20549. Employees may also obtain copies of these documents at prescribed rates from the Securities and Exchange Commission's Public Reference Room at 450 Fifth Street N.W., Washington, D.C. 20549. Employees may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Requests for such documents can also be directed to International Isotopes Inc., Attn: Chief Executive Officer, 4137 Commerce Circle, Idaho Falls, Idaho 83401, and the telephone number is (208) 524-5300.

In addition, the Company is required to file electronic versions of these documents with the Securities and Exchange Commission through the Securities and Exchange Commission's EDGAR system. The Securities and Exchange Commission maintains a web site at http://www.sec.gov that contains the information incorporated by reference in this prospectus. The Company's website also contains electronic versions of these documents. The Company's internet address is http://www.intisoid.com.


EXHIBIT 10.5

INTERNATIONAL ISOTOPES INC EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (as it may be amended or supplemented, this "Agreement") is entered into as of February 1, 2001, by and between International Isotopes Inc., a Texas corporation ("Company"), and Stephen Laflin.

RECITALS

A. Company desires to employ Employee as its President and CEO because of his experience and expertise and to secure his services upon the terms and subject to the conditions set forth in this Agreement.

B. Employee desires and is willing to accept such employment upon such terms and subject to the conditions.

THEREFORE, for and in consideration of the foregoing and the mutual covenants and agreements contained in this Agreement, Company and Employee agree as follows:

1. Employment. Upon the terms and subject to the conditions contained in this Agreement, Company hereby employs Employee; and Employee hereby accepts such employment, upon such terms and subject to such conditions.

2. Duties and Authority.

2.1 Duties of Employee. During the term of this Agreement, Employee will serve as Company's Chief Executive Officer of International Isotopes and will faithfully and to the best of his ability perform such duties consistent with the position of president and CEO as 1 are determined and directed by the Board of Directors, or as are necessary in the reasonable judgement of the Employee, to carry out his duties under this Agreement. In his capacity as President and Chief Executive Officer, Employee will be generally responsible for the implementation of directives of, and policies and procedures adopted by the Board of Directors and for the overall day-to-day management of duties. In performing his duties under this Agreement, Employee will fully support and cooperate with Company's efforts to develop its markets, expand its business, and operate profitably and in conformity with business and strategic plans approved from time to time by Company's Board of Directors.

2.2 Direction from the Board of Directors and Chairman of the Board. Employee will look primarily to the Board of Directors for direction and guidance as to the performance of Employee's duties under this Agreement; however, to facilitate communication between Employee and the Board of Directors, Employee will report on the status of Employee's activities and the performance of Employee's duties to the Chairman of the Board of Company at such times as he may be requested. Employee will receive and participate in a performance review with the Chairman of the Compensation Committee every six months or other times if required.

Employment Agreement Page 1


2.3 Employee's Authority. In performing his duties under this Agreement, Employee will have such authority as is necessary for him to implement the directives of, and policies and procedures adopted by the Board of Directors of the Company and to oversee the management of the Company's day to day affairs; but, from time to time as thought appropriate by Employee or Company's Chairman of the Board, Employee will discharge his duties in consultation with and under the direction of the Chairman of the Board of Company. Without limiting the generality of the foregoing, in exercising his authority as Chief Executive Officer of Company, Employee will have the authority for employing, dismissing, and assigning job duties and responsibilities to Company's employees.

2.4 Time and Attention to Services. Employee will devote all of his time and attention to the performance of his duties to Company during the term of this Agreement. Company, however, recognizes that Employee may be engaged in other non-conflicting passive business investments and in community activities unrelated to his duties under this Agreement that will require some portion of his time, and Company hereby consents to Employee's attention to such other activities so long as such activities (a) do not hinder Employee's ability to perform his duties under this Agreement and (b) do not represent a conflict of interest in contravention of the agreements contained in paragraph 11 or a competitive activity in contravention of the agreements contained in paragraph 13 of this Agreement.

2.5 Election as an Officer. Company will cause Employee to be elected to the office of Chief Executive Officer and Board of Directors (as to such other offices, if any, as Company's Board of Directors determines to be appropriate).

3. Term and Termination.

3.1 Term. This Agreement is effective as of the Effective Date and will continue in effect until February 28, 2007, unless it is (a) terminated in accordance with I paragraph 3.2 or (b) extended in accordance with paragraph 3.3.

3.2 Termination. This Agreement may be terminated prior to February 28 2007, as follows:

(a) Termination by Mutual Consent. This Agreement may be terminated at any time by the written mutual consent of Company and Employee.

(b) Termination By Company for Cause. This Agreement may be terminated by Company at any time for Cause by the delivery to Employee of a written notice of termination stating the effective date of termination and the basis upon which this Agreement is being terminated. As used in this Agreement, the term "Cause" means (a) a material default in the performance of Employee's duties under this Agreement, or (b) Employee's dishonesty, willful misconduct, breach of fiduciary duty involving personal profit, willful violation of any law, rule, or regulation, action (or omission) involving moral turpitude and reflecting unfavorably upon the public image of Company or its Affiliates, or action (or omission) abiding or abetting a competitor, supplier or customer of Company or its Affiliates to the material disadvantage of Company or its Affiliates; and the term "Affiliate" means any other person or entity who directly controls, is controlled by, or is under common control with Company or any Affiliate of Company (and "control" means possession, directly or indirectly, of power to direct or cause the direction of management or policies, whether through ownership of voting securities or otherwise). In the event of termination for Cause, Employee will be entitled to such salary and benefits as have accrued under this Agreement through the effective date of termination, but will not be entitled to any other salary, benefits, or other compensation after such date.

Employment Agreement Page 2


(c) Termination By Company Without Cause. This Agreement may be terminated by Company at any time without Cause by (a) the delivery to Employee of a written notice of termination not less than 60 days prior to the effective date of termination, or (b) a vote by the Board of Directors and Shareholders to effect the sale or dissolution of Company. Upon such termination, Employee will be paid salary and benefits as provided in this Agreement through the effective date of termination and for the period of 24 months after such date. The Company will not be obligated to pay any bonus after the effective date of termination except for bonus payments approved by the Board of Directors and Compensation Committee prior to the effective date of termination.

(d) Termination of Employee. This Agreement may be terminated by Employee at any time, with or without Cause, by the delivery to Company of a written notice of termination not less than 90 days prior to the effective date of termination. In the event of termination by Employee, Employee will be entitled to such salary and benefits as have accrued under this Agreement through the effective date of termination, but will not be entitled to any other salary, benefits, or other compensation after such date.

(e) Termination Upon Death or Disability of Employee. This Agreement will be terminated immediately upon the death or permanent disability (which shall be determined in accordance with Company's disability plan as then in effect, or if no such plan is then in effect, as determined in good faith by Company's Board of Directors at such time as Employee becomes physically or mentally incapable or properly performing his duties under this Agreement and such incapacity will exist or can reasonably be expected to exist for a period of ninety days or more) of Employee. In either such event, Employee or his beneficiary as designated in writing to Company (or his estate, if no such beneficiary has been designated) will be entitled to such benefits (i) as are consistent with Company policy then if effect or (ii) as are determined by Company's Board of Directors in its sole discretion.

3.3 Extension of Term. At the time period thirty-six (36) months after the effective date of this agreement, Employee and Company will reset the terms of this agreement, and at that time decide by mutual agreement to extend the term of the agreement. Each such extension, unless expressly agreed otherwise by Employee and Company, will be for five years commencing on January 1 of the year preceding the expiration of the original or any renewal term. Mutual agreement to extend the term of this Agreement shall be evidenced by either (a) a written agreement executed by Company and Employee or (b) the continuation of Employee's performance of services under this Agreement with the approval of Company and without notice of termination given by Company or Employee. Any extended term of this Agreement may be terminated as set forth in paragraph 3.2 above, unless otherwise agreed in writing by Company and Employee. In the event the term of this agreement is not reset by mutual agreement by Employee and Company, the original terms of the agreement will continue in force and the termination date will remain February 25, 2007.

Employment Agreement Page 3


4. Compensation.

4.1 Base Annual Salary. In consideration for the performance of his duties under this Agreement, Employee will be paid a base annual salary of $120,000, which shall be payable (less applicable withholding for federal taxes) in semi-monthly installments or otherwise in such manner as the salaries of other executive officers of Company are paid in accordance with Company policy.

4.2 Annual Salary Review. Company's Board of Directors and Compensation Committee will review Employee's salary level on an annual basis and may elect, on the basis of such review, to increase Employee's base annual salary; but any such increase in Employee's Salary will be made solely at the discretion of Company's Board of Directors.

Bonus. In addition to the annual salary to be paid to Employee pursuant to this Agreement, Employee will be considered for an annual bonus at the end of each calendar or fiscal year of Company. The Board of Directors, at its discretion, will determine the amount of the bonus, if any, to be paid to Employee after considering such factors related to the performance of Employee and of Company during the preceding fiscal year as the Board of Directors determines to be appropriate.

4.4 Independent Consideration. Concurrently with the execution of this Agreement, Company is making a payment of $100 to Employee as independent and additional consideration ("Independent Consideration") for Employee's agreement to comply with the provisions of paragraph 11 of this Agreement.

5. Expenses and Reimbursements. Employee will be entitled to reimbursement for reasonable out-of-pocket expenses incurred by Employee that are directly attributable to the performance of Employee's duties under this Agreement. Employee will adhere to Company's customary practices and procedures with respect to incurring out-of-pocket expenses and will present such expense statements, receipts, vouchers, or other evidence supporting expenses incurred by Employee as Company may from time to time request.

6. Benefits. During the term of this Agreement, Employee will be entitled to the benefits generally provided or made available to other executive officers of Company, including, but without limitation, such group medical (including dental) insurance and life insurance benefits as are made available to employees of Company generally and participation in any "cafeteria" plan or retirement plan that may be available to employees of Company (subject, however, to (i) eligibility and (ii) modification or elimination in accordance with Company's standard policies as in effect from time to time) and to the following specific benefits:

(a) Vacation. Employee will be entitled to such vacation time as is allotted to other executive officers of Company (but in no event less than fifteen working days in any calendar year).

(b) Sick Leave. Employee will be entitled to the benefits, and subject to all provisions of, Company's standard policies and procedures regarding sick leave and time off.

Employment Agreement Page 4


The Company will provide the employee with an equity position in the company in the month following the 2002 annual stockholders meeting. The amount and terms of that position will be seperatly described in an employee options agreement.

Confidentiality and Non-Disclosure. Employee acknowledges that in the performance of his duties to Company under this Agreement he will gain a close, personal, and special influence with Company's customers and suppliers and will obtain and/or develop certain trade secrets and valuable, confidential information of or pertaining to Company or its Affiliates, including, but without limitation, information concerning the following: operations; business opportunities; price and cost information; finances; customer names; customer prospects, and customer lists; the terms of contracts with customers, suppliers, and agents; business plans; marketing and sales plans; sales techniques; manuals; letters; notebooks; procedures; reports; products; processes; specifications; services; inventions; research and development; and other concepts or ideas involving or relating to the business or prospective business of Company (collectively, "Confidential Information"), which Confidential Information has been or will be uniquely developed by or for Company or its Affiliates and cannot be readily obtained by third parties from outside sources. Employee accordingly agrees as follows:

(c) Detrimental Statements. For so long as this Agreement remains in effect and for a period of 24 months after the date of termination or expiration of this Agreement (the "Applicable Period), Employee will not, directly or indirectly, in any individual or representative capacity whatsoever, make any statement, oral or written, or perform any act or omission which is or could be detrimental in any material respect to the goodwill of Company, provided that any truthful statement made by Employee in good faith shall not violate this subparagraph.

(d) Covenant of Confidentiality. All Confidential Information and other information communicated to Employee by, or otherwise belonging to, Company, its Affiliates, or their customers, whether before or after the Effective Date, shall at all times be held in strict confidence, shall be used only for the purpose of this Agreement, and shall not be disclosed by Employee without the prior written consent of Company, except as may be necessary by reason of legal, accounting, or regulatory requirements beyond the reasonable control of Employee.

(e) Return of Lists. Books. Records. and Property. Upon the expiration of the term or termination of this Agreement, Employee will surrender to Company all tangible Confidential Information in the possession of Employee, including, but without limitation, the originals and all copies of all lists, books, and records of or pertaining to any Confidential Information, and all other property in the possession of Employee belonging to Company or any of its Affiliates.

Employment Agreement Page 5


(f) Right to Injunctive Relief. Employee acknowledges that a violation or attempted violation on his part of any agreement in this paragraph 9 will cause irreparable damage to Company and to its Affiliates, and accordingly Employee agrees that Company shall be entitled as a matter of right to an injunction, out of any court of competent jurisdiction, restraining any violation or further violation of such agreements by Employee; and such right to an injunction shall be cumulative and in addition to whatever other remedies Company may have.

(g) Survival of Terms. The terms and agreements set forth in this paragraph 9 shall survive the expiration of the term or termination of this Agreement regardless of the reason. The existence of any claim of Employee, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by Company of the agreements contained in this paragraph 9.

(h) Separate Non-Disclosure Agreement. If after the Effective Date Company so requests, Employee will enter into a separate non-disclosure agreement the provisions of which are substantially the same as those contained in this paragraph 9.

7. Proprietary Information. Employee agrees to promptly and freely disclose to Company in writing any and all ideas, conceptions, inventions, improvements, suggestions for improvements, discoveries, formulae, processes, designs, software, hardware, circuitry, diagrams, copyrights, trade secrets, and any other proprietary information (collectively, "Proprietary Information"), whether patentable or not, which are conceived, developed, and made or acquired by Employee, alone or jointly with others, during the period of his employment by Company or using Company's time, data, facilities, and/or materials, and which are related to the products, business, or activities of Company or which Employee conceives, develops, makes, or acquires as a result of his employment by Company, and Employee agrees to assign and hereby does assign all of his right, title, and interest therein to Company. Whenever requested to do so by Company, Employee will execute applications, assignments, or other instruments, which Company deems necessary to apply for and obtain letters patent or copyrights of the United States or any foreign country, to otherwise protect Company's interest in any Proprietary Information, or to vest title to any Proprietary Information in Company. These obligations shall continue beyond the expiration or termination of Employee's employment, regardless of the reason for such termination, with respect to any Proprietary Information conceived, developed, made, or acquired by Employee during the period of his employment and shall be binding upon Employee's assigns, executors, administrators, and other legal representatives.

8. Conflict of Interest. In keeping with Employee's fiduciary duties to Company, Employee agrees that while employed by Company he will not, acting along or in conjunction with others, directly or indirectly, become involved in a conflict of interest or, upon discovery thereof, allow a conflict of interest to continue. Moreover, Employee agrees that he will immediately disclose to the Board of Directors any facts, which might involve any reasonable possibility of a conflict of interest. It is agreed that any direct or indirect interest in, connection with, or benefit from any outside activities, where such interest might in any way adversely affect Company, involves a possible conflict of interest. Circumstances in which a conflict of interest on the part of Employee might arise, and which must be reported immediately by Employee to the Board of Directors, include, but are not limited to, the following: (a) ownership of a material interest in any supplier, contractor, subcontractor, customer, or other entity with which Company does business;

Employment Agreement Page 6


(b) acting in any capacity, including director, officer, partner, consultant, employee, distributor, agent, or the like, for a supplier, contractor, subcontractor, customer, or other entity with which Company does business; (c) accepting, directly or indirectly, payment, service, or loans from a supplier, contractor, subcontractor, customer, or other entity with which Company does business, including, but not limited to, gifts, trips, entertainment, or other favors of more than a nominal value; (d) misuse of Company's information or facilities to which Employee has access in a manner which will be detrimental to Company's interest, such as utilization for Employee's own benefit of know-how, inventions, or information developed through Company's business activities; (e) disclosure or other misuse of Confidential Information of any kind obtained through Employee's connection with Company; (0the ownership, directly or indirectly, of a material interest in an enterprise in competition with Company, or acting as an owner, director, principal, officer, partner, consultant, employee, agent, servant, or otherwise of any enterprise which is in competition with Company; and (g) appropriation of a Corporate Opportunity, as defined in paragraph 11 of this Agreement.

9. Corporate Opportunities. Employee acknowledges that during the course of his employment by Company he may be offered or become aware of business or investment opportunities in which Company may or might have an interest (a "Corporate Opportunity") and that he has a duty to advise Company of any such Corporate Opportunities before acting upon them. Accordingly, Employee agrees (a) that he will disclose to Company's Board of Directors any Corporate Opportunity offered to Employee or of which Employee becomes aware, and (b) that he will not act upon any Corporate Opportunity for his own benefit or for the benefit of any person or entity other than Company without first obtaining the consent or approval of Company's Board of Directors (whose consent or approval may be granted or denied solely at the discretion of Company's Board of Directors).

10. Non-Competition.

10.1 Covenant Not to Compete. As an ancillary covenant to the terms and conditions set forth elsewhere in this Agreement, and in particular the covenants set forth in paragraph 9, paragraph 10, and paragraph 11 above, and in consideration of the mutual promises set forth in this Agreement and other good and valuable consideration received and to be received, including, but without limitation, the Independent Consideration, which has been paid to Employee in consideration of Employee's agreement to comply with the terms and conditions of this paragraph 12, Employee agrees that, during the term of this Agreement, and throughout the Applicable Period, Employee will not, directly or indirectly, own or become employed by or otherwise provide consulting services to, any business competitive with Company prior to the date of termination of this Agreement in any country in which Company commences business while this Agreement remains in effect. Employee understands that the current business activities of Company and its Affiliates include the production of high quality radioisotopes, pharmaceutical grade radiochemicals, finished radiopharmaceuticals and diagnostic ant therapeutic medical products and that Company and its Affiliates have plans to expand the scope of such activities and the geographic area of operations of Company and its Affiliates in the near future with the direct involvement of Employee, therefore, Employee agrees that the limitations as to time, geographical area, and scope of activity contained in this covenant do not impose a greater restraint than is necessary to protect the goodwill and other business interests of Company. If any provision of this covenant is found to be invalid in part or in whole, Company may elect, but shall not be required, to have such provision reformed, whether as to time, area covered, or otherwise, as and to the extent required for its validity under applicable law and, as so reformed, such provision shall be enforceable.

Employment Agreement Page 7


10.2 Right to Injunctive Relief. Employee acknowledges that a violation or attempted violation on his part of any agreement in this paragraph 13 will cause irreparable damage to Company and its Affiliates, and accordingly Employee agrees that Company shall be entitled as a manner of right to an injunction, out of any court of competent jurisdiction, restraining any violation or further violation of such agreements by Employee; such right to an injunction, however, shall be cumulative and in addition to whatever other remedies Company may have. Furthermore, Employee shall be entitled to seek a declaratory judgment regarding any conduct or enterprise to determine whether or not such conduct or violation is violative of the terms of this Agreement; provided however, that no suit shall be filed until Employee has given Company at least 15 days to respond to Employee's written request for permission to undertake certain requested acts. The terms and agreements set forth in this paragraph 13 shall survive the expiration of the term or termination of this Agreement for any reason. The existence of any claim of Employee, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by Company of the agreements contained in this paragraph 12.

10.3 Separate Non-Competition Agreement. If after the Effective Date Company so requests, Employee will enter into a separate non-competition agreement the provisions of which are substantially the same as those contained in this paragraph 12.

11. Indemnification. Company, shall, and does hereby, indemnify and agree to hold Employee harmless to the fullest extent provided to officers and directors of Company under Article VII of Company's First Amended and Restated Bylaws, as amended from time to time (the "Bylaws Indemnification"); provided that (a) Employee shall be entitled to all benefits provided to directors of Company under the Bylaws Indemnification, whether or not Employee is, or at any time is elected, a director of Company; (b) any determination of indemnification made under the Bylaws Indemnification with respect to Employee shall be made by special legal counsel selected by the mutual agreement of Company's Board of Directors and Employee (or, if Company's Board of Directors and Employee cannot agree, then by Company, but in such case, such legal counsel must be a partner or shareholder in a law firm headquartered in the State of Idaho or Texas and having no fewer than 100 lawyers); and (c) if for any reason the Bylaws Indemnification has been terminated or is otherwise inapplicable to Employee, Employee shall be entitled to indemnification to the fullest extent that a corporation may grant indemnification to a director, officer, and employee under the Texas Business Corporation Act, as the same exists or as it may hereafter be amended ("TBCA"), if Employee was, or is threatened to be made a named defendant or respondent in a preceding (as hereinafter defined) because Employee (i) is or was an employee of Company or an Affiliate of Company as a director, officer, partner, venturer, proprietor, trustee, employee, agent, or in a similar position in a partnership, joint venture, sole proprietorship, trust, employee benefit plan, or other enterprise in which Employee serves on behalf of Company or at Company's request. In the event of Employee's death such right shall inure to the benefit of Employee's heirs, successors, and assigns. The indemnification granted to Employee hereunder is a contract right and shall survive the expiration of the term or termination of this Agreement and Company shall be obligated to indemnify Employee pursuant to and in accordance with this paragraph 13 regardless of whether this Agreement shall have expired or shall have been terminated. The rights conferred above shall not be exclusive of any other right which Employee may have or hereafter acquire under any statute, bylaw, resolution of shareholders or directors, agreement or otherwise. As used in this paragraph, the term "proceeding" means any threatened, pending, or completed action, suit, or proceeding, whether a civil, criminal, or administrative proceeding or an arbitration or investigation, any appeal in any such action, suit, or proceeding, and any inquiry or investigation that could lead to such an action, suit, or proceeding.

Employment Agreement Page 8


12. Company's Right of Offset. Should Employee at any time be indebted to Company, or otherwise obligated to pay money to Company for any reason, Company, at its election, may offset amounts otherwise payable to Employee under this Agreement, including, but without limitation, salary and bonus payments, against any such indebtedness or amounts due from Employee to Company.

13. Miscellaneous.

13.1 Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE SUBSTANTIVE LAWS OF THE STATE OF IDAHO.

13.2 Entirety and Amendments. This Agreement embodies the entire agreement between the parties and supersedes all prior agreements and understandings relating to the subject matter hereof This Agreement may be amended or modified only in writing executed by Employee and the Chairman of the Board or another officer of the Company expressly authorized by Company's Board of Directors.

13.3 Notices. Any notice or other communication hereunder must be in writing to be effective and shall be deemed to have been given when personally delivered to Employee or Company or, if mailed, on the third day after it is enclosed in an envelope and sent certified mail/return receipt requested in the United States mail. Either party may from time to time change its address for notification purposes by giving the other party written notice of the new address and the date upon which it will become effective. The address for each party for notices hereunder is as follows:

Employee: Stephen Laflin

Company: International Isotopes Inc.

13.4 Attorney's Fees. In the event that either party is required to obtain the services of an attorney in order to enforce any right or obligation hereunder, the prevailing party shall be entitled to recover reasonable attorney's fees and court costs from the other party.

13.5 Assignability; Binding Nature. Neither this Agreement nor any right, duty, obligation, or interest hereunder may be assigned or delegated by one party hereto without the prior written consent of the other party hereto. This Agreement is binding upon Company and Employee and their respective successors, heirs and assigns

Employment Agreement Page 9


13.6 Headings. The headings of paragraphs contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement.

13.7 Severability. If, but only to the extent that, any provision of this Agreement is declared or found to be illegal, unenforceable, or void, then both Company and Employee shall be relieved of all obligations arising under such provision, it being the intent and agreement of Company and Employee that this Agreement shall be deemed amended by modifying such provision to the extent necessary to make it legal and enforceable while preserving its intent. If such amendment is not possible, another provision that is legal and enforceable and achieves the same objective shall be substituted therefor. If the remainder of this Agreement is not affected by such declaration or finding and is capable of substantial performance by both Company and Employee, then the remainder shall be enforced to the extent permitted by law.

13.8 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed to be part of the same instrument.

Employment Agreement Page 10


Executed as of the Effective Date set forth above by:

INTERNATIONAL ISOTOPES INC.

By:  /S/                                          /S/
     -------------------------                    -------------------------
     Name                                         Employee's Name

Title:  Chairman of the Board                     Title:  President & CEO
        ----------------------                            -----------------

Date:   23   Feb    2002                          Date:   Feb  23,  2002
        ----------------------                            -----------------

Employment Agreement Page 11


EXHIBIT 10.6

LEASE AGREEMENT

THIS LEASE AGREEMENT, is made and entered into as of this 2nd day of May, 2003, by and between ADRIAN RAND ROBISON and DOROTHY ROBISON, husband and wife, referred to herein as "Lessor", and INTERNATIONAL ISOTOPES, INC., a Texas corporation, referred to herein as "Lessee".

RECITALS:

A. Lessee previously entered into a Lease Agreement (the "Prior Lease Agreement") dated March 2,2003, with Allen Ball, acting not individually but as Trustee of the Allen Ball and Connie Ball Living Trust created under Trust Agreement dated January 6, 1990, and any amendments thereto ("Ball") pertaining to the Leased Premises hereinafter described. Ball subsequently sold the Leased Premises to Lessor and as a result thereof, Lessor has been leasing the Leased Premises to Lessee pursuant to the terms and provisions of the Prior Lease Agreement. Lessor is now remodeling the improvements located on the Leased Premises and as a result thereof Lessor and Lessee have agreed to enter into this Lease Agreement in substitution for the Prior Lease Agreement.

B. Lessee and Lessor have agreed that the term of the Prior Lease Agreement shall terminate effective as of midnight on July 3 1,2003, and shall at such time be replaced by this Lease Agreement.

AGREEMENTS:

In consideration of the mutual covenants, conditions and agreements contained herein and the payment of rents herein specified, it is agreed as follows:

1. DEMISED PREMISES. Lessor does hereby lease, demise and rent unto Lessee the following described premises and all improvements located thereon situated in the County of Bonneville, State of Idaho, to-wit (the "Leased Premises"):

Lot 4 Block 4, St. Leon Industrial Park, Division No. 2, according to the recorded plat thereof.

2. TERM. The term of this Lease Agreement shall be as follows:

2.1 Initial Term. The term of the Prior Lease Agreement shall terminate as of midnight on July 31, 2003, and thereafter the Leased Premises shall be leased to Lessee pursuant to the terms and provisions of this Lease Agreement. The initial term of this Lease Agreement shall be for a term of five
(5) years commencing on August 1, 2003 (the "Commencement Date") and extending to midnight on July 31, 2008, subject however to prior termination as hereinafter set forth. For purposes of this Lease Agreement, the term "Lease Year" shall refer to the period of time each year commencing on the 1st day of August and ending at midnight on the 31st day of July.


2.2 Option to Renew. The term of this Lease Agreement may be extended, at the option of the Lessee, for one (1) successive period of five (5) years, being herein sometimes referred to as the extended term, as follows:

Extended Term   --    Commencing five (5) years from the
                      Commencement Date and continuing for
                      five (5) years thereafter.

At the expiration of the Initial Term, if this Lease shall be in full force and effect and the Lessee shall have fully performed all of its terms and conditions, the Lessee shall have the option to extend this Lease, upon the same terms and conditions, with rent to be paid as set forth in Article 3 herein, for an extended term of five (5) years to commence immediately upon the termination of the Initial Term of this Lease. The option for such extended term shall be exercised by the Lessee giving written notice thereof to the Lessor not less than one hundred eighty (1 80) days prior to the expiration of the then current term.

The extended term shall be upon the same terms, covenants and conditions as the original term of this Lease. In the event this Lease is extended as aforesaid, a new Lease Agreement for the term of such extension shall be unnecessary on such extension, this Lease constituting a present demise for both the original and the extended term. Any termination of this Lease during the Initial Term shall terminate all rights of extension hereunder.

3. RENT AND SECURITY DEPOSIT. Lessee covenants, stipulates and agrees to pay to Lessor as rent for the Leased Premises the following:

3.1 Lessee shall pay to Lessor monthly rental payments in the amount of $7,252.00 each.

3.2 At the conclusion of each Lease Year during the term of this Lease Agreement (the "Adjustment Date"), the monthly rent as specified herein shall be adjusted according to the following terms. The adjusted rent shall be based on the percent change in the CPI published by the Bureau of Labor Statistics of the United States Department of Labor for All Urban Consumers, U.S. City Average (All Cities) for All Items with the index base being the current official base of 1982 - 1984 = 100 (hereafter the "CPI"). The monthly rent due following each Adjustment Date shall be increased by a percentage of tile initial rent determined by comparison of the CPI on the Adjustment Date to the CPI of the Base Month. The "Base Month", for purposes of the rent adjustment provided herein shall be August, 2003. The adjusted rent shall be computed by creating a fraction, the denominator of which is the CPI for the Base Month. The numerator of which shall be the CPI on the Adjustment Date. This fraction shall be multiplied by the initial rent of $7,252.00 to determine the amount of the adjusted rent. The adjusted monthly rent shall be the rent due hereunder during the next ensuing Lease Year until the next Adjustment Date. In no event, however, shall the amount of adjusted rent due be reduced below the rent of $7,252.00 per month.

2

3.3 In the event that the CPI for the Adjustment Date is not published or not available on the Adjustment Date, Lessee shall continue paying rent at the last effective rate until the CPI for the Adjustment Date becomes available. At that time the rent shall be adjusted as provided herein and Lessee shall pay to Lessor the difference between the rent due under the proper adjustment from the Adjustment Date to the date the adjusted rent is calculated and the amount of rent actually paid during that period.

3.4 In the event the publication of the CPI identified above is discontinued, the parties hereto shall thereafter accept comparable statistics on the cost of living as they shall be computed and published by an official agency or department of the United States of America or by a responsible financial entity of recognized authority then to be selected by the parties hereto, making such revisions as the circumstances may require to carry out the intent of this paragraph.

3.5 All monthly rental payments shall be paid in advance with the first months lease payments to be paid on or before August 1, 2003 and all subsequent lease payments to be paid on the 1st day of each month during the term of this Lease Agreement.

3.6 Lessee has pursuant to the terms of the Prior Lease Agreement previously deposited with Lessor the sum of $3,000.00. On or before August 1, 2003, Lessee shall deposit with Lessor the additional amount of $4,252.00 for a total amount on deposit with Lessor of $7,252.00. Such deposit amount of $7,252.00 shall be deposited with Lessor as security for the faithful performance by Lessee of all terms, provisions, conditions and covenants hereof upon the Lessee's part to be kept, observed and performed, and said sum shall be returned to Lessee after the time fixed as the expiration of this Lease Agreement; provided, however, Lessee shall have faithfully kept, observed and performed all the terms, provisions, conditions and covenants on Lessee's part to be kept and performed; that in case of default on the part of Lessee to comply with the provisions hereof, said deposit shall be used first for the payment of delinquent rental, secondly for the payment of costs and expenses incurred by Lessor in repairing damage to the Leased Premises occasioned by the tenancy, and thirdly, for the repair and renovation of the grounds, occasioned by the default on the part of Lessee to comply with the terms hereof. Any surplus over the amount deposited hereof, in excess of the costs and expenses of Lessor in repairing damages due to the fault or neglect of Lessee shall be returned to Lessee. In the event the deposit herein made is not sufficient to cover costs of such repair, Lessee agrees to forthwith pay to Lessor, or Lessor's agents, the amount necessary over and above such deposit, to repair the Leased premises.

3

3.7 In the event Lessee is delinquent in paying the rental payments or any other payments required of Lessee herein all such past due payments shall bear interest at eighteen percent (18%) per annum from the date of default until paid.

4. ASSIGNMENT OR SUBLEASING. Lessee shall not assign, mortgage, or encumber this Lease Agreement, nor sublet or permit the Leased Premises or any part thereof to be used by others for any purpose, without the prior written consent of Lessor being first obtained in each instance; provided, however, that regardless of any such assignment or sublease, Lessee shall remain primarily liable for the payment of the rent herein reserved and for the performance of all the other terms of this Lease Agreement required to be performed by Lessee. Lessor does hereby specifically consent to the sublease of this Lease Agreement by Lessee to its subsidiary, International Isotopes Idaho, Inc. Provided, however, regardless of such sublease, Lessee shall remain primarily liable for the payment of the rent herein reserved and for the performance of all the other terms of this Lease Agreement required to be performed by Lessee.

5. USAGE OF PREMISES AND COMPLIANCE WITH LAWS AND INSURANCE. Lessee shall not use, nor permit the use of the Leased Premises, for any other purpose or purposes or under any other trade name without the prior written consent of Lessor. The Leased Premises shall not be used for any unlawful purpose during the term of this Lease Agreement, and Lessee agrees to comply with all restrictive covenants (including any further covenants which may be recorded pertaining to the Premises) and all federal, state, county and city ordinances, laws and regulations, present or future, affecting the use of or the type of business to be carried on in the Leased Premises. Lessee shall not use the Leased Premises in a manner which shall increase the rate of fire or extended coverage insurance on the building situate on the Leased Premises over that in effect prior to this Lease Agreement. It is understood that, before Lessee or any sublessee of Lessee can conduct certain operations on the Leased Premises contemplated by Lessee, a license to conduct such operations will need to be obtained from the nuclear regulatory commission and other governmental agencies. It is anticipated that in connection with the issuance of such licenses, Lessee will be required to obtain a surety bond insuring against any damages caused to the Leased Premises by hazardous waste and materials. Lessor shall be named as an insured party and beneficiary of any such surety bond or insurance. THE PROVISIONS CONCERNING HAZARDOUS WASTE AND MATERIAL SET FORTH IN APPENDIX 1 ATTACHED HERETO ARE INCORPORATED HEREIN BY REFERENCE AND ARE SPECIFICALLY MADE A

PART OF THIS LEASE AGREEMENT.

4

6. UTILITIES. Lessee shall furnish and timely pay for all heat, gas, electricity, power, water, hot water, lights, telephone, and all other utilities of every type and nature whatsoever used in or about the Leased Premises at Lessee's own cost and expense, and shall indemnify Lessor against any liability on such account. Lessor shall be under no obligation to furnish or pay for any of such utilities.

7. LESSOR'S RIGHT OF ENTRY. Lessor or their agents shall have the right to enter the Leased Premises at any reasonable time upon notice to Lessee to examine the same and determine the state of repair or alteration which shall or may be necessary for the safety or preservation of the Leased Premises.

8. ALTERATIONS. No alteration, addition, or improvement to the Leased Premises shall be made by Lessee without the written consent of Lessor. Any alteration, addition or improvement made by Lessee after such consent shall have been given, and any fixtures installed as part thereof, shall at Lessor's option become the property of Lessor upon the termination of this Lease Agreement and be surrendered with the Leased Premises; provided, however, that Lessor shall have the right to require Lessee to remove such fixtures at Lessee's cost upon the termination of this Lease Agreement. Upon the removal of any -such fixtures, Lessee shall be required to promptly repair any damage or injury done to the Leased Premises by such removal and restore the Leased Premises to as good condition as the same are in at the time Lessee shall take possession, reasonable wear and tear excepted. Lessee shall indemnify Lessor against any mechanic's or materialman's lien or other lien arising out of the making of any alteration, repair, addition, or improvement by Lessee, and shall hold Lessor harmless of any such liens or claims, including reasonable attorney fees and costs that may be incurred in removing any such liens.

9. SIGNS. Lessee shall not affix or maintain upon the glass panes or supports of the windows, doors or the exterior walls of the Leased Premises, any signs, advertising placards, names, insignia, trademarks, descriptive material or any other such like items except as shall have first received the written approval of Lessor as to the size, type, color, location, copy, nature and display qualities. Lessee may, upon approval of Lessor, have windows or doors of the Leased Premises painted, or place decals thereon with the name of Lessee, Lessee's address and business hours, provided said painting or decals are removed upon termination or vacation of the Leased Premises at Lessee's expense.

10. WASTE. Lessee shall not commit any waste or damage to the Leased Premises hereby leased, nor permit any waste or damage to be done thereto.

5

11. PROTECTION OF PROPERTY. Lessee agrees to maintain the Leased Premises in as good condition as the same is in at the time Lessee shall take possession of the Leased Premises, reasonable wear and tear excepted. At the termination of this Lease Agreement in any manner Lessee will surrender the Leased Premises to Lessor in the condition above described. Damage to walls, doors, windows, ceiling tiles and other parts of the Leased Premises shall be repaired and painted by Lessee at Lessee's sole cost and expense and returned in good condition at the termination of this Lease Agreement and at the termination of this Lease Agreement carpets shall be repaired and cleaned by Lessee at Lessee's cost and expense. Upon the termination of this Lease Agreement, Lessee may remove any signs owned by Lessee from the Leased Premises, promptly repairing any damage or injury done to the Leased Premises by such removal and restoring the Leased Premises to the condition above described.

12. MAINTENANCE. All maintenance and repair necessary to keep the Leased Premises in good condition and repair shall be made at Lessee's sole cost and expense, including, but not limited to, normal maintenance and repairs to the furnace or any other heating or air conditioning equipment, electrical fixtures, all interior and exterior painting and decorating, glass replacement, plumbing and sewer repair, and all other repairs of every kind, nature and description. Lessee further agrees that all damage or injury done to the Leased Premises by Lessee or by any person who may be in or upon the Leased Premises at Lessee's invitation or with Lessee's permission shall be repaired by Lessee at their sole cost and expense.

13. INSURANCE.

13.1 Lessee shall maintain and pay for adequate fire and extended coverage insurance upon the improvements located on the Leased Premises.

13.2 Lessee shall also obtain, at Lessee's sole cost and expense, general public liability insurance protecting and indemnifying Lessor and Lessee against all claims for damages to person or property or for loss of life or of property occurring upon, in, or about the Leased Premises, with liability limits of $50,000.00 property damage and $500,000.00 with respect to injuries to any one person, and $1,000,000.00 in respect to any one accident or disaster or incident of negligence.

13.3 Lessee shall obtain all such insurance policies before Lessee takes possession of the Leased Premises. In the event of any loss or destruction of the Leased Premises by any insured cause, the insurance proceeds paid or payable as a result of said insured loss shall be paid to Lessor and Lessor shall use such insurance proceeds to repair the Leased Premises unless as a result of such loss or destruction this Lease Agreement is terminated in accordance with the provisions of paragraph 20 herein. In the event of such termination, Lessor, at Lessor's option, shall determine whether or not to retain the insurance proceeds for other purposes or use the insurance proceeds to repair or restore the Leased Premises. Lessor shall remain as co-insured on all such policies. Such insurance policies shall provide that all notices issued by the insurance company pertaining to any changes in insurance coverage under the insurance policy, delinquent premium notices, or other matters pertaining to the coverage provided by such insurance policies shall be sent to both Lessor and Lessee. Evidence of such insurance policies shall be delivered to Lessor. Lessor shall have the right at any time to require Lessee to provide to Lessor copy of such insurance policies, together with any amendments or additions to such insurance policies and evidence that all payments required to be made in order to maintain such insurance in full course and effect have been paid in full by Lessee.

6

14. TAXES AND ASSESSMENTS. Lessee shall pay all real estate taxes, real property assessments and Owner's Association dues or assessments levied against the Leased Premises pertaining to the term of this Lease Agreement. Lessee shall pay all other taxes, licenses, and assessments of every kind, nature and description, including all taxes and assessments on any equipment, machinery, or assets of any kind or nature placed in or upon the Leased Premises by Lessee.

15. FIRE RISK. Lessee shall not do anything in the Leased Premises or bring or keep anything therein which in any way increase or tend to increase the risk of fire or damage by explosion, or which will conflict with the regulations of the fire department or fire laws, or with any fire insurance policy on the building or any part thereof, or with any rules or ordinances established by the Health Department or with any municipal, state, county or federal laws, ordinances or regulations.

16. ACCEPTANCE OF PREMISES. Lessee has examined the Leased Premises and the buildings and improvements situate thereon, and accepts the same in the condition and state of repair they are now in.

17. QUIET ENJOYMENT. Lessor covenants and warrants that if Lessee shall faithfully and fully discharge the obligations herein set forth, Lessee shall have and enjoy during the term of this Lease Agreement, a quiet and undisturbed possession of the Leased Premises, together with all of its appurtenances.

18. LESSEE INDEMNIFICATION. Lessee covenants and agrees not to do or suffer anything to be done by which persons or property in or about or adjacent to the Leased Premises may be injured, damaged, or endangered. Lessee hereby agrees to indemnify Lessor against and to hold Lessor harmless from any and all claims or demands for loss of or damage to property or for injury or death to any person from any cause whatsoever while in, upon, or about the Leased Premises during the term of this Lease Agreement or any extension thereof. Lessee shall, at Lessee's own expense, maintain any workman's compensation insurance or any other form of insurance required by law upon the employees or agents employed by Lessee and Lessor shall have no responsibility with respect thereto.

7

19. CONDEMNATION. If the Leased Premises, or any substantial portion thereof, is condemned or taken by right of eminent domain, or by purchase in lieu thereof, then and in any such event, this Lease Agreement shall terminate and cease as of the time when possession is taken by the public authority and rental shall be accounted for between Lessor and Lessee as of the date of the surrender of possession. Such termination shall be without prejudice to the rights of either Lessor or Lessee to recover compensation from the condemning authority for any loss or damage caused by such condemnation. Neither Lessor nor Lessee shall have any rights in or to any award or payment made to the other by the condemning authority.

20. DESTRUCTION. It is understood and agreed that if the building upon the Leased Premises shall be destroyed by fire, the elements, riots, insurrections, explosions or any other cause, or be so damaged thereby that it becomes untenantable and cannot be rendered tenantable within ninety (90) days from the date of such damage, this Lease Agreement may be terminated by either Lessor or Lessee; provided, however, that in the event the building is so damaged, Lessee shall not be required to pay the rental herein provided during the term the Leased Premises are wholly unfit for occupancy. In the event that only a portion of the Leased Premises be damaged or become untenantable, then the rental during the period that said premises remain partially untenantable shall be reduced in the proportion that the untenantable portion of the Leased Premises bear to the total thereof. . Lessor shall make all reasonable effort to repair the Leased Premises within ninety (90)days or upon such extended period as both parties shall agree, provided that if said partially tenantable premises cannot be rendered fully tenantable within said ninety (90) days or extended period agreed upon by both Lessor or Lessee, from the date of said damage, this Lease Agreement can be terminated by either Lessor or Lessee.

21. DEFAULT.

A. Time and prompt performance of each and every term, covenant and condition of this Lease Agreement is material and of the essence of this Lease Agreement. Every term, covenant and condition is a material term, covenant and condition of this Lease Agreement. Performance means compliance that is full and to the letter of this Lease Agreement. Substantial compliance will not be sufficient. Performance by Lessee is a condition precedent to performance by Lessor.

B. The following or any of them constitute an event of default of the terms of this Lease Agreement:

8

(1) Failure by Lessee to pay when due any installment of rent or any other sum herein specified to be paid by Lessee if the failure continues for three (3) days after written notice has been given to Lessee;

(2) Abandonment of the Leased Premises by Lessee without cause (for the purposes hereof the failure to occupy and operate the Leased Premises for ten (10) consecutive days shall be conclusively deemed an abandonment of the Leased Premises by Lessee);

(3) Failure by Lessee to perform any other provision of this Lease Agreement required of Lessee, if the failure to perform the same is not cured within thirty (30) days after written notice has been given to Lessee;

(4) If Lessee shall file or have filed against Lessee in any court pursuant to any statute, either in the United States or of any other state, a Petition in Bankruptcy or Insolvency, or for reorganizations, or for appointment of a receiver or trustee of all or a substantial portion of the property owned by Lessee, or if Lessee makes an assignment for the benefit of creditors, or an execution or attachment shall be issued against Lessee on all or a substantial portion of Lessee's property, whereby all or any portion of the Leased Premises covered by this Lease Agreement or any improvements thereon shall be taken or occupied, or attempted to be taken or occupied by someone other than Lessee, except as may herein be otherwise expressly permitted, and such adjudication, appointment, assignment, petition, execution or attachment shall not be set aside, vacated, discharged or bonded within thirty (30) days after the termination, issuance, or filing of the same; and

(5) The taking by any person, except by Lessor or its agents or affiliates, of the leasehold created hereby or any part thereof upon execution, or other process of law or equity other than by assignment or sublease.

C. Upon the occurrence of any event of default, and the failure, neglect or refusal of Lessee to cure the same during any notice period required for such default specified above, without further notice to Lessee, Lessor shall be entitled to effectuate such rights and remedies against Lessee as are available to Lessor under the terms of this Lease Agreement and the laws of the State of Idaho, including, without limitation, the following remedies:

(1) Lessor shall have the immediate right, but not the obligation, to terminate this Lease Agreement, and all rights of Lessee hereunder by giving Lessee written notice of Lessor's election to terminate. No act by Lessor other than giving notice to Lessee shall terminate this Lease Agreement.

9

In the event of such termination, Lessee agrees to immediately surrender possession of the Leased Premises. Should Lessor terminate this Lease Agreement, it may recover from Lessee all damages Lessor may incur by reason of Lessee's breach, including the cost of recovering the Leased Premises, reasonable attorney fees, and the worth at the time of such termination of the excess, if any, of the amount of rent and charges equivalent to rent reserved in this Lease Agreement for the remainder of the stated term over the then reasonable rental value of the Leased Premises for the remainder of the stated term, all of which amount shall be immediately due and payable from Lessee to Lessor.

(2) Lessor shall also have the right, without process of law, to enter the Leased Premises and remove all persons and property from the Leased Premises without being deemed guilty of or liable in trespass. No such re-entry or taking possession of the Leased Premises by Lessor shall be construed as an election on its part to terminate this Lease Agreement unless a written notice of such intention is given by Lessor to Lessee. No such action by Lessor shall be considered or construed to be a forcible entry.

(3) Lessor may, at any time, and from time to time, without terminating this Lease Agreement, enforce all of its rights and remedies under this Lease Agreement, or allowed by law or equity, including the right to recover all rent as it becomes due.

(4) In addition to the other rights of Lessor herein provided, Lessor shall have the right, without terminating this Lease Agreement, at its option, with or without process of law, to reenter and retake possession of the Leased Premises, and all improvements thereon, and collect rents from any Sublessee and/or sublet the whole or any part of the Leased Premises for the account of Lessee, upon any terms or conditions determined by Lessor. Lessee shall be liable immediately to Lessor for all costs Lessor incurs in reletting the Leased Premises, including without limitation, brokers' commissions, expenses of remodeling the Leased Premises required by the reletting, and like costs. Re-letting can be for a period shorter or longer than the remaining term of this Lease Agreement. In the event of such re-letting, Lessor shall have the right to collect any rent which may become payable under any sublease and apply the same first to the payment of expenses incurred by Lessor in dispossessing Lessee, and in re-letting the Leased Premises, and, thereafter, to the payment of the rent herein required to be paid by Lessee, in fulfillment of Lessee's covenants hereunder; and Lessee shall be liable to Lessor for the rent herein required to be paid, less any amounts actually received by Lessor from a sublease, and after payment of expenses incurred, applied on account of the rent due hereunder. In the event of such election, Lessor shall not be deemed to have terminated this Lease Agreement by taking possession of the Leased Premises unless notice of termination, in writing, has been given by Lessor to Lessee.

10

D. The remedies provided in this Lease Agreement are cumulative in addition to any remedies now or later allowed by law or equity. The exercise of any remedy by Lessor shall not be exclusive of the right to effect any other remedy, allowed Lessor under the terms of this Lease Agreement, or now or later allowed by law or equity.

E. Any delay by Lessor in enforcing the terms of this Lease Agreement or any considerations or departures therefrom shall not operate to waive or be deemed to be a waiver of any right to require compliance that is fill and to the letter of this Lease Agreement or to thereafter require performance by Lessee in strict accordance with the terms of this Lease Agreement.

F. In the event that any remedy granted to Lessor under the terms of this Lease Agreement is held void or unenforceable, Lessor shall nevertheless have all of the other remedies provided in this Lease Agreement that are not contrary to law.

G. Lessee hereby expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Lessee being evicted or dispossessed for any cause, or in the event of Lessor obtaining possession of the -Leased Premises by reason of the violation by Lessee of any of the covenants and conditions of this Lease Agreement or otherwise.

22. ENFORCEMENT. Should either party default in the performance of any covenants or agreements contained herein, such defaulting party shall pay to the other party all costs and expenses, including but not limited to, reasonable attorney fees, including such fees on appeal, which the prevailing party may incur in enforcing this Lease Agreement or in pursuing any remedy allowed by law for breach hereof.

23. LESSOR'S RIGHT TO CURE LESSEE'S DEFAULTS. If Lessee shall default in the performance of any covenant or condition in this Lease Agreement required to be performed by Lessee, Lessor may, after thirty (30) days notice to Lessee, or without notice if in Lessor's opinion an emergency exists, perform such covenant or condition for the account and at the expense of Lessee, in which event Lessee shall reimburse Lessor for all sums paid to effect such cure, together with interest from the date of the expenditure at the rate of eighteen percent (18%) per annum and reasonable attorney fees. All amounts owed by Lessee to Lessor under this paragraph shall be additional rent. In order to collect such additional rent Lessor shall have all the remedies available under this Lease Agreement for a default in the payment of rent and the provisions of this paragraph shall survive the

11

27. LESSEE AS INDEPENDENT CONTRACTOR. Lessee's use of the Leased Premises shall be as an independent contractor and nothing herein shall be deemed to create a partnership, joint venture, employment, or master-servant relationship between the parties.

28. IDAHO LAW GOVERNS. This Lease Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of Idaho.

29. MODIFICATION. This Lease Agreement contains the entire agreement between the parties, and may not be modified or changed orally, but only by an agreement in writing and signed by the party against whom enforcement of any waiver, change, modification, or discharge is sought.

30. SEVERANCE AND VALIDITY. In the event any provision of this Lease Agreement or any part thereof shall be determined by any court of competent jurisdiction to be invalid, void, or otherwise unenforceable, the remaining provisions hereunder or parts thereof, shall remain in full force and effect, and shall in no way be affected, impaired or invalidated thereby, it being agreed that such remaining provisions shall be construed in a manner most closely approximating the intention of the parties with respect to the invalid, void or unenforceable provision or part thereof.

31. BINDING ON SUCCESSORS. It is further expressly agreed, that the provisions, stipulations, terms, covenants, conditions and undertakings in this Lease Agreement and any renewals thereof shall inure to the benefit of and bind the heirs, -executors, administrators and assigns or successors in interest of both the Lessor and Lessee.

32. MUTUAL RELEASE OF LIABILITY TO THE EXTENT OF INSURANCE COVERAGE. Neither Lessor nor Lessee shall be liable to the other for any business interruption or any loss or damage to property or injury to or death of persons occurring on the Leased Premises or the adjoining property, or in any manner growing out of or connected with Lessee's use and occupation of the Leased Premises, or the condition thereof, or the adjoining property, whether or not caused by the negligence or other fault of Lessor or Lessee or their respective agents, employees, subtenants, licensees, or assignees. This release shall apply only to the extent that such business interruption loss or damage to property, or injury to or death of persons is covered by insurance, regardless of whether such insurance is payable to or protects Lessor or Lessee or both. Nothing in this paragraph shall be construed to impose any other or greater liability upon either Lessor or Lessee than would have existed in the absence of the paragraph. This release shall be in effect only so long as the applicable insurance policies contain a clause to the effect that this release shall not affect the right of the insured to recover under such policies.

33. ASSIGNMENT BY LESSOR. It is understood that Lessor intends to sell the Leased Premises to a third party and assign Lessor's rights and obligations under this Lease Agreement to a third party. Any such sale of the Leased Premises by Lessor to a third party shall be subject to the terms and provisions of this Lease Agreement. Upon any such sale, Lessor may assign Lessor's rights and obligations under this Lease Agreement to the purchaser of the Leased Premises and upon such assignment Lessor shall be released from any further liability or obligation under this Lease Agreement.

12

34. LESSEE'S REPRESENTATIONS AND WARRANTIES. Lessee represents and warrants as follows: Lessee is a corporation duly organized, validly existing and in good standing under the laws of the State of Texas and Lessee has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now conducted. Lessee has full corporate power and authority to execute and deliver this Lease Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Lease Agreement and the consummation of the transactions contemplated hereby have been duly and validly authorized and approved by the Board of Directors of Lessee and no other corporate proceedings on the part of Lessee are necessary to authorize this Lease Agreement or the consummation of the transactions contemplated hereby. This Lease Agreement has been duly and validly executed and delivered by Lessee and constitutes a valid and binding agreement of Lessee, enforceable against it in accordance with its terms.

IN WITNESS WHEREOF, the parties have hereunto subscribed their names the day and year first above written.

LESSOR:

/S/ Adrian Rand Robison
-----------------------
Adrian Rand Robison


/S/ Dorothy Robison
-----------------------
Dorothy Robison

LESSEE:

INTERNATIONAL ISOTOPES, INC.

By:   /S/ Steve T. Laflin
      -------------------

Its:  President & CEO
      -------------------

13

APPENDIX 1
HAZARDOUS WASTE AND MATERIAL - INDEMNITY

Lessee shall not cause or permit any Hazardous Waste or Material (hereafter defined) to be brought upon, kept or used in or about the Leased Premises by Lessee, or agents, employees, contractors or invitees of Lessee, expect in strict compliance with all applicable federal. state and local laws. statutes. ordinances and regulations. Lessee agrees to indemnify, save and hold Lessor harmless from and against any claim, liability, damage, judgment, penalty, fine, cost, loss or expenses, including, without limitation, diminution in value of the Leased Premises, damages for loss or restriction on use of rentable or usable space or of any amenity of the Leased Premises, damages arising from any adverse impact on marketing of space, and sums paid in settlement of claims, reasonable attorney's fees, reasonable consultant fees, engineer's fees and other expert fees, which arise from or relate to the breach by Lessee of the prohibition herein contained and which arise during or after the lease term as a result of said breach. This indemnification and hold harmless of the Lessor by the Lessee for the breach of the prohibition herein contained includes, without limitation, reasonable costs incurred in connection with an investigation of site conditions or any clean up, remedial, removal or restoration work required by any federal, state or local governmental agency or political subdivision because of Hazardous Waste or Material present in the soil or ground water on or under the Leased Premises caused by or resulting from the breach by Lessee of the prohibition herein contained. Without limiting the foregoing, if the presence of any Hazardous Waste or Material on the Leased Premises is caused or permitted by Lessee and results in any contamination of the Leased Premises, Lessee shall promptly take all actions at Lessee's sole cost and expense as are necessary to return the Leased Premises to the condition necessary to meet the requirements of any competent governmental authorities with jurisdiction over the Leased Premises.

As used herein, the term "Hazardous Waste or Material" means any hazardous or toxic substance, material or waste which is or becomes regulated by any local, state or governmental authority charged with interpreting and enforcing the various statutes identified in this paragraph or similar statutes, or their state or local counterparts. The term "Hazardous Waste or Material" includes, without limitation, any material, waste or substance that is (i) petroleum, (ii) asbestos, (iii) designated as a "pollutant" pursuant to Section 311 of the Federal Water Pollution Control Act (33 U.S.C. ss 1321), (iv) defined as a "Hazardous Waste" pursuant to ss 1004 of the Federal Resource Conservation and Recovery Act, 42 U.S.C. ss 6901, et. seq. (42 U.S.C. ss 6903), or the Idaho Hazardous Waste Management Act of 1983, Title 39, Chapter 44, Idaho Code, (v) defined as a "hazardous substance" pursuant to ss 101 of the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. ss 9501, et seq., (vi) or otherwise regulated under the Toxic Substances Control Act, 15 U.S.C. ss 2601, et seq.; the Clean Air Act, 42 U.S.C. ss 7401, et seq.; the Clean Water Act, 33 U.S.C. ss 1251, et seq.; or (vii) defined as a "regulated substance" pursuant to subchapter IX, Solid Waste Disposal Act (regulation of underground storage tanks), 42 U.S.C. ss 6991, et seq.

14

EXHIBIT 10.7

OPTION TO PURCHASE AND
RIGHT OF FIRST REFUSAL

THIS OPTION TO PURCHASE AND RIGHT OF FIRST REFUSAL is made and entered into as of the 2nd day of May, 2003, by and between ADRIAN RAND ROBISON and DOROTHY ROBIS and wife, referred to herein as "Lessor" and INTERNATIONAL ISOTOPES, INC., a Texas corporation, referred to herein as "Lessee".

RECITALS:

A. Lessee previously entered into a Lease Agreement (the "Prior Lease Agreement") and an Option to Purchase and Right of First Refusal (the "Prior Option to Purchase and Right of First Refusal) dated March 2: 2000, with Allen Ball, acting not individually but as Trustee of the Allen Ball and Connie Ball Living Trust created under Trust Agreement dated January 6, 1990, and any amendments thereto ("Ball").

B. The interest of Ball in the Prior Lease Agreement and the Prior Option to Purchase and Right of First Refusal was transferred by Ball to Lessor in connection with the sale by Ball to Lessor of the following described premises and all improvements located thereon situate in the County of Bonneville, State of Idaho, to-wit (the "Leased Premises"):

Lot 4, Block 4, St. Leon Industrial Park, Division No. 2, according to the recorded plat thereof.

C. Lessee and Lessor are now entering into a New Lease Agreement pertaining to the Leased Premises which shall have a term which commences on August 1, 2003 (the "New lease Agreement"). In connection with the execution of the New Lease Agreement, Lessor and Lessee have agreed to execute this Option to Purchase and Right of First Refusal in substitution for the Prior Option to Purchase and Right of First Refusal.

AGREEMENTS:

NOW, THEREFORE, in consideration of the lease of the Leased Premises by Lessee, the mutual covenants set forth herein and for other good and valuable consideration, the parties agree as follows:

1. This Option to Purchase and Right of First Refusal shall substitute for the Prior Option to Purchase and Right of First Refusal and the Prior to Option to Purchase and Right of First Refusal shall have no further force and effect. The right of first refusal and option to purchase granted to Lessee herein shall be in effect only until the expiration of the term of the New Lease Agreement. The right of first refusal and option to purchase set forth herein may not be exercised by Lessee if:


(a) Lessee or a sublessee of Lessee authorized by Lessor is not in possession of the Leased Premises under the New Lease Agreement.

(b) Lessee is in default of any of the terms of the New Lease Agreement.

2. Except as otherwise provided for herein, in the event Lessor desires to sell, transfer or convey Lessor's interest in the Leased Premises, or any portion thereof, Lessor shall have the right to sell, transfer or convey Lessor's interest in the Leased Premises, or any portion thereof, only after complying with the following requirements:

(a) Lessor shall forward to Lessee by certified mail, return receipt requested, at 4137 Commerce Circle, Idaho Falls, Idaho 83401, or to such other address as Lessee shall have provided to Lessor in writing, written notice containing all of the terms and conditions on which Lessor desires to give, sell, transfer or convey the Leased Premises, or any portion thereof (the "Lessor's Notice of Transfer"). Said notice shall be deemed effective upon the date of its mailing.

(b) Upon mailing of Lessor's Notice of Transfer, Lessee shall then have the option to purchase the interest of Lessor in the Leased Premises, or such portion thereof, as is referred to in Lessor's Notice of Transfer upon the same terms as set forth in such notice.

(c) Lessee may exercise its option to purchase by mailing its written notice of exercise of option to Lessor within fifteen (15) days from the date of mailing of the notice to Lessee. Such notice of exercise of option shall be forwarded to Lessor by certified mail, return receipt requested, at Post Office Box 95, Rexburg, Idaho 83440, or to such other address as may be designated in writing to Lessee by Lessor. In the event Lessee exercises such option, then Lessee and Lessor must, within fifteen (15) days after the exercise of such option, enter into a binding written agreement for the transfer and/or the purchase of the Leased Premises upon the same terms and conditions set forth in Lessor's Notice of Transfer. Notwithstanding anything contained in the New Lease Agreement to the contrary, if Lessee exercises such option to purchase, then the term of the New Lease Agreement shall expire on the day of closing of the sales transaction.

2

(d) In the event that Lessee does not desire to exercise Lessee's option to purchase, Lessee shall, within fifteen (15) days of the mailing of Lessor's Notice of Transfer, mail by certified mail, return receipt requested, to Post Office Box 95, Rexburg, Idaho 83440, or such other address as Lessor shall have provided to Lessee in writing, Lessee's notice to Lessor that Lessee will not exercise said option. If Lessee fails to provide such notice that Lessee will not exercise such option, and Lessee does not exercise the option as provided in paragraph 2(c), then Lessor is hereby empowered to record Lessor's affidavit to the effect that Lessee did not timely exercise said option, which affidavit shall be conclusive as against Lessee of Lessee's failure to exercise such option. If Lessee fails to exercise such option in the manner provided in paragraph 2(c) above, then Lessor shall have the right to forthwith transfer or convey the Leased Premises or any portion thereof free and clear of this right of first refusal to whomsoever Lessor desires, provided that: (i) such sale, transfer or conveyance is consummated within one hundred eighty (180) days after the expiration of the time for Lessee to accept the offer,
(ii) such sale, transfer or conveyance is made in accordance with the terms and conditions set out in Lessor's Notice of Transfer, and (iii) the purchaser shall receive the Leased Premises subject to any remaining rights and obligations Lessor and Lessee may have under the New Lease Agreement. If Lessee fails to exercise such option in the manner provided in paragraph 2(c) above, then in such event Lessor shall have the right to forthwith transfer or convey the Leased Premises or any portion thereof free and clear of the option to purchase hereinafter set forth.

(e) Notwithstanding anything to the contrary herein, it is specifically understood and agreed that this right of first refusal shall not apply to any transfer, either with or without consideration, or whether by will, agreement, operation of law or otherwise, by Lessor to Immediate Family. "Immediate Family" means for purposes of this paragraph, Adrian Rand Robison and Dorothy Robison, husband and wife, the lineal descendants of Adrian Rand Robison and Dorothy Robison, the spouses of any such lineal descendants and the trustees of any trusts in which the beneficiaries of such trusts are any of the foregoing mentioned parties. Any such transfer to Immediate Family shall be subject, however, to the right of first refusal granted by this Agreement, and the Immediate Family shall be bound to comply with this right of first refusal and any subsequent transfer of the Leased Premises or any portion thereof.

4. Subject to the termination of the option granted herein under the conditions set forth in paragraph 2(d) above, Lessor grants unto Lessee the exclusive right and option, if Lessee shall not be in default of any of the terms of the New Lease Agreement, to purchase the Leased Premises and any additions and improvements thereon, together with any improvements that may have been made during the term of the New Lease Agreement, upon and subject to the following terms and conditions:

(a) Said option shall be exercisable only prior to the expiration of the term of the New Lease Agreement.

3

(b) To exercise this option, Lessee shall deliver to Lessor written notification of the date upon which Lessor is prepared to purchase and close the transaction upon the terms provided herein; provided, however, that Lessor shall be given at least thirty (30) days notice of the date of such closing.

(c) Within sixty (60) days after giving written notice of Lessee's intent to exercise the option to purchase, Lessee shall purchase the Leased Premises and the closing to complete such purchase shall be completed within said sixty (60) day period.

(d) If Lessee properly exercises the option to purchase set forth herein, the Leased Premises shall be sold to Lessee by Lessor and Lessee shall purchase the Leased Premises pursuant to the following terms and provisions:

(i) For purposes of this subparagraph the term "CPI" shall refer to the CPI published by the Bureau of Labor Statistics of the United States Department of Labor for All Urban Consumers, U.S. City Average (All Cities) for all items with the index base being the current official base of 1982-1984 = 100. If Lessee properly exercises the option to purchase prior to the expiration of the initial five (5) year term of the New Lease Agreement, the purchase price shall be computed as follows: a fraction shall be created, the denominator of which is the CPI for March, 2003, and the numerator of which shall be the CPI on the last day of the month prior to the date of closing. This fraction then shall be multiplied by $709,587.00. The purchase price shall be the higher of: (i) $709,587.00 or
(ii) the amount which is arrived at my multiplying $709,587.00 by the above referred to fraction.

(ii) If Lessee exercises the option to purchase set forth herein after the expiration of the initial five (5) year term of the New Lease Agreement, the purchase price of the Leased Premises shall be the fair market value of the Leased Premises at the time Lessee exercises the option to purchase. If Lessee and Lessor cannot agree upon the fair market value of the Leased Premises, the Leased Premises shall be appraised. If Lessee and Lessor cannot agree on an appraiser, they shall each appoint an appraiser. If the two (2) appraisers cannot agree upon the fair market value of the Leased Premises, they shall appoint a third appraiser, and the decision of a majority of the three (3) appraisers shall be binding on all parties. The cost of the appraisal shall be shared equally by the Lessor and the Lessee.

(iii) At closing, Lessor shall execute a Grant Deed and deliver such Grant Deed to Lessee for recording which such Grant Deed shall transfer title to the Leased Premises to Lessee. The Leased Premises shall be transferred to Lessee subject to all existing easements or claims of easements, patent reservations, rights-of-way, protective covenants, zoning ordinance, and applicable building codes, laws and regulations, encroachments, overlaps, boundary line disputes and other matters which would be disclosed by an accurate survey or inspection of the Leased Premises.

4

(iv) Lessee is responsible for payment of all taxes and assessments accruing on the Leased Premises during the term of the New Lease Agreement between Lessee and Lessor. In addition, Lessee shall pay all taxes and assessments levied upon the Leased Premises from and after the date of closing before the same become delinquent.

(v) Lessor shall provide to Lessee at the time of closing at Lessee's cost a standard form owners title insurance policy in the amount of the purchase price insuring title to the Leased Premises in Lessee, free and clear of any lien or encumbrance, excepting any lien or encumbrance that may have attached by reason of any act, deed or omission of Lessee and excepting the usual printed exceptions contained in such policies of title insurance, and taxes and assessments for the current year.

(vi) The Leased Premises shall be transferred to Lessee "as is" and Lessee understands that Lessor makes no warranties in regard to the Leased Premises, express or implied, except any warranties of title that may be otherwise contained in the Grant Deed from Lessor to Lessee.

(vii) Notwithstanding anything contained in the New Lease Agreement to the contrary, if Lessee exercises the option to purchase set forth herein, the term of the New Lease Agreement shall expire on the day of closing of the sales transaction. The closing on the sale of the transaction shall be handled by Bonneville Land & Title Company, and Lessor and Lessee shall each pay one-half (1/2) of the closing costs charged by Bonneville Land & Title Company. Lessee shall be responsible to pay any and all costs incurred in connection with any loan which may be obtained by Lessee in connection with the purchase of the Leased Premises, including, but not limited to, loan document preparation fees, tax service fees, appraisal fees and loan origination fees.

5. This Agreement shall inure to the benefit of and be binding upon the heirs, successors and assigns of the parties hereto.

6. Should either party default in the performance of any of the covenants or agreements contained herein, such defaulting party shall pay to the other party all costs and expenses, including, but not limited to, a reasonable attorney fee, including such fees on appeal, which the offended party may incur in enforcing this Agreement or in pursuing any remedy allowed by law for breach hereof, whether such is incurred by the filing of suit or otherwise.

5

IN WITNESS WHEREOF, the parties have hereunto set their hands the day and year first above written.

LESSOR:

/S/ Adrian Rand Robison
-----------------------
Adrian Rand Robison

LESSEE:

INTERNATIONAL ISOTOPES, INC.

By:   /S/ Steve T. Laflin
      -------------------

Its:  President & CEO
      -------------------

6

EXHIBIT 10.8

LEASE AGREEMENT

THIS LEASE AGREEMENT, is made and entered into as of this /flay of January, 2004, by and between ADRIAN RAND ROBISON and DOROTHY ROBISON, husband and wife, referred to herein as "Lessor", and INTERNATIONAL ISOTOPES, INC., a Texas corporation, referred to herein as "Lessee".

WITNESSETH:

In consideration of the mutual covenants, conditions and agreements contained herein and the payment of rents herein specified, it is agreed as follows:

1. DEMISED PREMISES. Lessor does hereby lease, demise and rent unto Lessee the following described premises and all improvements located thereon situated in the County of Bonneville, State of Idaho, to-wit (the "Leased Premises"):

Lot 3 Block 2, St. Leon Industrial Park, Division No. 1, according to the recorded plat thereof.

SUBJECT TO THE FOLLOWING:

1 Declaration of Covenants, Conditions and Restrictions for St. Leon Industrial Park, recorded in the records of Bonneville County, Idaho, on October 22, 1996, as Instrument No. 930434.

2 All existing easements or claims of easements, patent reservations, rights-of-way, protective covenants, zoning ordinances, and applicable building codes, laws and regulations, encroachments, overlaps, boundary line disputes and other matters which would be disclosed by an accurate survey or inspection of the premises.

2. TERM. The term of this Lease Agreement shall be as follows:

2.1 Initial Term. The initial term of this Lease Agreement shall be for a term of five (5) years commencing on February 1, 2004 (the "Commencement Date") and extending to midnight on January 31, 2009, subject however to prior termination as hereinafter set forth. For purposes of this Lease Agreement, the term "Lease Year" shall refer to the period of time each year commencing on the 1st day of February and ending at midnight on the 3 1st day of January.


2.2 Early Termination of Lease. Lessee has a patent purchase pending and Lessee is entering into this Lease Agreement under the assumption that such patent will be acquired prior to February 29, 2004. Notwithstanding anything contained herein to the contrary, the parties agree that Lessee, at Lessee's option, may terminate this Lease Agreement by giving written notice to Lessor of such termination prior to 5:00 p.m. Mountain Standard Time on February 29, 2004, if Lessee determines prior to such time that such patent will not be acquired. Such notice of termination must be sent by facsimile to Lessor in care of Charles A. Homer at 208-523-95 18 prior to 5.00 p.m. Mountain Standard Time on February 29, 2004. If Lessee properly terminates this Lease Agreement in such manner, Lessee shall vacate the Leased Premises within thirty (30) days of the date such notice is given and this Lease shall be terminated as of such time. Lessor shall in the event of such early termination retain the $3,000.00 deposit referred to in paragraph 3.6 herein, be entitled to receive and retain rent for the entire month of February, 2004, and for any time thereafter that Lessee retains possession of the Leased Premises. Lessee's right to terminate this Lease Agreement in the above described manner shall expire if Lessee does not send the notice of termination to Lessor in the above manner prior to 5:00 p.m. Mountain Standard Time on February 29, 2004.

2.3 Option to Renew. The term of this Lease Agreement may be extended, at the option of the Lessee, for one (1) successive period of five (5) years, being herein sometimes referred to as the extended term, as follows:

Extended Term - Commencing five (5) years from the Commencement Date and continuing for five (5) years thereafter.

At the expiration of the Initial Term, if this Lease shall be in full force and effect and the Lessee shall have fully performed all of its terms and conditions, the Lessee shall have the option to extend this Lease, upon the same terms and conditions, with rent to be paid as set forth in Article 3 herein, for an extended term of five (5) years to commence immediately upon the termination of the Initial Term of this Lease. The option for such extended term shall be exercised by the Lessee giving written notice thereof to the Lessor not less than one hundred eighty (1 80) days prior to the expiration of the then current term.

The extended term shall be upon the same terms, covenants and conditions as the original term of this Lease. In the event this Lease is extended as aforesaid, a new Lease Agreement for the term of such extension shall be unnecessary on such extension, this Lease constituting a present demise for both the original and the extended term. Any termination of this Lease during the Initial Term shall terminate all rights of extension hereunder.

2

3. RENT AND SECURITY DEPOSIT. Lessee covenants, stipulates and agrees to pay to Lessor as rent for the Leased Premises the following:

3.1 Lessee shall pay to Lessor monthly rental payments in the amount of $4,309.50 each.

3.2 At the conclusion of each Lease Year during the term of this Lease Agreement (the "Adjustment Date"), the monthly rent as specified herein shall be adjusted according to the following terms. The adjusted rent shall be based on the percent change in the CPI published by the Bureau of Labor Statistics of the United States Department of Labor for All Urban Consumers, U.S. City Average (All Cities) for All Items with the index base being the current official base of 1982 -1984 = 100 (hereafter the "CPI"). The monthly rent due following each Adjustment Date shall be increased by a percentage of the initial rent determined by comparison of the CPI on the Adjustment Date to the CPI of the Base Month. The "Base Month", for purposes of the rent adjustment provided herein shall be February, 2004. The adjusted rent shall be computed by creating a fraction, the denominator of which is the CPI for the Base Month. The numerator of which shall be the CPI on the Adjustment Date. This fraction shall be multiplied by the initial rent of $4,309.50 to determine the amount of the adjusted rent. The adjusted monthly rent shall be the rent due hereunder during the next ensuing Lease Year until the next Adjustment Date. In no event, however, shall the amount of adjusted rent due be reduced below the rent of $4,309.50 per month.

3.3 In the event that the CPI for the Adjustment Date is not published or not available on the Adjustment Date, Lessee shall continue paying rent at the last effective rate until the CPI for the Adjustment Date becomes available. At that time the rent shall be adjusted as provided herein and Lessee shall pay to Lessor the difference between the rent due under the proper adjustment from the Adjustment Date to the date the adjusted rent is calculated and the amount of rent actually paid during that period.

3.4 In the event the publication of the CPI identified above is discontinued, the parties hereto shall thereafter accept comparable statistics on the cost of living as they shall be computed and published by an official agency or department of the United States of America or by a responsible financial entity of recognized authority then to be selected by the parties hereto, making such revisions as the circumstances may require to carry out the intent of this paragraph.

3

3.5 All monthly rental payments shall be paid in advance with the first months lease payments to be paid on or before February 1,2004 and all subsequent lease payments to be paid on the 1st day of each month during the term of this Lease Agreement.

3.6 Lessee has on this date deposited with Lessor the sum of $3,000.00. Such deposit amount of $3,000.00 shall be deposited with Lessor as security for the faithful performance by Lessee of all terms, provisions, conditions and covenants hereof upon the Lessee's part to be kept, observed and performed, and said sum shall be returned to Lessee after the time fixed as the expiration of this Lease Agreement; provided, however, Lessee shall have faithfully kept, observed and performed all the terms, provisions, conditions and covenants on Lessee's part to be kept and performed; that in case of default on the part of Lessee to comply with the provisions hereof, said deposit shall be used first for the payment of delinquent rental, secondly for the payment of costs and expenses incurred by Lessor in repairing damage to the Leased Premises occasioned by the tenancy, and thirdly, for the repair and renovation of the grounds, occasioned by the default on the part of Lessee to comply with the terms hereof. Any surplus over the amount deposited hereof, in excess of the costs and expenses of Lessor in repairing damages due to the fault or neglect of Lessee shall be returned to Lessee. In the event the deposit herein made is not sufficient to cover costs of such repair, Lessee agrees to forthwith pay to Lessor, or Lessor's agents, the amount necessary over and above such deposit, to repair the Leased Premises.

3.7 In the event Lessee is delinquent in paying the rental payments or any other payments required of Lessee herein all such past due payments shall bear interest at eighteen percent (1 8%) per annum from the date of default until paid.

4. ASSIGNMENT OR SUBLEASING. Lessee shall not assign, mortgage, or encumber this Lease Agreement, nor sublet or permit the Leased Premises or any part thereof to be used by others for any purpose, without the prior written consent of Lessor being first obtained in each instance; provided, however, that regardless of any such assignment or sublease, Lessee shall remain primarily liable for the payment of the rent herein reserved and for the performance of all the other terms of this Lease Agreement required to be performed by Lessee. Lessor does hereby specifically consent to the sublease of this Lease Agreement by Lessee to its subsidiary, International Isotopes Idaho, Inc. Provided, however, regardless of such sublease, Lessee shall remain primarily liable for the payment of the rent herein reserved and for the performance of all the other terms of this Lease Agreement required to be performed by Lessee.

4

5. USAGE OF PREMISES AND COMPLIANCE WITH LAWS AND INSURANCE. Lessee shall not use, nor permit the use of the Leased Premises, for any other purpose or purposes or under any other trade name without the prior written consent of Lessor. The Leased Premises shall not be used for any unlawful purpose during the term of this Lease Agreement, and Lessee agrees to comply with all restrictive covenants (including any further covenants which may be recorded pertaining to the Premises) and all federal, state, county and city ordinances, laws and regulations, present or future, affecting the use of or the type of business to be carried on in the Leased Premises. Lessee shall not use the Leased Premises in a manner which shall increase the rate of fire or extended coverage insurance on the building situate on the Leased Premises over that in effect prior to this Lease Agreement. It is understood that before Lessee or any sublessee of Lessee can conduct certain operations on the Leased Premises contemplated by Lessee, a license to conduct such operations will need to be obtained from the nuclear regulatory commission and other governmental agencies. It is anticipated that in connection with the issuance of such licenses, Lessee will be required to obtain a surety bond insuring against any damages caused to the Leased Premises by hazardous waste and materials. Lessor shall be named as an insured party and beneficiary of any such surety bond or insurance. THE PROVISIONS CONCERNING HAZARDOUS WASTE AND MATERIAL SET FORTH IN APPENDIX 1 ATTACHED HERETO ARE INCORPORATED HEREIN BY REFERENCE AND ARE SPECIFICALLY MADE A

PART OF THIS LEASE AGREEMENT.

6. UTILITIES. Lessee shall furnish and timely pay for all heat, gas, electricity, power, water, hot water, lights, telephone, and all other utilities of every type and nature whatsoever used in or about the Leased Premises at Lessee's own cost and expense, and shall indemnify Lessor against any liability on such account. Lessor shall be under no obligation to furnish or pay for any of such utilities.

7. LESSOR'S RIGHT OF ENTRY. Lessor or their agents shall have the right to enter the Leased Premises at any reasonable time upon notice to Lessee to examine the same and determine the state of repair or alteration which shall or may be necessary for the safety or preservation of the Leased Premises.

8. ALTERATIONS. No alteration, addition, or improvement to the Leased Premises shall be made by Lessee witho.ut the written consent of Lessor. Any alteration, addition or improvement made by Lessee after such consent shall have been given, and any fixtures installed as part thereof, shall at Lessor's option become the property of Lessor upon the termination of this Lease Agreement and be surrendered with the Leased Premises; provided, however, that Lessor shall have the right to require Lessee to remove such fixtures at Lessee's cost upon the termination of this Lease Agreement. Upon the removal of any such fixtures, Lessee shall be required to promptly repair any damage or injury done to the Leased Premises by such removal and restore the Leased Premises to as good condition as the same are in at the time Lessee shall take possession, reasonable wear and tear excepted. Lessee shall indemnify Lessor against any mechanic's or materialman's lien or other lien arising out of the making of any alteration, repair, addition, or improvement by Lessee, and shall hold Lessor harmless of any such liens or claims, including reasonable attorney fees and costs that may be incurred in removing any such liens.

5

9. SIGNS. Lessee shall not affix or maintain upon the glass panes or supports of the windows, doors or the exterior walls of the Leased Premises, any signs, advertising placards, names, insignia, trademarks, descriptive material or any other such like items except as shall have first received the written approval of Lessor as to the size, type, color, location, copy, nature and display qualities. Lessee may, upon approval of Lessor, have windows or doors of the Leased Premises painted, or place decals thereon with the name of Lessee, Lessee's address and business hours, provided said painting or decals are removed upon termination or vacation of the Leased Premises at Lessee's expense.

10. WASTE. Lessee shall not commit any waste or damage to the Leased Premises hereby leased, nor permit any waste or damage to be done thereto.

11. PROTECTION OF PROPERTY. Lessee agrees to maintain the Leased Premises in as good condition as the same is in at the time Lessee shall take possession of the Leased Premises, reasonable wear and tear excepted. At the termination of this Lease Agreement in any manner Lessee will surrender the Leased Premises to Lessor in the condition above described. Damage to walls, doors, windows, ceiling tiles and other parts of the Leased Premises shall be repaired and painted by Lessee at Lessee's sole cost and expense and returned in good condition at the termination of this Lease Agreement and at the termination of this Lease Agreement carpets shall be repaired and cleaned by Lessee at Lessee's cost and expense. Upon the termination of this Lease Agreement, Lessee may remove any signs owned by Lessee from the Leased Premises, promptly repairing any damage or injury done to the Leased Premises by such removal and restoring the Leased Premises to the condition above described.

12. MAINTENANCE. All maintenance and repair necessary to keep the Leased Premises in good condition and repair shall be made at Lessee's sole cost and expense, including, but not limited to, normal maintenance and repairs to the furnace or any other heating or air conditioning equipment, electrical fixtures, all interior and exterior painting and decorating, glass replacement, plumbing and sewer repair, and all other repairs of every kind, nature and description. Lessee further agrees that all damage or injury done to the Leased Premises by Lessee or by any person who may be in or upon the Leased Premises at Lessee's invitation or with Lessee's permission shall be repaired by Lessee at their sole cost and expense.

6

13. INSURANCE.

13.1 Lessee shall maintain and pay for adequate fire and extended coverage insurance upon the improvements located on the Leased Premises.

13.2 Lessee shall also obtain, at Lessee's sole cost and expense, general public liability insurance protecting and indemnifying Lessor and Lessee against all claims for damages to person or property or for loss of life or of property occurring upon, in, or about the Leased Premises, with liability limits of $50,000.00 property damage and $500,000.00 with respect to injuries to any one person, and $1,000,000.00 in respect to any one accident or disaster or incident of negligence.

13.3 Lessee shall obtain all such insurance policies before Lessee takes possession of the Leased Premises. In the event of any loss or destruction of the Leased Premises by any insured cause, the insurance proceeds paid or payable as a result of said insured loss shall be paid to Lessor and Lessor shall use such insurance proceeds to repair the Leased Premises unless as a result of such loss or destruction this Lease Agreement is terminated in accordance with the provisions of paragraph 20 herein. In the event of such termination, Lessor, at Lessor's option, shall determine whether or not to retain the insurance proceeds for other purposes or use the insurance proceeds to repair or restore the Leased Premises. Lessor shall remain as co-insured on all such policies. Such insurance policies shall provide that all notices issued by the insurance company pertaining to any changes in insurance coverage under the insurance policy, delinquent premium notices, or other matters pertaining to the coverage provided by such insurance policies shall be sent to both Lessor and Lessee. Evidence of such insurance policies shall be delivered to Lessor. Lessor shall have the right at any time to require Lessee to provide to Lessor copy of such insurance policies, together with any amendments or additions to such insurance policies and evidence that all payments required to be made in order to maintain such insurance in full course and effect have been paid in full by Lessee.

14. TAXES AND ASSESSMENTS. Lessee shall pay all real estate taxes, real property assessments and Owner's Association dues or assessments levied against the Leased Premises pertaining to the term of this Lease Agreement. Lessee shall pay all other taxes, licenses, and assessments of every kind, nature and description, including all taxes and assessments on any equipment, machinery, or assets of any kind or nature placed in or upon the Leased Premises by Lessee.

7

15. FIRE RISK. Lessee shall not do anything in the Leased Premises or bring or keep anything therein which in any way increase or tend to increase the risk of fire or damage by explosion, or which will conflict with the regulations of the fire department or fire laws, or with any fire insurance policy on the building or any part thereof, or with any rules or ordinances established by the Health Department or with any municipal, state, county or federal laws, ordinances or regulations.

16. ACCEPTANCE OF PREMISES. Lessee has examined the Leased Premises and the buildings and improvements situate thereon, and accepts the same in the condition and state of repair they are now in.

17. QUIET ENJOYMENT. Lessor covenants and warrants that if Lessee shall faithfully and fully discharge the obligations herein set forth, Lessee shall have and enjoy during the term of this Lease Agreement, a quiet and undisturbed possession of the Leased Premises, together with all of its appurtenances.

18. LESSEE INDEMNIFICATION. Lessee covenants and agrees not to do or suffer anything to be done by which persons or property in or about or adjacent to the Leased Premises may be injured, damaged, or endangered. Lessee hereby agrees to indemnify Lessor against and to hold Lessor harmless from any and all claims or demands for loss of or damage to property or for injury or death to any person from any cause whatsoever while in, upon, or about the Leased Premises during the term of this Lease Agreement or any extension thereof. Lessee shall, at Lessee's own expense, maintain any workman's compensation insurance or any other form of insurance required by law upon the employees or agents employed by Lessee and Lessor shall have no responsibility with respect thereto.

19. CONDEMNATION. If the Leased Premises, or any substantial portion thereof, is condemned or taken by right of eminent domain, or by purchase in lieu thereof, then and in any such event, this Lease Agreement shall terminate and cease as of the time when possession is taken by the public authority and rental shall be accounted for between Lessor and Lessee as of the date of the surrender of possession. Such termination shall be without prejudice to the rights of either Lessor or Lessee to recover compensation from the condemning authority for any loss or damage caused by such condemnation. Neither Lessor nor Lessee shall have any rights in or to any award or payment made to the other by the condemning authority.

8

20. DESTRUCTION. It is understood and agreed that if the building upon the Leased Premises shall be destroyed by fire, the elements, riots, insurrections, explosions or any other cause, or be so damaged thereby that it becomes untenantable and cannot be rendered tenantable within ninety (90) days from the date of such damage, this Lease Agreement may be terminated by either Lessor or Lessee; provided, however, that in the event the building is so damaged, Lessee shall not be required to pay the rental herein provided during the term the Leased Premises are wholly unfit for occupancy. In the event that only a portion of the Leased Premises be damaged or become untenantable, then the rental during the period that said premises remain partially untenantable shall be reduced in the proportion that the untenantable portion of the Leased Premises bear to the total thereof. Lessor shall make all reasonable effort to repair the Leased Premises within ninety (90) days or upon such extended period as both parties shall agree, provided that if said partially tenantable premises cannot be rendered fully tenantable within said ninety (90) days or extended period agreed upon by both Lessor or Lessee, from the date of said damage, this Lease Agreement can be terminated by either Lessor or Lessee.

21. DEFAULT

A. Time and prompt performance of each and every term, covenant and condition of this Lease Agreement is material and of the essence of this Lease Agreement. Every term, covenant and condition is a material term, covenant and condition of this Lease Agreement. Performance means compliance that is full and to the letter of this Lease Agreement. Substantial compliance will not be sufficient. Performance by Lessee is a condition precedent to performance by Lessor.

B. The following or any of them constitute an event of default of the terms of this Lease Agreement:

(1) Failure by Lessee to pay when due any installment of rent or any other sum herein specified to be paid by Lessee if the failure continues for three (3) days after written notice has been given to Lessee;

(2) Abandonment of the Leased Premises by Lessee without cause (for the purposes hereof the failure to occupy and operate the Leased Premises for ten (10) consecutive days shall be conclusively deemed an abandonment of the Leased Premises by Lessee);

(3) Failure by Lessee to perform any other provision of this Lease Agreement required of Lessee, if the failure to perform the same is not cured within thirty (30) days after written notice has been given to Lessee;

9

(4) If Lessee shall file or have filed against Lessee in any court pursuant to any statute, either in the United States or of any other state, a Petition in Bankruptcy or Insolvency, or for reorganizations, or for appointment of a receiver or trustee of all or a substantial portion of the property owned by Lessee, or if Lessee makes an assignment for the benefit of creditors, or an execution or attachment shall be issued against Lessee on all or a substantial portion of Lessee's property, whereby all or any portion of the Leased Premises covered by this Lease Agreement or any improvements thereon shall be taken or occupied, or attempted to be taken or occupied by someone other than Lessee, except as may herein be otherwise expressly permitted, and such adjudication, appointment, assignment, petition, execution or attachment shall not be set aside, vacated, discharged or bonded within thirty (30) days after the termination, issuance, or filing of the same; and

(5) The taking by any person, except by Lessor or its agents or affiliates, of the leasehold created hereby or any part thereof upon execution, or other process of law or equity other than by assignment or sublease.

C. Upon the occurrence of any event of default, and the failure, neglect or refusal of Lessee to cure the same during any notice period required for such default specified above, without further notice to Lessee, Lessor shall be entitled to effectuate such rights and remedies against Lessee as are available to Lessor under the terms of this Lease Agreement and the laws of the State of Idaho, including, without limitation, the following remedies:

(1) Lessor shall have the immediate right, but not the obligation, to terminate this Lease Agreement, and all rights of Lessee hereunder by giving Lessee written notice of Lessor's election to terminate. No act by Lessor other than giving notice to Lessee shall terminate this Lease Agreement. In the event of such termination, Lessee agrees to immediately surrender possession of the Leased Premises. Should Lessor terminate this Lease Agreement, it may recover from Lessee all damages Lessor may incur by reason of Lessee's breach, including the cost of recovering the Leased Premises, reasonable attorney fees, and the worth at the time of such termination of the excess, if any, of the amount of rent and charges equivalent to rent reserved in this Lease Agreement for the remainder of the stated term over the then reasonable rental value of the Leased Premises for the remainder of the stated term, all of which amount shall be immediately due and payable from Lessee to Lessor.

10

(2) Lessor shall also have the right, without process of law, to enter the Leased Premises and remove all persons and property from the Leased Premises without being deemed guilty of or liable in trespass. No such re-entry or taking possession of the Leased Premises by Lessor shall be construed as an election on its part to terminate this Lease Agreement unless a written notice of such intention is given by Lessor to Lessee. No such action by Lessor shall be considered or construed to be a forcible entry.

(3) Lessor may, at any time, and from time to time, without terminating this Lease Agreement, enforce all of its rights and remedies under this Lease Agreement, or allowed by law or equity, including the right to recover all rent as it becomes due.

(4) In addition to the other rights of Lessor herein provided, Lessor shall have the right, without terminating this Lease Agreement, at its option, with or without process of law, to reenter and retake possession of the Leased Premises, and all improvements thereon, and collect rents from any Sublessee and/or sublet the whole or any part of the Leased Premises for the account of Lessee, upon any terms or conditions determined by Lessor. Lessee shall be liable immediately to Lessor for all costs Lessor incurs in reletting the Leased Premises, including without limitation, brokers' commissions, expenses of remodeling the Leased Premises required by the reletting, and like costs. Re-letting can be for a period shorter or longer than the remaining term of this Lease Agreement. In the event of such re-letting, Lessor shall have the right to collect any rent which may become payable under any sublease and apply the same first to the payment of expenses incurred by Lessor in dispossessing Lessee, and in re-letting the Leased Premises, and, thereafter, to the payment of the rent herein required to be paid by Lessee, in fulfillment of Lessee's covenants hereunder; and Lessee shall be liable to Lessor for the rent herein required to be paid, less any amounts actually received by Lessor from a sublease, and after payment of expenses incurred, applied on account of the rent due hereunder. In the event of such election, Lessor shall not be deemed to have terminated this Lease Agreement by taking possession of the Leased Premises unless notice of termination, in writing, has been given by Lessor to Lessee.

D. The remedies provided in this Lease Agreement are cumulative in addition to any remedies now or later allowed by law or equity. The exercise of any remedy by Lessor shall not be exclusive of the right to effect any other remedy, allowed Lessor under the terms of this Lease Agreement, or now or later allowed by law or equity.

11

E. Any delay by Lessor in enforcing the terms of this Lease Agreement or any considerations or departures therefrom shall not operate to waive or be deemed to be a waiver of any right to require compliance that is full and to the letter of this Lease Agreement or to thereafter require performance by Lessee in strict accordance with the terms of this Lease Agreement.

F. In the event that any remedy granted to Lessor under the terms of this Lease Agreement is held void or unenforceable, Lessor shall nevertheless have all of the other remedies provided in this Lease Agreement that are not contrary to law.

G. Lessee hereby expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Lessee being evicted or dispossessed for any cause, or in the event of Lessor obtaining possession of the Leased Premises by reason of the violation by Lessee of any of the covenants and conditions of this Lease Agreement or otherwise.

22. ENFORCEMENT. Should either party default in the performance of any covenants or agreements contained herein, such defaulting party shall pay to the other party all costs and expenses, including but not limited to, reasonable attorney fees, including such fees on appeal, which the prevailing party may incur in enforcing this Lease Agreement or in pursuing any remedy allowed by law for breach hereof.

23. LESSOR'S RIGHT TO CURE LESSEE'S DEFAULTS. If Lessee shall default in the performance of any covenant or condition in this Lease Agreement required to be performed by Lessee, Lessor may, after thirty (30) days notice to Lessee, or without notice if in Lessor's opinion an emergency exists, perform such covenant or condition for the account and at the expense of Lessee, in which event Lessee shall reimburse Lessor for all sums paid to effect such cure, together with interest from the date of the expenditure at the rate of eighteen percent (18%) per annum and reasonable attorney fees. All amounts owed by Lessee to Lessor under this paragraph shall be additional rent. In order to collect such additional rent Lessor shall have all the remedies available under this Lease Agreement for a default in the payment of rent and the provisions of this paragraph shall survive the termination of this Lease Agreement. Nothing in this paragraph provided shall in any way require Lessor to perform or correct any such defaults on the part of Lessee.

24. NOTICES. Service of any notice permitted or required under the terms of this Lease Agreement shall be deemed complete upon the deposit of the same in the United States

12

27. LESSEE AS INDEPENDENT CONTRACTOR. Lessee's use of the Leased Premises shall be as an independent contractor and nothing herein shall be deemed to create a partnership, joint venture, employment, or master-servant relationship between the parties.

28. IDAHO LAW GOVERNS. This Lease Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of Idaho.

29. MODIFICATION. This Lease Agreement contains the entire agreement between the parties, and may not be modified or changed orally, but only by an agreement in writing and signed by the party against whom enforcement of any waiver, change, modification, or discharge is sought.

30. SEVERANCE AND VALIDITY. In the event any provision of this Lease Agreement or any part thereof shall be determined by any court of competent jurisdiction to be invalid, void, or otherwise unenforceable, the remaining provisions hereunder or parts thereof, shall remain in full force and effect, and shall in no way be affected, impaired or invalidated thereby, it being agreed that such remaining provisions shall be construed in a manner most closely approximating the intention of the parties with respect to the invalid, void or unenforceable provision or part thereof.

31. BINDING ON SUCCESSORS. It is further expressly agreed, that the provisions, stipulations, terms, covenants, conditions and undertakings in this Lease Agreement and any renewals thereof shall inure to the benefit of and bind the heirs, executors, administrators and assigns or successors in interest of both the Lessor and Lessee.

32. MUTUAL RELEASE OF LIABILITY TO THE EXTENT OF INSURANCE COVERAGE. Neither Lessor nor Lessee shall be liable to the other for any business interruption or any loss or damage to property or injury to or death of persons occurring on the Leased Premises or the adjoining property, or in any manner growing out of or connected with Lessee's use and occupation of the Leased Premises, or the condition thereof, or the adjoining property, whether or not caused by the negligence or other fault of Lessor or Lessee or their respective agents, employees, subtenants, licensees, or assignees. This release shall apply only to the extent that such business interruption loss or damage to property, or injury to or death of persons is covered by insurance, regardless of whether such insurance is payable to or protects Lessor or Lessee or both. Nothing in this paragraph shall be construed to impose any other or greater liability upon either Lessor or Lessee than would have existed in the absence of the paragraph. This release shall be in effect only so long as the applicable insurance policies contain a clause to the effect that this release shall not affect the right of the insured to recover under such policies.

13

APPENDIX 1
HAZAKDOUS WASTE AND MATERIAL - INDEMNITY

Lessee shall not cause or permit any Hazardous Waste or Material (hereafter defined) to be brought upon, kept or used in or about the Leased Premises by Lessee, or agents, employees, contractors or invitees of Lessee, expect in strict compliance with all applicable federal. state and local laws. statutes. ordinances and regulations. Lessee agrees to indemnify, save and hold Lessor harmless from and against any claim, liability, damage, judgment, penalty, fine, cost, loss or expenses, including, without limitation, diminution in value of the Leased Premises, damages for loss or restriction on use of rentable or usable space or of any amenity of the Leased Premises, damages arising from any adverse impact on marketing of space, and sums paid in settlement of claims, reasonable attorney's fees, reasonable consultant fees, engineer's fees and other expert fees, which arise from or relate to the breach by Lessee of the prohibition herein contained and which arise during or after the lease term as a result of said breach. This indemnification and hold harmless of the Lessor by the Lessee for the breach of the prohibition herein contained includes, without limitation, reasonable costs incurred in connection with an investigation of site conditions or any clean up, remedial, removal or restoration work required by any federal, state or local governmental agency or political subdivision because of Hazardous Waste or Material present in the soil or ground water on or under the Leased Premises caused by or resulting from the breach by Lessee of the prohibition herein contained. Without limiting the foregoing, if the presence of any Hazardous Waste or Material on the Leased Premises is caused or permitted by Lessee and results in any contamination of the Leased Premises, Lessee shall promptly take all actions at Lessee's sole cost and expense as are necessary to return the Leased Premises to the condition necessary to meet the requirements of any competent governmental authorities with jurisdiction over the Leased Premises.

As used herein, the term "Hazardous Waste or Material" means any hazardous or toxic substance, material or waste which is or becomes regulated by any local, state or governmental authority charged with interpreting and enforcing the various statutes identified in this paragraph or similar statutes, or their state or local counterparts. The term "Hazardous Waste or Material" includes, without limitation, any material, waste or substance that is (i) petroleum, (ii) asbestos, (iii) designated as a "pollutant" pursuant to Section 311 of the Federal Water Pollution Control Act (33 U.S.C. ss.1321), (iv) defined as a "Hazardous Waste" pursuant to ss 1004 of the Federal Resource Conservation and Recovery Act, 42 U.S.C. ss.6901, et. seq. (42 U.S.C. ss.6903), or the Idaho Hazardous Waste Management Act of 1983, Title 39, Chapter 44, Idaho Code, (v) defined as a "hazardous substance" pursuant to ss.101 of the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. ss.9501, et seq., (vi) or otherwise regulated under the Toxic Substances Control Act, 15 U.S.C. ss.2601, et seq.; the Clean Air Act, 42 U.S.C. ss.7401, et seq.; the Clean Water Act, 33 U.S.C. ss.1251, et seq.; or (vii) defined as a "regulated substance" pursuant to subchapter IX, Solid Waste Disposal Act (regulation of underground storage tanks), 42 U.S.C. ss.6991, et seq.

14

EXHIBIT 10.9

OPTION T0 PURCHASE AND
RIGHT OF FIRST REFUSAL

THIS OPTION TO PURCHASE AND RIGHT OF FIRST REFUSAL is made and entered into as of the 14th day of January, 2004. by and between ADRIAN RAND ROBISON and DOROTHY ROBISON, husband and wife, referred to herein as "Lessor" and INTERNATIONAL ISOTOPES, INC., a Texas corporation, referred to herein as "Lessee".

RECITALS:

A. Lessor and Lessee are simultaneous with the execution of this Agreement entering into a Lease Agreement (the "Lease Agreement") wherein Lessor is leasing to Lessee the following described premises and all improvements located thereon situate in the County of Bonneville, State of Idaho, to-wit (the "Leased Premises"):

Lot 3, Block 2, St. Leon Industrial Park, Division No. 1, according to the recorded plat thereof.

SUBJECT TO THE FOLLOWING:

1. Declaration of Covenants, Conditions and Restrictions for St. Leon Industrial Park, recorded in the records of Bonneville County, Idaho, on October 22,1996, as Instrument No. 930434.

2. All existing easements or claims of easements, patent reservations, rights-of-way, protective covenants, zoning ordinances, and applicable building codes, laws and regulations, encroachments, overlaps, boundary line disputes and other matters which would be disclosed by an accurate survey or inspection of the premises.

B. Lessor has agreed to grant to Lessee the right of first refusal and option to purchase set forth herein.

AGREEMENTS:

NOW, THEREFORE, in consideration of the lease of the Leased Premises by Lessee, the mutual covenants set forth herein and for other good and valuable consideration, the parties agree as follows:


1. The right of first refusal and option to purchase granted to Lessee herein shall be in effect only until the expiration of the term of the Lease Agreement. The right of first refusal and option to purchase set forth herein may not be exercised by Lessee if:

(a) Lessee or a sublessee of Lessee authorized by Lessor is not in possession of the Leased Premises under the Lease Agreement.

(b) Lessee is in default of any of the terms of the Lease Agreement.

2. Except as otherwise provided for herein, in the event Lessor desires to sell, transfer or convey Lessor's interest in the Leased Premises, or any portion thereof, Lessor shall have the right to sell, transfer or convey Lessor's interest in the Leased Premises, or any portion thereof, only after complying with the following requirements:

(a) Lessor shall forward to Lessee by certified mail, return receipt requested, at 4137 Commerce Circle, Idaho Falls, Idaho 83401, or to such other address as Lessee shall have provided to Lessor in writing, written notice containing all of the terms and conditions on which Lessor desires to give, sell, transfer or convey the Leased Premises, or any portion thereof (the "Lessor's Notice of Transfer"). Said notice shall be deemed effective upon the date of its mailing.

(b) Upon mailing of Lessor's Notice of Transfer, Lessee shall then have the option to purchase the interest of Lessor in the Leased Premises, or such portion thereof, as is referred to in Lessor's Notice of Transfer upon the same terms as set forth in such notice.

(c) Lessee may exercise its option to purchase by mailing its written notice of exercise of option to Lessor within fifteen (15) days from the date of mailing of the notice to Lessee. Such notice of exercise of option shall be forwarded to Lessor by certified mail, return receipt requested, at Post Office Box 95, Rexburg, Idaho 83440, or to such other address as may be designated in writing to Lessee by Lessor. In the event Lessee exercises such option, then Lessee and Lessor must, within fifteen (15) days after the exercise of such option, enter into a binding written agreement for the transfer and/or the purchase of the Leased Premises upon the same terms and conditions set forth in Lessor's Notice of Transfer. Not withstanding anything contained in the Lease Agreement to the contrary, if Lessee exercises such option to purchase, then the term of the Lease Agreement shall expire on the day of closing of the sales transaction.

2

(d) In the event that Lessee does not desire to exercise Lessee's option to purchase, Lessee shall, within fifteen (15) days of the mailing of Lessor's Notice of Transfer, mail by certified mail, return receipt requested, to Post Office Box 95, Rexburg, Idaho 83440, or such other address as Lessor shall have provided to Lessee in writing, Lessee's notice to Lessor that Lessee will not exercise said option. If Lessee fails to provide such notice that Lessee will not exercise such option, and Lessee does not exercise the option as provided in paragraph
2(c), then Lessor is hereby empowered to record Lessor's affidavit to the effect that Lessee did not timely exercise said option, which affidavit shall be conclusive as against Lessee of Lessee's failure to exercise such option. If Lessee fails to exercise such option in the manner provided in paragraph 2(c) above, then Lessor shall have the right to forthwith transfer or convey the Leased Premises or any portion thereof free and clear of this right of first refusal to whomsoever Lessor desires, provided that: (i) such sale, transfer or conveyance is consummated within one hundred eighty (180) days after the expiration of the time for Lessee to accept the offer, (ii) such sale, transfer or conveyance is made in accordance with the terms and conditions set out in Lessor's Notice of Transfer, and
(iii) the purchaser shall receive the Leased Premises subject to any remaining rights and obligations Lessor and Lessee may have under the Lease Agreement. If Lessee fails to exercise such option in the manner provided in paragraph 2(c) above, then in such event Lessor shall have the right to forthwith transfer or convey the Leased Premises or any portion thereof free and clear of the option to purchase hereinafter set forth.

(e) Notwithstanding anything to the contrary herein, it is specifically understood and agreed that this right of first refusal shall not apply to any transfer, either with or without consideration, or whether by will, agreement, operation of law or otherwise, by Lessor to Immediate Family. "Immediate Family" means for purposes of this paragraph, Adrian Rand Robison and Dorothy Robison, husband and wife, the lineal descendants of Adrian Rand Robison and Dorothy Robison, the spouses of any such lineal descendants and the trustees of any trusts in which the beneficiaries of such trusts are any of the foregoing mentioned parties. Any such transfer to Immediate Family shall be subject, however, to the right of first refusal granted by this Agreement, and the Immediate Family shall be bound to comply with this right of first refusal and any subsequent transfer of the Leased Premises or any portion thereof.

4. Subject to the termination of the option granted herein under the conditions set forth in paragraph 2(d) above, Lessor grants unto Lessee the exclusive right and option, if Lessee shall not be in default of any of the terms of the Lease Agreement, to purchase the Leased Premises and any additions and improvements thereon, together with any improvements that may have been made during the term of the Lease Agreement, upon and subject to the following terms and conditions:

(a) Said option shall be exercisable only prior to the expiration of the term of the Lease Agreement.

3

(b) To exercise this option, Lessee shall deliver to Lessor written notification of the date upon which Lessor is prepared to purchase and close the transaction upon the terms provided herein; provided, however, that Lessor shall be given at least thirty (30) days notice of the date of such closing.

(c) Within sixty (60) days after giving written notice of Lessee's intent to exercise the option to purchase, Lessee shall purchase the Leased Premises and the closing to complete such purchase shall be completed within said sixty (60) day period.

(d) If Lessee properly exercises the option to purchase set forth herein, the Leased Premises shall be sold to Lessee by Lessor and Lessee shall purchase the Leased Premises pursuant to the following terms and provisions:

(i) For purposes of this subparagraph the term "CPI" shall refer to the CPI published by the Bureau of Labor Statistics of the United States Department of Labor for All Urban Consumers, U.S. City Average (All Cities) for all items with the index base being the current official base of 1982-1984 = 100. If Lessee properly exercises the option to purchase prior to the expiration of the initial five (5) year term of the Lease Agreement, the purchase price shall be computed as follows: a fraction shall be created, the denominator of which is the CPI for December, 2003, and the numerator of which shall be the CPI on the last day of the month prior to the date of closing. This fraction then shall be multiplied by $480,000.00. The purchase price shall be the higher of:
(i) $480,000.00 or (ii) the amount which is arrived at my multiplying $480,000.00 by the above referred to fraction.

(ii) If Lessee exercises the option to purchase set forth herein after the expiration of the initial five (5) year term of the Lease Agreement, the purchase price of the Leased Premises shall be the fair market value of the Leased Premises at the time Lessee exercises the option to purchase. If Lessee and Lessor cannot agree upon the fair market value of the Leased Premises, the Leased Premises shall be appraised. If Lessee and Lessor cannot agree on an appraiser, they shall each appoint an appraiser. If the two (2) appraisers cannot agree upon the fair market value of the Leased Premises, they shall appoint a third appraiser, and the decision of a majority of the three (3) appraisers shall be binding on all parties. The cost of the appraisal shall be shared equally by the Lessor and the Lessee.

(iii) At closing, Lessor shall execute a Grant Deed and deliver such Grant Deed to Lessee for recording which such Grant Deed shall transfer title to the Leased Premises to Lessee. The Leased Premises shall be transferred appeal, which the offended party may incur in enforcing this Agreement or in pursuing any remedy allowed by law for breach hereof, whether such is incurred by the filing of suit or otherwise.

4

IN WITNESS WHEREOF, the parties have hereunto set their hands the day and year first above written.

LESSOR:

/S/ Adrian Rand Robison
-----------------------
Adrian Rand Robison



/S/ Dorothy Robison
-----------------------
Dorothy Robison

LESSEE:

INTERNATIONAL ISOTOPES, INC.

By:   /S/ Steve T. Laflin
      -------------------

Its:  President & CEO
      -------------------

5

EXHIBIT 10.10

_____________________________________________________________________________________________
LOAN NUMBER             LOAN NAME               ACCT. NUMBER      NOTE DATE      INITIALS
   48107        International Isotopes, Inc.       243059          07/01/04         MDH
NOTE AMOUNT          INDEX (w/Margin)               RATE        MATURITY DATE   LOAN PURPOSE
$250,000.00     Texas State Bank Base Rate          7.5%           07/01/05      Commercial
                       plus 1.OOO%

                                     Creditor Use Only
_____________________________________________________________________________________________

PROMISSORY NOTE
(Commercial - Revolving Draw - Variable Rate)

DATE AND PARTIES. The date of this Promissory Note (Note) is July 1, 2004. The parties and their addresses are:

LENDER:
TEXAS STATE BANK
3900 North 10th Street
McAllen, Texas 78501-1719
Telephone: (956) 631-5401

BORROWER:
INTERNATIONAL ISOTOPES, INC.
a Texas Corporation
4137 Commerce Circle
Idaho Falls, Idaho 83401

1. DEFINITIONS. As used in this Note, the terms have the following meanings:

A. Pronouns. The pronouns "I," "me," and "my" refer to each Borrower signing this Note, Individually and together with their heirs, successors and assigns, and each other person or legal entity (including guarantors, endorsers, and sureties) who agrees to pay this Note. "You" and "Your" refer to the Lender, with its participants or syndicators, successors and assigns, or any person or company that acquires an interest in the loan.

B. Note. Note refers to this document, and any extensions, renewals, modifications and substitutions of this Note.

C. Loan. Loan refers to this transaction generally, including obligations and duties arising from the terms of all documents prepared or submitted for this transaction such as applications, security agreements, disclosures or notes, and this Note.

D. Property. Property is any property, real, personal or intangible, that secures my performance of the obligations of this Loan.

E. Percent. Rates and rate change limitations are expressed as annualized percentages.

2. PROMISE TO PAY. For value received, I promise to pay you or your order, at your address, or at such other location as you may designate, amounts advanced from time to time under the terms of this Note up to the maximum outstanding principal balance of $250,000.00 (Principal), plus interest from the date of disbursement, on the unpaid outstanding Principal balance until this Note matures or this obligation is accelerated.

I may borrow up to the Principal amount more than one time.

3. ADVANCES. Advances under this Note are made according to the following terms and conditions.

A. Requests for Advances. My requests are a warranty that I am in compliance with all the Loan documents. When required by you for a particular method of advance, my requests for an advance must specify the requested amount and the date and be accompanied with any agreements, documents, and instruments that you require for the Loan. Any payment by you of any check, share draft or other charge may, at your option, constitute an advance on the Loan to me. All advances will be made in United States dollars. I will indemnify you and hold you harmless for your reliance on any request for advances that you reasonably believe to be genuine. To the extent permitted by law, I will indemnify you and hold you harmless when the person making any request represents that I authorized this person to request an advance even when this person is unauthorized or this person's signature is not genuine.

I or anyone I authorize to act on my behalf may request advances by the following methods.

(1) I make a request in person.
(2) I make a request by phone.
(3) I make a request by fax.

B. Advance Limitations. In addition to any other Loan conditions, requests for, and access to, advances are subject to the following limitations.

(1) Obligatory Advances. You will make all Loan advances subject to this Agreement's terms and conditions.

(2) Advance Amount. Subject to the terms and conditions contained in this Note, advances will me made in exactly the amount I request.

(3) Cut-Off Time. Requests for an advance received before 04:00 PM will be made on any day that you are open for business, on the day for which the advance is requested.

(4) Disbursement of Advances. On my fulfillment of this Note's terms and conditions, you will disburse the advance in any manner as you and I agree.

(5) Credit Limit. I understand that you will not ordinarily grant a request for an advance that would cause the unpaid principal of my Loan to be greater than the Principal limit. You may, at your option, grant such a request without obligating yourselves to do so in the future.

(6) Records. Your records will be conclusive evidence as to the amount of advances, the Loan's unpaid principal balances and the accrued interest.

4. INTEREST. Interest will accrue on the unpaid balance of this Note at the rate of 7.5 percent (Interest Rate) until July 2, 2004, after which time it may change as described in the Variable Rate subsection.

A. Post-Maturity Interest. After maturity or acceleration, interest will accrue at the highest rate permitted by law.

B. Maximum Interest Amount. Any amount assessed or collected as interest under the terms of this Note or obligation will be limited to the Maximum Lawful Amount of interest allowed by state or federal law. Amounts collected in excess of the Maximum Lawful Amount will be applied first to the unpaid Principal balance. Any remainder will be refunded to me. The maximum interest rate producing the Maximum Lawful Amount will be the quarterly ceiling rate announced by the Credit Commissioner from time to time hereafter.

C. Statutory Authority. The amount assessed or collected on this Note is authorized by the Texas usury laws under Tex. Fin. Code, Ch. 303. The provisions of Tex. Fin. Code, Ch. 346 do not apply to this Note.

D. Accrual. During the scheduled term of this Loan interest accrues using an Actual/360 days counting method.

E. Variable Rate. The Interest Rate may change during the term of this transaction.

(1) Index. Beginning with the first Change Date, the Interest Rate will be based on the following Index: the base commercial lending rate announced by Texas State Bank.

The Current Index is the most recent index figure available on each Change Date. You do not guaranty by selecting this Index, or the margin, that the Interest Rate on this Note will be the same rate you charge on any other loans or class of loans you make to me or other borrowers. If this Index is no longer available, you will substitute a similar Index. You will give me notice of your choice.

(2) Change Date. Each date on which the Interest Rate may change is called a Change Date. The Interest Rate may change July 2, 2004 and daily thereafter.

(3) Calculation Of Change. On each Change Date, you will calculate the Interest Rate, which will be the Current Index plus 1.000 percent. The result of this calculation will be rounded to the nearest .001 percent. Subject to any limitations, this will be the Interest Rate until the next Change Date. The new Interest Rate will become effective on each Change Date. The Interest Rate and other charges on this Note will never exceed the highest rate or charge allowed by law for this Note.

(4) Limitations. The Interest Rate changes are subject to the following limitations.

(a) Lifetime. The Interest Rate will never be less than 7.500 percent.

(5) Effect Of Variable Rate. A change in the Interest Rate will have the following effect on the payments: The amount of scheduled payments and the amount of the final payment will change.

(5) REMEDIAL CHARGES. In addition to interest or other finance charges, I agree that I will pay these additional fees based on my method and pattern of payment. Additional remedial charges may be described elsewhere in this Note.

A. Late Charge. If a payment is more than 10 days late, I will be charged 5.000 percent of the Amount of Payment. I will pay this late charge promptly but only once for each late payment.


B. Returned Check Charge. I agree to pay a fee not to exceed $30.00 for each check, negotiable order of withdrawal or draft I issue in connection with this Loan that is returned because it has been dishonored.

C. Stop Payment. A(n) Stop Payment equal to $25.00.

6. PAYMENT. I agree to pay all accrued interest on the balance outstanding from time to time in regular payments beginning October 1, 2004, then on the same day in each 3rd month thereafter. Any payment scheduled for a date falling beyond the last day of the month, will be due on the last day. A final payment of the entire unpaid outstanding balance of Principal and interest will be due July 1, 2005.

Payments will be rounded to the nearest $.01. With the final payment I also agree to pay any additional fees or charges owing and the amount of any advances you have made to others on my behalf. Payments scheduled to be paid on the 29th. 30th or 31st day of a month that contains no such day will, instead, be made on the last day of such month.

Interest payments will be applied first to any charges I owe other than late charges, then to accrued, but unpaid interest, then to late charges. Principal payments will be applied first to the outstanding Principal balance, then to any late charges. If you and I agree to a different application of payments, we will describe our agreement on this Note. The actual amount of my final payment will depend on my payment record.

7. PREPAYMENT. I may prepay this Loan in full or in part at any time. Any partial prepayment will not excuse any later scheduled payments until I pay in full.

8. LOAN PURPOSE. The purpose of this Loan is for renewal O/P working capital.

9. SECURITY. This Loan is secured by separate security instruments prepared together with this Note as follows:

Document Name Parties to Document Security Agreement -International Isotopes, Inc. International Isotopes, Inc.

10. DEFAULT. I will be in default if any of the following occur:

A. Payments. I fail to make a payment in full when due.

B. Insolvency or Bankruptcy. I make an assignment for the benefit of creditors or become insolvent, either because my liabilities exceed my assets or I am unable to pay my debts as they become due; or I petition for protection under federal, state or local bankruptcy, insolvency or debtor relief laws, or am the subject of a petition or action under such laws and fail to have the petition or action dismissed within a reasonable period of time not to exceed 60 days.

C. Business Termination. I merge, dissolve, reorganize, end my business or existence, or a partner or majority owner dies is declared legally incompetent.

D. Failure to Perform. I fail to perform any condition or to keep any promise or covenant of this Note.

E. Other Documents. A default occurs under the terms of any other transaction document.

F. Other Agreements. I am in default on any other debt or agreement I have with you.

G. Misrepresentation. I make any verbal or written statement or provide any financial information that is untrue, inaccurate, or conceals a material fact at the time it is made or provided.

H. Judgment. I fail to satisfy or appeal any judgment against me.

I. Forfeiture. The Property is used in a manner or for a purpose that threatens confiscation by a legal authority.

J. Name Change. I change my name or assume an additional name without notifying you before making such a change.

K. Property Transfer. I transfer all or a substantial part of my money or property.

L. Property Value. The value of the Property declines or is impaired.

M. Material Change. Without first notifying you, there is a material change in my business, including ownership, management, and financial conditions.

N. Insecurity. You reasonably believe that you are insecure.

11. ASSUMPTIONS. Someone buying the Property cannot assume the obligation. You may declare the entire balance of the Note to be immediately due and payable upon the creation of, or contract for the creation of, any lien, encumbrance, or transfer of the Property. However, I may sell or similarly dispose of any Property that is inventory.

12. WAIVERS AND CONSENT. To the extent not prohibited by law, I waive protest, presentment for payment, demand, notice of acceleration, notice of intent to accelerate and notice of dishonor.

A. Additional Waivers By Borrower. In addition, I, and any party to this Note and Loan, to the extent permitted by law, consent to certain actions you may take, and generally waive defenses that may be available based on these actions or based on the status of a party to this Note.

(1)You may renew or extend payments on this Note, regardless of the number of such renewals or extensions.

(2)You may release any Borrower, endorser, guarantor, surety, accommodation maker or any other co-signer.

(3) You may release, substitute or impair any Property securing this Note.

(4)You, or any institution participating in this Note, may invoke your right of set-off.

(5) You may enter into any sales, repurchases or participations of this Note to any person in any amounts and I waive notice of such sales, repurchases or participations.

(6) 1 agree that any of us signing this Note as a Borrower is authorized to modify the terms of this Note or any instrument securing, guarantying or relating to this Note.

B. No Waiver By Lender. Your course of dealing, or your forbearance from, or delay in, the exercise of any of your rights, remedies, privileges or right to insist upon my strict performance of any provisions contained in this Note, or other Loan documents, shall not be construed as a waiver by you, unless any such waiver is in writing and is signed by you.

13. REMEDIES. After I default, and after you give any legally required notice and opportunity to cure the default, you may at your option do any one 01 more of the following.

A. Acceleration. You may make all or any part of the amount owing by the terms of this Note immediately due.

B. Sources. You may use any and all remedies you have under state or federal law or in any instrument securing this Note.

C. Insurance Benefits. You may make a claim for any and all insurance benefits or refunds that may be available on my default.

D. Payments Made On My Behalf. Amounts advanced on my behalf will be immediately due and may be added to the balance owing under the terms of this Note, and accrue interest at the highest post-maturity interest rate.

E. Termination. You may terminate my right to obtain advances and may refuse to make any further extensions of credit.

F. Set-Off. You may use the right of set-off. This means you may set-off any amount due and payable under the terms of this Note against any right I have to receive money from you. My right to receive money from you includes any deposit or share account balance I have with you; any money owed to me on an item presented to you or in your possession for collection or exchange; and any repurchase agreement or other non-deposit obligation. "Any amount due and payable under the terms of this Note" means the total amount to which you are entitled to demand payment under the terms of this Note at the time you set-off. Subject to any other written contract, if my right to receive money from you is also owned by someone who has not agreed to pay this Note, you1 right of set-off will apply to my interest in the obligation and to any other amounts I could withdraw on my sole request or endorsement. Your right of set-off does not apply to an account or other obligation where my rights arise only in a representative capacity. It also does not apply to any Individual Retirement Account or other tax-deferred retirement account. You will not be liable for the dishonor of any check when the dishonor occurs because you set-off against any of my accounts. I agree to hold you harmless from any such claims arising as a result of your exercise of your right of set-off.

G. Waiver. Except as otherwise required by law, by choosing any one or more of these remedies you do not give up your right to use any other remedy. You do not waive a default if you choose not to use a remedy. By electing not to use any remedy, you do not waive your right to later consider the event a default and to use any remedies if the default continues or occurs again.

14. COLLECTION EXPENSES AND ATTORNEYS' FEES. On or after Default, to the extent permitted by law, I agree to pay all expenses of collection, enforcement or protection of your rights and remedies under this Note. Expenses include, but are not limited to, reasonable attorneys' fees, court costs, and other legal expenses. These expenses are due and payable immediately. If not paid immediately, these expenses will bear interest from the date of payment until paid in full at the highest interest rate in effect as provided for in the terms of this Note. All fees and expenses will be secured by the Property I have granted to you, if any. To the extent permitted by the United States Bankruptcy Code, I agree to pay the reasonable attorneys' fees you incur to collect this Debt as awarded by any court exercising jurisdiction under the Bankruptcy Code.

2

15. WARRANTIES AND REPRESENTATIONS. I make to you the following warranties and representations which will continue as long as this Note is in effect:

A. Power. I am duly organized, and validly existing and in good standing in all jurisdictions in which I operate. I have the power and authority to enter into this transaction and to carry on my business or activity as it is now being conducted and, as applicable, am qualified to do so in each jurisdiction in which I operate.

B. Authority. The execution, delivery and performance of this Note and the obligation evidenced by this Note are within my powers, have been duly authorized, have received all necessary governmental approval, will not violate any provision of law, or order of court or governmental agency, and will not violate any agreement to which I am a party or to which I am or any of my Property is subject.

C. Name and Place of Business. Other than previously disclosed in writing to you I have not changed my name or principal place of business within the last 10 years and have not used any other trade or fictitious name. Without your prior written consent, I do not and will not use any other name and will preserve my existing name, trade names and franchises.

16. INSURANCE. I agree to obtain the insurance described in this Loan Agreement.

A. Property Insurance. I will insure or retain insurance coverage on the Property and abide by the insurance requirements of any security instrument securing this Loan.

B. Insurance Warranties. I agree to purchase any insurance coverages that are required, in the amounts you require, as described in this or any other documents I sign for this Loan. I will provide you with continuing proof of coverage. I will buy or provide insurance from a firm licensed to do business in the State where the Property is located. I will have the insurance company name you as loss payee on any insurance policy. You will apply the insurance proceeds toward what I owe you on the outstanding balance. I agree that if the insurance proceeds do not cover the amounts I still owe you, I will pay the difference. I will keep the insurance until all debts secured by this agreement are paid. If I want to buy the insurance from you, I have signed a separate statement agreeing to this purchase.

17. APPLICABLE LAW. This Note is governed by the laws of Texas, the United States of America and to the extent required, by the laws of the jurisdiction where the Property is located. In the event of a dispute, the exclusive forum, venue and place of jurisdiction will be in Texas, unless otherwise required by law.

18. JOINT AND INDIVIDUAL LIABILITY AND SUCCESSORS. My obligation to pay this Loan is independent of the obligation of any other person who has also agreed to pay it. You may sue me alone, or anyone else who is obligated on this Loan, or any number of us together, to collect this Loan. Extending this Loan or new obligations under this Loan, will not affect my duty under this Loan and I will still be obligated to pay this Loan. The duties and benefits of this Loan will bind and benefit the successors and assigns of you and me.

19. AMENDMENT, INTEGRATION AND SEVERABILITY. This Note may not be amended or modified by oral agreement. No amendment or modification of this Note is effective unless made in writing and executed by you and me. This Note is the complete and final expression of the agreement. If any provision of this Note is unenforceable, then the unenforceable provision will be severed and the remaining provisions will still be enforceable.

20. INTERPRETATION. Whenever used, the singular includes the plural and the plural includes the singular. The section headings are for convenience only and are not to be used to interpret or define the terms of this Note.

21. NOTICE, FINANCIAL REPORTS AND ADDITIONAL DOCUMENTS. Unless otherwise required by law, any notice will be given by delivering it or mailing it by first class mail to the appropriate party's address listed in the DATE AND PARTIES section, or to any other address designated in writing. Notice to one party will be deemed to be notice to all parties. I will inform you in writing of any change in my name, address or other application information. I will provide you any financial statement or information you request. All financial statements and information I give you will be correct and complete. I agree to sign, deliver, and file any additional documents or certifications that you may consider necessary to perfect, continue, and preserve my obligations under this Loan and to confirm your lien status on any Property. Time is of the essence.

22. CREDIT INFORMATION. I agree to supply you with whatever information you reasonably feel you need to decide whether to continue this Loan. You will make requests for this information without undue frequency, and will give me reasonable time in which to supply the information.

23. ERRORS AND OMISSIONS. I agree, if requested by you, to fully cooperate in the correction, if necessary, in the reasonable discretion of you of any and all loan closing documents so that all documents accurately describe the loan between you and me. I agree to assume all costs including by way of illustration and not limitation, actual expenses, legal fees and marketing losses for failing to reasonably comply with your requests within thirty (301 days.

THIS WRITTEN LOAN AGREEMENT REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

24. SIGNATURES. By signing, I agree to the terms contained in this Note. I also acknowledge receipt of a copy of this Note.

BORROWER:

International Isotopes, Inc.

By:  /S/  Steve Laflin 7-9-04
     -----------------------------
     Steve Laflin, President & CEO

LENDER:

Texas State Bank

By:

M. Douglas Harris, Vice President

3

SECURITY AGREEMENT

DATE AND PARTIES. The date of this Security Agreement (Agreement) is July 1, 2004. The parties and their addresses are:

SECURED PARTY:

TEXAS STATE BANK
3900 North 10th Street
McAllen, Texas 78501-1719

DEBTOR:

INTERNATIONAL ISOTOPES, INC.

a Texas Corporation
4137 Commerce Circle
Idaho Falls, Idaho 83401

The pronouns "you" and "your" refer to the Secured Party. The pronouns "I," "me" and "my" refer to each person or entity signing this Agreement as Debtor and agreeing to give the Property described in this Agreement as security for the Secured Debts.

1. SECURED DEBTS. This Agreement will secure the following Secured Debts:

A. Specific Debts. The following debts and all extensions, renewals, refinancings, modifications and replacements. A promissory note or other agreement, No. 48107, dated July 1, 21004, from me to you, in the amount of $250,000.00.

B. Sums Advanced. All sums advanced and expenses incurred by you under the terms of this Agreement.

2. SECURITY INTEREST. To secure the payment and performance of the Secured Debts, I give you a security interest in all of the Property described in this Agreement that I own or have sufficient rights in which to transfer an interest, now or in the future, wherever the Property is or will be located, and all proceeds and products from the Property (including, but not limited to, all parts, accessories, repairs, replacements, improvements, and accessions to the Property). Property is is11 the collateral given as security for the Secured Debts and described in this Agreement, and includes all obligations that support the payment or performance of the Property. "Proceeds" includes anything acquired upon the sale, lease, license, exchange, or other disposition of the Property; any rights and claims arising from the Property; and any collections and distributions on account of the Property.

This Agreement remains in effect until terminated in writing, even if the Secured Debts are paid and you are no longer obligated to advance funds to me under any loan or credit agreement.

3. PROPERTY DESCRIPTION. The Property is described as follows:

A. Inventory. All inventory which I hold for ultimate sale or lease, or which has been or will be supplied under contracts of service, or which are raw materials, work in process, or materials used or consumed in my business.

B. Accounts and Other Rights to Payment. All rights I have now or in the future to payments including, but not limited to, payment for property or services sold, leased, rented, licensed, or assigned, whether or not I have earned such payment by performance. This includes any rights and interests (including all liens and security interests) which I may have by law or agreement against any Account Debtor or obligor of mine.

C. Instruments, Documents and Chattel Paper. All instruments and rights I have now or in the future to payments including, but not limited to, rights to payment arising out of all present and future documents, instruments, tangible and electronic chattel paper, and loans and obligations receivable. This includes any rights and interests (including all liens and security interests) which I may have by law or agreement against any Account Debtor or obligor of mine.

D. General Intangibles. All general intangibles including, but not limited to, tax refunds, applications for patents, patents, copyrights, trademarks, trade secrets, good will, trade names, customer lists, permits and franchises, payment intangibles, computer programs and all supporting information provided in connection with a transaction relating to computer programs, and the right to use my name.

E. Equipment. All equipment including, but not limited to, all machinery. vehicles, furniture, fixtures, manufacturing equipment, farm machinery and equipment, shop equipment, office and recordkeeping equipment, and parts and tools. All equipment described in a list or schedule which I give to you will also be included in the Property, but such a list is not necessary for a valid security interest in my equipment.

F. Specific Property.

4. WARRANTIES AND REPRESENTATIONS. I make to you the following warranties and representations which will continue as long as this Agreement is in effect:

A. Power. I am duly organized, and validly existing and in good standing in all jurisdictions in which I operate. I have the power and authority to enter into this transaction and to carry on my business or activity as it is now being conducted and, as applicable, am qualified to do so in each jurisdiction in which I operate.

B. Authority. The execution, delivery and performance of this Agreement and the obligation evidenced by this Agreement are within my powers, have been duly authorized, have received all necessary governmental approval, will not violate any provision of law, or order of court or governmental agency, and will not violate any agreement to which I am a party or to which I am or any of my property is subject.

C. Name and Location. My name indicated in the DATE AND PARTIES section is my exact legal name. I am an entity organized and registered under the laws of Texas. I will provide verification of registration and location upon your request. I will provide you with at least 30 days notice prior to any change in my name, address, or state of organization or registration.

D. Business Name. Other than previously disclosed in writing to you I have not changed my name or principal place of business within the last 10 years and have not used any other trade or fictitious name. Without your prior written consent, I do not and will not use any other name and will preserve my existing name, trade-names and franchises.

E. Ownership of Property. I represent: that I own all of the Property. Your claim to the Property is ahead of the claims of any other creditor, except as disclosed in writing to you prior to any advance on the Secured Debts. The collateral that is the subject of the chattel paper is perfected and preserved. I represent that I am the original owner of the Property and, if I am not, that I have provided you with a list of prior owners of the Property.

5. DUTIES TOWARD PROPERTY.

A. Protection of Secured Party's Interest. I will defend the Property against any other claim. I agree to do whatever you require to protect your security interest and to keep your claim in the Property ahead of the claims of other creditors. I will not do anything to harm your position. I will keep books, records and accounts about the Property and my business in general. I will let you examine these and make copies at any reasonable time. I will prepare any report or accounting you request which deals with the Property.

B. Use, Location, and Protection of the Property. I will keep the Property in my possession and in good repair. I will use it only for commercial purposes. I will not change this specified use without your prior written consent. You have the right of reasonable access to inspect the Property and I will immediately inform you of any loss or damage to the Property. I will not cause or permit waste to the Property.

I will keep the Property at my address listed in the DATE AND PARTIES section unless we agree I may keep it at another location. If the Property is to be used in other states, I will give you a list of those states. The location of the Property is given to aid in the identification of the Property. It does not in any way limit the scope of the security interest granted to you. I will notify you in writing and obtain your prior written consent to any change in location of any of the Property. I will not use the Property in violation of any law. I will notify you in writing prior to any change in my address, name or, if an organization, any change in my identity or structure.

Until the Secured Debts are fully paid and this Agreement is terminated, I will not grant a security interest in any of the Property without your prior written consent. I will pay all taxes and assessments levied or assessed against me or the Property and provide timely proof of payment of these taxes and assessments upon request.

C. Selling, Leasing or Encumbering the Property. I will not sell, offer to sell, lease, or otherwise transfer or encumber the Property without your prior written permission, except for Inventory sold in the ordinary course of business at fair market value, or at a minimum price established between you and me. If I am in default under this Agreement, I may not sell the Inventory portion of the Property even in the ordinary course of business, Any disposition of the Property contrary to this Agreement will violate your rights. Your permission to sell the Property may be reasonably withheld without regard to the creditworthiness of any buyer or transferee. I will not permit the Property to be the subject of any court order affecting my rights to the Property in any action by anyone other than you. If the Property includes chattel paper or instruments, either as original collateral or as proceeds of the Property, I will note your security interest on the face of the chattel paper or instruments.

1

D. Additional Duties Specific to Accounts. I will not settle any Account for less than its full value without your written permission. Until you tell me otherwise, I will collect all Accounts in the ordinary course of business. I will not dispose of the Accounts by assignment without your prior written consent. I will keep the proceeds from all the Accounts and any goods which are returned to me or which I take back. I will not commingle them with any of my other property. I will deliver the Accounts to you at your request. If you ask me to pay you the full price on any returned items or items retaken by me, I will do so. I will make no material change in the terms of any Account, and I will give you any statements, reports, certificates, lists of Account Debtors (showing names, addresses and amounts owing), invoices applicable to each Account, and other data in any way pertaining to the Accounts as you may request.

6. INSURANCE. I agree to keep the Property insured against the risks reasonably associated with the Property. I will maintain this insurance in the amounts you require. This insurance will last until the Property is released from this Agreement. I may choose the insurance company, subject to your approval, which will not be unreasonably withheld.

I will have the insurance company name you as loss payee on any insurance policy. I will give you and the insurance company immediate notice of any loss. You may apply the insurance proceeds toward what is owed on the Secured Debts. Yo11 may require added security as a condition of permitting any insurance proceeds to be used to repair or replace the Property.

If you acquire the Property in damaged condition, my right to any insurance policies and proceeds will pass to you to the extent of the Secured Debts.

I will immediately notify you of cancellation or termination of insurance. If I fail to keep the Property insured, you may obtain insurance to protect your interest in the Property. This insurance may include coverages not originally required of me, may be written by a company other than one I would choose, and may be written at a higher rate than I could obtain if I purchased the insurance.

7. COLLATERAL PROTECTION INSURANCE. As part of this Agreement, I am giving you a security interest in the Property described in the Property Description Section. I am required to maintain insurance on the Property in the amount you specify, subject to applicable law. I agree to purchase the collateral insurance from an insurer authorized to do business in Texas or an eligible surplus lines insurer to the extent permitted by law. I will name you as loss payee under the policy. I may be required to deliver to you a copy of the collateral protection insurance policy and proof of payment of premiums. If I fail to meet any of these requirements, you may retain collateral protection insurance on my behalf. You are not required to purchase any type or amount of insurance. You may obtain replacement cost insurance if authorized under applicable law, subject to policy limits. If you purchase insurance for the Property, I will be responsible for the cost of that insurance, including interest and any other charges incurred by you in connection with the placement of collateral protection insurance to the extent permitted by law. I understand that insurance you obtain may cost significantly greater than the cost of insurance I could have obtained. Amounts that I owe are due and payable upon demand or on such other terms as you require to the extent permitted by law.

8. COLLECTION RIGHTS OF THE SECURED PARTY. Account Debtor means the person who is obligated on an account, chattel paper, or general intangible. I authorize you to notify my Account Debtors of your security interest and to deal with the Account Debtors' obligations at your discretion. You may enforce the obligations of an Account Debtor, exercising any of my rights with respect to the Account Debtors' obligations to make payment or otherwise render performance to me, including the enforcement of any security interest that secures such obligations. You may apply proceeds received from the Account Debtors to the Secured Debts or you may release such proceeds to me.

I specifically and irrevocably authorize you to exercise any of the following powers at my expense, without limitation, until the Secured Debts are paid in full:

A. demand payment and enforce collection from any Account Debtor or Obligor by suit or otherwise

B. enforce any security interest. lien or encumbrance given to secure the payment or performance of any Account Debtor or any obligation constituting Property.

C. file proofs of claim or similar documents in the event of bankruptcy, insolvency or death of any person obligated as an Account Debtor.

D. compromise, release, extend, or exchange any indebtedness of an Account Debtor.

E. take control of any proceeds of the Account Debtors' obligations and any returned or repossessed goods.

F. endorse all payments by any Account Debtor which may come into your possession as payable to me.

G. deal in all respects as the holder and owner of the Account Debtors' obligations.

9. AUTHORITY TO PERFORM. I authorize you to do anything you deem reasonably necessary to protect the Property, and perfect and continue your security interest in the Property. If I fail to perform any of my duties under this Agreement or any other security interest, you are authorized, without notice to me, to perform the duties or cause them to be performed. These authorizations include, but are not limited to, permission to:

A. pay and discharge taxes, liens, security interests or other encumbrances at any time levied or placed on the Property.

B. pay any rents or other charges under any lease affecting the Property.

C. order and pay for the repair, maintenance and preservation of the Property.

D. sign, when permitted by law, and file any financing statements on my behalf and pay for filing and recording fees pertaining to the Property.

E. place a note on any chattel paper indicating your interest in the Property.

F. take any action you feel necessary to realize on the Property, including performing any part of a contract or endorsing it in my name.

G. handle any suits or other proceedings involving the Property in my name.

H. prepare, file, and sign my name to any necessary reports or accountings.

I. make an entry on my books and records showing the existence of this Agreement.

J. notify any Account Debtor of your interest in the Property and tell the Account Debtor to make payments to you or someone else you name.

If you perform for me, you will use reasonable care. Reasonable care will not include: any steps necessary to preserve rights against prior parties; the duty to send notices, perform services or take any other action in connection with the management of the Property; or the duty to protect, preserve or maintain any security interest given to others by me or other parties. Your authorization to perform for me will not create an obligation to perform and your failure to perform will not preclude you from exercising any other rights under the law or this Agreement.

If you come into actual or constructive possession of the Property, you will preserve and protect the Property. For purposes of this paragraph, you will be in actual possession of the Property only when you have physical, immediate and exclusive control over the Property and you have affirmatively accepted that control. You will be in constructive possession of the Property only when you have both the power and the intent to exercise control over the Property.

10. DEFAULT. I will be in default if any of the following occur:

A. Payments. I fail to make a payment in full when due.

B. Insolvency or Bankruptcy. I make an assignment for the benefit of creditors or become insolvent, either because my liabilities exceed my assets or I am unable to pay my debts as they become due; or I petition for protection under federal, state or local bankruptcy, insolvency or debtor relief laws, or am the subject of a petition or action under such laws and fail to have the petition or action dismissed within a reasonable period of time not to exceed 60 days.

C. Business Termination. I merge, dissolve, reorganize, end my business or existence, or a partner or majority owner dies or is declared legally incompetent.

D. Failure to Perform. I fail to perform any condition or to keep any promise or covenant of this Agreement.

E. Other Documents. A default occurs under the terms of any other transaction document.

F. Other Agreements. I am in default on any other debt or agreement I have with you.

G. Misrepresentation. I make any verbal or written statement or provide any financial information that is untrue, inaccurate, or conceals a material fact at the time it is made or provided.

H. Judgment. I fail to satisfy or appeal any judgment against me.

I. Forfeiture. The Property is used in a manner or for a purpose that threatens confiscation by a legal authority.

J. Name Change. I change my name or assume an additional name without notifying you before making such a change

K. Property Transfer. I transfer all or a substantial part of my money or property.

L. Property Value. The value of the Property declines or is impaired.

M. Material Change. Without first notifying you, there is a material change in my business, including ownership, management, and financial conditions.

N. Insecurity. You reasonably believe that you are insecure.

2

11. REMEDIES. After I default, and after you give any legally required notice and opportunity to cure the default, you may at your option do any one or more of the following.

A. Acceleration. You may make all or any part of the amount owing by the terms of the Secured Debts immediately due.

B. Sources. You may use any and all remedies you have under state or federal law or in any instrument evidencing or pertaining to the Secured Debts.

C. Insurance Benefits. You may make a claim for any and all insurance benefits or refunds that may be available on my default.

D. Payments Made On My Behalf. Amounts advanced on my behalf will be immediately due and may be added to the Secured Debts.

E. Assembly of Property. You may require me to gather the Property and make it available to you in a reasonable fashion.

F. Repossession. You may repossess the Property so long as the repossession does not involve a breach of the peace. You may sell the Property as provided by law. You may apply what you receive from the sale of the Property to your expenses, your attorneys' fees and legal expenses (where not prohibited by law), and any debt I owe you. If what you receive from the sale of the Property does not satisfy the debt, I will be liable for the deficiency (where permitted by law). In some cases, you may keep the Property to satisfy the debt.

Where a notice is required. I agree that ten days prior written notice sent by first class mail to my address listed in this Agreement will be reasonable notice to me under the Texas Uniform Commercial Code. If the Property is perishable or threatens to decline speedily in value, you may, without notice to me, dispose of any or all of the Property in a commercially reasonable manner at my expense following any commercially reasonable preparation or processing.

If any items not otherwise subject to this Agreement are contained in the Property when you take possession, you may hold these items for me at my risk and you will not be liable for taking possession of them.

G. Use and Operation. You may enter upon my premises and take possession of all or any part of my property for the purpose of preserving the Property or its value, so long as you do not breach the peace. You may use and operate my property for the length of time you feel is necessary to protect your interest, all without payment or compensation to me.

H. Waiver. By choosing any one or more of these remedies you do not give up your right to use any other remedy. You do not waive a default if you choose not to use a remedy. By electing not to use any remedy, you do not waive your right to later consider the event a default and to use any remedies if the default continues or occurs again.

12. WAIVER OF CLAIMS. I waive all claims for loss or damage caused by your acts or omissions where you acted reasonably and in good faith.

13. PERFECTION OF SECURITY INTEREST. I authorize you to file a financing statement covering the Property. I will comply with, facilitate, and otherwise assist you in connection with obtaining perfection or control over the Property for purposes of perfecting your security interest under the Uniform Commercial Code.

14. APPLICABLE LAW. This Agreement is governed by the laws of Texas, the United States of America and to the extent required, by the laws of the jurisdiction where the Property is located. In the event of a dispute, the exclusive forum, venue and place of jurisdiction will be in Texas, unless otherwise required by law.

15. JOINT AND INDIVIDUAL LIABILITY AND SUCCESSORS. Each Debtor's obligations under this Agreement are independent of the obligations of any other Debtor. You may sue each Debtor individually or together with any other Debtor. You may release any part of the Property and I will still be obligated under this Agreement for the remaining Property. The duties and benefits of this Agreement will bind and benefit the successors and assigns of you and me.

16. AMENDMENT, INTEGRATION AND SEVERABILITY. This Agreement may not be amended or modified by oral agreement. No amendment or modification of this Agreement is effective unless made in writing and executed by you and me. This Agreement is the complete and final expression of the understanding between you and me. If any provision of this Agreement IS unenforceable, then the unenforceable provision will be severed and the remaining provisions will still be enforceable.

17. INTERPRETATION. Whenever used, the singular includes the plural and the plural includes the singular. The section headings are for convenience only and are not to be used to interpret or define the terms of this Agreement.

18. NOTICE, FINANCIAL REPORTS AND ADDITIONAL DOCUMENTS. Unless otherwise required by law, any notice will be given by delivering it or mailing it by first class mail to the appropriate party's address listed in the DATE AND PARTIES section, or to any other address designated in writing. Notice to one party will be deemed to be notice to all parties. I will inform you in writing of any change in my name, address or other application information. I will provide you any financial statement or information you request. All financial statements and information I give you will be correct and complete. I agree to sign, deliver, and file any additional documents or certifications that you may consider necessary to perfect, continue, and preserve my obligations under this Agreement and to confirm your lien status on any Property. Time is of the essence.

THIS WRITTEN LOAN AGREEMENT REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

SIGNATURES. By signing, I agree to the terms contained in this Agreement. I also acknowledge receipt of a copy of this Agreement.

DEBTOR:

International Isotopes, Inc.

By: /S/ Steve Laflin 7-9-04
    -----------------------------
    Steve Laflin, President & CEO

SECURED PARTY:

Texas State Bank

By:

M. Douglas Harris, Vice President

3

DISBURSEMENT AUTHORIZATION

DATE AND PARTIES. The date of this Disbursement Authorization is July 1, 2004. The parties and their addresses are:

LENDER:
TEXAS STATE BANK
3900 North 10th Street
McAllen, Texas 78501-1719

Telephone: (956) 631-5401

BORROWER:
INTERNATIONAL ISOTOPES, Inc.

a Texas Corporation
4137 Commerce Circle
Idaho Falls, Idaho 83401

1. DEFINITIONS. As used in this Disbursement Authorization, the terms have the following meanings:

A. Pronouns. The pronouns "I", "me" and "my" refer to all Borrowers signing this Disbursement Authorization, individually and together with their heirs, executors, administrators, successors and assigns. "You" and "Your" refer to the Lender, with its participants, successors and assigns, or any person or company that acquires an interest in the Loan.

B. Loan. "Loan" refers to this transaction generally, including obligations and duties arising from the terms of all documents prepared or submitted for this transaction such as applications, security agreements, disclosures or notes, and this Disbursement Authorization.

2. DISBURSEMENT SUMMARY. The following summarizes the disbursements from the Loan.

Initial Advance                                                         $0.00
   Cash Paid In                                              $0.00
   Amount Contributed by Borrower                            $0.00
Total Cash Received (see Cash Payment Summary)                          $0.00
   Disbursed to Borrowers                                    $0.00
   Disbursed to Lender                                       $0.00
   Disbursed to Other Payees                                 $0.00
Total Amounts Disbursed                                                 $0.00
Amount Remaining To Be Disbursed                                        $0.00
Undisbursed Fees/charges                                                $0.00

3. DISBURSEMENT AUTHORIZATION. I authorize you to disburse the following amounts from my Loan.

DISBURSED TO:                      DATE:                     AMOUNT DISBURSED:
Disbursements to Borrower:                                              $0.00
Disbursements to Lender:                                                $0.00
Disbursements to third parties:                                         $0.00
TOTAL DISBURSED:                                                        $0.00

Remaining Credit Line: $250,000.00

I acknowledge receipt of a copy of this Disbursement Authorization on July 1, 2004.

BORROWER:

International Isotopes, Inc.

By: /S/ Steve Laflin 7-9-04
    -----------------------------
    Steve Laflin, President & CEO

1

LOAN INFORMATION REPORT

 Loan Number           48107

 Loan Officer          M. Douglas Harris

 Loan Summary          This is a(n) Commercial, New, Secured, Revolving,
                       Variable loan.


 Lender Information    001 Comm
                       Texas State Bank
                       3900 North 10th Street, McAllen, TX 78501-1719
                       (956) 631 -5401


 BORROWERS

 Host ID:              243059

 Name:                 International Isotopes, Inc.

 DBA:

 Address:              4137 Commerce Circle, Idaho Falls, ID 83401

 EIN:                  74-2763837

 Phone:

 NAlC -Primary:

 NAlC -Secondary:


 GENERAL INFORMATION
 Specific Loan Purpose:    for renewal O/P working capital


User Defined Fields:

Class Code                                         05
Branch                                             01
Purpose Code                                       530
Opened By Responsibility Code                      039
Product Code                                       10405
Collateral Code                                    0052
Rate Index (if variable rate)                      01
Payment Code                                       2
Loan Rating Code                                   02
Census Tract Number                                0.00

CALCULATION TERMS


PAYMENT INFORMATION

 Repayment Method                   Accrued Interest Only
 Credit Limit                       $250,000.00
 Payment Frequency                  Quarterly
 Funding Date                       July 1, 2004
 Note Date                          July 1, 2004
 First Payment Date                 October 1, 2004
 Accrual Method                     Actual/360
 Term of the Loan                   1 years
 Maturity Date                      July 1, 2005


 VARIABLE RATE

 Index                              Texas State Bank Base Rate
 Market as Percent of Index         0.000 %
 Margin as Percentage Points        1,000 %
 Rounded to the Nearest             .001 %
 Market Rate                        7.500 %
 Lock Margin for (Days)
 Margin Expiration Date
 Initial Rate Definition            Specific Value
 Initial Rate                       7.500 %
 Discount                           0.000 %
 Periodic Cap                       0.000 %
 Initial Rate Subject to Floor      Yes
 Initial Rate Subject to Ceiling    No
 Floor Definition                   Specific Value
 Floor                              7.500 %

1

Floor Margin                       0.000%
Ceiling Definition                 None
Ceiling                            0.000%
Ceiling Margin                     0.000%
Rate Change Affects                Payment Amount and Amount Due at Maturity
Initial Rate Hold Date             July 2, 2004
Initial Rate Hold Term             1 Days
Rate Change Frequency              1 Days
Initial Payment Hold (Payments)    1 payments
Payment Change Frequency;          1 payments

ADVANCE INFORMATION

Initial Advance                    50.00
Minimum Advance                    SO.00
Advance Type                       Obligatory
Advances are equal to or a         No
multiple of the minimum
Number Authorized Persons
Deposit Account Number

LATE CHARGES

If a payment is more than 10 days late, I will be charged 5.000 percent of the Amount of Payment. I will pay this late charge promptly but only once for each late payment.

COLLATERAL

Collateral Type                    Accounts & Contract Rights (Generally)
Specific Collateral Description
Additional Comments
Location Address                   4137 Commerce Circle, Idaho Falls, ID 83401




Collateral Type                    General Intangibles (Generally)
Specific Collateral Description
Additional Comments
Location Address                   4137 Commerce Circle, Idaho Falls, ID 83401




Collateral Type                    Inventory
Specific Collateral Description
Additional Comments
Location Address                   4137 Commerce Circle, Idaho Falls, ID 83401




Collateral Type                    Equipment (Generally)
Specific Collateral Description
Additional Comments
Location Address                   4137 Commerce Circle, Idaho Falls, ID 83401



Collateral Type                    Chattel Paper
Specific Collateral Description
Additional Comments
Location Address                   4137 Commerce Circle, Idaho Falls, ID 83401

2

EXHIBIT 10.11

_____________________________________________________________________________________________
LOAN NUMBER             LOAN NAME               ACCT. NUMBER      NOTE DATE      INITIALS
   48108        International Isotopes, Inc.       243059          07/01/04         MDH
NOTE AMOUNT          INDEX (w/Margin)               RATE        MATURITY DATE   LOAN PURPOSE
$733,595.00     Texas State Bank Base Rate          7.5%           02/01/06      Commercial
                       plus 1.OOO%

                                     Creditor Use Only
_____________________________________________________________________________________________

PROMISSORY NOTE
(Commercial - Single Advance - Variable Rate)

DATE AND PARTIES. The date of this Promissory Note (Note) is July 1, 2004. The parties and their addresses are:

LENDER:
TEXAS STATE BANK
3900 North 10th Street
McAllen, Texas 78501- 1719

Telephone: (956) 631-5401

BORROWER:
INTERNATIONAL ISOTOPES, Inc.

a Texas Corporation
4137 Commerce Circle
Idaho Falls, Idaho 83401

1. DEFINITIONS. As used in this Note, the terms have the following meanings:

A. Pronouns. The pronouns "I," "me," and "my" refer to each Borrower signing this Note. individually and together with their heirs, successors and assigns, and each other person or legal entity (including guarantors, endorsers, and sureties) who agrees to pay this Note. "You" and "Your" refer to the Lender, with its participants or syndicators, successors and assigns, or any person or company that acquires an interest in the Loan.

B. Note. Note refers to this document, and any extensions, renewals, modifications and substitutions of this Note,

C. Loan. Loan refers to this transaction generally, including obligations and duties arising from the terms of all documents prepared or submitted for this transaction such as applications. security agreements, disclosures or notes, and this Note.

D. Property. Property is any property, real, personal or intangible, that secures my performance of the obligations of this Loan.

E. Percent. Rates and rate change limitations are expressed as annualized percentages.

2. PROMISE TO PAY. For value received, I promise to pay you or your order, at your address, or at such other location as you may designate, the principal sum of $733,595.00 (Principal) plus interest from July 1, 2004 on the unpaid Principal balance until this Note matures or this obligation is accelerated.

3. INTEREST. Interest will accrue on the unpaid Principal balance of this Note at the rate of 7.5 percent (Interest Rate) until July 2, 2004, after which time it may change as described in the Variable Rate subsection.

A. Post-Maturity Interest. After maturity or acceleration, interest will accrue at highest rate permitted by law.

B. Maximum Interest Amount. Any amount assessed or collected as interest under the terms of this Note or obligation will be limited to the Maximum Lawful Amount of interest allowed by state or federal law. Amounts collected in excess of the Maximum Lawful Amount will be applied first to the unpaid Principal balance. Any remainder will be refunded to me. The maximum interest rate producing the Maximum Lawful Amount will be the quarterly ceiling rate announced by the Credit Commissioner from time to time hereafter.

C. Statutory Authority. The amount: assessed or collected on this Note is authorized by the Texas usury laws under Tex. Fin. Code. Ch. 303.

D. Accrual. During the scheduled term of this Loan interest accrues using an Actual1360 days counting method.

E. Variable Rate. The Interest Rate may change during the term of this transaction.

(1) Index. Beginning with the first Change Date, the Interest Rate will be based on the following index: the base commercial lending rate announced by Texas State Bank.

The Current index is the most recent index figure available on each Change Date. You do not guaranty by selecting this Index, or the margin, that the Interest Rate on this Note will be the same rate you charge on any other loans or class of loans you make to me or other borrowers. If this Index is no longer available, you will substitute a similar index. You will give me notice of your choice.

(2) Change Date. Each date on which the Interest Rate may change is called a Change Date. The Interest Rate may change July 2, 2005 and daily thereafter.

(3) Calculation Of Change. On each Change Date, you will calculate the Interest Rate, which will be the Current Index plus 1.000 percent. The result of this calculation will be rounded to the nearest .001 percent. Subject to any limitations, this will be the Interest Rate until the next Change Date. The new Interest Rate will become effective on each Change Date. The Interest Rate and other charges on this Note will never exceed the highest rate or charge allowed by law for this Note.

(4) Limitations. The Interest Rate changes are subject to the following limitations:

(a) Lifetime. The Interest Rate will never be less than 7.500 percent.

(5) Effect Of Variable Rate. A change in the Interest Rate will have the following effect on the payments: The amount of scheduled payments will change.

4. REMEDIAL CHARGES. In addition to interest or other finance charges, I agree that I will pay these additional fees based on my method and pattern of payment. Additional remedial charges may be described elsewhere in this Note.

A. Late Charge. If a payment is more than 10 days late, I will be charged 5.000 percent of the Amount of Payment. I will pay this late charge promptly but only once for each late payment.

B. Returned Check Charge. I agree to pay a fee not to exceed $30.00 for each check, negotiable order of withdrawal or draft I issue in connection with this Loan that is returned because it has been dishonored.

C. Stop Payment. A(n) Stop Payment equal to $25.00.

5. PAYMENT. I agree to pay this Note as follows: 6 monthly payments of accrued interest beginning on August 01, 2004, then 12 monthly payments of accrued interest plus $1,500.00 to principal beginning February 01, 2005, and a final payment of the entire unpaid outstanding balance of Principal and Interest will be due on February 01, 2006.

Payments will be rounded to the nearest $.01. With the final payment I also agree to pay any additional fees or charges owing and the amount of any advances you have made to others on my behalf. Payments scheduled to be paid on the 29th. 30th or 31st day of a month that contains no such day will, instead, be made on the last day of such month.

Each payment I make on this Note will be applied first to interest that is due then to principal that is due, and finally to any charges that I owe other than principal and interest. If you and I agree to a different application of payments, we will describe our agreement on this Note. The actual amount of my final payment will depend on my payment record.

6. PREPAYMENT. I may prepay this Loan in full or in part at any time. Any partial prepayment will not excuse any later scheduled payments until I pay in full.

7. LOAN PURPOSE. The purpose of this Loan is a renewal O/P payoff note #31083169

8. SECURITY. This Loan is secured by separate security instruments prepared together with this Note as follows:

Document Name Parties to Document Security Agreement - International Isotopes, Inc. International Isotopes, Inc.

9. DEFAULT. I will be in default if any of the following occur:

A. Payments. I fail to make a payment in full when due.

B. Insolvency. I make an assignment for the benefit of creditors or become insolvent, either because my liabilities exceed my assets or I am unable to pay my debts as they become due.

1

C. Business Termination. I merge, dissolve, reorganize, end my business or existence, or a partner or majority owner dies or is declared legally incompetent.

D. Failure to Perform. I fail to perform any condition or to keep any promise or covenant of this Note.

E. Other Documents. A default occurs under the terms of any other transaction document.

F. Other Agreements. I am in default on any other debt or agreement I have with you.

G. Misrepresentation. I make any verbal or written statement or provide any financial information that is untrue, inaccurate, or conceals a material fact at the time it is made or provided.

H. Judgment. I fail to satisfy or appeal any judgment against me.

I. Forfeiture. The Property is used in a manner or for a purpose that threatens confiscation by a legal authority.

J. Name Change. I change my name or assume an additional name without notifying you before making such a change.

K. Property Transfer. I transfer all or a substantial part of my money or property.

L. Property Value. The value of the Property declines or is impaired.

M. Material Change. Without first notifying you, there is a material change in my business, including ownership, management, and financial conditions.

N. Insecurity. You reasonably believe that you are insecure.

10. ASSUMPTIONS. Someone buying the Property cannot assume the obligation. You may declare the entire balance of the Note to be immediately due and payable upon the creation of, or contract for the creation of, any lien, encumbrance, or transfer of the Property. However, I may sell or similarly dispose of any Property that is inventory.

11. WAIVERS AND CONSENT. To the extent not prohibited by law, I waive protest, presentment for payment, demand, notice of acceleration. notice of intent to accelerate and notice of dishonor.

A. Additional Waivers By Borrower. In addition, I, and any party to this Note and Loan, to the extent permitted by law, consent to certain actions you may take, and generally waive defenses that may be available based on these actions or based on the status of a party to this Note.

(1) You may renew or extend payments on this Note, regardless of the number of such renewals or extensions.

(2) You may release any Borrower, endorser, guarantor, surety, accommodation maker or any other co-signer.

(3) You may release, substitute or impair any Property securing this Note.

(4) You, or any institution participating in this Note, may invoke your right of set-off.

(5) You may enter into any sales, repurchases or participations of this Note to any person in any amounts and I waive notice of such sales, repurchases or participations.

(6) I agree that any of us signing this Note as a Borrower is authorized to modify the terms of this Note or any instrument securing, guarantying or relating to this Note.

B. No Waiver By Lender. Your course of dealing, or your forbearance from, or delay in, the exercise of any of your rights, remedies, privileges or right to insist upon my strict performance of any provisions contained in this Note, or other Loan documents. shall not be construed as a waiver by you, unless any such waiver is in writing and is signed by you.

12. REMEDIES. After I default, and after you give any legally required notice and opportunity to cure the default, you may at your option do any one more of the following.

A. Acceleration. You may make all or any part of the amount owing by the terms of this Note immediately due.

B. Sources. You may use any and all remedies you have under state or federal law or in any instrument securing this Note.

C. Insurance Benefits. You may make a claim for any and all insurance benefits or refunds that may be available on my default.

D. Payments Made On My Behalf. Amounts advanced on my behalf will be immediately due and may be added to the balance owing under the terms of this Note, and accrue interest at the highest post-maturity interest rate.

E. Set-Off. You may use the right of set-off. This means you may set-off any amount due and payable under the terms of this Note against any right I have to receive money from you. My right to receive money from you includes any deposit or share account balance I have with you; any money owed to me on an item presented to you or in your possession for collection or exchange; and any repurchase agreement or other non-deposit obligation. "Any amount due and payable under the terms of this Note" means the total amount to which you are entitled to demand payment under the terms of this Note at the time you set-off. Subject to any other written contract, if my right to receive money from you is also owned by someone who has not agreed to pay this Note, your right of set-off will apply to my interest in the obligation and to any other amounts I could withdraw on my sole request or endorsement. Your right of set-off does not apply to an account or other obligation where my rights arise only in a representative capacity. It also does not apply to any Individual Retirement Account or other tax-deferred retirement account. You will not be liable for the dishonor of any check when the dishonor occurs because you set-off against any of my accounts. I agree to hold you harmless from any such claims arising as a result of your exercise of your right of set-off.

F. Waiver. Except as otherwise required by law, by choosing any one or more of these remedies you do not give up your right to use any other remedy. You do not waive a default if you choose not to use a remedy. By electing not to use any remedy, you do not waive your right to later consider the event a default and to use any remedies if the default continues or occurs again.

13. COLLECTION EXPENSES AND ATTORNEYS' FEES. On or after Default, to the extent permitted by law, I agree to pay all expenses of collection, enforcement or protection of your rights and remedies under this Note. Expenses include, but are not limited to, reasonable attorneys' fees, court costs, and other legal expenses. These expenses are due and payable immediately. If not paid immediately, these expenses will bear interest from the date of payment until paid in full at the highest interest rate in effect as provided for in the terms of this Note. All fees and expenses will be secured by the Property I have granted to you, if any. To the extent permitted by the United States Bankruptcy Code, I agree to pay the reasonable attorneys' fees you incur to collect this Debt as awarded by any court exercising jurisdiction under the Bankruptcy Code.

14. WARRANTIES AND REPRESENTATIONS. I make to you the following warranties and representations which will continue as long as this Note is in effect:

A. Power. I am duly organized, and validly existing and in good standing in all jurisdictions in which I operate. I have the power and authority to enter into this transaction and to carry on my business or activity as it is now being conducted and, as applicable, am qualified to do so in each jurisdiction in which I operate.

B. Authority. The execution, delivery and performance of this Note and the obligation evidenced by this Note are within my powers, have been duly authorized, have received all necessary governmental approval, will not violate any provision of law, or order of court or governmental agency, and will not violate any agreement to which I am a party or to which I am or any of my Property is subject.

C. Name and place of Business. Other than previously disclosed in writing to you I have not changed my name or principal place of business within the last 10 years and have not used any other trade or fictitious name. Without your prior written consent, I do not and will not use any other name and will preserve my existing name, trade names and franchises.

15. INSURANCE. I agree to obtain the insurance described in this Loan Agreement.

A. Property Insurance. I will insure or retain insurance coverage on the Property and abide by the insurance requirements of any security instrument securing this Loan.

B. Insurance Warranties. I agree to purchase any insurance coverages that are required, in the amounts you require, as described in this or any other documents I sign for this Loan. I will provide you with continuing proof of coverage. I will buy or provide insurance from a firm licensed to do business in the State where the Property is located. I will have the insurance company name you as loss payee on any insurance policy. You will apply the insurance proceeds toward what I owe you on the outstanding balance. I agree that if the insurance proceeds do not cover the amounts I still owe you, I will pay the difference. I will keep the insurance until all debts secured by this agreement are paid. If I want to buy the insurance from you, I have signed a separate statement agreeing to this purchase.

16. APPLICABLE LAW. This Note is governed by the laws of Texas, the United States of America and to the extent required, by the laws of the jurisdiction where the Property is located. In the event of a dispute, the exclusive forum, venue and place of jurisdiction will be in Texas, unless otherwise required by law.

17. JOINT AND INDIVIDUAL LIABILITY AND SUCCESSORS. My obligation to pay this Loan is independent of the obligation of any other person who has also agreed to pay it. You may sue me alone, or anyone else who is obligated on this Loan, or any number of us together, to collect this Loan. Extending this Loan or new obligations under this Loan, will not affect my duty under this Loan and I will still be obligated to pay this Loan. The duties and benefits of this Loan will bind and benefit the successors and assigns of you and me.

18. AMENDMENT, INTEGRATION AND SEVERABILITY. This Note may not be amended or modified by oral agreement. No amendment or modification of this Note is effective unless made in writing and executed by you and me. This Note is the complete and final expression of the agreement. If any provision of this Note is unenforceable, then the unenforceable provision will be severed and the remaining provisions will still be enforceable.

2

19. INTERPRETATION. Whenever used, the singular includes the plural and the plural includes the singular. The section headings are for convenience only and are not to be used to interpret or define the terms of this Note.

20. NOTICE, FINANCIAL REPORTS AND ADDITIONAL DOCUMENTS. Unless otherwise required by law, any notice will be given by delivering it or mailing it by first class mail to the appropriate party's address listed in the DATE AND PARTIES section, or to any other address designated in writing. Notice to one party will be deemed to be notice to all parties. I will inform you in writing of any change in my name, address or other application information. I will provide you any financial statement or information you request. All financial statements and information I give you will be correct and complete. I agree to sign, deliver, and file any additional documents or certifications that you may consider necessary to perfect, continue, and preserve my obligations under this Loan and to confirm your lien status on any Property. Time is of the essence.

21. CREDIT INFORMATION. I agree to supply you with whatever information you reasonably request. You will make requests for this information without undue frequency, and will give me reasonable time in which to supply the information.

22. ERRORS AND OMISSIONS. I agree, if requested by you, to fully cooperate in the correction, if necessary, in the reasonable discretion of you of any and all loan closing documents so that all documents accurately describe the loan between you and me. I agree to assume all costs including by way of illustration and not limitation, actual expenses, legal fees and marketing losses for failing to reasonably comply with your requests within thirty (30)days.

THIS WRITTEN LOAN AGREEMENT REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

23. SIGNATURES. By signing, I agree to the terms contained in this Note. I also acknowledge receipt of a copy of this Note.

BORROWER:

International Isotopes, Inc.

By: /S/ Steve Laflin 7-9-04
    ----------------------------
    Steve Laflin, President, CEO

LENDER:

Texas State Bank

By:

M. Douglas Harris, Vice President

3

SECURITY AGREEMENT

DATE AND PARTIES. The date of this Security Agreement (Agreement) is July 01, 2004. The parties and their addresses are:

SECURED PARTY:
TEXAS STATE BANK
3900 North 10th Street
McAllen, Texas 78501-1719

DEBTOR:
INTERNATIONAL ISOTOPES, INC.

a Texas Corporation
4137 Commerce Circle
Idaho Falls, Idaho 83401

The pronouns "you" and "your" refer to the Secured Party. The pronouns "I," "me" and "my" refer to each person or entity signing this Agreement as Debtor and agreeing to give the Property described in this Agreement as security for the Secured Debts.

1. SECURED DEBTS. This Agreement will secure the following Secured Debts:

A. Specific Debts. The following debts and all extensions, renewals, refinancings, modifications and replacements. A promissory note or other agreement, No. 48108, dated July 1, 2004, from me to you, in the amount of $733,595.00.

B. Sums Advanced. All sums advanced and expenses incurred by you under the terms of this Agreement.

2. SECURITY INTEREST. To secure the payment and performance of the Secured Debts, I give you a security interest in ail of the Property described in this Agreement that I own or have sufficient rights in which to transfer an interest, now or in the future, wherever the Property is or will be located, and all proceeds and products from the Property (including, but not limited to, all parts, accessories, repairs, replacements, improvements, and accessions to the Property). Property is all the collateral given as security for the Secured Debts and described in this Agreement, and includes all obligations that support the payment or performance of the Property. "Proceeds" includes anything acquired upon the sale, lease, license, exchange, or other disposition of the Property; any rights and claims arising from the Property; and any collections and distributions on account of the Property.

This Agreement remains in effect until terminated in writing, even if the Secured Debts are paid and you are no longer obligated to advance funds to me under any loan or credit agreement.

3. PROPERTY DESCRIPTION. The Property is described as follows:

A. Inventory. All inventory which I hold for ultimate sale or lease, or which has been or will be supplied under contracts of service, or which are raw materials, work in process, or materials used or consumed in my business.

B. Accounts and Other Rights to Payment. All rights I have now or in the future to payments including, but not limited to, payment for property or services sold, leased, rented, licensed, or assigned, whether or not I have earned such payment by performance. This includes any rights and interests (including all liens and security interests) which I may have by law or agreement against any Account Debtor or obligor of mine.

C. Instruments, Documents and Chattel Paper. All instruments and rights I have now or in the future to payments including, but not limited to, rights to payment arising out of all present and future documents, instruments, tangible and electronic chattel paper, and loans and obligations receivable. This includes any rights and interests [including all liens and security interests) which I may have by law or agreement against any Account Debtor or obligor of mine.

D. General Intangibles. All general intangibles including, but not limited to, tax refunds, applications for patents, patents, copyrights, trademarks, trade secrets, good will, trade names, customer lists, permits and franchises, payment intangibles, computer programs and all supporting information provided in connection with a transaction relating to computer programs, and the right to use my name.

E. Equipment. All equipment including, but not limited to, all machinery, vehicles, furniture, fixtures, manufacturing equipment, farm machinery and equipment, shop equipment, office and recordkeeping equipment, and parts and tools. All equipment described in a list or schedule which I give to you will also be included in the Property, but such a list is not necessary for a valid security interest in my equipment.

F. Specific Property. Any and All deposit accounts, payment intangibles, investment property and software together with all supporting obligation and proceeds of same property and all after-acquired collateral of the same classification.

4. WARRANTIES AND REPRESENTATIONS. I make to you the following warranties and representations which will continue as long as this Agreement is in effect:

A. Power. I am duly organized, and validly existing and in good standing in all jurisdictions in which 1 operate. I have the power and authority to enter into this transaction and to carry on my business or activity as it is now being conducted and, as applicable, am qualified to do so in each jurisdiction in which I operate.

B. Authority. The execution, delivery and performance of this Agreement and the obligation evidenced by this Agreement are within my powers, have been duly authorized, have received all necessary governmental approval, will not violate any provision of law, or order of court or governmental agency, and will not violate any agreement to which I am a party or to which I am or any of my property is subject.

C. Name and Location. My name indicated in the DATE AND PARTIES section is my exact legal name. I am an entity organized and registered under the laws of Texas. I will provide verification of registration and location upon your request. I will provide you with at least 30 days notice prior to any change in my name, address, or state of organization or registration.

D. Business Name. Other than previously disclosed in writing to you I have not changed my name or principal place of business within the last 10 years and have not used any other trade or fictitious name. Without your prior written consent, I do not and will not use any other name and will preserve my existing name, trade names and franchises.

E. Ownership of Property. I represent that I own all of the Property. Your claim to the Property is ahead of the claims of any other creditor, except as disclosed in writing to you prior to any advance on the Secured Debts. The collateral that is the subject of the chattel paper is perfected and preserved. I represent that I am the original owner of the Property and, if I am not, that I have provided you with a list of prior owners of the Property.

5. DUTIES TOWARD PROPERTY.

A. Protection of Secured Party's Interest. I will defend the Property against any other claim. I agree to do whatever you require to protect your security interest and to keep your claim in the Property ahead of the claims of other creditors. I will not do anything to harm your position. I will keep books. records and accounts about the Property and my business in general. I will let you examine these and make copies at any reasonable time. I will prepare any report or accounting you request which deals with the Property.

B. Use, Location, and Protection of the Property. I will keep the Property in my possession and in good repair. I will use it only for commercial purposes. I will not change this specified use without your prior written consent. You have the right of reasonable access to inspect the Property and I will immediately inform you of any loss or damage to the Property. I will not cause or permit waste to the Property.

I will keep the Property at my address listed in the DATE AND PARTIES section unless we agree I may keep it at another location. If the Property is to be used in other states, I will give you a list of those states. The location of the Property is given to aid in the identification of the Property. It does not in any way limit the scope of the security interest granted to you. I will notify you in writing and obtain your prior written consent to any change in location of any of the Property. I will not use the Property in violation of any law. I will notify you in writing prior to any change in my address, name or, if an organization, any change in my identity or structure.

Until the Secured Debts are fully paid and this Agreement is terminated, I will not grant a security interest in any of the Property without your prior written consent. I will pay all taxes and assessments levied or assessed against me or the Property and provide timely proof of payment of these taxes and assessments upon request.

C. Selling, Leasing or Encumbering the Property. I will not sell, offer to sell, lease, or otherwise transfer or encumber the Property without your prior written permission, except for inventory sold in the ordinary course of business at fair market value, or at a minimum price established between you and me. If I am in default under this Agreement, I may not sell the inventory portion of the Property even in the ordinary course of business. Any disposition of the Property contrary to this Agreement will violate your rights. Your permission to sell the Property may be reasonably withheld without regard to the creditworthiness of any buyer or transferee. I will not permit the Property to be the subject of any court order affecting my rights to the Property in any action by anyone other than you. If the Property includes chattel paper or instruments, either as original collateral or as proceeds of the Property, I will note your security interest on the face of the chattel paper or instruments.

1

D. Additional Duties Specific to Accounts. I will not settle any Account for less than its full value without your written permission. Until you tell me otherwise, I will collect all Accounts in the ordinary course of business. I will not dispose of the Accounts by assignment without your prior written consent. I will keep the proceeds from all the Accounts and any goods which are returned to me or which I take back. I will not commingle them with any of my other property. I will deliver the Accounts to you at your request. If you ask me to pay you the full price on any returned items or items retaken by me, I will do so. I will make no material change in the terms of any Account, and I will give you any statements, reports, certificates, lists of Account Debtors (showing names, addresses and amounts owing), invoices applicable to each Account, and other data in any way pertaining to the Accounts as you may request.

6. INSURANCE. I agree to keep the Property insured against the risks reasonably associated with the Property. I will maintain this insurance in the amounts you require. This insurance will last until the Property is released from this Agreement. I may choose the insurance company, subject to your approval, which will not be unreasonably withheld.

I will have the insurance company name you as loss payee on any insurance policy. I will give you and the insurance company immediate notice of any loss. You may apply the insurance proceeds toward what is owed on the Secured Debts. You may require added security as a condition of permitting any insurance proceeds to be used to repair or replace the Property.

If you acquire the Property in damaged condition, my right to any insurance policies and proceeds will pass to you to the extent of the Secured Debts.

I will immediately notify you of cancellation or termination of insurance. If I fail to keep the Property insured, you may obtain insurance to protect your interest in the Property. This insurance may include coverages not originally required of me, may be written by a company other than one I would choose, and may be written at a higher rate than I could obtain if I purchased the insurance.

7. COLLATERAL PROTECTION INSURANCE. As part of this Agreement, I am giving you a security interest in the Property described in the Property Description Section. I am required to maintain insurance on the Property in the amount you specify, subject to applicable law. I agree to purchase the collateral insurance from an insurer authorized to do business in Texas or an eligible surplus lines insurer to the extent permitted by law. I will name you as loss payee under the policy. I may be required to deliver to you a copy of the collateral protection insurance policy and proof of payment of premiums. If I fail to meet any of these requirements, you may obtain collateral protection insurance on my behalf. You are not required to purchase any type or amount of insurance. You may obtain replacement cost insurance if authorized under applicable law, subject to policy limits. If you purchase insurance for the Property, I will be responsible for the cost of that insurance, including interest and any other charges incurred by you in connection with the placement of collateral protection insurance to the extent permitted by law. I understand that insurance you obtain may cost significantly greater than the cost of insurance I could have obtained. Amounts that I owe are due and payable upon demand or on such other terms as you require to the extent permitted by law.

8. COLLECTION RIGHTS OF THE SECURED PARTY. Account Debtor means the person who is obligated on an account, chattel paper, or general intangible. I authorize you to notify my Account Debtors of your security interest and to deal with the Account Debtors' obligations at your discretion. You may enforce the obligations of an Account Debtor, exercising any of my rights with respect to the Account Debtors' obligations to make payment or otherwise render performance to me, including the enforcement of any security interest that secures such obligations. You may apply proceeds received from the Account Debtors to the Secured Debts or you may release such proceeds to me. I specifically and irrevocably authorize you to exercise any of the following powers at my expense, without limitation, until the Secured Debts are paid in full:

A. demand payment and enforce collection from any Account Debtor or Obligor by suit or otherwise.

B. enforce any security interest, lien or encumbrance given to secure the payment or performance of any Account Debtor or any obligation constituting Property.

C. file proofs of claim or similar documents in the event of bankruptcy, insolvency or death of any person obligated as an Account Debtor.

D. compromise, release, extend, or exchange any indebtedness of an Account Debtor.

E. take control of any proceeds of the Account Debtors' obligations and any returned or repossessed goods.

F. endorse all payments by any Account Debtor which may come into your possession as payable to me.

G. deal in all respects as the holder and owner of the Account Debtors' obligations.

9. AUTHORITY TO PERFORM. I authorize you to do anything you deem reasonably necessary to protect the Property, and perfect and continue your security interest in the Property. If I fail to perform any of my duties under this Agreement or any other security interest, you are authorized, without notice to me, to perform the duties or cause them to be performed. These authorizations include, but are not limited to, permission to:

A. pay and discharge taxes, liens, security interests or other encumbrances at any time levied or placed on the Property.

B. pay any rents or other charges under any lease affecting the Property.

C. order and pay for the repair, maintenance and preservation of the Property.

D. sign, when permitted by law, and file any financing statements on my behalf and pay for filing and recording fees pertaining to the Property.

E. place a note on any chattel paper indicating your interest in the Property.

F. take any action you feel necessary to realize on the Property, including performing any part of a contract or endorsing it in my name.

G. handle any suits or other proceedings involving the Property in my name.

H. prepare, file, and sign my name to any necessary reports or accountings.

I. make an entry on my books and records showing the existence of this Agreement.

J. notify any Account Debtor of your interest in the Property and tell the Account Debtor to make payments to you or someone else you name.

If you perform for me, you will use reasonable care. Reasonable care will not include: any steps necessary to preserve rights against prior parties; the duty to send notices, perform services or take any other action in connection with the management of the Property; or the duty to protect, preserve or maintain any security interest given to others by me or other parties. Your authorization to perform for me will not create an obligation to perform and your failure to perform will not preclude you from exercising any other rights under the law or this Agreement.

If you come into actual or constructive possession of the Property, you will preserve and protect the Property. For purposes of this paragraph, you will be in actual possession of the Property only when you have physical, immediate and exclusive control over the Property and you have affirmatively accepted that control. You will be in constructive possession of the Property only when you have both the power and the intent to exercise control over the Property.

10. DEFAULT. I will be in default if any of the following occur:

A. Payments. I fail to make a payment in full when due.

B. Insolvency. I make an assignment for the benefit of creditors or become insolvent, either because my liabilities exceed my assets or I am unable to pay my debts as they become due.

C. Business Termination. I merge, dissolve, reorganize, end my business or existence, or a partner or majority owner dies or is declared legally incompetent.

D. Failure to Perform. I fail to perform any condition or to keep any promise or covenant of this Agreement.

E. Other Documents. A default occurs under the terms of any other transaction document.

F. Other Agreements. I am in default on any other debt or agreement I have with you.

G. Misrepresentation. I make any verbal or written statement or provide any financial information that is untrue, inaccurate, or conceals a material fact at the time it is made or provided.

H. Judgment. I fail to satisfy or appeal any judgment against me.

I. Forfeiture. The Property is used in a manner or for a purpose that threatens confiscation by a legal authority.

J. Name Change. I change my name or assume an additional name without notifying you before making such a change.

K. Property Transfer. I transfer all or a substantial part of my money or property.

L. Property Value. The value of the Property declines or is impaired.

M. Material Change. Without first notifying you, there is a material change in my business, including ownership, management, and financial conditions.

N. Insecurity. You reasonably believe that you are insecure.

2

11. REMEDIES. After I default, and after you give any legally required notice and opportunity to cure the default, you may at your option do any one or more of the following.

A. Acceleration. You may make all or any part of the amount owing by the terms of the Secured Debts immediately due.

B. Sources. You may use any and all remedies you have under state or federal law or in any instrument evidencing or pertaining to the Secured Debts.

C. Insurance Benefits. You may make a claim for any and all insurance benefits or refunds that may be available on my default.

D. Payments Made On My Behalf. Amounts advanced on my behalf will be immediately due and may be added to the Secured Debts.

E. Assembly of Property. You may require me to gather the Property and make it available to you in a reasonable fashion.

F. Repossession. You may repossess the Property so long as the repossession does not involve a breach of the peace. You may sell the Property as provided by law. You may apply what you receive from the sale of the Property to your expenses, your attorneys' fees and legal expenses (where not prohibited by law), and any debt I owe you. If what you receive from the sale of the Property does not satisfy the debt, I will be liable for the deficiency (where permitted by law). In some cases, you may keep the Property to satisfy the debt.

Where a notice is required, I agree that ten days prior written notice sent by first class mail to my address listed in this Agreement will be reasonable notice to me under the Texas Uniform Commercial Code. If the Property is perishable or threatens to decline speedily in value, you may, without notice to me, dispose of any or all of the Property in a commercially reasonable manner at my expense following any commercially reasonable preparation or processing.

If any items not otherwise subject to this Agreement are contained in the Property when you take possession, you may hold these items for me at my risk and you will not be liable for taking possession of them.

G. Use and Operation. You may enter upon my premises and take possession of all or any part of my property for the purpose of preserving the Property or its value, so long as you do not breach the peace. You may use and operate my property for the length of time you feel is necessary to protect your interest, all without payment or compensation to me.

H. Waiver. By choosing any one or more of these remedies you do not give up your right to use any other remedy. You do not waive a default if you choose not to use a remedy. By electing not to use any remedy, you do not waive your right to later consider the event a default and to use any remedies if the default continues or occurs again.

12. WAIVER OF CLAIMS. I waive all claims for loss or damage caused by your acts or omissions where you acted reasonably and in good faith.

13. PERFECTION OF SECURITY INTEREST. I authorize you to file a financing statement covering the Property. I will comply with, facilitate, and otherwise assist you in connection with obtaining perfection or control over the Property for purposes of perfecting your security interest under the Uniform Commercial Code.

14. APPLICABLE LAW. This Agreement is governed by the laws of Texas, the United States of America and to the extent required, by the laws of the jurisdiction where the Property is located. In the event of a dispute, the exclusive forum, venue and place of jurisdiction will be in Texas, unless otherwise required by law.

15. JOINT AND INDIVIDUAL LIABILITY AND SUCCESSORS. Each Debtor's obligations under this Agreement are independent of the obligations of any other Debtor. You may sue each Debtor individually or together with any other Debtor. You may release any part of the Property and I will still be obligated under this Agreement for the remaining Property. The duties and benefits of this Agreement will bind and benefit the successors and assigns of you and me.

16. AMENDMENT, INTEGRATION AND SEVERABILITY. This Agreement may not be amended or modified by oral agreement. No amendment or modification of this Agreement is effective unless made in writing and executed by you and me. This Agreement is the complete and final expression of the understanding between you and me. If any provision of this Agreement is unenforceable, then the unenforceable provision will be severed and the remaining provisions will still be enforceable.

17. INTERPRETATION. Whenever used, the singular includes the plural and the plural includes the singular. The section headings are for convenience only and are not to be used to interpret or define the terms of this Agreement.

18. NOTICE, FINANCIAL REPORTS AND ADDITIONAL DOCUMENTS. Unless otherwise required by law, any notice will be given by delivering it or mailing it by first class mail to the appropriate party's address listed in the DATE AND PARTIES section, or to any other address designated in writing. Notice to one party will be deemed to be notice to all parties. I will inform you in writing of any change in my name, address or other application information. I will provide you any financial statement or information you request. All financial statements and information I give you will be correct and complete. I agree to sign, deliver, and file any additional documents or certifications that you may consider necessary to perfect, continue, and preserve my obligations under this Agreement and to confirm your lien status on any Property. Time is of the essence.

REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

SIGNATURES. By signing, I agree to the terms contained in this Agreement. I also acknowledge receipt of a copy of this Agreement.

DEBTOR:

International Isotopes, Inc.

By: /S/ Steve Laflin 7-9-04
    -----------------------------
    Steve Laflin, President & CEO

SECURED PARTY:

Texas State Bank

By:

M. Douglas Harris, Vice President

3

LOAN INFORMATION REPORT

Loan Number                              48108
Loan Officer                             M. Douglas Harris
Loan Summary                             This is a(n) Commercial, New, Secured,
                                         Term, Variable loan.


Lender Information                       001 Comm
                                         Texas State Bank
                                         3900 North 10th Street
                                         McAllen, TX 78501-1719
                                         (956) 631-5401

BORROWERS

Host ID:                                 243059
Name:                                    International Isotopes, Inc.
DBA:
Address:                                 4137 Commerce Circle
                                         Idaho Falls, ID 83401
EIN:                                     74-2763837
Phone:
NAlC -Primary:

NAlC -Secondary:

GENERAL INFORMATION

Specific Loan Purpose:                   a renewal O/P payoff note #3 1083 169


User Defined Fields:

Class Code                               05
Branch                                   01
Purpose Code                             540
Opened By Responsibility Code            039
Product Code                             10405
Collateral Code                          0052
Rate Index (if variable rate)            01
Payment Code                             2
Loan Rating Code                         02
Census Tract Number                      0.00

CALCULATION TERMS

INPUT VALUES

PAYMENT INFORMATION

    Repayment Method                                                 Custom
    Amount Requested                                            $733,595.00
    Outstanding Balance                                               $0.00
    Payment Frequency                                               Monthly
    Number of Amortized Payments                                          0
    Funding Date                                               July 1, 2004
    Note Date                                                  July 1, 2004
        Funding Date is used to calculate the beginning
        of interest accrual
    First Payment Date                                       August 1, 2004
    Days to First Payment                                                31
    Accrual Method                                               Actual/360
    First Period Accrual Method                                  Actual/360
    Prepay Odd Days Interest                                             No
         Collect Odd Days As                                            N/A

____________________________________________________________________________

    INTEREST RATE DEFINITION
    Variable Interest Rate

1

Index                                         Texas State Bank Base Rate
Index Rate                                                        6.500%
Market as Percent of Index                                        0.000%
Margin as Percentage Points                                       1.OOO%
Market Rate                                                       7.500%
Round to the Nearest                                               .001%
Lock Margin For (number of days)
Lock Expiration Date
Initial Rate Definition                                   Specific Value
Initial Rate Subject to Floor                                         No
Initial Rate Subject to Ceiling                                       No
Initial Rate                                                      7.500%
Discount/Premium
Calculated Initial Rate                                           7.500%
Periodic Cap                                                      0.000%
Floor Definition                                          Specific Value
Floor                                                             7.500%
Floor Margin                                                      0.000%
Calculated Floor                                                  7.500%
Ceiling Definition                                                  None
Ceiling                                                           0.000%
Ceiling Margin                                                    0.000%
Calculated Ceiling                                                0.000%
Rate Change Affects                                       Payment Amount
Initial Rate Hold Date                                      July 2, 2004
Initial Rate Hold Term and Units                                  1 Days
Rate Change Frequency and Units                                   1 Days
Two Step                                                              No
Initial Payment Hold                                          1 payments
Payment Change Frequency                                      1 payments

CALCULATED VALUES

PROCEEDS INFORMATION

Loan Amount                                                        $0.00
Charges Not Affecting APR                                          $0.00
Charges Affecting APR                                              $0.00
Odd Days Prepaid/Credit                                            $0.00
    0 Days
Pro Rata Charge                                                    $0.00
Prepaid Insurance                                                  $0.00
Escrow                                                             $0.00
Insurance Renewal                                                  $0.00
Single Premium PMI
Interest                                                           $0.00
Interest Reserve (Calculated)
Interest Reserve (Lender)
Minimum Interest Applies                                              No
Finance Charge                                                     $0.00
Amount Financed                                                    $0.00
Proceeds                                                           $0.00


PAYMENT STREAM INFORMATION

Number of Payments Amount of Payments When Payments Are Due

__________________   ___________________   _____________________________________
               N/A                   N/A   6 monthly payments of accrued
                                           interest beginning on August 01,
                                           2004, then 12 monthly payments of
                                           accrued interest plus $1,500.00 to
                                           principal beginning February 01,
                                           2005, and a final payment of the
                                           entire unpaid outstanding balance of
                                           Principal and Interest will be due on
                                           February 01, 2006
________________________________________________________________________________
Total of Payments                                                          $0.00

Maturity Date
                                APR 0.000%


LATE CHARGES

If a payment is more than 10 days late, I will be charged 5.000 percent of the Amount of Payment. I will pay this late charge promptly but only once for each late payment.

INSURANCE DETAIL

Credit Life Plan Selected N/A

2

Credit Disability Plan Selected                           N/A
Total Premium                                           $0.00
Cost Per Day                                            $0.00


Amount of Decreasing Insurance                          $0.00
Amount of Level Insurance                               $0.00
Amount of Disability Insurance                          $0.00
Monthly Disability Benefit                              $0.00


Decreasing Term               0.000 Months             0 Days
Level Term                    0.000 Months             0 Days
Disability Term               0.000 Months             0 Days


POST MATURITY RATE DETAIL

Post Maturity interest will accrue at highest rate permitted by law


CUSTOM DETAIL

Loan Amount              $0.00
Maturity Date            February 1, 2006
Repayment Description    6 monthly payments of accrued interest beginning on
                         August 01, 2004, then 12 monthly payments of accrued
                         interest plus $1.500.00 to principal beginning February
                         01, 2005, and a final payment of the entire unpaid
                         outstanding balance of Principal and Interest will be
                         due on February 01, 2006

Fees and Charges
Description


COLLATERAL

Collateral Type                      Accounts & Contract Rights (Generally)
Specific Collateral Description
Additional Comments
Location Address                     4137 Commerce Circle, Idaho Falls, ID 83401




Collateral Type                      Equipment (Generally)
Specific Collateral Description
Additional Comments
Location Address                     4137 Commerce Circle, Idaho Falls, ID 83401



Collateral Type                      General Intangibles (Generally)
Specific Collateral Description
Additional Comments
Location Address                     4137 Commerce Circle, Idaho Falls, ID 83401




Collateral Type                      Inventory
Specific Collateral Description
Additional Comments
Location Address                     4137 Commerce Circle, Idaho Falls, ID 83401




Collateral Type                      Chattel Paper
Specific Collateral Description      Any and All deposit accounts, payment
                                     intangibles, investment property and
                                     software together with all supporting
                                     obligation and proceeds of same property
                                     and all after-acquired collateral of the
                                     same classification.
Additional Comments
Location Address                     4137 Commerce Circle, Idaho Falls, ID 83401

3

___________________________________________________________________________________________________

                LOAN NUMBER      ACCT. NUMBER       NOTE DATE       NOTE AMOUNT       MATURITY DATE
PRIOR
OBLIGATION         48108            243059           07101104       $733,595.00         02/01/06
INFORMATION


                LOAN NUMBER           ACCT. NUMBER         MODIFICATION DATE            NOTE AMOUNT
AMENDED
OBLIGATION         48108                 243059                07/01/04                 $733,595.00
INFORMATION
                MATURITY DATE       INDEX (w/margin)         INTEREST RATE               INITIALS

                  02/01/06           Not Applicable              7.5%                      MDH


                                Creditor Use Only
___________________________________________________________________________________________________

DEBT MODIFICATION AGREEMENT

DATE AND PARTIES. The date of this Debt Modification Agreement iModification1 is July 1, 2004. The parties and their addresses are:

LENDER:
TEXAS STATE BANK
3900 North 10th Street
McAllen, Texas 78501-1719

Telephone: (956) 63l-5401

BORROWER:
INTERNATIONAL ISOTOPES, INC.

a Texas Corporation
4137 Commerce Circle
Idaho Falls, Idaho 83401

1. DEFINITIONS. In this Modification, these terms have the following meanings:

A. Pronouns. The pronouns "I,' "me," and "my" refer to each Borrower signing this Modification, individually and together with their heirs, executors, administrators, successors, and assigns. "You" and "your" refer to the Lender, with its participants or syndicators, successors and assigns, or any person or entity that acquires an interest in the Modification or Prior Obligation.

B. Amended Obligation. Amended Obligation is the resulting agreement that is created when the Modification amends the Prior Obligation. It is described above in the AMENDED OBLIGATION INFORMATION section.

C. Loan. Loan refers to this transaction generally. It includes the obligations and duties arising from the terms of all documents prepared or submitted in association with the Prior Obligation and this modification, such as applications, security agreements, disclosures, notes, agreements, and this Modification.

D. Modification. Modification refers to this Debt Modification Agreement.

E. Prior Obligation. Prior Obligation refers to my existing agreement described above in the PRIOR OBLIGATION INFORMATION section, and any previous extensions, renewals, modifications or substitutions of it.

2. BACKGROUND. You and I have previously entered into a Prior Obligation. As of the date of this Modification, the outstanding, unpaid balance of the Prior Obligation is $733,595.00. Conditions have changed since the execution of the Prior 0bligation instruments. In response, and for value received, you and I agree to modify the terms of the Prior Obligation, as provided for in this Modification.

3. TERMS. The Prior Obligation is modified as follows:

A. Interest. Our agreement for the payment of interest is modified to read:

(1) INTEREST. Interest will accrue on the unpaid Principal balance of this loan at the rate of 7.5 percent (Interest Rate).

(a) Maximum Interest Amount. Any amount assessed or collected as interest under the terms of this loan or obligation will be limited to the Maximum Lawful Amount of interest allowed by state or federal law. Amounts collected in excess of the Maximum Lawful Amount will be applied first to the unpaid Principal balance. Any remainder will be refunded to me.

(b) Statutory Authority. The amount assessed or collected on this loan is authorized by the Texas usury law, under Tex. Fin. Code. Ch. 303.

(c) Accrual. During the scheduled term of this Loan Interest accrues using an Actual/360 days counting method.

B. Payments. The payment provision 1s modified to lead:

(1) PAYMENT. I agree to pay this loan as follows: 6 monthly payments of accrued interest beginning on August 01, 2004, then 12 monthly payments of accrued interest plus $1,500.00 principal payment beginning February 01, 2005, and a final payment of the entire unpaid outstanding balance of Principal and Interest will be due on February 01, 2008.

Payments will be refunded to the nearest $.01. With the final payment I also agree to pay any additional fees or charges owing and the amount of any advances you have made to others on my behalf. Payments scheduled to be paid on the 29th, 30th or 31st day of a month that contains no such day will, instead, be made on the last day of such month.

C. Fees and Charges. As additiona1 consideration for your consent to enter into this Modification Agreement, I agree to pay, or have paid these additional fees and charges:

(1) Stop Payment. A(n) Stop Payment equal to $25.00.

(2) Late Charge. If a payment is more than 10 days late, I will be charged 5.000 percent of the Amount of Payment. I will pay this late charge promptly but only once for each late payment.

(3) Returned Check Charge, I agree to pay a fee not to exceed $30.00 for each check, negotiable order of withdrawal or draft I issue in connection with this Loan that is returned because it has been dishonored.

4. CONTINUATION OF TERMS. Except as specifically amended by this Modification, all of the terms of the Prior Obligation shall remain in full force and effect

4

5. WAIVER. I waive all claims, defenses, setoffs, or counterclaims relating to the Prior Obligation, or any document securing the Prior Obligation, that I may have. Any party to the Prior Obligation that does not sign this Modification, shall remain liable under the terms of the Prior Obligation unless released in writing by you.

6. ADDITIONAL TERMS. Interest will accrue at the fixed rate of 7.50% as indicated on 3A for 12 months. Fix rate will be adjusted to change on July 1, 2005 to a variable rate of Texas State Bank Base Rate plus 1%. Interest rate will change on a daily basis and will effect the amount of scheduled payment.

Interest rate will never be less than 7.50 percent for entire term of the loan,

THIS WRITTEN LOAN AGREEMENT REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

7. SIGNATURES. By signing, I agree to the terms contained in this Modification. I also acknowledge receipt of a copy of this Modification.

BORROWER:

International Isotopes, Inc.

By:   /S/ Steve Laflin
      -----------------------------
      Steve Laflin, President & CEO

LENDER:

Texas State Bank

By:  /S/ M. Douglas Harris
     ---------------------------------
     M. Douglas Harris, Vice President

5

EXHIBIT 10.12

UNSECURED NOTE

Date: April 1, 2002

MAKER: International Isotopes Inc., a Texas corporation

MAKER'S Mailing Address:

4137 Commerce Circle
Idaho Falls, Idaho 83401

PAYEE: William Nicholson

PAYEE'S Mailing Address and Place for Payment:

121 Post Oak Lane, Suite 2105
Houston, TX 77024

Principal Amount: Nine Hundred Nine Thousand Seven Hundred Thirty Seven and 00/100 Dollars ($909,737)

Annual Interest Rate on Unpaid Principal from Date: Seven percent (7%)

Annual Interest Rate on Matured, Unpaid Amounts: Ten percent (10%)

Terms of Payment (principal and interest):

Annual Payments: On April 1 of each year during the term of this Note,

                  MAKER shall  make a payment of interest and principal
                  in accordance with the following terms:

Interest:         All interest accrued for the prior year is to be paid
                  to the extent Net Profits  from the prior fiscal year
                  of MAKER are  available.  For  purposes of this Note,
                  "Net Profits" shall mean revenues less expenses,  but
                  excluding  any  taxes to be paid and prior to (i) the
                  payment   of  any  bonus   compensation   to  MAKER'S
                  management  or  employees  or (ii) the payment of any
                  dividends   or   other   distributions   to   MAKER'S
                  shareholders.  If Net Profits  from the prior  fiscal
                  year  are not  adequate  to make an  annual  interest
                  payment  when due,  then MAKER  shall be  required to

make quarterly payments (on each July 1, October 1, and January 1) of Net Profits until all interest payments that were due on the previous April 1 have been paid in full, at which time interest payments shall revert back to annual payments on April 1 of each year.


Principal:       An annual principal payment equal to:

                 30% x (Net Profit for the prior  fiscal year less any
                 interest paid pursuant to the previous paragraph)

Date of First Annual Payment: April 1, 2003

Maturity Date: April 1, 2012

MAKER promises to pay PAYEE installments of principal and interest due and payable in annual installments on the dates and as described above, continuing regularly until the Maturity Date, when the entire balance, principal and accrued interest, shall be due and payable; interest being calculated on the unpaid principal to the date of each installment paid.

The MAKER of the Note reserves the right to prepay, prior to maturity, all or any part of the principal of the Note without penalty, and interest immediately shall cease on any amount so prepaid.

SECURITY FOR PAYMENT: This Note is unsecured. Without the prior written consent of MAKER, which consent shall not unreasonably be withheld, PAYEE shall not pledge any assets as security for repayment of any obligation, except to Texas State Bank or any other financial institution that becomes MAKER'S primary bank lender.

MAKER promises to pay to the order of PAYEE at the place for payment and according to the terms of payment the principal amount plus interest at the rates stated above. All unpaid amounts shall be due by the final scheduled payment date.

On default in the payment of this Note or in the performance of any obligation hereunder, the unpaid principal balance and earned interest on this Note shall become immediately due at the election of PAYEE. MAKER and each surety, endorser, and guarantor waive all demands for payment, presentations for payment, notices of intention to accelerate maturity, notices of acceleration of maturity, protests, and notices of protest.

If this Note is given to an attorney for collection or enforcement, or if suit is brought for collection or enforcement, or if it is collected or enforced through probate, bankruptcy, or other judicial proceeding, then MAKER shall pay PAYEE all costs of collection and enforcement, including reasonable attorney's fees and court costs, in addition to other amounts due. Reasonable attorney's fees shall be 5% of all amounts due unless either party pleads otherwise.

2

Interest on the debt evidenced by this Note shall not exceed the maximum amount of nonusurious interest that may be contracted for, taken, reserved, charged, or received under law; any interest in excess of that maximum amount shall be credited on the principal of the debt or, if that has been paid, refunded. On any acceleration or required or permitted repayment, any such excess hall be canceled automatically as of the acceleration or prepayment or, if already paid, credited on the principal of the debt, or, if the principal of the debt has been paid, refunded. The provision overrides other provisions in this and all other instruments concerning the debt.

This Note shall be construed in accordance with the laws of the State of Texas.

When the context requires, singular nouns and pronouns include the plural.

This Note supercodes and is in lieu of all agreements and notes, whether written or oral, between MAKER and PAYEE preceeding the date of this Note, and all such prior notes and/or agreements are hereby declared null and void.

INTERNATIONAL ISOTOPES INC.

By:     /S/ Steve Laflin  3-29-02
        -------------------------
Name:   Steve Laflin
Title:  President & CEO

Acknowledged by PAYEE;

/S/ William Nicholson
---------------------
William Nicholson

3

EXHIBIT 10.13

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this "Agreement"), is made and entered into as of January 21, 2004, by and between the undersigned lender ("Lender") and International Isotopes Inc., a Texas corporation ("Borrower'7).

WITNESSETH:

WHEREAS, Borrower desires to borrow from Lender, and Lender is willing to loan to Borrower, the principal amount of $ 156,000.00 , to be evidenced by an unsecured convertible promissory note in the form set forth on Exhibit A attached hereto (the "Convertible Note" or the "Note'7).

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby specifically acknowledged, the parties hereto agree as follows:

1. Closing; Delivery. Upon the terms and subject to the conditions herein, Borrower agrees to issue to the Lender the Convertible Note and Lender agrees to lend to Borrower pursuant to the terms of the Convertible Note and this Agreement, a maximum principal amount of $ 156,000.00 (the "Loan"). The execution and delivery of the Convertible Note and the delivery of the proceeds of the Loan shall take place at closing (the "Closing") to be held on January 23, 2004 at 9:00 a.m., Mountain time, or on such other date and at such other time as may be mutually agreed upon (the "Closing Date"). The Closing shall be held at the offices of the Borrower or at such other place as may be mutually agreed upon.

2. Representations and Warranties of Lender. Lender hereby represents and warrants that as of the Closing Date:

a. Purchase Entirely for Own Account. Lender is acquiring the Note and any securities issuable upon conversion of the Note to be received by Lender (the "Securities") for investment for Lender's owl account and not with a view to or for resale in connection with, any distribution thereof. Lender understands that the Securities have not been registered under the Securities Act of 1933, as amended (the "Act"), by reason of a specific exemption from the registration provisions of the Act that depends upon, among other things, the bona fide nature of the investment intent as expressed herein.

b. Investment Experience. Lender is an accredited investor within the meaning of Regulation D prescribed by the Securities and Exchange Commission pursuant to the Act and by virtue or Lender's experience in evaluating and investing in private placement transactions of securities in companies similar to Borrower, such Lender is capable of evaluating the merits and risks of Lender's investment in Borrower and has the capacity to protect Lender's own interests.

1

c. Restricted Securities. Lender acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act, or unless an exemption from such registration is available. Lender is aware of the provisions of Rule 144 and 144A promulgated under the Act that permit limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

3. Representations and Warranties of Borrower. Borrower hereby represents and warrants that, as of the Closing Date:

a. Authority. Borrower has all requisite legal and corporate power and authority and has obtained all approvals and consents necessary to enter into this Agreement and the Note and to carry out and perform its obligations under the terms of this Agreement and the Note.

4. Covenant Concerning Confidential Information. Lender understands that in connection with the negotiation of this Agreement and the Note it may become privy to material non-public information concerning Borrower and its business operations including proposed new business opportunities. Lender agrees that it will keep such information confidential and will not disclose any material non-public information concerning Borrower to any third person and will not purchase or sell or enter into any agreement to purchase or sell securities of Borrower so long as Lender is in possession of any material information concerning Borrower which has not yet been announced publicly, either through a Borrower press release or in a disclosure filing with the Securities and Exchange Commission.

5. Conditions of Lender's Obligations at Closing. The obligations of the Lender under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against the Lender without its written consent:

a. Note. Borrower shall have executed and delivered to Lender an original copy of this Agreement and the Note in the form attached as Exhibit A for the Loan.

b. Patent Acquisition. All conditions precedent to the closing of that certain Asset Acquisition Agreement entered into as of November 24, 2003 between the Borrower and International Machine Design, LLC shall have been satisfied.

c. Minimum Loan Amount. The Company shall have received a minimum of $650,000 pursuant to the Note and other similar unsecured convertible promissory notes from existing Borrower shareholders.

6. Registration Rights. Borrower hereby covenants to include in its next registration of its securities under the Securities Act of 1933 the registration, on behalf of the Lender, as a selling shareholder, of that number of shares of its common stock that would be issuable upon a full conversion of the principal amount of Lender's Note. Such "piggy back" registration rights shall be subject to limitation due to underwriter's discretion based on an assessment of market conditions in the event that the Company's next registered offering of securities involves a traditional underwriting, provided that any such limitation shall affect Lender and other similarly situated holders of Borrower notes on an equal percentage basis according to the number of conversion shares held by Lender and such other noteholders. All expenses of such registration, including the expenses of a single law firm representing the interests of Lender and all other similarly situated selling shareholders, shall be borne by Borrower.

2

7. SEC Filings. Borrower hereby covenants, at its expense, to make any filings with the Securities and Exchange Commission required of Lender in connection with the issuance of the Note or any underlying shares of stock issuable upon conversion of the Note, including any Form 3s or 4s and any filings required under Section 13(d) of the Securities and Exchange Act of 1934. Lender agrees to cooperate with Borrower's legal counsel in providing the necessary information for such filings.

8. Miscellaneous.

a. Severabilitv. If any of the provisions of this Agreement shall be held to be invalid or unenforceable, this Agreement shall be construed as if not containing those provisions and the rights and obligations of the parties hereto shall be construed and enforced accordingly.

b. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy of other reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

c. Governing Law: Jurisdiction. This Agreement shall be construed in accordance with and governed by the laws of the State of Texas without regard to the conflicts of law principles thereof.

d. Integration. This Agreement and each Note (together with the exhibits and documents referenced herein and therein) contain the entire agreement of the parties relating to the subject matter hereof and supersedes all prior offers, letters, agreements and understandings of the parties.

e. Waiver and Amendment. Any term of this Agreement may be amended only with the written consent of Borrower and Lender. The observance of any term of this Agreement may be waived only if such waiver is in writing signed by the party waiving such term.

f. Headings. The headings in this Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

g. Transfer and Assignment. The rights and obligations of Lender and Borrower hereunder and pursuant to the Note may not be transferred or assigned by either party without the prior written consent of the other, except that Lender may transfer or assign its rights and obligations under this Agreement or the Note to an affiliate, partner or limited partner of Lender. Except as otherwise provided in this Agreement and the Note, the provisions of this Agreement and the Note shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

3

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

BORROWER:

INTERNATIONAL ISOTOPES INC.
a Texas corporation

By:    /S/ Steve T. Laflin
       -------------------
Name:  Steve T. Laflin
Title: President

LENDER:

By:    /S/ Ralph Richart
       -----------------
Name:  Ralph Richart

SIGNATURE PAGE TO INTERNATIONAL ISOTOPES INC.
NOTE PURCHASE AGREEMENT

4

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF. THE SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT, EXCEPT UNDER CERTAIN SPECIFIC LIMITED CIRCUMSTANCES, AN OPINION OF COUNSEL FOR THE HOLDER, CONCURRED IN BY COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

UNSECURED CONVERTIBLE PROMISSORY NOTE

                                                              Idaho Falls, Idaho

$156,000.00                                                   January 21,2004


         1.     Principal and Interest.

(a) International Isotopes Inc., a Texas corporation (the "Company"), for value received, hereby promises to pay to the order of Ralph Richart (the "Holder") in lawful money of the United States at the address of the Holder set forth below, the principal amount of Hundred and Fifty Six Thousand Dollars ($156,000.00) (the "Principal"), together with simple interest at the rate of six percent (6%) per annum. Interest shall be computed on a 365-day year for the actual number of days elapsed.

(b) The Principal of this Note shall be due and payable on December 30, 2005 (the "Maturity Date"). Accrued interest on this Note shall be payable in a5G-s 6ri June 30, 2004, December 30, 2004, June 30, 2005 and on the Maturity Date. This Note may be prepaid without penalty, in whole or in part, at any time.

(c) Upon payment in full of all principal and interest payable hereunder, this Note shall be surrendered to the Company for cancellation.

2. Conversion.

(a) Conversion. The outstanding principal balance of this Note and all interest accrued and unpaid thereon may be converted at the option of the Holder at any time into shares of the Company's common stock, par value $.01 per share at a conversion price equal to the average of the closing bid prices of the Company's common stock on the third through the eighth trading days following the Company's announcement of its acquisition of certain fluorine extraction process patents from International Machine Design, LLC, such announcement to be made by the Company within two (2) business days of the closing of the acquisition of the patents.

(b) Option Exercise. At least 10 days (but not more than 30 days) prior to the conversion date, Holder shall notify the Company of its desire to convert all or part of this Note to common stock. Holder's notice shall specify the conversion date and the amount of principal and accrued interest to be converted. Any notice required or that may be given under this Note shall be in writing and shall be deemed to have been duly given when delivered, transmitted by telecopier (with receipt confirmed) or mailed by registered or certified first class mail, postage prepaid, return receipt requested to the parties hereto at the address set forth below (as the same may be changed from time to time by notice similarly given) or the last known business or residence address of much other person as may be designated by either party hereto in writing.

5

(i) If to Company:

International Isotopes Inc. 4137 Commerce Circle Idaho Falls, Idaho 83401 Fax: (208) 524-141 1

(ii) If to Holder:

Ralph Richart
VC 14-212
630 West 168th St.

New York, NY 10032

(c) Mechanics of Conversion. Upon conversion of this entire Note as set forth above, the outstanding principal and accrued interest of the Note shall be converted as elected by Holder without any further action by the Holder and whether or not the Note is surrendered to the Company or its transfer agent. The Company shall not be obligated to issue certificates evidencing the shares of the securities issuable upon conversion unless such Note is either delivered to the Company or its transfer agent, or the Holder notifies the Company or its transfer agent that such Note has been lost, stolen or destroyed and executes an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such Note. The Company shall, as soon as practicable after such delivery, or such agreement and indemnification, issue and deliver to such Holder, a certificate or certificates for the securities to which the Holder shall be entitled and a check payable to the Holder in the amount of any cash amounts payable as the result of a conversion into fractional shares of common stock. Such conversion shall be deemed to have been made on the conversion date specified in Holder's notice of conversion. The person or persons entitled to receive securities issuable upon such conversion shall be treated for all purposes as the record holder or holders of such securities on such date. If the Holder elects to convert less than the entire principal amount of the Note, upon Lender's surrender of the original Note, Borrower shall deliver to Lender a new Note in an amount equal to the principal amount of the original Note that has not been converted to common stock.

3. Attorneys Fees. If the indebtedness represented by this Note or any part thereof is collected in bankruptcy, receivership or other judicial proceedings or if this Note is placed in the hands of attorneys for collection after default, the Company agrees to pay, in addition to the principal and interest payable hereunder, reasonable attorneys' fees and costs incurred by the Holder.

2

4. Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF TEXAS AS SUCH 1,AWS ARE APPLIED TO AGREEMENTS BETWEEN TEXAS RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN TEXAS.

HOLDER: INTERNATIONAL ISOTOPES INC.

By:      /S/ Ralph Richart           By:    /S/ Steve T. Laflin
         ------------------                 -------------------
Name:    Ralph Richart               Name:  Steve T. Laflin
Address: VC 14-212                   Title: President
         630 West 168th St.
         New York, NY 10032

3

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this "Agreement"), is made and entered into as of January 23, 2004, by and between the undersigned lender ("Lender") and International Isotopes Inc., a Texas corporation ("Borrower").

WITNESSETH:

WHEREAS, Borrower desires to borrow from Lender, and Lender is willing to loan to Borrower, the principal amount of $ 130,500.00 ,to be evidenced by an unsecured convertible promissory note in the form set forth on Exhibit A attached hereto (the "Convertible Note" or the "Note '7).

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby specifically acknowledged, the parties hereto agree as follows:

1. Closing; Delivery. Upon the terms and subject to the conditions herein, Borrower agrees to issue to the Lender the Convertible Note and Lender agrees to lend to Borrower pursuant to the terms of the Convertible Note and this Agreement, a maximum principal amount of $ 130,500.00 (the "Loan J'). The execution and delivery of the Convertible Note and the delivery of the proceeds of the Loan shall take place at closing (the "Closing") to be held on January 28, 2004 at 9:00 a.m., Mountain time, or on such other date and at such other time as may be mutually agreed upon (the "Closing Date"). The Closing shall be held at the offices of the Borrower or at such other place as may be mutually agreed upon.

2. Representations and Warranties of Lender. Lender hereby represents and warrants that as of the Closing Date:

a. Purchase Entirely for Own Account. Lender is acquiring the Note and any securities issuable upon conversion of the Note to be received by Lender (the "Securities") for investment for Lender's own account and not with a view to or for resale in connection with, any distribution thereof. Lender understands that the Securities have not been registered under the Securities Act of 1933, as amended (the "Act"), by reason of a specific exemption from the registration provisions of the Act that depends upon, among other things, the bona fide nature of the investment intent as expressed herein.

b. Investment Experience. Lender is an accredited investor within the meaning of Regulation D prescribed by the Securities and Exchange Commission pursuant to the Act and by virtue of Lender's experience in evaluating and investing in private placement transactions of securities in companies similar to Borrower, such Lender is capable of evaluating the merits and risks of Lender's investment in Borrower and has the capacity to protect Lender's own interests.

1

c. Restricted Securities. Lender acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act, or unless an exemption from such registration is available. Lender is aware of the provisions of Rule 144 and 144A promulgated under the Act that permit limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

3. Representations and Warranties of Borrower. Borrower hereby represents and warrants that, as of the Closing Date:

a. Authority. Borrower has all requisite legal and corporate power and authority and has obtained all approvals and consents necessary to enter into this Agreement and the Note and to carry out and perform its obligations under the terms of this Agreement and the Note.

4. Covenant Concerning Confidential Information. Lender understands that in connection with the negotiation of this Agreement and the Note it may become privy to material non-public information concerning Borrower and its business operations including proposed new business opportunities. Lender agrees that it will keep such information confidential and will not disclose any material non-public information concerning Borrower to any third person and will not purchase or sell or enter into any agreement to purchase or sell securities of Borrower so long as Lender is in possession of any material information concerning Borrower which has not yet been announced publicly, either through a Borrower press release or in a disclosure filing with the Securities and Exchange Commission.

5. Conditions of Lender's Obligations at Closing. The obligations of the Lender under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against the Lender without its written consent:

a. Note. Borrower shall have executed and delivered to Lender an original copy of this Agreement and the Note in the form attached as Exhibit A for the Loan.

b. Patent Acquisition. All conditions precedent to the closing of that certain Asset Acquisition Agreement entered into as of November 24, 2003 between the Borrower and International Machine Design, LLC shall have been satisfied.

c. Minimum Loan Amount. The Company shall have received a minimum of $650,000 pursuant to the Note and other similar unsecured convertible promissory notes from existing Borrower shareholders.

6. Registration Rights. Borrower hereby covenants to include in its next registration of its securities under the Securities Act of 1933 the registration, on behalf of the Lender, as a selling shareholder, of that number of shares of its common stock that would be issuable upon a full conversion of the principal amount of Lender's Note. Such "piggy back" registration rights shall be subject to limitation due to underwriter's discretion based on an assessment of market conditions in the event that the Company's next registered offering of securities involves a traditional underwriting, provided that any such limitation shall affect Lender and other similarly situated holders of Borrower notes on an equal percentage basis according to the number of conversion shares held by Lender and such other noteholders. All expenses of such registration, including the expenses of a single law firm representing the interests of Lender and all other similarly situated selling shareholders, shall be borne by Borrower.

2

7. SEC Filings. Borrower hereby covenants, at its expense, to make any filings with the Securities and Exchange Commission required of Lender in connection with the issuance of the Note or any underlying shares of stock issuable upon conversion of the Note, including any Form 3s or 4s and any filings required under Section 13(d) of the Securities and Exchange Act of 1934. Lender agrees to cooperate with Borrower's legal counsel in providing the necessary information for such filings.

8. Miscellaneous.

a. Severability. If any of the provisions of this Agreement shall be held to be invalid or unenforceable, this Agreement shall be construed as if not containing those provisions and the rights and obligations of the parties hereto shall be construed and enforced accordingly.

b. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy of other reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

c. Governing Law: Jurisdiction. This Agreement shall be construed in accordance with and governed by the laws of the State of Texas without regard to the conflicts of law principles thereof.

d. Integration. This Agreement and each Note (together with the exhibits and documents referenced herein and therein) contain the entire agreement of the parties relating to the subject matter hereof and supersedes all prior offers, letters, agreements and understandings of the parties.

e. Waiver and Amendment. Any term of this Agreement may be amended only with the written consent of Borrower and Lender. The observance of any term of this Agreement may be waived only if such waiver is in writing signed by the party waiving such term.

f. Headings. The headings in this Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

g. Transfer and Assignment. The rights and obligations of Lender and Borrower hereunder and pursuant to the Note may not be transferred or assigned by either party without the prior written consent of the other, except that Lender may transfer or assign its rights and obligations under this Agreement or the Note to an affiliate, partner or limited partner of Lender. Except as otherwise provided in this Agreement and the Note, the provisions of this Agreement and the Note shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

3

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

BORROWER:

INTERNATIONAL ISOTOPES INC.
a Texas corporation

By:    /S/ Steve T. Laflin
       -------------------
Name:  Steve T. Laflin
Title: President

LENDER:

By:    /S/ William Nicholson
       ---------------------
Name:  William Nicholson

SIGNATURE PAGE TO INTERNATIONAL ISOTOPES INC.
NOTE PURCHASE AGREEMENT

4

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF. THE SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT, EXCEPT UNDER CERTAIN SPECIFIC LIMITED CIRCUMSTANCES, AN OPINION OF COUNSEL FOR THE HOLDER, CONCURRED IN BY COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

UNSECURED CONVERTIBLE PROMISSORY NOTE

                                                              Idaho Falls, Idaho

$130,500.00                                                   January 23,2004


         1.     Principal and Interest.

(a) International Isotopes Inc., a Texas corporation (the "Company"), for value received, hereby promises to pay to the order of William Nicholson (the "Holder") in lawful money of the United States at the address of the Holder set forth below, the principal amount of One Hundred Thirty Thousand Five Hundred Dollars ($130,500.00) (the "Principal"), together with simple interest at the rate of six percent (6%) per annum. Interest shall be computed on a 365-day year for the actual number of days elapsed.

(b) The Principal of this Note shall be due and payable on December 30, 2005 (the "Maturity Date"). Accrued interest on this Note shall be payable in arrears on June 30, 2004, December 30, 2004, June 30, 2005 and on the Maturity Date. This Note may be prepaid without penalty, in whole or in part, at any time.

(c) Upon payment in full of all principal and interest payable hereunder, this Note shall be surrendered to the Company for cancellation.

2. Conversion.

(a) Conversion. The outstanding principal balance of this Note and all interest accrued and unpaid thereon may be converted at the option of the Holder at any time into shares of the Company's common stock, par value $.01 per share at a conversion price equal to the average of the closing bid prices of the Company's common stock on the third through the eighth trading days following the Company's announcement of its acquisition of certain fluorine extraction process patents from International Machine Design, LLC, such announcement to be made by the Company within two (2) business days of the closing of the acquisition of the patents.

(b) Option Exercise. At least 10 days (but not more than 30 days) prior to the conversion date, Holder shall notify the Company of its desire to convert all or part of this Note to common stock. Holder's notice shall specify the conversion date and the amount of principal and accrued interest to be converted. Any notice required or that may be given under this Note shall be in writing and shall be deemed to have been duly given when delivered, transmitted by

1

4. Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF TEXAS AS SUCH LAWS ARE APPLIED TO AGREEMENTS BETWEEN TEXAS RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN TEXAS.

HOLDER:                                  INTERNATIONAL ISOTOPES INC.



By:      /S/ William Nicholson           By:   /S/ Steve T. Laflin
         ---------------------                 -------------------
Name:    William Nicholson               Name: Steve T. Laflin

Address: 121 N. Post Oak Ln. Ste. 2105 Title: President Houston, TX 77024

3

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this "Agreement"), is made and entered into as of January 21, 2004, by and between the undersigned lender ("Lender") and International Isotopes Inc., a Texas corporation ("Borrower").

WITNESSETH:

WHEREAS, Borrower desires to borrow from Lender, and Lender is willing to loan to Borrower, the principal amount of $ 26,000.00 , to be evidenced by an unsecured convertible promissory note in the form set forth on Exhibit A attached hereto (the "Convertible Note" or the "Note ").

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby specifically acknowledged, the parties hereto agree as follows:

1. Closing; Delivery. Upon the terms and subject to the conditions herein, Borrower agrees to issue to the Lender the Convertible Note and Lender agrees to lend to Borrower pursuant to the terms of the Convertible Note and this Agreement, a maximum principal amount of $ 26,000.00 (the "Loan"). The execution and delivery of the Convertible Note and the delivery of the proceeds of the Loan shall take place at closing (the "Closing") to be held on January 23, 2004 at 9:00 a.m., Mountain time, or on such other date and at such other time as may be mutually agreed upon (the "Closing Date"). The Closing shall be held at the offices of the Borrower or at such other place as may be mutually agreed upon.

2. Representations and Warranties of Lender. Lender hereby represents and warrants that as of the Closing Date:

a. Purchase Entirely for Own Account. Lender is acquiring the Note and any securities issuable upon conversion of the Note to be received by Lender (the "Securities") for investment for Lender's own account and not with a view to or for resale in connection with, any distribution thereof. Lender understands that the Securities have not been registered under the Securities Act of 1933, as amended (the "Act"), by reason of a specific exemption from the registration provisions of the Act that depends upon, among other things, the bona fide nature of the investment intent as expressed herein.

b. Investment Experience. Lender is an accredited investor within the meaning of Regulation D prescribed by the Securities and Exchange Commission pursuant to the Act and by virtue of Lender's experience in evaluating and investing in private placement transactions of securities in companies similar to Borrower, such Lender is capable of evaluating the merits and risks of Lender's investment in Borrower and has the capacity to protect Lender's own interests.

1

c. Restricted Securities. Lender acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act, or unless an exemption from such registration is available. Lender is aware of the provisions of Rule 144 and 144A promulgated under the Act that permit limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

3. Representations and Warranties of Borrower. Borrower hereby represents and warrants that, as of the Closing Date:

a. Authority. Borrower has all requisite legal and corporate power and authority and has obtained all approvals and consents necessary to enter into this Agreement and the Note and to carry out and perform its obligations under the terms of this Agreement and the Note.

4. Covenant Concerning Confidential Information. Lender understands that in connection with the negotiation of this Agreement and the Note it may become privy to material non-public information concerning Borrower and its business operations including proposed new business opportunities. Lender agrees that it will keep such information confidential and will not disclose any material non-public information concerning Borrower to any third person and will not purchase or sell or enter into any agreement to purchase or sell securities of Borrower so long as Lender is in possession of any material information concerning Borrower which has not yet been announced publicly, either through a Borrower press release or in a disclosure filing with the Securities and Exchange Commission.

5. Conditions of Lender's Obligations at Closing. The obligations of the Lender under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against the Lender without its written consent:

a. Note. Borrower shall have executed and delivered to Lender an original copy of this Agreement and the Note in the form attached as Exhibit A for the Loan.

b. Patent Acquisition. All conditions precedent to the closing of that certain Asset Acquisition Agreement entered into as of November 24, 2003 between the Borrower and International Machine Design, LLC shall have been satisfied.

c. Minimum Loan Amount. The Company shall have received a minimum of $650,000 pursuant to the Note and other similar unsecured convertible promissory notes from existing Borrower shareholders.

6. Registration Rights. Borrower hereby covenants to include in its next registration of its securities under the Securities Act of 1933 the registration, on behalf of the Lender, as a selling shareholder, of that number of shares of its common stock that would be issuable upon a full conversion of the principal amount of Lender's Note. Such "piggy back" registration rights shall be subject to limitation due to underwriter's discretion based on an assessment of market conditions in the event that the Company's next registered offering of securities involves a traditional underwriting, provided that any such limitation shall affect Lender and other similarly situated holders of Borrower notes on an equal percentage basis according to the number of conversion shares held by Lender and such other noteholders. All expenses of such registration, including the expenses of a single law firm representing the interests of Lender and all other similarly situated selling shareholders, shall be borne by Borrower.

2

7. SEC Filings. Borrower hereby covenants, at its expense, to make any filings with the Securities and Exchange Commission required of Lender in connection with the issuance of the Note or any underlying shares of stock issuable upon conversion of the Note, including any Form 3s or 4s and any filings required under Section 13(d) of the Securities and Exchange Act of 1934. Lender agrees to cooperate with Borrower's legal counsel in providing the necessary information for such filings.

8. Miscellaneous.

a. Severabilitv. If any of the provisions of this Agreement shall be held to be invalid or unenforceable, this Agreement shall be construed as if not containing those provisions and the rights and obligations of the parties hereto shall be construed and enforced accordingly.

b. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy of other reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

c. Governing Law: Jurisdiction. This Agreement shall be construed in accordance with and governed by the laws of the State of Texas without regard to the conflicts of law principles thereof.

d. Integration. This Agreement and each Note (together with the exhibits and documents referenced herein and therein) contain the entire agreement of the parties relating to the subject matter hereof and supersedes all prior offers, letters, agreements and understandings of the parties.

e. Waiver and Amendment. Any term of this Agreement may be amended only with the written consent of Borrower and Lender. The observance of any term of this Agreement may be waived only if such waiver is in writing signed by the party waiving such term.

f. Headings. The headings in this Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

g. Transfer and Assignment. The rights and obligations of Lender and Borrower hereunder and pursuant to the Note may not be transferred or assigned by either party without the prior written consent of the other, except that Lender may transfer or assign its rights and obligations under this Agreement or the Note to an affiliate, partner or limited partner of Lender. Except as otherwise provided in this Agreement and the Note, the provisions of this Agreement and the Note shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

3

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

BORROWER:

INTERNATIONAL ISOTOPES INC.
a Texas corporation

By:     /S/ Steve T. Laflin
        -------------------
Name:   Steve T. Laflin
Title:  President

LENDER:

By:     /S/ Christopher Grosso
        ----------------------
Name:   Christopher Grosso

SIGNATURE PAGE TO INTERNATIONAL ISOTOPES INC.

NOTE PURCHASE AGREEMENT

4

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF. THE SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT, EXCEPT UNDER CERTAIN SPECIFIC LIMITED CIRCUMSTANCES, AN OPINION OF COUNSEL FOR THE HOLDER, CONCURRED IN BY COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

UNSECURED CONVERTIBLE PROMISSORY NOTE

                                                              Idaho Falls, Idaho

$26,000.00                                                    January 21,2004


         1.     Principal and Interest.

(a) International Isotopes Inc., a Texas corporation (the "Company"), for value received, hereby promises to pay to the order of Christopher Grosso (the "Holder") in lawful money of the United States at the address of the Holder set forth below, the principal amount of Twenty Six Thousand Dollars ($ 26,000.00 ) (the "Principal"), together with simple interest at the rate of six percent (6%) per annum. Interest shall be computed on a 365-day year for the actual number of days elapsed.

(b) The Principal of this Note shall be due and payable on December 30, 2005 (the "Maturity Date"). Accrued interest on this Note shall be payable in arrears on June 30, 2004, December 30, 2004, June 30, 2005 and on the Maturity Date. This Note may be prepaid without penalty, in whole or in part, at any time.

(c) Upon payment in full of all principal and interest payable hereunder, this Note shall be surrendered to the Company for cancellation.

2. Conversion.

(a) Conversion. The outstanding principal balance of this Note and all interest accrued and unpaid thereon may be converted at the option of the Holder at any time into shares of the Company's common stock, par value $.01 per share at a conversion price equal to the average of the closing bid prices of the Company's common stock on the third through the eighth trading days following the Company's announcement of its acquisition of certain fluorine extraction process patents from International Machine Design, LLC, such announcement to be made by the Company within two (2) business days of the closing of the acquisition of the patents.

(b) Option Exercise. At least 10 days (but not more than 30 days) prior to the conversion date, Holder shall notify the Company of its desire to convert all or part of this Note to common stock. Holder's notice shall specify the conversion date and the amount of principal and accrued interest to be converted. Any notice required or that may be given under this Note shall be in writing and shall be deemed to have been duly given when delivered, transmitted by telecopier (with receipt confirmed) or mailed by registered or certified first class mail, postage prepaid, return receipt requested to the parties hereto at the address set forth below (as the same may be changed from time to time by notice similarly given) or the last known business or residence address of much other person as may be designated by either party hereto in writing.

1

(i) If to Company:

International Isotopes Inc. 4137 Commerce Circle Idaho Falls, Idaho 83401 Fax: (208) 524-1411

(ii) If to Holder:

Christopher Grosso 480 Broadway, Suite 310 Saratoga Springs, NY 12866

(c) Mechanics of Conversion. Upon conversion of this entire Note as set forth above, the outstanding principal and accrued interest of the Note shall be converted as elected by Holder without any further action by the Holder and whether or not the Note is surrendered to the Company or its transfer agent. The Company shall not be obligated to issue certificates evidencing the shares of the securities issuable upon conversion unless such Note is either delivered to the Company or its transfer agent, or the Holder notifies the Company or its transfer agent that such Note has been lost, stolen or destroyed and executes an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such Note. The Company shall, as soon as practicable after such delivery, or such agreement and indemnification, issue and deliver to such Holder, a certificate or certificates for the securities to which the Holder shall be entitled and a check payable to the Holder in the amount of any cash amounts payable as the result of a conversion into fractional shares of common stock. Such conversion shall be deemed to have been made on the conversion date specified in Holder's notice of conversion. The person or persons entitled to receive securities issuable upon such conversion shall be treated for all purposes as the record holder or holders of such securities on such date. If the Holder elects to convert less than the entire principal amount of the Note, upon Lender's surrender of the original Note, Borrower shall deliver to Lender a new Note in an amount equal to the principal amount of the original Note that has not been converted to common stock.

3. Attorneys Fees. If the indebtedness represented by this Note or any part thereof is collected in bankruptcy, receivership or other judicial proceedings or if this Note is placed in the hands of attorneys for collection after default, the Company agrees to pay, in addition to the principal and interest payable hereunder, reasonable attorneys' fees and costs incurred by the Holder.

2

4. Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF TEXAS AS SUCH LAWS ARE APPLIED TO AGREEMENTS BETWEEN TEXAS RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN TEXAS.

HOLDER: INTERNATIONAL ISOTOPES INC.

By:      /S/ Chistopher Grosso           By:    /S/ Steve T. Laflin
         ---------------------                  -------------------
Name:    Chistopher Grosso               Name:  Steve T. Laflin

Address: 480 Broadway, Suite 310 Title: President Saratoga Springs, NY 12866

3

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this "Agreement"), is made and entered into as of January 21, 2004, by and between the undersigned lender ("Lender") and International Isotopes Inc., a Texas corporation ("Borrower").

WITNESSETH:

WHEREAS, Borrower desires to borrow from Lender, and 1,ender is willing to loan to Borrower, the principal amount of $ 29,000.00, to be evidenced by an unsecured convertible promissory note in the form set forth on Exhibit A attached hereto (the "Convertible Note" or the "Note").

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby specifically acknowledged, the parties hereto agree as follows:

1. Closing; Delivery. Upon the terms and subject to the conditions herein, Borrower agrees to issue to the Lender the Convertible Note and Lender agrees to lend to Borrower pursuant to the terms of the Convertible Note and this Agreement, a maximum principal amount of $ 29,000.00 (the "Loan"). The execution and delivery of the Convertible Note and the delivery of the proceeds of the Loan shall take place at closing (the "Closing") to be held on January 23, 2004 at 9:00 a.m., Mountain time, or on such other date and at such other time as may be mutually agreed upon (the "Closing Date '7). The Closing shall be held at the offices of the Borrower or at such other place as may be mutually agreed upon.

2 Representations and Warranties of Lender. Lender hereby represents and warrants that as of the Closing Date:

a. Purchase Entirely for Own Account. Lender is acquiring the Note and any securities issuable upon conversion of the Note to be received by Lender (the "Securities") for investment for Lender's own account and not with a view to or for resale in connection with, any distribution thereof. Lender understands that the Securities have not been registered under the Securities Act of 1933, as amended (the "Act"), by reason 01a specific exemption from the registration provisions of the Act that depends upon, among other things, the bona fide nature of the investment intent as expressed herein.

b. Investment Experience. Lender is an accredited investor within the meaning of Regulation D prescribed by the Securities and Exchange Commission pursuant to the Act and by virtue of Lender's experience in evaluating and investing in private placement transactions of securities in companies similar to Borrower, such Lender is capable of evaluating the merits and risks of Lender's investment in Borrower and has the capacity to protect Lender's own interests.

1

c. Restricted Securities. Lender acknowledges that the Securities must be held 'indefinitely unless subsequently registered under the Act, or unless an exemption from such registration is available. Lender is aware of the provisions of Rule 144 and 144A promulgated under the Act that permit limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

3. Representations and Warranties of Borrower. Borrower hereby represents and warrants that, as of the Closing Date:

a. Authority. Borrower has all requisite legal and corporate power and authority and has obtained all approvals and consents necessary to enter into this Agreement and the Note and to carry out and perform its obligations under the terms of this Agreement and the Note.

4. Covenant Concerning Confidential Information. Lender understands that in connection with the negotiation of this Agreement and the Note it may become privy to material non-public information concerning Borrower and its business operations including proposed new business opportunities. Lender agrees that it will keep such information confidential and will not disclose any material non-public information concerning Borrower to any third person and will not purchase or sell or enter into any agreement to purchase or sell securities of Borrower so long as Lender is in possession of any material information concerning Borrower which has not yet been announced publicly, either through a Borrower press release or in a disclosure filing with the Securities and Exchange Commission.

5. Conditions of Lender's Obligations at Closing. The obligations of the Lender under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against the Lender without its written consent:

a. Note. Borrower shall have executed and delivered to Lender an original copy of this Agreement and the Note in the form attached as Exhibit A for the Loan.

b. Patent Acquisition. All conditions precedent to the closing of that certain Asset Acquisition Agreement entered into as of November 24, 2003 between the Borrower and International Machine Design, LLC shall have been satisfied.

c. Minimum Loan Amount. The Company shall have received a minimum of $650,000 pursuant to the Note and other similar unsecured convertible promissory notes from existing Borrower shareholders.

6. Registration Rights. Borrower hereby covenants to include in its next registration of its securities under the Securities Act of 1933 the registration, on behalf of the Lender, as a selling shareholder, of that number of shares of its common stock that would be issuable upon a full conversion of the principal amount of Lender's Note. Such "piggy back" registration rights shall be subject to limitation due to underwriter's discretion based on an assessment of market conditions in the event that the Company's next registered offering of securities involves a traditional underwriting, provided that any such limitation shall affect Lender and other similarly situated holders of Borrower notes on an equal percentage basis according to the number of conversion shares held by Lender and such other noteholders. All expenses of such registration, including the expenses of a single law firm representing the interests of Lender and all other similarly situated selling shareholders, shall be borne by Borrower.

2

7. SEC Filings. Borrower hereby covenants, at its expense, to make any filings with the Securities and Exchange Commission required of Lender in connection with the issuance of the Note or any underlying shares of stock issuable upon conversion of the Note, including any Form 3s or 4s and any filings required under Section 13(d) of the Securities and Exchange Act of 1934. Lender agrees to cooperate with Borrower's legal counsel in providing the necessary information for such filings.

8. Miscellaneous.

a. Severability. If any of the provisions of this Agreement shall be held to be invalid or unenforceable, this Agreement shall be construed as if not containing those provisions and the rights and obligations of the parties hereto shall be construed and enforced accordingly.

b. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy of other reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

c. Governing Law: Jurisdiction. This Agreement shall be construed in accordance with and governed by the laws of the State of Texas without regard to the conflicts of law principles thereof.

d. Integration. This Agreement and each Note (together with the exhibits and documents referenced herein and therein) contain the entire agreement of the parties relating to the subject matter hereof and supersedes all prior offers, letters, agreements and understandings of the parties.

e. Waiver and Amendment. Any term of this Agreement may be amended only with the written consent of Borrower and Lender. The observance of any term of this Agreement may be waived only if such waiver is in writing signed by the party waiving such term.

f. Headings. The headings in this Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

g. Transfer and Assignment. The rights and obligations of Lender and Borrower hereunder and pursuant to the Note may not be transferred or assigned by either party without the prior written consent of the other, except that Lender may transfer or assign its rights and obligations under this Agreement or the Note to an affiliate, partner or limited partner of Lender. Except as otherwise provided in this Agreement and the Note, the provisions of this Agreement and the Note shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

3

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

BORROWER:

INTERNATIONAL ISOTOPES INC.
a Texas corporation

By:    /S/ Steve T. Laflin
       -------------------
Name:  Steve T. Laflin
Title: President

LENDER:

By:    /S/ Thomas Kershner
       -------------------
Name:  Thomas Kershner

SIGNATURE PAGE TO INTERNATIONAL ISOTOPES INC.
NOTE PURCHASE AGREEMENT

4

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF. THE SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT, EXCEPT UNDER CERTAIN SPECIFIC LIMITED CIRCUMSTANCES, AN OPINION OF COUNSEL FOR THE HOLDER, CONCURRED IN BY COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

UNSECURED CONVERTIBLE PROMISSORY NOTE

                                                              Idaho Falls, Idaho

$29,000.00                                                    January 21,2004


         1.     Principal and Interest.

(a) International Isotopes Inc., a Texas corporation (the "Company"), for value received, hereby promises to pay to the order of Thomas Kershner (the "Holder") in lawful money of the United States at the address of the Holder set forth below, the principal amount of Twenty Nine Thousand Dollars ($29,000.00) (the "Principal"), together with simple interest at the rate of six percent (6%) per annum. Interest shall be computed on a 365-day year for the actual number of days elapsed.

(b) The Principal of this Note shall be due and payable on December 30, 2005 (the "Maturity Date"). Accrued interest on this Note shall be payable in arrears on June 30, 2004, December 30, 2004, June 30, 2005 and on the Maturity Date. This Note may be prepaid without penalty, in whole or in part, at any time.

(c) Upon payment in full of all principal and interest payable hereunder, this Note shall be surrendered to the Company for cancellation.

2. Conversion.

(a) Conversion. The outstanding principal balance of this Note and all interest accrued and unpaid thereon may be converted at the option of the Holder at any time into shares of the Company's common stock, par value $.01 per share at a conversion price equal to the average of the closing bid prices of the Company's common stock on the third through the eighth trading days following the Company's announcement of its acquisition of certain fluorine extraction process patents from International Machine Design, LLC, such announcement to be made by the Company within two (2) business days of the closing of the acquisition of the patents.

(b) Option Exercise. At least 10 days (but not more than 30 days) prior to the conversion date, Holder shall notify the Company of its desire to convert all or part of this Note to common stock. Holder's notice shall specify the conversion date and the amount of principal and accrued interest to be converted. Any notice required or that may be given under this Note shall be in writing and shall be deemed to have been duly given when delivered, transmitted by telecopier (with receipt confirmed) or mailed by registered or certified first class mail, postage prepaid, return receipt requested to the parties hereto at the address set forth below (as the same may be changed from time to time by notice similarly given) or the last known business or residence address of much other person as may be designated by either party hereto in writing.

1

(i) If to Company:

International Isotopes Inc. 4137 Commerce Circle Idaho Falls, Idaho 83401 Fax: (208) 524-1411

(ii) If to Holder:

Thomas Kershner 258E. Sanford St.

Glens Falls, NY 12801

(c) Mechanics of Conversion. Upon conversion of this entire Note as set forth above, the outstanding principal and accrued interest of the Note shall be converted as elected by Holder without any further action by the Holder and whether or not the Note is surrendered to the Company or its transfer agent. The Company shall not be obligated to issue certificates evidencing the shares of the securities issuable upon conversion unless such Note is either delivered to the Company or its transfer agent, or the Holder notifies the Company or its transfer agent that such Note has been lost, stolen or destroyed and executes an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such Note. The Company shall, as soon as practicable after such delivery, or such agreement and indemnification, issue and deliver to such Holder, a certificate or certificates for the securities to which the Holder shall be entitled and a check payable to the Holder in the amount of any cash amounts payable as the result of a conversion into fractional shares of common stock. Such conversion shall be deemed to have been made on the conversion date specified in Holder's notice of conversion. The person or persons entitled to receive securities issuable upon such conversion shall be treated for all purposes as the record holder or holders of such securities on such date. If the Holder elects to convert less than the entire principal amount of the Note, upon Lender's surrender of the original Note, Borrower shall deliver to Lender a new Note in an amount equal to the principal amount of the original Note that has not been converted to common stock.

3. Attorneys Fees. If the indebtedness represented by this Note or any part thereof is collected in bankruptcy, receivership or other judicial proceedings or if this Note is placed in the hands of attorneys for collection after default, the Company agrees to pay, in addition to the principal and interest payable hereunder, reasonable attorneys' fees and costs incurred by the Holder.

2

4. Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF TEXAS AS SUCH LAWS ARE APPLIED TO AGREEMENTS BETWEEN TEXAS RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN TEXAS.

HOLDER: INTERNATIONAL ISOTOPES INC.

By:   /S/ Thomas Kershner              By:    /S/ Steve T. Laflin
      -------------------                     -------------------
Name: Thomas Kershner                  Name:  Steve T. Laflin
Address: 258 E. Sanford St.           Title:  President
         Glens Falls, NY 12801

3

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this "Agreement"), is made and entered into as of January 23, 2004, by and between the undersigned lender ("Lender") and International Isotopes Inc., a Texas corporation ("Borrower").

WITNESSETH:

WHEREAS, Borrower desires to borrow from Lender, and Lender is willing to loan to Borrower, the principal amount of $ 162,500.00 ,to be evidenced by an unsecured convertible promissory note in the form set forth on Exhibit A attached hereto (the "Convertible Note" or the "Note'7).

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby specifically acknowledged, the parties hereto agree as follows:

1. Closing; Delivery. Upon the terms and subject to the conditions herein, Borrower agrees to issue to the Lender the Convertible Note and Lender agrees to lend to Borrower pursuant to the terms of the Convertible Note and this Agreement, a maximum principal amount of $ 162,500.00 (the "Loan"). The execution and delivery of the Convertible Note and the delivery of the proceeds of the Loan shall take place at closing (the "Closing") to be held on January 28, 2004 at 9:00 a.m., Mountain time, or on such other date and at such other time as may be mutually agreed upon (the "Closing Date"). The Closing shall be held at the offices of the Borrower or at such other place as may be mutually agreed upon.

2. Representations and Warranties of Lender. Lender hereby represents and warrants that as of the Closing Date:

a. Purchase Entirely for Own Account. Lender is acquiring the Note and any securities issuable upon conversion of the Note to be received by Lender (the "Securities") for investment for Lender's own account and not with a view to or for resale in connection with, any distribution thereof. Lender understands that the Securities have not been registered under the Securities Act of 1933, as amended (the "Act"), by reason of a specific exemption from the registration provisions of the Act that depends upon, among other things, the bona fide nature of the investment intent as expressed herein.

b. Investment Experience. Lender is an accredited investor within the meaning of Regulation D prescribed by the Securities and Exchange Commission pursuant to the Act and by virtue of Lender's experience in evaluating and investing in private placement transactions of securities in companies similar to Borrower, such Lender is capable of evaluating the merits and risks of Lender's investment in Borrower and has the capacity to protect Lender's own interests.

1

c. Restricted Securities. Lender acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act, or unless an exemption from such registration is available. Lender is aware of the provisions of Rule 144 and 144A promulgated under the Act that permit limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

3. Representations and Warranties of Borrower. Borrower hereby represents and warrants that, as of the Closing Date:

a. Authority. Borrower has all requisite legal and corporate power and authority and has obtained all approvals and consents necessary to enter into this Agreement and the Note and to carry out and perform its obligations under the terms of this Agreement and the Note.

4. Covenant Concerning Confidential Information. Lender understands that in connection with the negotiation of this Agreement and the Note it may become privy to material non-public information concerning Borrower and its business operations including proposed new business opportunities. Lender agrees that it will keep such information confidential and will not disclose any material non-public information concerning Borrower to any third person and will not purchase or sell or enter into any agreement to purchase or sell securities of Borrower so long as Lender is in possession of any material information concerning Borrower which has not yet been announced publicly, either through a Borrower press release or in a disclosure filing with the Securities and Exchange Commission.

5. Conditions of Lender's Obligations at Closing. The obligations of the Lender under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against the Lender without its written consent:

a. Note. Borrower shall have executed and delivered to Lender an original copy of this Agreement and the Note in the form attached as Exhibit A for the Loan.

b. Patent Acquisition. All conditions precedent to the closing of that certain Asset Acquisition Agreement entered into as of November 24, 2003 between the Borrower and International Machine Design, LLC shall have been satisfied.

c. Minimum Loan Amount. The Company shall have received a minimum of $650,000 pursuant to the Note and other similar unsecured convertible promissory notes from existing Borrower shareholders.

6. Registration Rights. Borrower hereby covenants to include in its next registration of its securities under the Securities Act of 1933 the registration, on behalf of the Lender, as a selling shareholder, of that number of shares of its common stock that would be issuable upon a full conversion of the principal amount of Lender's Note. Such "piggy back" registration rights shall be subject to limitation due to underwriter's discretion based on an assessment of market conditions in the event that the Company's next registered offering of securities involves a traditional underwriting, provided that any such limitation shall affect Lender and other similarly situated holders of Borrower notes on an equal percentage basis according to the number of conversion shares held by Lender and such other noteholders. All expenses of such registration, including the expenses of a single law firm representing the interests of Lender and all other similarly situated selling shareholders, shall be borne by Borrower.

2

7. SEC Filings. Borrower hereby covenants, at its expense, to make any filings with the Securities and Exchange Commission required of Lender in connection with the issuance of the Note or any underlying shares of stock issuable upon conversion of the Note, including any Form 3s or 4s and any filings required under Section 13(d) of the Securities and Exchange Act of 1934. Lender agrees to cooperate with Borrower's legal counsel in providing the necessary information for such filings.

8. Miscellaneous.

a. Severability. If any of the provisions of this Agreement shall be held to be invalid or unenforceable, this Agreement shall be construed as if not containing those provisions and the rights and obligations of the parties hereto shall be construed and enforced accordingly.

b. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy of other reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

c. Governing Law: Jurisdiction. This Agreement shall be construed in accordance with and governed by the laws of the State of Texas without regard to the conflicts of law principles thereof.

d. Integration. This Agreement and each Note (together with the exhibits and documents referenced herein and therein) contain the entire agreement of the parties relating to the subject matter hereof and supersedes all prior offers, letters, agreements and understandings of the parties.

e. Waiver and Amendment. Any term of this Agreement may be amended only with the written consent of Borrower and Lender. The observance of any term of this Agreement may be waived only if such waiver is in writing signed by the party waiving such term.

f. Headings. The headings in this Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

g. Transfer and Assignment. The rights and obligations of Lender and Borrower hereunder and pursuant to the Note may not be transferred or assigned by either party without the prior written consent of the other, except that Lender may transfer or assign its rights and obligations under this Agreement or the Note to an affiliate, partner or limited partner of Lender. Except as otherwise provided in this Agreement and the Note, the provisions of this Agreement and the Note shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

3

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

BORROWER:

INTERNATIONAL ISOTOPES INC.
a Texas corporation

By:    /S/ Steve T. Laflin
       ----------------------
Name:  Steve T. Laflin
Title: President

LENDER:

By:     /S/ John McCormack
        ---------------------
Name:   John McCormack

SIGNATURE PAGE TO INTERNATIONAL ISOTOPES INC.
NOTE PURCHASE AGREEMENT

4

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF. THE SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT, EXCEPT UNDER CERTAIN SPECIFIC LIMITED CIRCUMSTANCES, AN OPINION OF COUNSEL FOR THE HOLDER, CONCURRED IN BY COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

UNSECURED CONVERTIBLE PROMISSORY NOTE

                                                              Idaho Falls, Idaho

$162,500.00                                                   January 23,2004


         1.     Principal and Interest.

(a) International Isotopes Inc., a Texas corporation (the "Company"), for value received, hereby promises to pay to the order of John McCormack (the "Holder") in lawful money of the United States at the address of the Holder set forth below, the principal amount of One Hundred Sixty Two Thousand Five Hundred Dollars ($162,500.00) (the "Principal"), together with simple interest at the rate of six percent (6%) per annum. Interest shall be computed on a 365-day year for the actual number of days elapsed.

(b) The Principal of this Note shall be due and payable on December 30, 2005 (the "Maturity Date"). Accrued interest on this Note shall be payable in arrears on June 30, 2004, December 30, 2004, June 30, 2005 and on the Maturity Date. This Note may be prepaid without penalty, in whole or in part, at any time.

(c) Upon payment in full of all principal and interest payable hereunder, this Note shall be surrendered to the Company for cancellation.

2. Conversion.

(a) Conversion. The outstanding principal balance of this Note and all interest accrued and unpaid thereon may be converted at the option of the Holder at any time into shares of the Company's common stock, par value $.01 per share at a conversion price equal to the average of the closing bid prices of the Company's common stock on the third through the eighth trading days following the Company's announcement of its acquisition of certain fluorine extraction process patents from International Machine Design, LLC, such announcement to be made by the Company within two (2) business days of the closing of the acquisition of the patents.

(b) Option Exercise. At least 10 days (but not more than 30 days) prior to the conversion date, Holder shall notify the Company of its desire to convert all or part of this Note to common stock. Holder's notice shall specify the conversion date and the amount of principal and accrued interest to be converted. Any notice required or that may be given under this Note shall be in writing and shall be deemed to have been duly given when delivered, transmitted by telecopier (with receipt confirmed) or mailed by registered or certified first class mail, postage prepaid, return receipt requested to the parties hereto at the address set forth below (as the same may be changed from time to time by notice similarly given) or the last known business or residence address of much other person as may be designated by either party hereto in writing.

1

(i) If to Company:

International Isotopes Inc. 4137 Commerce Circle Idaho Falls, Idaho 83401 Fax: (208) 524-1411

(ii) If to Holder:

John McCormack
1303 Campbell
Houston, TX 77055

(c) Mechanics of Conversion. Upon conversion of this entire Note as set forth above, the outstanding principal and accrued interest of the Note shall be converted as elected by Holder without any further action by the Holder and whether or not the Note is surrendered to the Company or its transfer agent. The Company shall not be obligated to issue certificates evidencing the shares of the securities issuable upon conversion unless such Note is either delivered to the Company or its transfer agent, or the Holder notifies the Company or its transfer agent that such Note has been lost, stolen or destroyed and executes an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such Note. The Company shall, as soon as practicable after such delivery, or such agreement and indemnification, issue and deliver to such Holder, a certificate or certificates for the securities to which the Holder shall be entitled and a check payable to the Holder in the amount of any cash amounts payable as the result of a conversion into fractional shares of common stock. Such conversion shall be deemed to have been made on the conversion date specified in Holder's notice of conversion. The person or persons entitled to receive securities issuable upon such conversion shall be treated for all purposes as the record holder or holders of such securities on such date. If the Holder elects to convert less than the entire principal amount of the Note, upon Lender's surrender of the original Note, Borrower shall deliver to Lender a new Note in an amount equal to the principal amount of the original Note that has not been converted to common stock.

3. Attorneys Fees. If the indebtedness represented by this Note or any part thereof is collected in bankruptcy, receivership or other judicial proceedings or if this Note is placed in the hands of attorneys for collection after default, the Company agrees to pay, in addition to the principal and interest payable hereunder, reasonable attorneys' fees and costs incurred by the Holder.

2

4. Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF TEXAS AS SUCH LAWS ARE APPLIED TO AGREEMENTS BETWEEN TEXAS RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN TEXAS.

HOLDER: INTERNATIONAL ISOTOPES INC.

By:    /S/ John McCormack               By:    /S/ Steve T. Laflin
       ------------------                      -------------------
Name:  John McCormack                   Name:  Steve T. Laflin

Address: 1303 Campbell Rd. Title: President Houston, TX 77055

3

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this "Agreement"), is made and entered into as of January 21, 2004, by and between the undersigned lender ("Lender") and International Isotopes Inc., a Texas corporation ("Borrower").

WITNESSETH:

WHEREAS, Borrower desires to borrow from Lender, and Lender is willing to loan to Borrower, the principal amount of $ 73,000.00 ,to be evidenced by an unsecured convertible promissory note in the form set forth on Exhibit A attached hereto (the "Convertible Note" or the "Note'7).

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby specifically acknowledged, the parties hereto agree as follows:

1. Closing; Delivery. Upon the terms and subject to the conditions herein, Borrower agrees to issue to the Lender the Convertible Note and Lender agrees to lend to Borrower pursuant to the terms of the Convertible Note and this Agreement, a maximum principal amount of $ 73,000.00 (the "Loan"). The execution and delivery of the Convertible Note and the delivery of the proceeds of the Loan shall take place at closing (the "Closing") to be held on January 23, 2004 at 9:00 a.m., Mountain time, or on such other date and at such other time as may be mutually agreed upon (the "Closing Date"). The Closing shall be held at the offices of the Borrower or at such other place as may be mutually agreed upon.

2. Representations and Warranties of Lender. Lender hereby represents and warrants that as of the Closing Date:

a. Purchase Entirely for Own Account. Lender is acquiring the Note and any securities issuable upon conversion of the Note to be received by Lender (the "Securities") for investment for Lender's own account and not with a view to or for resale in connection with, any distribution thereof. Lender understands that the Securities have not been registered under the Securities Act of 1933, as amended (the "Act"), by reason of a specific exemption from the registration provisions of the Act that depends upon, among other things, the bona fide nature of the investment intent as expressed herein.

b. Investment Experience. Lender is an accredited investor within the meaning of Regulation D prescribed by the Securities and Exchange Commission pursuant to the Act and by virtue of Lender's experience in evaluating and investing in private placement transactions of securities in companies similar to Borrower, such Lender is capable of evaluating the merits and risks of Lender's investment in Borrower and has the capacity to protect Lender's own interests.

1

c. Restricted Securities. Lender acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act, or unless an exemption from such registration is available. Lender is aware of the provisions of Rule 144 and 144A promulgated under the Act that permit limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

3. Representations and Warranties of Borrower. Borrower hereby represents and warrants that, as of the Closing Date:

a. Authority. Borrower has all requisite legal and corporate power and authority and has obtained all approvals and consents necessary to enter into this Agreement and the Note and to carry out and perform its obligations under the terms of this Agreement and the Note.

4. Covenant Concerning Confidential Information. Lender understands that in connection with the negotiation of this Agreement and the Note it may become privy to material non-public information concerning Borrower and its business operations including proposed new business opportunities. Lender agrees that it will keep such information confidential and will not disclose any material non-public information concerning Borrower to any third person and will not purchase or sell or enter into any agreement to purchase or sell securities of Borrower so long as Lender is in possession of any material information concerning Borrower which has not yet been announced publicly, either through a Borrower press release or in a disclosure filing with the Securities and Exchange Commission.

5. Conditions of Lender's Obligations at Closing. The obligations of the Lender under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against the Lender without its written consent:

a. Note. Borrower shall have executed and delivered to Lender an original copy of this Agreement and the Note in the form attached as Exhibit A for the Loan. b. Patent Acquisition. All conditions precedent to the closing of that certain Asset Acquisition Agreement entered into as of November 24, 2003 between the Borrower and International Machine Design, LLC shall have been satisfied.

c. Minimum Loan Amount. The Company shall have received a minimum of $650,000 pursuant to the Note and other similar unsecured convertible promissory notes from existing Borrower shareholders.

6. Registration Rights. Borrower hereby covenants to include in its next registration of its securities under the Securities Act of 1933 the registration, on behalf of the Lender, as a selling shareholder, of that number of shares of its common stock that would be issuable upon a full conversion of the principal amount of Lender's Note. Such "piggy back" registration rights shall be subject to limitation due to underwriter's discretion based on an assessment of market conditions in the event that the Company's next registered offering of securities involves a traditional underwriting, provided that any such limitation shall affect Lender and other similarly situated holders of Borrower notes on an equal percentage basis according to the number of conversion shares held by Lender and such other noteholders. All expenses of such registration, including the expenses of a single law firm representing the interests of Lender and all other similarly situated selling shareholders, shall be borne by Borrower.

2

7. SEC Filings. Borrower hereby covenants, at its expense, to make any filings with the Securities and Exchange Commission required of Lender in connection with the issuance of the Note or any underlying shares of stock issuable upon conversion of the Note, including any Form 3s or 4s and any filings required under Section 13(d) of the Securities and Exchange Act of 1934. Lender agrees to cooperate with Borrower's legal counsel in providing the necessary information for such filings.

8. Miscellaneous.

a. Severability. If any of the provisions of this Agreement shall be held to be invalid or unenforceable, this Agreement shall be construed as if not containing those provisions and the rights and obligations of the parties hereto shall be construed and enforced accordingly.

b. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy of other reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

c. Governing Law: Jurisdiction. This Agreement shall be construed in accordance with and governed by the laws of the State of Texas without regard to the conflicts of law principles thereof.

d. Integration. This Agreement and each Note (together with the exhibits and documents referenced herein and therein) contain the entire agreement of the parties relating to the subject matter hereof and supersedes all prior offers, letters, agreements and understandings of the parties.

e. Waiver and Amendment. Any term of this Agreement may be amended only with the written consent of Borrower and Lender. The observance of any term of this Agreement may be waived only if such waiver is in writing signed by the party waiving such term.

f. Headings. The headings in this Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

g. Transfer and Assignment. The rights and obligations of Lender and Borrower hereunder and pursuant to the Note may not be transferred or assigned by either party without the prior written consent of the other, except that Lender may transfer or assign its rights and obligations under this Agreement or the Note to an affiliate, partner or limited partner of Lender. Except as otherwise provided in this Agreement and the Note, the provisions of this Agreement and the Note shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

3

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

BORROWER:

INTERNATIONAL ISOTOPES INC.
a Texas corporation

By:    /S/ Steve T. Laflin
       -------------------
Name:  Steve T. Laflin
Title: President

LENDER:

By:    /S/ James Keane
       ------------------
Name:  James Keane

SIGNATURE PAGE TO INTERNATIONAL ISOTOPES INC.

NOTE PURCHASE AGREEMENT

4

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF. THE SECURITIES MAY NOT BE SOLD OK OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT, EXCEPT UNDER CERTAIN SPECIFIC LIMITED CIRCUMSTANCES, AN OPINION OF COUNSEL FOR THE HOLDER, CONCURRED IN BY COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

UNSECURED CONVERTIBLE PROMISSORY NOTE

                                                              Idaho Falls, Idaho

$ 73,000.00                                                   January 21, 2004


         1.     Principal and Interest.

(a) International Isotopes Inc., a Texas corporation (the "Company"), for value received, hereby promises to pay to the order of James Keane (the "Holder") in lawful money of the United States at the address of the Holder set forth below, the principal amount of Seventy Three Thousand Dollars ($ 73,000.00) (the "Principal"), together with simple interest at the rate of six percent (6%) per annum. Interest shall be computed on a 365-day year for the actual number of days elapsed.

(b) The Principal of this Note shall be due and payable on December 30, 2005 (the "Maturity Date"). Accrued interest on this Note shall be payable in arrears on June 30, 2004, December 30, 2004, June 30, 2005 and on the Maturity Date. This Note may be prepaid without penalty, in whole or in part, at any time.

(c) Upon payment in full of all principal and interest payable hereunder, this Note shall be surrendered to the Company for cancellation.

2. Conversion.

(a) Conversion. The outstanding principal balance of this Note and all interest accrued and unpaid thereon may be converted at the option of the Holder at any time into shares of the Company's common stock, par value $.01 per share at a conversion price equal to the average of the closing bid prices of the Company's common stock on the third through the eighth trading days following the Company's announcement of its acquisition of certain fluorine extraction process patents from International Machine Design, LLC, such announcement to be made by the Company within two (2) business days of the closing of the acquisition of the patents.

(b) Option Exercise. At least 10 days (but not more than 30 days) prior to the conversion date, Holder shall notify the Company of its desire to convert all or part of this Note to common stock. Holder's notice shall specify the conversion date and the amount of principal and accrued interest to be converted. Any notice required or that may be given under this Note shall be in writing and shall be deemed to have been duly given when delivered, transmitted by telecopier (with receipt confirmed) or mailed by registered or certified first class mail, postage prepaid, return receipt requested to the parties hereto at the address set forth below (as the same may be changed from time to time by notice similarly given) or the last known business or residence address of much other person as may be designated by either party hereto in writing.

1

(i) If to company:

International Isotopes Inc. 4137 Commerce Circle Idaho Falls, Idaho 83401 Fax: (208) 524-1411

(ii) If to Holder:

James Keane
Fifty Broadway
New York, NY 10004

(c) Mechanics of Conversion. Upon conversion of this entire Note as set forth above, the outstanding principal and accrued interest of the Note shall be converted as elected by Holder without any further action by the Holder and whether or not the Note is surrendered to the Company or its transfer agent. The Company shall not be obligated to issue certificates evidencing the shares of the securities issuable upon conversion unless such Note is either delivered to the Company or its transfer agent, or the Holder notifies the Company or its transfer agent that such Note has been lost, stolen or destroyed and executes an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such Note. The Company shall, as soon as practicable after such delivery, or such agreement and indemnification, issue and deliver to such Holder, a certificate or certificates for the securities to which the Holder shall be entitled and a check payable to the Holder in the amount of any cash amounts payable as the result of a conversion into fractional shares of common stock. Such conversion shall be deemed to have been made on the conversion date specified in Holder's notice of conversion. The person or persons entitled to receive securities issuable upon such conversion shall be treated for all purposes as the record holder or holders of such securities on such date. If the Holder elects to convert less than the entire principal amount of the Note, upon Lender's surrender of the original Note, Borrower shall deliver to Lender a new Note in an amount equal to the principal amount of the original Note that has not been converted to common stock.

3. Attorneys Fees. If the indebtedness represented by this Note or any part thereof is collected in bankruptcy, receivership or other judicial proceedings or if this Note is placed in the hands of attorneys for collection after default, the Company agrees to pay, in addition to the principal and interest payable hereunder, reasonable attorneys' fees and costs incurred by the Holder.

2

4. Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF TEXAS AS SUCH LAWS ARE APPLIED TO AGREEMENTS BETWEEN TEXAS RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN TEXAS.

HOLDER: INTERNATIONAL ISOTOPES INC.

By:    /S/ James Keane               By:    /S/ Steve T. Laflin
       ---------------                      -------------------
Name:  James Keane                   Name:  Steve T. Laflin

Address: Fifty Broadway Title: President New York, NY 10004

3

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this "Agreement"), is made and entered into as of January 21, 2004, by and between the undersigned lender ("Lender") and International Isotopes Inc., a Texas corporation ("Borrower").

WITNESSETH:

WHEREAS, Borrower desires to borrow from Lender, and Lender is willing to loan to Borrower, the principal amount of $ 73,000.00 ,to be evidenced by an unsecured convertible promissory note in the form set forth on Exhibit A attached hereto (the "Convertible Note" or the "Note '7.

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby specifically acknowledged, the parties hereto agree as follows:

1. Closing; Delivery. Upon the terms and subject to the conditions herein, Borrower agrees to issue to the Lender the Convertible Note and Lender agrees to lend to Borrower pursuant to the terms of the Convertible Note and this Agreement, a maximum principal amount of $ 73,000.00 (the "Loan"). The execution and delivery of the Convertible Note and the delivery of the proceeds of the Loan shall take place at closing (the "Closing") to be held on January 23, 2004 at 9:00 a.m., Mountain time, or on such other date and at such other time as may be mutually agreed upon (the "Closing Date"). The Closing shall be held at the offices of the Borrower or at such other place as may be mutually agreed upon.

2. Representations and Warranties of Lender. Lender hereby represents and warrants that as of the Closing Date:

a. Purchase Entirely for Own Account. Lender is acquiring the Note and any securities issuable upon conversion of the Note to be received by Lender (the "Securities") for investment for Lender's own account and not with a view to or for resale in connection with, any distribution thereof. Lender understands that the Securities have not been registered under the Securities Act of 1933, as amended (the "Act"), by reason of a specific exemption from the registration provisions of the Act that depends upon, among other things, the bona fide nature of the investment intent as expressed herein.

b. Investment Experience. Lender is an accredited investor within the meaning of Regulation D prescribed by the Securities and Exchange Commission pursuant to the Act and by virtue of Lender's experience in evaluating and investing in private placement transactions of securities in companies similar to Borrower, such Lender is capable of evaluating the merits and risks of Lender's investment in Borrower and has the capacity to protect Lender's own interests.

1

c. Restricted Securities. Lender acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act, or unless an exemption from such registration is available. Lender is aware of the provisions of Rule 144 and 144A promulgated under the Act that permit limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

3. Representations and Warranties of Borrower. Borrower hereby represents and warrants that, as of the Closing Date:

a. Authority. Borrower has all requisite legal and corporate power and authority and has obtained all approvals and consents necessary to enter into this Agreement and the Note and to carry out and perform its obligations under the terms of this Agreement and the Note.

4. Covenant Concerning Confidential Information. Lender understands that in connection with the negotiation of this Agreement and the Note it may become privy to material non-public information concerning Borrower and its business operations including proposed new business opportunities. Lender agrees that it will keep such information confidential and will not disclose any material non-public information concerning Borrower to any third person and will not purchase or sell or enter into any agreement to purchase or sell securities of Borrower so long as Lender is in possession of any material information concerning Borrower which has not yet been announced publicly, either through a Borrower press release or in a disclosure filing with the Securities and Exchange Commission.

5. Conditions of Lender's Obligations at Closing. The obligations of the Lender under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against the Lender without its written consent:

a. Note. Borrower shall have executed and delivered to Lender an original copy of this Agreement and the Note in the form attached as Exhibit A for the Loan.

b. Patent Acquisition. All conditions precedent to the closing of that certain Asset Acquisition Agreement entered into as of November 24, 2003 between the Borrower and International Machine Design, LLC shall have been satisfied.

c. Minimum Loan Amount. The Company shall have received a minimum of $650,000 pursuant to the Note and other similar unsecured convertible promissory notes from existing Borrower shareholders.

6. Registration Rights. Borrower hereby covenants to include in its next registration of its securities under the Securities Act of 1933 the registration, on behalf of the Lender, as a selling shareholder, of that number of shares of its common stock that would be issuable upon a full conversion of the principal amount of Lender's Note. Such "piggy back" registration rights shall be subject to limitation due to underwriter's discretion based on an assessment of market conditions in the event that the Company's next registered offering of securities involves a traditional underwriting, provided that any such limitation shall affect Lender and other similarly situated holders of Borrower notes on an equal percentage basis according to the number of conversion shares held by Lender and such other noteholders. All expenses of such registration, including the expenses of a single law firm representing the interests of Lender and all other similarly situated selling shareholders, shall be borne by Borrower.

2

7. SEC Filings. Borrower hereby covenants, at its expense, to make any filings with the Securities and Exchange Commission required of Lender in connection with the issuance of the Note or any underlying shares of stock issuable upon conversion of the Note, including any Form 3s or 4s and any filings required under Section 13(d) of the Securities and Exchange Act of 1934. Lender agrees to cooperate with Borrower's legal counsel in providing the necessary information for such filings.

8. Miscellaneous.

a. Severability. If any of the provisions of this Agreement shall be held to be invalid or unenforceable, this Agreement shall be construed as if not containing those provisions and the rights and obligations of the parties hereto shall be construed and enforced accordingly.

b. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy of other reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

c. Governing Law: Jurisdiction. This Agreement shall be construed in accordance with and governed by the laws of the State of Texas without regard to the conflicts of law principles thereof.

d. Integration. This Agreement and each Note (together with the exhibits and documents referenced herein and therein) contain the entire agreement of the parties relating to the subject matter hereof and supersedes all prior offers, letters, agreements and understandings of the parties.

e. Waiver and Amendment. Any term of this Agreement may be amended only with the written consent of Borrower and Lender. The observance of any term of this Agreement may be waived only if such waiver is in writing signed by the party waiving such term.

f. Headings. The headings in this Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

g. Transfer and Assignment. The rights and obligations of Lender and Borrower hereunder and pursuant to the Note may not be transferred or assigned by either party without the prior written consent of the other, except that Lender may transfer or assign its rights and obligations under this Agreement or the Note to an affiliate, partner or limited partner of Lender. Except as otherwise provided in this Agreement and the Note, the provisions of this Agreement and the Note shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

3

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

BORROWER:

INTERNATIONAL ISOTOPES INC.
a Texas corporation

By:     /S/ Steve T. Laflin
        -------------------
Name:   Steve T. Laflin
Title:  President

LENDER:

By:    /S/ Walter O'Hearn
       ------------------
Name:  Walter O'Hearn

SIGNATURE PAGE TO INTERNATIONAL ISOTOPES INC.

NOTE PURCHASE AGREEMENT

4

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF. THE SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT, EXCEPT UNDER CERTAIN SPECIFIC LIMITED CIRCUMSTANCES, AN OPINION OF COUNSEL FOR THE HOLDER, CONCURRED IN BY COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED.

UNSECURED CONVERTIBLE PROMISSORY NOTE

                                                              Idaho Falls, Idaho

$73,000.00                                                    January 21, 2004


         1.     Principal and Interest.

(a) International Isotopes Inc., a Texas corporation (the "Company"), for value received, hereby promises to pay to the order of Walter O'Hearn (the "Holder") in lawful money of the United States at the address of the Holder set forth below, the principal amount of Seventy Three Thousand Dollars ($73,000.00) (the "Principal"), together with simple interest at the rate of six percent (6%) per annum. Interest shall be computed on a 365-day year for the actual number of days elapsed.

(b) The Principal of this Note shall be due and payable on December 30, 2005 (the "Maturity Date"). Accrued interest on this Note shall be payable in arrears on June 30, 2004, December 30, 2004, June 30, 2005 and on the Maturity Date. This Note may be prepaid without penalty, in whole or in part, at any time.

(c) Upon payment in full of all principal and interest payable hereunder, this Note shall be surrendered to the Company for cancellation.

2. Conversion.

(a) Conversion. The outstanding principal balance of this Note and all interest accrued and unpaid thereon may be converted at the option of the Holder at any time into shares of the Company's common stock, par value $.01 per share at a conversion price equal to the average of the closing bid prices of the Company's common stock on the third through the eighth trading days following the Company's announcement of its acquisition of certain fluorine extraction process patents from International Machine Design, LLC, such announcement to be made by the Company within two (2) business days of the closing of the acquisition of the patents.

(b) Option Exercise. At least 10 days (but not more than 30 days) prior to the conversion date, Holder shall notify the Company of its desire to convert all or part of this Note to common stock. Holder's notice shall specify the conversion date and the amount of principal and accrued interest to be converted. Any notice required or that may be given under this Note shall be in writing and shall be deemed to have been duly given when delivered, transmitted by telecopier (with receipt confirmed) or mailed by registered or certified first class mail, postage prepaid, return receipt requested to the parties hereto at the address set forth below (as the same may be changed from time to time by notice similarly given) or the last known business or residence address of much other person as may be designated by either party hereto in writing.

1

(i) If to Company:

International Isotopes Inc. 4137 Commerce Circle Idaho Falls, Idaho 83401 Fax: (208) 524- 14 11

(ii) If to Holder:

Walter O'Hearn 1115 5th Ave, Apt 4A New York, NY 10128

(c) Mechanics of Conversion. Upon conversion of this entire Note as set forth above, the outstanding principal and accrued interest of the Note shall be converted as elected by Holder without any further action by the Holder and whether or not the Note is surrendered to the Company or its transfer agent. The Company shall not be obligated to issue certificates evidencing the shares of the securities issuable upon conversion unless such Note is either delivered to the Company or its transfer agent, or the Holder notifies the Company or its transfer agent that such Note has been lost, stolen or destroyed and executes an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such Note. The Company shall, as soon as practicable after such delivery, or such agreement and indemnification, issue and deliver to such Holder, a certificate or certificates for the securities to which the Holder shall be entitled and a check payable to the Holder in the amount of any cash amounts payable as the result of a conversion into fractional shares of common stock. Such conversion shall be deemed to have been made on the conversion date specified in Holder's notice of conversion. The person or persons entitled to receive securities issuable upon such conversion shall be treated for all purposes as the record holder or holders of such securities on such date. If the Holder elects to convert less than the entire principal amount of the Note, upon Lender's surrender of the original Note, Borrower shall deliver to Lender a new Note in an amount equal to the principal amount of the original Note that has not been converted to common stock.

3. Attorneys Fees. If the indebtedness represented by this Note or any part thereof is collected in bankruptcy, receivership or other judicial proceedings or if this Note is placed in the hands of attorneys for collection after default, the Company agrees to pay, in addition to the principal and interest payable hereunder, reasonable attorneys' fees and costs incurred by the Holder.

2

4. Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF TEXAS AS SUCH LAWS ARE APPLIED TO AGREEMENTS BETWEEN TEXAS RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN TEXAS.

HOLDER: INTERNATIONAL ISOTOPES INC.

By:    /S/ Walter O'Hearn                By:    /S/ Steve T. Laflin
       ------------------                       -------------------
Name:  Walter O'Hearn                    Name:  Steve T. Laflin

Address: 1115 5th Ave, Apt 4A Title: President New York, NY 10128

3

EXHIBIT 21

SUBSIDARIES

International Isotopes Idaho Inc. is the sole subsidiary of International Isotopes Inc.

Date: March 29, 2005


/S/ Steve T. Laflin
-----------------------
Steve T. Laflin
Chief Executive Officer


Exhibit 31.1

I, Steve T. Laflin, certify that:

I have reviewed this Annual Report on Form 10-KSB of International Isotopes, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 29, 2005


/S/  Steve T. Laflin
-----------------------
Steve T. Laflin
Chief Executive Officer


Exhibit 31.2

I, Steve T. Laflin, certify that:

I have reviewed this Annual Report on Form 10-KSB of International Isotopes, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 29, 2005


/S/ Steve T. Laflin
-----------------------
Steve T. Laflin
Chief Financial Officer


EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of International Isotopes, Inc. (the "Company") on Form 10-KSB for the year ended December 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the "Form 10-KSB"), I, Steve T. Laflin, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Form 10-KSB fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) The information contained in the Form 10-KSB fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 29, 2005                            /S/ Steve T. Laflin
                                                 --------------------------
                                                 Steve T. Laflin
                                                 Chief Executive Officer and
                                                 Chief Financial Officer